0000950170-24-057022.txt : 20240509 0000950170-24-057022.hdr.sgml : 20240509 20240509162054 ACCESSION NUMBER: 0000950170-24-057022 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 78 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Dianthus Therapeutics, Inc. /DE/ CENTRAL INDEX KEY: 0001690585 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38541 FILM NUMBER: 24931046 BUSINESS ADDRESS: STREET 1: 300 TECHNOLOGY SQUARE STREET 2: 8TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-201-2700 MAIL ADDRESS: STREET 1: 300 TECHNOLOGY SQUARE STREET 2: 8TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Magenta Therapeutics, Inc. DATE OF NAME CHANGE: 20161121 10-Q 1 dnth-20240331.htm 10-Q 10-Q
falseQ10001690585--12-310001690585us-gaap:CommonStockMember2024-03-310001690585dnth:IontasLimitedMember2023-01-012023-03-310001690585dnth:AlloyTherapeuticsLlcMembersrt:MaximumMemberdnth:SecondSelectedAntibodyMemberdnth:DevelopmentMilestoneMember2024-03-310001690585dnth:AlloyTherapeuticsLlcMembersrt:MaximumMemberdnth:DevelopmentMilestoneMemberdnth:FirstSelectedAntibodyMember2024-03-310001690585us-gaap:GeneralAndAdministrativeExpenseMemberus-gaap:EmployeeStockOptionMember2024-01-012024-03-310001690585us-gaap:CommonStockMember2023-03-310001690585dnth:InducementPlanMember2024-01-012024-03-310001690585dnth:AlloyTherapeuticsLlcMember2024-01-012024-03-310001690585us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001690585us-gaap:PrivatePlacementMemberdnth:PrefundedWarrantsMember2024-01-222024-01-220001690585us-gaap:WarrantMember2020-04-3000016905852023-01-012023-03-310001690585dnth:UpfrontPaymentMemberdnth:ZenasBiopharmaLimitedMember2022-06-300001690585us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001690585dnth:ZenasBiopharmaLimitedMemberdnth:DianthusMember2023-03-130001690585us-gaap:WarrantMember2021-04-012021-04-300001690585us-gaap:ComputerEquipmentMember2024-03-310001690585us-gaap:PrivatePlacementMember2024-01-242024-01-240001690585us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001690585us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-03-310001690585us-gaap:CommonStockMember2023-09-110001690585srt:MaximumMemberdnth:TwoThousandAndEighteenStockOptionAndIncentivePlanMemberus-gaap:RestrictedStockMember2024-01-012024-03-310001690585us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001690585us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001690585us-gaap:PrivatePlacementMember2024-01-222024-01-220001690585us-gaap:RetainedEarningsMember2024-03-310001690585dnth:InducementPlanMember2023-01-012023-12-310001690585us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-03-3100016905852023-09-110001690585dnth:FirstDevelopmentProgramMemberdnth:CommercialMilestoneMemberdnth:IontasLimitedMember2024-03-310001690585us-gaap:AdditionalPaidInCapitalMember2024-03-310001690585dnth:PrefundedWarrantsMember2023-09-110001690585us-gaap:AdditionalPaidInCapitalMember2022-12-310001690585us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001690585dnth:ZenasBiopharmaLimitedMemberus-gaap:RoyaltyMember2024-01-012024-03-310001690585us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001690585us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001690585dnth:ZenasBiopharmaLimitedMemberdnth:FairmountFundsMember2024-03-310001690585us-gaap:ComputerEquipmentMember2023-12-310001690585us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001690585us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310001690585us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001690585dnth:TwoThousandAndNineteenEmployeeStockPurchasePlanMember2024-01-012024-01-0100016905852024-01-012024-03-310001690585us-gaap:ConvertiblePreferredStockMember2024-01-012024-03-310001690585dnth:ZenasBiopharmaLimitedMember2023-12-310001690585dnth:TwoThousandAndNineteenEmployeeStockPurchasePlanMember2023-01-012023-03-310001690585dnth:ZenasBiopharmaLimitedMember2023-01-012023-03-310001690585us-gaap:USTreasurySecuritiesMember2023-12-310001690585srt:MaximumMemberdnth:InducementPlanMember2024-02-290001690585us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001690585us-gaap:RetainedEarningsMember2023-12-310001690585dnth:ZenasBiopharmaLimitedMemberdnth:TellusBioventuresLlcMember2024-03-310001690585dnth:DevelopmentMilestoneMemberdnth:OmniabIncMember2024-03-310001690585us-gaap:PrivatePlacementMemberdnth:PrefundedWarrantsMember2024-01-220001690585us-gaap:CommonStockMember2023-12-310001690585us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001690585us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001690585dnth:AlloyTherapeuticsLlcMembersrt:MaximumMemberdnth:FirstSelectedAntibodyMemberdnth:CommercialMilestoneMember2024-03-310001690585us-gaap:PreferredStockMemberus-gaap:ConvertiblePreferredStockMember2023-12-310001690585us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001690585us-gaap:PreferredStockMemberus-gaap:ConvertiblePreferredStockMember2023-03-310001690585us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001690585dnth:ZenasBiopharmaLimitedMember2024-03-310001690585us-gaap:RestrictedStockMember2024-01-012024-03-310001690585us-gaap:FairValueMeasurementsRecurringMember2023-12-310001690585dnth:WarrantsMember2023-01-012023-03-310001690585us-gaap:WarrantMember2023-01-012023-09-300001690585srt:MinimumMemberdnth:TwoThousandAndNineteenEmployeeStockPurchasePlanMember2024-01-012024-03-3100016905852024-05-060001690585srt:MaximumMemberdnth:TwoThousandAndEighteenStockOptionAndIncentivePlanMemberdnth:StockOptionsAndStockAppreciationRightsMember2024-01-012024-03-310001690585us-gaap:WarrantMember2021-04-300001690585dnth:TwoThousandAndNineteenStockPlanMember2019-07-310001690585us-gaap:AdditionalPaidInCapitalMember2023-12-3100016905852023-01-012023-12-310001690585dnth:TwoThousandAndEighteenStockOptionAndIncentivePlanMember2024-03-310001690585us-gaap:RetainedEarningsMember2023-03-310001690585us-gaap:AdditionalPaidInCapitalMember2023-03-310001690585us-gaap:PreferredStockMemberus-gaap:ConvertiblePreferredStockMember2024-03-310001690585us-gaap:GeneralAndAdministrativeExpenseMemberus-gaap:EmployeeStockOptionMember2023-01-012023-03-310001690585us-gaap:RetainedEarningsMember2024-01-012024-03-310001690585us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001690585us-gaap:RelatedPartyMember2023-01-012023-03-310001690585us-gaap:RetainedEarningsMember2023-01-012023-03-310001690585dnth:OmniabIncMember2024-01-012024-03-310001690585us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-3100016905852023-12-310001690585dnth:ZenasBiopharmaLimitedMemberdnth:MilestoneMember2022-06-300001690585dnth:IontasLimitedMember2024-01-012024-03-310001690585us-gaap:PrivatePlacementMemberdnth:PrefundedWarrantsMember2024-01-240001690585us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001690585dnth:TwoThousandAndNineteenEmployeeStockPurchasePlanMember2024-03-310001690585us-gaap:PreferredStockMemberus-gaap:ConvertiblePreferredStockMember2022-12-310001690585us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001690585dnth:AlloyTherapeuticsLlcMember2023-01-012023-03-310001690585us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001690585us-gaap:FurnitureAndFixturesMember2024-03-3100016905852024-03-310001690585dnth:ZenasBiopharmaLimitedMemberdnth:FairmountFundsMember2023-03-152023-03-150001690585us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001690585us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001690585us-gaap:CommonStockMember2022-12-310001690585dnth:ZenasBiopharmaLimitedMember2022-01-012022-06-300001690585us-gaap:FairValueMeasurementsRecurringMember2024-03-310001690585dnth:LicenseRevenueMemberdnth:ZenasBiopharmaLimitedMember2024-01-012024-03-310001690585us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001690585us-gaap:RelatedPartyMember2024-01-012024-03-310001690585us-gaap:FurnitureAndFixturesMember2023-12-310001690585us-gaap:RetainedEarningsMember2022-12-310001690585srt:MaximumMemberdnth:TwoThousandAndEighteenStockOptionAndIncentivePlanMemberdnth:CertainIncentiveStockOptionsMember2024-01-012024-03-3100016905852023-09-112023-09-110001690585dnth:SecondDevelopmentProgramMemberdnth:DevelopmentMilestoneMemberdnth:IontasLimitedMember2024-03-310001690585dnth:WarrantsMember2024-01-012024-03-3100016905852022-12-3100016905852023-03-310001690585us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001690585dnth:LicenseRevenueMemberdnth:ZenasBiopharmaLimitedMember2023-01-012023-03-310001690585us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:EmployeeStockOptionMember2024-01-012024-03-310001690585us-gaap:ConvertiblePreferredStockMember2023-01-012023-03-310001690585dnth:AlloyTherapeuticsLlcMembersrt:MaximumMemberdnth:SecondSelectedAntibodyMemberdnth:CommercialMilestoneMember2024-03-310001690585dnth:OmniabIncMember2023-01-012023-03-310001690585dnth:FirstDevelopmentProgramMemberdnth:DevelopmentMilestoneMemberdnth:IontasLimitedMember2024-03-310001690585us-gaap:RestrictedStockMember2023-01-012023-03-310001690585us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001690585us-gaap:PrivatePlacementMember2024-01-220001690585dnth:ZenasBiopharmaLimitedMember2024-01-012024-03-310001690585dnth:TwoThousandAndEighteenStockOptionAndIncentivePlanMemberus-gaap:RestrictedStockMembersrt:MinimumMember2024-01-012024-03-310001690585us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-03-310001690585us-gaap:CommonStockMember2024-01-012024-03-310001690585us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:EmployeeStockOptionMember2023-01-012023-03-310001690585dnth:ZenasBiopharmaLimitedMemberdnth:DianthusMember2023-03-132023-03-130001690585dnth:TwoThousandAndEighteenStockOptionAndIncentivePlanMember2024-01-012024-01-010001690585dnth:TwoThousandAndNineteenEmployeeStockPurchasePlanMember2024-01-012024-03-310001690585dnth:TwoThousandAndEighteenStockOptionAndIncentivePlanMember2024-01-012024-03-310001690585us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001690585dnth:ZenasBiopharmaLimitedMember2020-12-310001690585dnth:UpfrontPaymentMemberdnth:ZenasBiopharmaLimitedMember2021-09-300001690585us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001690585us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001690585us-gaap:USTreasurySecuritiesMember2024-03-31xbrli:purexbrli:sharesiso4217:GBPiso4217:USDiso4217:USDxbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________________ to _________________

Commission File Number: 001-38541

 

Dianthus Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

81-0724163

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

7 Times Square, 43rd Floor

New York, New York

10036

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (929) 999-4055

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.001 par value

 

DNTH

 

The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

 

 

 

 

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of May 6, 2024, the registrant had 29,349,469 shares of common stock, $0.001 par value per share, outstanding.

 

 


Table of Contents

 

 

 

Page

 

 

 

PART I.

FINANCIAL INFORMATION

1

 

 

 

Item 1.

Condensed Consolidated Financial Statements (Unaudited)

1

 

Condensed Consolidated Balance Sheets

1

 

Condensed Consolidated Statements of Operations and Comprehensive Loss

2

 

Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Equity/(Deficit)

3

 

Condensed Consolidated Statements of Cash Flows

4

 

Notes to Unaudited Condensed Consolidated Financial Statements

5

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

24

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

38

Item 4.

Controls and Procedures

38

 

 

 

PART II.

OTHER INFORMATION

40

 

 

 

Item 1.

Legal Proceedings

40

Item 1A.

Risk Factors

40

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

41

Item 3.

Defaults Upon Senior Securities

41

Item 4.

Mine Safety Disclosures

41

Item 5.

Other Information

41

Item 6.

Exhibits

42

Signatures

43

 

i


SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this Quarterly Report on Form 10-Q are forward-looking statements, including, without limitation, statements concerning our plans, objectives, goals, expectations, hopes, beliefs, intentions, assumptions, projections, estimates or strategies and any underlying assumptions regarding the future, our future results of operations and financial position, including the sufficiency of our existing cash resources to fund our operations for as long as anticipated, our liquidity, capital resources, costs and expenses, capital requirements, commitments and contingencies, the development or commercial potential of DNTH103 or any other product candidate, our anticipated preclinical and clinical drug development activities, in particular with respect to DNTH103, and any timelines, developments or results in connection therewith, the efficacy, safety profile, dosing amount or frequency, method of delivery or other potential therapeutic benefits of DNTH103, the receipt or timing of potential regulatory designations, approvals and commercialization of any product candidates and other statements, including those included under the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Quarterly Report on Form 10-Q. In some cases, you can identify forward-looking statements by terms such as “aim,” “may,” “might,” “will,” “would,” “shall,” “objective,” “intend,” “target,” “should,” “could,” “can,” “expect,” “anticipate,” “believe,” “design,” “estimate,” “forecast,” “predict,” “project,” “potential,” “possible,” “plan,” “seek,” “contemplate,” “goal,” “likely” or “continue” or the negative of these terms and similar expressions intended to identify forward-looking statements, but the absence of these terms does not mean that a statement is not forward-looking. Forward-looking statements are not historical facts and are based on our current expectations and beliefs with respect to future events and their potential effects and impacts. There can be no assurance that future events affecting us will be those that have been anticipated. Given the significant risks and uncertainties, you should not place undue reliance on these forward-looking statements.

 

There are a number of risks, uncertainties and other factors that could cause our actual results or outcomes, or the timing of our results or outcomes, to differ materially from the forward-looking statements expressed or implied in this Quarterly Report on Form 10-Q. Such risks, uncertainties and other factors include, among others, the following risks, uncertainties and factors:

expectations regarding the strategies, prospects, plans, expectations and objectives of our management for future operations of the Company;
risks associated with our ability to manage expenses and unanticipated spending and costs that could reduce our cash resources;
risks related to our ability to correctly estimate our operating expenses and other events;
changes in capital resource requirements;
our ability to obtain, maintain and protect our intellectual property rights, in particular those related to our product candidates;
our ability to advance the development of our product candidates or preclinical activities under the timelines we anticipate in planned and future clinical trials;
our ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of our product candidates;
our ability to realize the anticipated benefits of our research and development programs, strategic partnerships, licensing programs or other collaborations;
regulatory requirements or developments, and our ability to obtain necessary approvals from the U.S. Food and Drug Administration (the “FDA”) or other regulatory authorities;
our ability to manufacture product candidates in conformity with the FDA or other regulatory authorities’ requirements and to scale up manufacturing of our product candidates to commercial scale, if approved;
changes to clinical trial designs and regulatory pathways;
developments and projections relating to our expected or existing competitors or industry;
unexpected costs, charges or expenses resulting from the Reverse Merger;
legislative, regulatory, political, geopolitical and macroeconomic developments beyond our control, including inflationary pressures, general economic slowdown or a recession, high interest rates, changes in monetary policy, instability in financial institutions, the prospect of a shutdown of the U.S. federal government, the ongoing conflict in Ukraine, conflict in the Middle East and rising tensions between China and Taiwan;

ii


success in retaining, recruiting or changes required in, our officers, key employees or directors;
the liquidity and trading of our securities;
regulatory actions with respect to our product candidates or our competitors’ products and product candidates;
our ability to successfully develop and commercialize any technology that we may in-license or products we may acquire;
our ability to successfully operate in non-U.S. jurisdictions in which we may choose to do business, including compliance with applicable regulatory requirements and laws;
our reliance on third-party contract development and manufacturer organizations to manufacture and supply product candidates;
our ability to establish satisfactory pricing and obtain adequate reimbursement from government and third-party payors of products and product candidates that receive regulatory approvals, if any;
our ability to successfully commercialize product candidates, if approved, and the rate and degree of market acceptance of such product candidates;
risks related to our ability to obtain additional financing and raise capital as necessary to fund operations or pursue business opportunities;
the direct and indirect effects of widespread health emergencies on our workforce, operations, financial results and cash flows;
severe weather and seasonal factors;
our inability to continue to grow and manage our growth effectively;
our inability to comply with, and the effect on our business of, evolving legal standards and regulations, including those concerning data protection, consumer privacy and sustainability and evolving labor standards; and
our ability to remediate material weaknesses or other deficiencies in our internal control over financial reporting or to maintain effective disclosure controls and procedures and internal control over financial reporting.

 

There may be other factors that may cause our actual results or outcomes, or the timing of those results or outcomes, to differ materially from the forward-looking statements expressed or implied in this Quarterly Report on Form 10-Q, including factors disclosed in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Quarterly Report on Form 10-Q, in the section titled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in our other filings with the Securities and Exchange Commission (“SEC”). You should evaluate all forward-looking statements made in this Quarterly Report on Form 10-Q in the context of these risks and uncertainties.

 

We caution you that the risks, uncertainties and other factors referred to above and elsewhere in this Quarterly Report on Form 10-Q may not contain all of the risks, uncertainties and other factors that may affect our future results, operations and outcomes. Moreover, new risks emerge from time to time. It is not possible for us to predict all risks. In addition, we cannot assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. Past performance is not indicative of future performance.

 

Any forward-looking statements contained in this Quarterly Report on Form 10-Q apply only as of the date of this Quarterly Report on Form 10-Q and are expressly qualified in their entirety by the cautionary statements included in this Quarterly Report on Form 10-Q. Except as required by law, we disclaim any intent to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in assumptions or otherwise.

 

 

iii


Explanatory Note

Unless context otherwise requires, references to “we,” “our,” “us,” “Dianthus,” the “Company,” or the “combined company” in this Quarterly Report on Form 10-Q refer to Dianthus Therapeutics, Inc. (formerly Magenta Therapeutics, Inc.) after the completion of the Reverse Merger (as defined elsewhere in this Quarterly Report on Form 10-Q), the term “Former Dianthus” refers to Dianthus Therapeutics OpCo, Inc. (formerly Dianthus Therapeutics, Inc.), and the term “Magenta” refers to the Company prior to completion of the Reverse Merger.


 

iv


PART I—FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements (Unaudited)

DIANTHUS THERAPEUTICS, INC.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

(unaudited)

 

 

March 31,
2024

 

 

December 31,
2023

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

329,724

 

 

$

132,325

 

Short-term investments

 

 

47,312

 

 

 

41,393

 

Receivable from related party

 

 

435

 

 

 

294

 

Unbilled receivable from related party

 

 

441

 

 

 

184

 

Prepaid expenses and other current assets

 

 

3,014

 

 

 

3,255

 

Total current assets

 

 

380,926

 

 

 

177,451

 

Property and equipment, net

 

 

195

 

 

 

185

 

Right-of-use operating lease assets

 

 

530

 

 

 

615

 

Other assets and restricted cash

 

 

811

 

 

 

1,154

 

Total assets

 

$

382,462

 

 

$

179,405

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

2,612

 

 

$

2,610

 

Accrued expenses

 

 

5,847

 

 

 

6,504

 

Current portion of deferred revenue - related party

 

 

100

 

 

 

100

 

Current portion of operating lease liabilities

 

 

400

 

 

 

417

 

Total current liabilities

 

 

8,959

 

 

 

9,631

 

Deferred revenue - related party

 

 

719

 

 

 

736

 

Long-term operating lease liabilities

 

 

97

 

 

 

168

 

Total liabilities

 

 

9,775

 

 

 

10,535

 

Commitments and contingencies (Note 15)

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock; $0.001 par value per share; authorized shares – 10,000,000 
   at March 31, 2024 and December 31, 2023; issued and outstanding –
none at
   March 31, 2024 and December 31, 2023

 

 

 

 

 

 

Common stock; $0.001 par value per share; authorized shares – 150,000,000
   at March 31, 2024 and December 31, 2023; issued and outstanding
   shares –
29,348,626 and 14,817,696 at March 31, 2024 and
   December 31, 2023, respectively

 

 

29

 

 

 

15

 

Additional paid-in capital

 

 

475,856

 

 

 

258,231

 

Accumulated deficit

 

 

(103,171

)

 

 

(89,423

)

Accumulated other comprehensive (loss)/income

 

 

(27

)

 

 

47

 

Total stockholders’ equity

 

 

372,687

 

 

 

168,870

 

Total liabilities and stockholders’ equity

 

$

382,462

 

 

$

179,405

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

1


DIANTHUS THERAPEUTICS, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

(unaudited)

 

 

Three Months Ended March 31,

 

 

2024

 

 

2023

 

Revenues:

 

 

 

 

 

 

License revenue - related party

 

$

874

 

 

$

476

 

Operating expenses:

 

 

 

 

 

 

Research and development

 

 

13,078

 

 

 

5,847

 

General and administrative

 

 

5,640

 

 

 

2,312

 

Total operating expenses

 

 

18,718

 

 

 

8,159

 

Loss from operations

 

 

(17,844

)

 

 

(7,683

)

Other income/(expense):

 

 

 

 

 

 

Interest income

 

 

4,222

 

 

 

606

 

Loss on currency exchange, net

 

 

(12

)

 

 

(9

)

Other expense

 

 

(114

)

 

 

(3

)

Total other income

 

 

4,096

 

 

 

594

 

Net loss

 

$

(13,748

)

 

$

(7,089

)

Net loss per share attributable to common stockholders,
   basic and diluted

 

$

(0.54

)

 

$

(8.10

)

Weighted-average number of shares of common stock outstanding,
   used in computing net loss per share of common stock, basic and diluted

 

 

25,665,475

 

 

 

874,709

 

Comprehensive loss:

 

 

 

 

 

 

Net loss

 

$

(13,748

)

 

$

(7,089

)

Other comprehensive (loss)/income:

 

 

 

 

 

 

Change in unrealized (losses)/gains related to available-for-sale debt securities

 

 

(74

)

 

 

104

 

Total other comprehensive (loss)/income

 

 

(74

)

 

 

104

 

Total comprehensive loss

 

$

(13,822

)

 

$

(6,985

)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

2


DIANTHUS THERAPEUTICS, INC.

Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Equity/(Deficit)

(in thousands, except share data)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other

 

 

Total

 

 

Convertible Preferred Stock

 

 

 

Common Stock

 

 

Additional

 

 

Accumulated

 

 

Comprehensive

 

 

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

Paid-in Capital

 

 

Deficit

 

 

Income/(Loss)

 

 

Equity/(Deficit)

 

Balance, December 31, 2023

 

 

 

 

$

 

 

 

 

14,817,696

 

 

$

15

 

 

$

258,231

 

 

$

(89,423

)

 

$

47

 

 

$

168,870

 

Issuance of common stock and pre-funded warrants in
connection with the private placement, net of issuance costs of $
14,665

 

 

 

 

 

 

 

 

 

14,500,500

 

 

 

14

 

 

 

215,319

 

 

 

 

 

 

 

 

 

215,333

 

Exercise of stock options

 

 

 

 

 

 

 

 

 

30,430

 

 

 

 

 

 

271

 

 

 

 

 

 

 

 

 

271

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2,035

 

 

 

 

 

 

 

 

 

2,035

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(13,748

)

 

 

 

 

 

(13,748

)

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(74

)

 

 

(74

)

Balance, March 31, 2024

 

 

 

 

$

 

 

 

 

29,348,626

 

 

$

29

 

 

$

475,856

 

 

$

(103,171

)

 

$

(27

)

 

$

372,687

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2022

 

 

33,336,282

 

 

$

118,024

 

 

 

 

875,279

 

 

$

 

 

$

1,661

 

 

$

(45,868

)

 

$

(161

)

 

$

(44,368

)

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

533

 

 

 

 

 

 

 

 

 

533

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(7,089

)

 

 

 

 

 

(7,089

)

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

104

 

 

 

104

 

Balance, March 31, 2023

 

 

33,336,282

 

 

$

118,024

 

 

 

 

875,279

 

 

$

 

 

$

2,194

 

 

$

(52,957

)

 

$

(57

)

 

$

(50,820

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3


DIANTHUS THERAPEUTICS, INC.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

 

 

Three Months Ended March 31,

 

 

2024

 

 

2023

 

Cash flows from operating activities:

 

 

 

 

 

 

Net loss

 

$

(13,748

)

 

$

(7,089

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Depreciation expense

 

 

22

 

 

 

14

 

Stock-based compensation expense

 

 

2,035

 

 

 

533

 

Accretion of discount on short-term investments

 

 

(518

)

 

 

(358

)

Amortization of right-of-use operating lease assets

 

 

85

 

 

 

67

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Receivable from related party

 

 

(141

)

 

 

789

 

Unbilled receivable from related party

 

 

(257

)

 

 

377

 

Prepaid expenses and other current assets

 

 

241

 

 

 

116

 

Other assets

 

 

343

 

 

 

5

 

Accounts payable, accrued expenses and operating lease liabilities

 

 

(2,986

)

 

 

(4,729

)

Deferred revenue - related party

 

 

(17

)

 

 

(9

)

Net cash used in operating activities

 

 

(14,941

)

 

 

(10,284

)

Cash flows from investing activities:

 

 

 

 

 

 

Capital expenditures

 

 

(32

)

 

 

(14

)

Purchases of short-term investments

 

 

(20,475

)

 

 

(3,855

)

Proceeds from maturities of short-term investments

 

 

15,000

 

 

 

22,000

 

Net cash (used in)/provided by investing activities

 

 

(5,507

)

 

 

18,131

 

Cash flows from financing activities:

 

 

 

 

 

 

Proceeds from exercise of stock options

 

 

271

 

 

 

 

Proceeds from the private placement

 

 

229,998

 

 

 

 

Payment of issuance costs in connection with the private placement

 

 

(12,422

)

 

 

 

Proceeds from issuance of promissory notes payable to related party

 

 

 

 

 

377

 

Repayment of promissory notes payable to related party

 

 

 

 

 

(377

)

Net cash provided by financing activities

 

 

217,847

 

 

 

 

Increase in cash, cash equivalents and restricted cash

 

 

197,399

 

 

 

7,847

 

Cash, cash equivalents and restricted cash, beginning of period

 

 

132,391

 

 

 

15,425

 

Cash, cash equivalents and restricted cash, end of period

 

$

329,790

 

 

$

23,272

 

Supplemental Disclosure

 

 

 

 

 

 

Cash and cash equivalents

 

$

329,724

 

 

$

23,212

 

Restricted cash

 

 

66

 

 

 

60

 

Total cash, cash equivalents and restricted cash

 

$

329,790

 

 

$

23,272

 

Cash paid for interest

 

$

 

 

$

 

Cash paid for taxes

 

$

 

 

$

 

Issuance costs in connection with the private placement included in accounts payable

 

$

30

 

 

$

 

Issuance costs in connection with the private placement included in accrued expenses

 

$

2,213

 

 

$

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4


DIANTHUS THERAPEUTICS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share data, unless otherwise stated)

1. Organization, Description of Business and Liquidity

Business

Dianthus Therapeutics, Inc. (formerly Magenta Therapeutics, Inc.) (the “Company” or “Dianthus”) is a clinical-stage biotechnology company focused on developing next-generation complement therapeutics for patients with severe autoimmune and inflammatory diseases. The Company’s corporate headquarters are in New York, New York.

Currently, the Company is devoting substantially all efforts and resources toward product research and development of its product candidates. The Company has incurred losses from operations and negative operating cash flows since its inception. There can be no assurance that its research and development programs will be successful, that products developed, if any, will obtain necessary regulatory approval, or that any approved product, if any, will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its key employees, consultants, and advisors.

Reverse Merger and Pre-Closing Financing

On September 11, 2023, the Company completed its business combination with Dianthus Therapeutics OpCo, Inc. (formerly Dianthus Therapeutics, Inc.) (“Former Dianthus”) in accordance with the terms of the Agreement and Plan of Merger, dated as of May 2, 2023 (the “Merger Agreement”), by and among the Company, Dio Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”), and Former Dianthus, pursuant to which, among other matters, Merger Sub merged with and into Former Dianthus, with Former Dianthus surviving as a wholly owned subsidiary of the Company (the “Reverse Merger”). In connection with the completion of the Reverse Merger, the Company changed its name from “Magenta Therapeutics, Inc.” to “Dianthus Therapeutics, Inc.,” and the business conducted by the Company became primarily the business conducted by Former Dianthus. Unless context otherwise requires, references herein to “Dianthus,” the “Company,” or the “combined company” refer to Dianthus Therapeutics, Inc. (formerly Magenta Therapeutics, Inc.) after completion of the Reverse Merger, the term “Former Dianthus” refers to Dianthus Therapeutics OpCo, Inc. (formerly Dianthus Therapeutics, Inc.), and the term “Magenta” refers to the Company prior to completion of the Reverse Merger. The Company was incorporated in June 2015 and Former Dianthus was incorporated in May 2019.

Immediately prior to the effective time of the Reverse Merger, the Company effected a 1-for-16 reverse stock split of its common stock (the “Reverse Stock Split”). Unless noted otherwise, all references herein to share and per share amounts reflect the Reverse Stock Split.

At the effective time of the Reverse Merger, the Company issued an aggregate of 11,021,248 shares of Company common stock to the Former Dianthus stockholders, based on the exchange ratio of approximately 0.2181 shares of Company common stock for each share of Former Dianthus common stock, including those shares of Former Dianthus common stock issued upon the conversion of Former Dianthus preferred stock and those shares of the Former Dianthus common stock issued in the pre-closing financing (as defined below), resulting in 14,817,696 shares of Company common stock being issued and outstanding following the effective time of the Reverse Merger.

At the effective time of the Reverse Merger, the 2019 Stock Plan (as discussed in Note 12) was assumed by the Company, and each outstanding and unexercised option to purchase shares of Former Dianthus common stock immediately prior to the effective time of the Reverse Merger was assumed by the Company and converted into an option to purchase shares of Company common stock, with necessary adjustments to the number of shares and exercise price to reflect the exchange ratio, and each outstanding and unexercised warrant to purchase shares of Former Dianthus common stock immediately prior to the effective time of the Reverse Merger (including the Former Dianthus pre-funded warrants sold in the pre-closing financing) was converted into a warrant to purchase shares of Company common stock, with necessary adjustments to the number of shares and exercise price to reflect the exchange ratio.

5


The Reverse Merger was accounted for as a reverse recapitalization in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). Under this method of accounting, Former Dianthus was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the expectation that, immediately following the Reverse Merger: (i) Former Dianthus’ stockholders own a substantial majority of the voting rights in the combined company; (ii) Former Dianthus’ largest stockholders retain the largest interest in the combined company; (iii) Former Dianthus designated a majority (six of eight) of the initial members of the board of directors of the combined company; and (iv) Former Dianthus’ executive management team became the management team of the combined company. Accordingly, for accounting purposes: (i) the Reverse Merger was treated as the equivalent of Former Dianthus issuing stock to acquire the net assets of Magenta; (ii) the net assets of Magenta are recorded at their acquisition-date fair value in the unaudited condensed consolidated financial statements of Former Dianthus and (iii) the reported historical operating results of the combined company prior to the Reverse Merger are those of Former Dianthus. Additional information regarding the Reverse Merger is included in Note 3. Historical common stock figures of Former Dianthus have been retroactively restated based on the exchange ratio of approximately 0.2181.

On September 11, 2023, prior to the effective time of the Reverse Merger, the Company entered into a contingent value rights agreement (the “CVR Agreement”) with a rights agent, pursuant to which pre-Reverse Merger holders of Magenta common stock received one non-transferable contingent value right (each, a “CVR”) for each outstanding share of Magenta common stock held by such stockholder immediately prior to the effective time of the Reverse Merger on September 11, 2023. Subject to, and in accordance with, the terms and conditions of the CVR Agreement, each CVR represents the contractual right to receive a pro rata portion of the proceeds, if any, received by the Company as a result of (i) contingent payments made to the Company, such as milestone, royalty or earnout, when received under any pre-Reverse Merger disposition agreements related to Magenta’s pre-Reverse Merger assets and (ii) the Company’s sale of assets after the effective date of the Reverse Merger and prior to December 31, 2023, in each case, received within a three-year period following the closing of the Reverse Merger. As of March 31, 2024, no payments have been received under the CVR Agreement.

Concurrently with the execution and delivery of the Merger Agreement, and in order to provide Former Dianthus with additional capital for its development programs, Former Dianthus entered into a subscription agreement, as amended (the “Subscription Agreement”), with certain investors named therein (the “Investors”), pursuant to which, subject to the terms and conditions of the Subscription Agreement, immediately prior to the effective time of the Reverse Merger, Former Dianthus issued and sold, and the Investors purchased, (i) 2,873,988 shares of Former Dianthus common stock and (ii) 210,320 pre-funded warrants, exercisable for 210,320 shares of Former Dianthus common stock, at a purchase price of approximately $23.34 per share or $23.34 per warrant, for an aggregate purchase price of approximately $72.0 million (the “pre-closing financing”).

2024 Private Placement

On January 22, 2024, the Company entered into a securities purchase agreement for a private placement with certain institutional and accredited investors. At the closing of the private placement on January 24, 2024, the Company sold and issued 14,500,500 shares of common stock at a price per share of $12.00, and pre-funded warrants to purchase 4,666,332 shares of common stock at a purchase price of $11.999 per pre-funded warrant, which represents the per share purchase price of the common stock less the $0.001 per share exercise price for each pre-funded warrant, for an aggregate purchase price of approximately $230 million. The pre-funded warrants are exercisable at any time after the date of issuance. A holder of pre-funded warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. A holder of pre-funded warrants may increase or decrease this percentage to a percentage not in excess of 19.99% by providing at least 61 days’ prior notice to the Company.

Risks and Uncertainties

The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on its key personnel, market acceptance of products, product liability, protection of proprietary technology, ability to raise additional financing and compliance with government regulations. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve profitability.

The Company’s lead product candidate that is in development and any future product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure, and extensive compliance-reporting capabilities. Even if its product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales.

6


Liquidity

In accordance with Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the accompanying unaudited condensed consolidated financial statements were issued (the “issuance date”):

Since its inception, the Company has funded its operations primarily with outside capital and has incurred significant recurring losses, including net losses of $13.7 million and $7.1 million for the three months ended March 31, 2024 and 2023, respectively. In addition, the Company had an accumulated deficit of $103.2 million as of March 31, 2024;
The Company expects to continue to incur significant recurring losses and rely on outside capital to fund its operations for the foreseeable future; and
As of the issuance date, the Company expects that its existing cash, cash equivalents and short-term investments on hand will be sufficient to fund its obligations as they become due for at least twelve months beyond the issuance date. The Company expects that its research and development and general and administrative costs will continue to increase significantly, including in connection with conducting clinical trials and manufacturing for its existing product candidate and any future product candidates to support commercialization and providing general and administrative support for its operations, including the costs associated with operating as a public company.

In the event the Company is unable to secure additional outside capital, management will be required to seek other alternatives which may include, among others, a delay or termination of clinical trials or the development of its product candidates, temporary or permanent curtailment of the Company’s operations, a sale of assets, or other alternatives with strategic or financial partners.

The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties. Accordingly, the unaudited condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements as of March 31, 2024 and for the three months ended March 31, 2024 and 2023 have been prepared in conformity with U.S. GAAP, for interim financial information and pursuant to Article 10 of Regulation S-X of the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s audited financial statements and include only normal and recurring adjustments that the Company believes are necessary to fairly state the Company’s financial position and the results of its operations and cash flows. The results for the three months ended March 31, 2024 are not necessarily indicative of the results expected for the full fiscal year or any subsequent interim period. The unaudited condensed consolidated balance sheet as of December 31, 2023 has been derived from the audited financial statements at that date but does not include all disclosures required by U.S. GAAP for complete financial statements. Because all of the disclosures required by U.S. GAAP for complete financial statements are not included herein, these unaudited condensed consolidated financial statements and the notes accompanying them should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2023, which are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (“SEC”) on March 21, 2024. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results may differ materially from those estimates.

7


Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates including the following: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Significant estimates are used in the following areas, among others: the recognition of research and development expense, stock-based compensation expense and revenue recognition.

Cash and Cash Equivalents

All short-term, highly liquid investments with original maturities of 90 days or less are considered to be cash and cash equivalents. The carrying amounts reported in the unaudited condensed consolidated balance sheets for cash and cash equivalents are valued at cost, which approximates fair value.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and short-term investments. The Company regularly maintains deposits in accredited financial institutions in excess of federally insured limits. The Company invests its excess cash primarily in money market funds, U.S. treasury securities and U.S. government agency securities in accordance with the Company’s investment policy. The Company’s investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. The Company has not experienced any realized losses related to its cash, cash equivalents and short-term investments and management believes the Company is not exposed to significant risks of losses.

As of March 31, 2024 and December 31, 2023, the Company held cash deposits at Silicon Valley Bank (“SVB”) in excess of government insured limits. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation was appointed as receiver. No losses were incurred by the Company on deposits that were held at SVB. Management believes that the Company is not currently exposed to significant credit risk as the vast majority of the Company’s deposits were either owned directly by the Company and held in custody at a third-party financial institution or, subsequent to March 10, 2023, have been transferred to a third-party financial institution. The Company does not currently have any other significant relationships with SVB.

Short-term Investments

Short-term investments consist of investments in U.S. treasury and U.S. government agency securities. Management of the Company determines the appropriate classification of the securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. The Company classifies its short-term investments as available-for-sale pursuant to ASC 320, Investments – Debt and Equity Securities, and reports them at fair value in short-term investments with unrealized gains and losses reported as a component of accumulated other comprehensive income loss on the unaudited condensed consolidated balance sheet. Realized gains and losses and declines in value judged to be other than temporary are included as a component of interest income based on the specific identification method.

When the fair value is below the amortized cost of a marketable security, an estimate of expected credit losses is made in accordance with ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The credit-related impairment amount is recognized in the unaudited condensed consolidated statements of operations and comprehensive loss. Credit losses are recognized through the use of an allowance for credit losses account in the unaudited condensed consolidated balance sheet and subsequent improvements in expected credit losses are recognized as a reversal of an amount in the allowance account. If the Company has the intent to sell the security or it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis, then the allowance for the credit loss is written-off and the excess of the amortized cost basis of the asset over its fair value is recorded in the unaudited condensed consolidated statements of operations and comprehensive loss. There were no credit losses recorded during the three months ended March 31, 2024 or 2023.

Additional information regarding short-term investments is included in Note 4.

8


Receivable from Related Party and Unbilled Receivable from Related Party

The receivable from related party and unbilled receivable from related party results from option and license agreements with Zenas BioPharma Limited (“Zenas”), a related party. See Notes 13 and 16 for more information. The receivable represents amounts earned and billed to Zenas but not yet collected while unbilled receivable represents amounts earned but not yet billed to Zenas. The receivable and unbilled receivable are reported at net realizable value. The Company regularly evaluates the creditworthiness of Zenas and their financial condition and does not require collateral from Zenas. As of March 31, 2024 and December 31, 2023, no allowance for doubtful accounts was recorded as all accounts were considered collectible.

Property and Equipment

Property and equipment are recorded at cost. Depreciation is provided using the straight-line method over estimated useful lives of three years for computer equipment and five years for furniture and fixtures. Expenditures for major renewals and betterments that extend the useful lives are capitalized. Expenditures for normal maintenance and repairs are expensed as incurred. The cost of assets sold or abandoned, and the related accumulated depreciation are eliminated from the accounts and any gains or losses are recognized in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss of the respective period.

Leases

Operating leases are accounted for in accordance with ASU 2016-02, Leases, as amended (“ASC 842”). Right-of-use lease assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company’s leases do not provide an implicit rate, management used the Company’s incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The right-of-use asset is based on the measurement of the lease liability and includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. Rent expense for operating leases is recognized on a straight-line basis over the lease term. The Company does not have any leases classified as finance leases. Management have elected the practical expedient to exclude short-term leases from right-of-use assets and lease liabilities.

The Company’s leases do not have significant rent escalation, holidays, concessions, material residual value guarantees, material restrictive covenants or contingent rent provisions. The Company’s leases include both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component as management have elected the practical expedient to group lease and non-lease components for all leases.

Additional information and disclosures required under ASC 842 are included in Note 9.

Restricted Cash

In accordance with ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, restricted cash is included as a component of cash, cash equivalents and restricted cash in the accompanying unaudited condensed consolidated statements of cash flows. Restricted cash serves as collateral for a letter of credit securing office space. Restricted cash is recorded within other assets and restricted cash line item in the accompanying unaudited condensed consolidated balance sheet.

Fair Value Measurements

The Company calculates the fair value of assets and liabilities that qualify as financial instruments and includes additional information in the notes to the unaudited condensed consolidated financial statements when the fair value is different than the carrying value of these financial instruments.

The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. ASC Topic 820, Fair Value Measurements and Disclosures (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available.

9


Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect management’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality.

The three levels of the fair value hierarchy are described below:

Level 1 - Quoted prices in active markets for identical assets or liabilities.
Level 2 - Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs.

To the extent that a valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by management in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

Management has segregated all financial assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. The Company’s valuation techniques for its Level 2 financial assets included using quoted prices for similar assets in active markets and quoted prices for similar assets in markets that are not active.

The estimated fair value of receivable from related party, unbilled receivable from related party, accounts payable and accrued expenses approximate their carrying amounts due to the relatively short maturity of these instruments.

Additional information regarding fair value measurements is included in Note 7.

Classification of Convertible Preferred Stock

Convertible preferred stock was recorded at its original issuance price, less direct and incremental offering costs, as stipulated by its terms. The Company had applied the guidance in ASC 480-10-S99, Distinguishing Liabilities from Equity-Overall-SEC Materials, and had therefore classified the convertible preferred stock outside of stockholders’ equity/(deficit). In September 2023, all outstanding shares of convertible preferred stock were converted into shares of common stock immediately prior to the effective time of the Reverse Merger. Additional information and disclosures are included in Note 11.

Segment Information

Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s CODM is its Chief Executive Officer (“CEO”). The Company operates as a single operating segment and has one reportable segment.

License Revenue – Related Party

To date, the Company’s only revenue has been attributable to an upfront payment and cost reimbursements under the Company’s license agreement with Zenas. The Company has not generated any revenue from product sales and does not expect to generate any revenue from product sales for the foreseeable future.

10


The Company recognizes revenue pursuant to ASC 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the performance obligation is satisfied.

The Company evaluates the performance obligations promised in a contract that are based on goods and services that will be transferred to the customer and determine whether those obligations are both (i) capable of being distinct and (ii) distinct in the context of the contract. To the extent a contract includes multiple promised goods and services, the Company applies judgment to determine whether promised goods and services are both capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations.

The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential transaction price and the likelihood that the transaction price will be received. Variable consideration is included in the transaction price if, in management’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. The Company then allocates the transaction price to each performance obligation and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied.

Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company’s unaudited condensed consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve months this will be classified in current liabilities.

Additional information and disclosures required under ASC 606 are included in Note 13.

Research and Development Costs

Research and development expenses are recorded as expense, as incurred. Research and development expenses consists of (i) costs to engage contractors who specialize in the development activities of the Company; (ii) external research and development costs incurred under arrangements with third parties, such as contract research organizations and consultants; and (iii) costs associated with preclinical activities and regulatory operations.

The Company enters into consulting, research, and other agreements with commercial firms, researchers, and others for the provision of goods and services. Under such agreements, the Company may pay for services on a monthly, quarterly, project or other basis. Such arrangements are generally cancelable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided by the service providers and vendors, whereas payments are dictated by the terms of each agreement. As such, depending on the timing of payment relative to the receipt of goods or services, management may record either prepaid expenses or accrued services. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company.

Patent Costs

Patent costs are expensed as incurred and recorded within general and administrative expenses.

Income Taxes

Income taxes are recorded in accordance with ASC 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities and for loss and credit carryforwards using enacted tax rates anticipated to be in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if, based upon the weight of available evidence, it is more likely than not that some or all the deferred tax assets will not be realized.

11


The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position, as well as consideration of the available facts and circumstances. As of March 31, 2024 and December 31, 2023, the Company did not have any material uncertain tax positions. The Company recognizes interest and penalties related to uncertain tax positions, if any exist, in income tax expense.

Stock-Based Compensation

The Company accounts for stock-based compensation awards in accordance with ASC Topic 718, Compensation – Stock Compensation (“ASC 718”). ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the unaudited condensed consolidated statements of operations and comprehensive loss based on their fair values. All of the stock-based awards are subject only to service-based vesting conditions. Management estimates the fair value of the stock option awards using the Black-Scholes option pricing model, which requires the input of assumptions, including (a) the fair value of the Company’s common stock, (b) the expected stock price volatility, (c) the calculation of expected term of the award, (d) the risk-free interest rate and (e) expected dividends. Management estimates the fair value of the restricted stock awards, if any, using the fair value of the Company’s common stock. Forfeitures are recognized as they are incurred.

Prior to the Reverse Merger, management utilized valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation, to estimate the fair value of Former Dianthus common stock. Each valuation methodology included estimates and assumptions that required management’s judgment. These estimates and assumptions included objective and subjective factors, including external market conditions, the prices at which Former Dianthus sold shares of convertible preferred stock, the superior rights and preferences of the convertible preferred stock senior to Former Dianthus common stock at the time, and a probability analysis of various liquidity events, such as a public offering or sale of Former Dianthus, under differing scenarios. Changes to the key assumptions used in the valuations could have resulted in materially different fair values of Former Dianthus common stock at each valuation date. Following the Reverse Merger, the fair value of the Company’s common stock is based on the closing stock price on the date of grant as reported on the Nasdaq Capital Market.

Prior to the Reverse Merger, due to a lack of company-specific historical and implied volatility data, management based its estimate of expected volatility on the historical volatility of a representative group of companies with similar characteristics to the Company, including stage of product development and life science industry focus. Management believes the group selected had sufficiently similar economic and industry characteristics and includes companies that are most representative of the Company. Following the Reverse Merger, expected volatility at the date of grant is estimated using a “look-back” period, which coincides with the expected term, of the Company's stock price as reported on the Nasdaq Capital Market.

Management uses the simplified method, as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term. The risk-free interest rate is based on observed interest rates appropriate for the term of the awards. The dividend yield assumption is based on history and expectation of paying no dividends.

Compensation expense related to stock-based awards is calculated on a straight-line basis by recognizing the grant date fair value, over the associated service period of the award, which is generally the vesting term.

Additional information regarding stock-based compensation is included in Note 12.

Comprehensive Loss

The only component of comprehensive loss other than net loss is change in unrealized gains/losses related to available-for-sale debt securities.

12


Net Loss per Share

Basic and diluted net loss per share attributable to common stockholders are calculated in conformity with the two-class method required for participating securities. Convertible preferred stock is a participating security in distributions of the Company. During the three months ended March 31, 2023, the net loss attributable to common stockholders was not allocated to the convertible preferred shares as the holders of convertible preferred shares did not have a contractual obligation to share in losses. Under the two-class method, basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. During the three months ended March 31, 2023, the weighted-average number of shares of common stock outstanding used in the basic net loss per share calculation did not include unvested restricted common stock as these shares were considered contingently issuable shares until they vested.

Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, stock options and unvested restricted common stock, if any, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. For all periods presented, basic and diluted net loss per share were the same, as any additional share equivalents would be anti-dilutive.

Additional information is included in Note 14.

Recently Issued Accounting Pronouncements

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods beginning after December 14, 2024, with early adoption permitted. The Company is currently evaluating the guidance and has not determined the impact this standard may have on the consolidated financial statements.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures, to enhance the transparency and decision usefulness of income tax disclosures. The enhancement will provide information to better assess how an entity’s operations and related tax risks and tax planning and operational opportunities affect its tax rate and prospects for future cash flows. Investors currently rely on the rate reconciliation table and other disclosures, including total income taxes paid, to evaluate income tax risks and opportunities. ASU No. 2023-09 is effective for fiscal years beginning after December 15, 2024 and early adoption is permitted. The Company is currently evaluating the impact ASU No. 2023-09 will have on the consolidated financial statements and related disclosures.

3. Reverse Merger

As described in Note 1, Merger Sub merged with and into Former Dianthus, with Former Dianthus surviving as a wholly owned subsidiary of the Company on September 11, 2023. The Reverse Merger was accounted for as a reverse asset acquisition accounted for as a reverse recapitalization in accordance with U.S. GAAP with Former Dianthus as the accounting acquirer of Magenta. At the effective time of the Reverse Merger, substantially all of the assets of Magenta consisted of cash and cash equivalents, marketable securities, as well as other nominal non-operating assets. Under such reverse recapitalization accounting, the assets and liabilities of Magenta were recorded at their fair value in Magenta’s financial statements at the effective time of the Merger, which approximated book value due to the short-term nature. No goodwill or intangible assets were recognized.

As part of the recapitalization, the Company obtained the assets and liabilities listed below:

 

Cash and cash equivalents

 

$

69,738

 

Other current assets

 

 

2,473

 

Accrued liabilities

 

 

(616

)

Net assets acquired

 

$

71,595

 

 

With respect to the CVRs issued in connection with the Reverse Merger, the Company believes that the achievement of the milestones outlined in the CVR Agreement are highly susceptible to factors outside the Company's influence that are not expected to be resolved for a long period of time, if at all. In particular, these amounts are primarily influenced by the actions and judgments of third parties and the buyers of such assets and are based on the buyers of such assets progressing the in-process research and development assets into clinical trials, and in the case of one of the agreements, to a regulatory milestone. If the Company were to

13


record a receivable for such contingent payments, it would also record a corresponding liability. As of March 31, 2024, no receivables are recorded on the unaudited condensed consolidated balance sheet relating to such contingent payments.

 

 

4. Short-Term Investments

The following table provides a summary of short-term investments:

 

 

March 31, 2024

 

 

Amortized
Cost

 

 

Gross
Unrealized
Gain

 

 

Gross
Unrealized
Loss

 

 

Fair Value

 

Available-for-sale, short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

$

46,327

 

 

$

2

 

 

$

(27

)

 

$

46,302

 

U.S. government agency securities

 

 

1,011

 

 

 

 

 

 

(1

)

 

 

1,010

 

Total available-for-sale, short-term investments

 

$

47,338

 

 

$

2

 

 

$

(28

)

 

$

47,312

 

 

 

December 31, 2023

 

 

Amortized
Cost

 

 

Gross
Unrealized
Gain

 

 

Gross
Unrealized
Loss

 

 

Fair Value

 

Available-for-sale, short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

$

36,370

 

 

$

48

 

 

$

 

 

$

36,418

 

U.S. government agency securities

 

 

4,976

 

 

 

 

 

 

(1

)

 

 

4,975

 

Total available-for-sale, short-term investments

 

$

41,346

 

 

$

48

 

 

$

(1

)

 

$

41,393

 

 

5. Prepaid Expenses and Other Current Assets

The following table provides a summary of prepaid expenses and other current assets:

 

 

March 31,
2024

 

 

December 31,
2023

 

Prepaid materials, supplies and research and development services

 

$

1,512

 

 

$

2,155

 

Prepaid subscriptions, software and other administrative services

 

 

1,030

 

 

 

504

 

Prepaid insurance

 

 

472

 

 

 

596

 

Prepaid expenses and other current assets

 

$

3,014

 

 

$

3,255

 

 

6. Property and Equipment

The following table provides a summary of property and equipment:

 

 

March 31,
2024

 

 

December 31,
2023

 

Computer equipment

 

$

263

 

 

$

234

 

Furniture and fixtures

 

 

51

 

 

 

48

 

Subtotal

 

 

314

 

 

 

282

 

Less: accumulated depreciation

 

 

(119

)

 

 

(97

)

Property and equipment, net

 

$

195

 

 

$

185

 

 

Depreciation expense was $22 and $14 in the three months ended March 31, 2024 and 2023, respectively.

14


7. Fair Value of Financial Instruments

The following table provides a summary of financial assets measured at fair value on a recurring basis:

 

 

Fair Value at

 

 

 

 

 

 

 

 

 

 

Description

 

March 31,
2024

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Recurring Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

327,973

 

 

$

327,973

 

 

$

 

 

$

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

 

46,302

 

 

 

46,302

 

 

 

 

 

 

 

U.S. government agency securities

 

 

1,010

 

 

 

 

 

 

1,010

 

 

 

 

Total assets measured at fair value

 

$

375,285

 

 

$

374,275

 

 

$

1,010

 

 

$

 

 

 

Fair Value at

 

 

 

 

 

 

 

 

 

 

 

December 31,

 

 

 

 

 

 

 

 

 

 

Description

 

2023

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Recurring Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

131,193

 

 

$

131,193

 

 

$

 

 

$

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

 

36,418

 

 

 

36,418

 

 

 

 

 

 

 

U.S. government agency securities

 

 

4,975

 

 

 

 

 

 

4,975

 

 

 

 

Total assets measured at fair value

 

$

172,586

 

 

$

167,611

 

 

$

4,975

 

 

$

 

 

There were no transfers between levels for the three months ended March 31, 2024 or for the year ended December 31, 2023.

8. Accrued Expenses

The following table provides a summary of accrued expenses:

 

 

March 31,
2024

 

 

December 31,
2023

 

Accrued issuance costs in connection with the private placement

 

$

2,213

 

 

$

 

Accrued external research and development

 

 

1,635

 

 

 

456

 

Accrued compensation

 

 

1,443

 

 

 

5,361

 

Accrued professional fees

 

 

345

 

 

 

422

 

Other accrued expenses

 

 

211

 

 

 

265

 

Accrued expenses

 

$

5,847

 

 

$

6,504

 

 

9. Leases

The Company leases space under operating leases for administrative offices in New York, New York, and Waltham, Massachusetts and wet laboratory space in Watertown, Massachusetts. The Company also leased office space under operating leases, which had a non-cancelable lease term of less than one year and, therefore, management elected the practical expedient to exclude these short-term leases from right-of-use assets and lease liabilities.

15


The following table provides a summary of the components of lease costs and rent:

 

 

Three Months Ended March 31,

 

 

2024

 

 

2023

 

Operating lease cost

 

$

103

 

 

$

87

 

Variable lease cost

 

 

8

 

 

 

7

 

Total operating lease costs

 

$

111

 

 

$

94

 

 

The Company recorded operating lease costs of $95 and $94 within the general and administrative expenses line item in the unaudited condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2024 and 2023, respectively. The Company recorded the operating lease costs of $16 and nil within the research and development expenses line item in the unaudited condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2024 and 2023, respectively.

Maturities of operating lease liabilities, which do not include short-term leases, as of March 31, 2024, are as follows:

 

2024 (remaining 9 months)

 

$

314

 

2025

 

 

222

 

Total undiscounted operating lease payments

 

 

536

 

Less: imputed interest

 

 

(39

)

Present value of operating lease liabilities

 

$

497

 

 

 

 

 

Balance sheet classification:

 

 

 

Current portion of operating lease liabilities

 

$

400

 

Long-term operating lease liabilities

 

 

97

 

Total operating lease liabilities

 

$

497

 

 

The weighted-average remaining term of operating leases was 16 months and the weighted-average discount rate used to measure the present value of operating lease liabilities was 10.7% as of March 31, 2024.

10. Common Stock

At the closing of the private placement on January 24, 2024, the Company issued 14,500,500 shares of common stock and pre-funded warrants to purchase 4,666,332 shares of common stock with a $0.001 per share exercise price. The pre-funded warrants are exercisable at any time after the date of issuance.

At the effective time of the Reverse Merger on September 11, 2023, the Company issued an aggregate of 11,021,248 shares of Company common stock to the Former Dianthus stockholders, based on the exchange ratio of approximately 0.2181 shares of Company common stock for each share of Former Dianthus common stock, including those shares of Former Dianthus common stock issued upon the conversion of Former Dianthus preferred stock and those shares of the Former Dianthus common stock issued in the pre-closing financing. In conjunction with the pre-closing financing, the Company also issued pre-funded warrants to purchase 210,320 shares of common stock with a $0.001 per share exercise price. The pre-funded warrants are exercisable at any time after the date of issuance.

As of March 31, 2024 and December 31, 2023, the Company was authorized to issue up to 150,000,000 shares of $0.001 par value of Company common stock. As of March 31, 2024 and December 31, 2023, the Company had issued and outstanding shares of common stock of 29,348,626 and 14,817,696, respectively.

Each share of Company common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Company’s board of directors, if any. No dividends have been declared or paid by the Company through March 31, 2024.

The Company had the following shares of Company common stock reserved for future issuance as of March 31, 2024 and December 31, 2023:

 

16


 

As of March 31, 2024

 

 

As of December 31, 2023

 

Issuance of common stock upon exercise of stock options

 

 

3,097,438

 

 

 

1,749,475

 

Equity awards available for grant under stock award plans

 

 

441,590

 

 

 

879,461

 

Shares available for issuance under the Employee Stock Purchase Plan

 

 

99,578

 

 

 

37,078

 

Issuance of common stock upon exercise of warrants

 

 

4,881,329

 

 

 

214,997

 

Total common stock reserved for future issuance

 

 

8,519,935

 

 

 

2,881,011

 

 

 

11. Preferred Stock and Convertible Preferred Stock

Preferred Stock

As of March 31, 2024, the Company was authorized to issue up to 10,000,000 shares of preferred stock at a par value of $0.001. As of March 31, 2024, no shares of preferred stock were issued and outstanding.

Convertible Preferred Stock

On September 11, 2023, the Company completed the Reverse Merger with Former Dianthus in accordance with the Merger Agreement. Under the terms of the Merger Agreement, immediately prior to the effective time of the Reverse Merger, each share of Former Dianthus convertible preferred stock was converted into a share of Former Dianthus common stock. At closing of the Reverse Merger, the Company issued an aggregate of 7,269,183 shares of its common stock to Former Dianthus convertible preferred stockholders, based on the exchange ratio of approximately 0.2181 shares of Company common stock for each share of Former Dianthus common stock outstanding immediately prior to the Reverse Merger.

 

12. Stock-Based Compensation

2018 Stock Option and Incentive Plan

The Company grants stock-based awards under the Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan (the “2018 Incentive Plan”), which originally became effective on June 19, 2018 as the Magenta Therapeutics, Inc. 2018 Stock Option and Incentive Plan and was amended and restated in September 2023 and renamed the Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan. The 2018 Incentive Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, unrestricted stock awards, cash-based awards, and dividend equivalent rights. In connection with the Reverse Merger, the 2018 Incentive Plan also provided for the assumption of shares remaining available for delivery under the 2019 Stock Plan (as defined below), and such shares will be available for the granting of awards under the 2018 Incentive Plan in accordance with applicable stock exchange requirements. The Company also has outstanding stock options under the Magenta Therapeutics, Inc. 2016 Stock Option and Grant Plan, as amended (the “2016 Plan”), but is no longer granting awards under the 2016 Plan.

The 2018 Incentive Plan provides that the number of shares reserved and available for issuance under the 2018 Incentive Plan will automatically increase each January 1 by 4% of the outstanding number of shares of the Company’s common stock on the immediately preceding December 31 or such lesser number of shares as determined by the Company’s board of directors or compensation committee of the board of directors. The number of shares reserved for issuance under the 2018 Incentive Plan increased by 592,707 on January 1, 2024. Shares of common stock underlying any awards under the 2018 Incentive Plan, the 2019 Stock Plan and the 2016 Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) will be available for future awards under the 2018 Incentive Plan. As of March 31, 2024, 171,590 shares of the Company’s common stock were available for grant under the 2018 Incentive Plan.

The 2018 Incentive Plan is administered by either the board of directors or the compensation committee of the board of directors. The exercise prices, vesting and other restrictions are determined at the discretion of the administrator, except that the term of stock options and stock appreciation rights may not be greater than ten years (or five years for certain incentive stock options). Awards typically vest over 12 months to four years. The exercise price for stock options granted may not be less than the fair value of

17


common stock as of the date of grant (or 110% of the fair value of common stock for certain incentive stock options). The fair value of common stock is based on quoted market prices.

2019 Stock Plan

In July 2019, Former Dianthus’ Board of Directors adopted, and the Former Dianthus’ stockholders approved, the Dianthus Therapeutics, Inc. 2019 Stock Plan (the “2019 Stock Plan”). In connection with the Reverse Merger, the Company assumed options to purchase shares of Former Dianthus’s common stock that were outstanding under the 2019 Stock Plan immediately prior to the Reverse Merger and such options were converted into options to purchase 1,273,454 shares of Company’s common stock (the “Assumed Options”). No further awards will be made under the 2019 Stock Plan; however, the Assumed Options will remain outstanding under the 2019 Stock Plan in accordance with their terms, as adjusted to reflect the Reverse Merger.

2019 Employee Stock Purchase Plan

Employees may elect to participate in the Dianthus Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the “ESPP”). The purchase price of common stock under the ESPP is equal to 85% of the lower of the fair market value of the common stock on the offering date or the exercise date. The six-month offering periods previously began in December and June of each year. During the three months ended March 31, 2024 and 2023, there were no shares of common stock purchased under the ESPP. As of March 31, 2024, 99,578 shares remained available for issuance under the ESPP.

The ESPP provides that the number of shares reserved and available for issuance under the ESPP will automatically increase each January 1 through January 1, 2029, by the lesser of (i) 1% of the number of shares issued and outstanding on the immediately preceding December 31, (ii) 62,500 shares and (iii) such number of shares as determined by the Company’s board of directors or its appointed administrator. The number of shares reserved for issuance under the ESPP increased by 62,500 on January 1, 2024.

Stock Option Inducement Grant and Inducement Plan

In December 2023, the Company’s board of directors granted an option to purchase 96,000 shares of common stock to a new hire as an inducement grant. In February 2024, the Company’s board of directors approved the Dianthus Therapeutics, Inc. Equity Inducement Plan (the “Inducement Plan”), which provides for up to 300,000 shares of common stock for inducement awards. As of March 31, 2024, there were 270,000 shares available to be granted under the Inducement Plan.

Stock Options

The following table summarizes stock option activity for the three months ended March 31, 2024:

 

 

Number of
stock options
outstanding

 

 

Weighted
average
exercise price
per share

 

 

Weighted
average
remaining
contractual
term

 

 

Aggregate
intrinsic
value

 

 

 

 

 

 

 

 

(in years)

 

 

 

 

Balance at January 1, 2024

 

 

1,749,475

 

 

$

10.61

 

 

 

8.4

 

 

$

3,181

 

Options granted, fair value of $14.03 per share

 

 

1,400,200

 

 

 

18.10

 

 

 

 

 

 

16,669

 

Options exercised

 

 

(30,430

)

 

 

8.61

 

 

 

 

 

 

465

 

Options forfeited

 

 

(21,807

)

 

 

13.98

 

 

 

 

 

 

227

 

Balance at March 31, 2024

 

 

3,097,438

 

 

$

13.99

 

 

 

8.8

 

 

$

51,070

 

Exercisable options at March 31, 2024

 

 

776,110

 

 

$

11.81

 

 

 

7.8

 

 

$

15,598

 

Unvested options at March 31, 2024

 

 

2,321,328

 

 

$

14.72

 

 

 

9.1

 

 

$

35,472

 

 

The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the common stock for those options that had exercise prices lower than the fair value of the common stock.

The weighted average grant-date fair value per share of stock options granted during the three months ended March 31, 2024 was $14.03 per share.

18


The table below summarizes the assumptions used to determine the grant-date fair value of stock options issued, presented on a weighted average basis during the three months ended March 31, 2024 and 2023.

 

Three Months Ended March 31,

 

 

 

2024

 

 

2023

 

Risk-free interest rate

 

 

4.0

%

 

 

3.6

%

Expected term (in years)

 

 

6.0

 

 

6.1

 

Expected volatility

 

 

93.1

%

 

 

84.1

%

Expected dividend yield

 

 

0.0

%

 

 

0.0

%

Stock Warrants

In April 2021, Former Dianthus issued 4,677 warrants for the purchase of common stock at an exercise price of $1.65 per share. The warrants vested on July 30, 2023 and had a grant date fair value of $1.16 per warrant. Former Dianthus has not issued any warrants since April 2021. As of March 31, 2024, the warrants have a weighted average remaining contractual term of 7.1 years.

Stock-based Compensation Expense

The following table provides a summary of stock-based compensation expense related to stock options, restricted stock units, restricted stock, and warrants:

 

 

 

Three Months Ended March 31,

 

 

2024

 

 

2023

 

Research and development

 

$

839

 

 

$

191

 

General and administrative

 

 

1,196

 

 

 

342

 

Total stock-based compensation expense

 

$

2,035

 

 

$

533

 

 

As of March 31, 2024, there was $25.2 million of total unrecognized compensation cost related to granted stock options. The Company expects to recognize that cost over a remaining weighted-average period of 3.3 years.

13. License Revenue – Related Party

In September 2020, the Company entered into an Option Agreement with Zenas (“Zenas Option”), a related party (See Note 16). Through the Zenas Option, the Company provided Zenas an option to enter into an exclusive license agreement for the development and commercialization of products arising from its research of monoclonal antibody antagonists targeting certain specific complement proteins.

In September 2021, the Company notified Zenas that it had elected the first antibody sequence as a clinical candidate. In October 2021, Zenas notified the Company that it was exercising its option for such clinical candidate. The Zenas Option provided that upon the exercise of the option, the Company would negotiate in good faith a license agreement with Zenas pursuant to which it would grant Zenas the exclusive license with respect to the antibody sequences for the Zenas territory, which includes People’s Republic of China, including Hong Kong, Macau, and Taiwan. In accordance with Zenas Option, within 60 days following the execution of a license agreement, Zenas agreed to pay the Company a one-time payment of $1.0 million for the exercise of the corresponding option. In addition, in connection with the exercise of the Zenas Option, Zenas was required to reimburse the Company for a portion of chemistry, manufacturing, and controls-related (“CMC”) costs and expenses from the date of delivery of its option exercise notice through the execution of a license agreement.

In June 2022, the Company and Zenas executed the license agreement (“Zenas License”). The Zenas Option and Zenas License are collectively referred to as the “Zenas Agreements.” The Zenas License provides Zenas with a license in the People’s Republic of China, including Hong Kong, Macau, and Taiwan, for the development and commercialization of sequences and products under the first antibody sequence. The Company is also obligated to perform certain research and development and CMC services, and will also participate in a joint steering committee (“JSC”). Under the Zenas License, Zenas also has the right to exercise an option with respect to a second antibody sequence. If Zenas exercises the option and pays the Company the option exercise fee related to the second antibody sequence, the Company will grant Zenas an exclusive license to the sequences and products under this second antibody sequence.

19


Since the Zenas Agreements were negotiated with a single commercial objective, they are treated as a combined contract for accounting purposes. The Company assessed the Zenas Agreements in accordance with ASC 606 and concluded that it represents a contract with a customer and is within the scope of ASC 606. The Company determined that there is one combined performance obligation that consists of the license and data transfer, the research and development and CMC services, and the participation in the JSC. The Company determined that Zenas’ right to exercise an option with respect to a second antibody sequence does not represent a material right.

The consideration under the Zenas Agreements includes the following payments by Zenas to the Company: (i) a $1.0 million upfront payment upon execution of the Zenas License; (ii) an approximate $1.1 million payment representing reimbursement for a portion of development costs previously incurred by the Company; (iii) reimbursement of a portion of all CMC-related costs and expenses for the first antibody sequence through the manufacture of the first two batches of drug product; (iv) reimbursement of a portion of all non-CMC-related costs and expenses for the development of the first antibody sequence through the first regulatory approval; (v) development milestones totaling up to $11.0 million; and (vi) royalties on net sales ranging from the mid-single digits to the low teens.

The Company determined that the combined performance obligation is satisfied over time; therefore, the Company will recognize the transaction price from the license agreement over the Company’s estimated period to complete its activities. The Company concluded that it will utilize a cost-based input method to measure its progress toward completion of its performance obligation and to calculate the corresponding amount of revenue to recognize each period. The Company believes this is the best measure of progress because other measures do not reflect how the Company transfers its performance obligation to Zenas. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs expected to be incurred for the combined performance obligation. These costs consist primarily of third-party contract costs. Revenue will be recognized based on the level of costs incurred relative to the total budgeted costs for the combined performance obligation. A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligation. In making such estimates, judgment is required to evaluate assumptions related to cost estimates.

The Company also determined that the milestone payments of $11.0 million are variable consideration under ASC 606 which need to be added to the transaction price when it is probable that a significant revenue reversal will not occur. Based on the nature of the milestones, such as the regulatory approvals which are generally not within the Company’s control, the Company will not consider achievement of this milestone to be probable until the uncertainty associated with such milestone has been resolved. When it is probable that a significant reversal of revenue will not occur, the milestone payment will be added to the transaction price for which the Company recognizes revenue. As of March 31, 2024, no milestones had been achieved.

There is a sales or usage-based royalty exception within ASC 606 that applies when a license of intellectual property is the predominant item to which the royalty relates. In accordance with this royalty exception, the Company will recognize royalty revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). As of March 31, 2024, no royalty revenue had been recognized.

For the three months ended March 31, 2024 and 2023, the Company recognized related party license revenue totaling $0.9 million and $0.5 million, respectively, associated with the Zenas Agreements. As of March 31, 2024, the Company recorded a related party receivable of $0.4 million, unbilled related party receivable of $0.4 million, current deferred related party revenue of $0.1 million and noncurrent deferred related party revenue of $0.7 million on its unaudited condensed consolidated balance sheet. As of December 31, 2023, the Company recorded a related party receivable of $0.3 million, unbilled related party receivable of $0.2 million, current deferred related party revenue of $0.1 million and noncurrent deferred related party revenue of $0.7 million on its unaudited condensed consolidated balance sheet.

20


14. Net Loss Per Share

Basic and diluted net loss per share of common stock are calculated as follows:

 

 

 

Three Months Ended March 31,

 

 

2024

 

 

2023

 

Numerator:

 

 

 

 

 

 

Net loss

 

$

(13,748

)

 

$

(7,089

)

Denominator:

 

 

 

 

 

 

Weighted-average shares of common stock outstanding

 

 

25,665,475

 

 

 

875,279

 

Less: weighted-average unvested restricted shares of common stock

 

 

 

 

 

(570

)

Weighted-average shares used to compute net loss per share of common stock, basic and diluted

 

 

25,665,475

 

 

 

874,709

 

Net loss per share attributable to common stockholders, basic and diluted

 

$

(0.54

)

 

$

(8.10

)

 

The Company’s potential dilutive securities, which include convertible preferred stock, stock options, unvested restricted shares of common stock, and warrants for the purchase of common stock, have been excluded from the computation of diluted net loss per share as the effect would be antidilutive. Therefore, the weighted-average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share is the same. The following potential dilutive securities, presented on an as converted basis, were excluded from the calculation of net loss per share due to their anti-dilutive effect:

 

 

Three Months Ended March 31,

 

 

2024

 

 

2023

 

Convertible preferred stock (as converted)

 

 

 

 

 

7,269,183

 

Stock options outstanding

 

 

3,097,438

 

 

 

1,447,743

 

Unvested restricted shares of common stock

 

 

 

 

 

444

 

Warrants for the purchase of common stock

 

 

4,881,329

 

 

 

4,677

 

Total

 

 

7,978,767

 

 

 

8,722,047

 

 

15. Commitments and Contingencies

Alloy Therapeutics, LLC

In August 2019, the Company entered into a license agreement with Alloy Therapeutics, LLC (“Alloy”). The license agreement was amended in October 2022. The license agreement with Alloy grants to the Company the following:

A worldwide, non-exclusive license to use the Alloy technology solely to generate Alloy antibodies and platform assisted antibodies for internal, non-clinical research purposes, and
With respect to Alloy antibodies and platform assisted antibodies that are selected by the Company for inclusion into a partnered antibody program, a worldwide, assignable license to make, have made, use, offer for sale, sell, import, develop, manufacture, and commercialize products comprising partnered antibody programs selected from Alloy antibodies and platform assisted antibodies in any field of use.

The Company pays annual license fees and annual partnered antibody program fees totaling $0.1 million to Alloy. The Company is also obligated to pay a $0.1 million fee to Alloy if the Company sublicenses a product developed with Alloy antibodies or platform assisted antibodies. Upon the achievement, with the first selected antibody for products developed with Alloy, of (i) certain development milestones and (ii) certain commercial milestones, the Company is obligated to make additional payments to Alloy of up to $1.8 million and $11.0 million, respectively. Upon the achievement, with the second selected antibody for products developed with Alloy, of (i) certain development milestones and (ii) certain commercial milestones, the Company is obligated to make additional payments to Alloy of up to $3.1 million and $15.0 million, respectively. The Company did not record any amounts owed under the Alloy license agreement during the three months ended March 31, 2024 or 2023.

21


OmniAb, Inc.

In September 2022, the Company entered into a commercial platform license agreement and services agreement with two subsidiaries of Ligand Pharmaceuticals Incorporated. In November 2022, Ligand spun-off these subsidiaries into a separate legal entity, OmniAb, Inc. (“OmniAb”). The platform license agreement and services agreement with OmniAb grants to the Company the following.

A worldwide, non-exclusive, non-sublicensable license under the OmniAb technology to use chicken animals (solely at OmniAb’s facilities and through OmniAb personnel) for generation of OmniAb antibodies for research purposes.
A worldwide, non-exclusive license under the OmniAb technology to use rodent animals (solely at approved contract research organization (“CRO”) facilities and through approved CRO personnel) for generation of OmniAb antibodies for research purposes. Such license is non-sublicensable except to an approved CRO.

Upon the achievement of certain development milestones, the Company is obligated to make additional payments to OmniAb of up to $12.2 million. Upon the achievement of certain commercial milestones, the Company is obligated to make royalty payments in the low to mid-single digits. The Company recorded nil and $0.1 million for amounts owed under the OmniAb license agreement within research and development expenses line item in the unaudited condensed consolidated statements of operations and comprehensive loss during the three months ended March 31, 2024 and 2023, respectively.

IONTAS Limited

In July 2020, the Company entered into a collaborative research agreement with IONTAS Limited (“IONTAS”) to perform certain milestone-based research and development activities for the Company under its first development program. This agreement was amended in January 2023 to extend their services to additional development programs. IONTAS provides dedicated resources to perform the research and development activities and receives compensation for those resources as well as success-based milestone payments.

Upon the achievement, with the first development program with IONTAS, of (i) certain development milestones and (ii) certain commercial milestones, the Company is obligated to make additional payments to IONTAS of up to £3.1 million (approximately $3.9 million based on the March 31, 2024 exchange rate) and £2.3 million (approximately $2.9 million based on the March 31, 2024 exchange rate), respectively. Upon the achievement, with the second development program with IONTAS, of certain development milestones, the Company is obligated to make additional payments to IONTAS of up to £2.5 million (approximately $3.2 million based on the March 31, 2024 exchange rate). The Company recorded $0.3 million and $0.4 million during the three months ended March 31, 2024 and 2023, respectively, for amounts owed under the IONTAS collaborative research license agreement within the research and development expenses line item in the unaudited condensed consolidated statement of operations and comprehensive loss.

Indemnification Agreements

In the ordinary course of business, the Company may provide indemnification of varying scope and terms to employees, consultants, vendors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. To date, the Company has not incurred any material costs as a result of such indemnification agreements. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and has not accrued any liabilities related to such obligations in its unaudited condensed consolidated financial statements as of March 31, 2024 and December 31, 2023.

Litigation

From time to time, the Company may be exposed to litigation relating to potential products and operations. The Company is not currently engaged in any legal proceedings that are expected, individually or in the aggregate, to have a material adverse effect on its financial condition, results of operations or cash flows.

Other

As of March 31, 2024 and December 31, 2023, the Company had standing agreements with consultants, contractors or service providers whose terms do not yield material long-term commitments.

22


16. Related Party Transactions

Zenas BioPharma Limited

The Company is a party to option and license agreements with Zenas, a related party. The Company considers Zenas to be a related party because (i) Tellus BioVentures LLC (“Tellus”), whose sole member is a significant shareholder in the Company and serves as Chairman of the Board of Directors of the Company, is also a significant shareholder in Zenas and serves as Chief Executive Officer and Chairman of the Board of Directors of Zenas and (ii) Fairmount Healthcare Fund LP and Fairmount Healthcare Fund II LP (together, the “Fairmount Funds”), who are significant shareholders in the Company and have a seat on the Board of Directors of the Company, are also significant shareholders in Zenas and have a seat on the Board of Directors of Zenas. As of March 31, 2024, Tellus and affiliated entities owned approximately 5%, and the Fairmount Funds and affiliated entities owned approximately 9% of the Company’s outstanding shares. See Note 13 for more information. In connection with these agreements, the Company recognized $0.9 million and $0.5 million within the license revenue – related party line item in the unaudited condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024, the Company recorded a related party receivable of $0.4 million, unbilled related party receivable of $0.4 million, current deferred related party revenue of $0.1 million and noncurrent deferred related party revenue of $0.7 million on its unaudited condensed consolidated balance sheet. As of December 31, 2023, the Company recorded a related party receivable of $0.3 million, unbilled related party receivable of $0.2 million, current deferred related party revenue of $0.1 million and noncurrent deferred related party revenue of $0.7 million on its unaudited condensed consolidated balance sheet.

In 2020, Zenas issued 156,848 common shares to the Company in exchange for the Zenas Option. The Company determined that the fair value on the date of issuance and as of March 31, 2024 and December 31, 2023, respectively, was not material to its unaudited condensed consolidated financial statements. The Company used the measurement alternative as the measurement attribute for accounting for the Zenas common shares which does not require it to assess the fair value of the common stock at each reporting period as the fair value of the Zenas common shares is not readily determinable nor is there a reliable source for observable transactions from which the Company could determine a fair value. In addition, the Company does not have ready access to significant events occurring at Zenas. If the Company does identify observable price changes in orderly transactions for the identical or similar common shares of Zenas, the Company will measure the common shares at fair value as of the date that the observable transaction occurred.

On March 13, 2023, the Fairmount Funds issued promissory notes in the aggregate principal amount of $0.4 million to Former Dianthus at an interest rate of 4.5% per annum. On March 15, 2023, Former Dianthus repaid principal and interest in the amount of $0.4 million to the Fairmount Funds in satisfaction of its obligations under the promissory notes.

17. Subsequent Events

The Company evaluated subsequent events from March 31, 2024, the date of these unaudited condensed consolidated financial statements, through May 9, 2024, which represents the date the unaudited condensed consolidated financial statements were issued, for events requiring recording or disclosure in the unaudited condensed consolidated financial statements for the three months ended March 31, 2024. The Company concluded that no events have occurred that would require recognition or disclosure in the unaudited condensed consolidated financial statements.

23


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q. This discussion contains forward-looking statements that involve risks and uncertainties, including those described in the section titled “Special Note Regarding Forward-Looking Statements” included elsewhere in this Quarterly Report on Form 10-Q. Our actual results and the timing of selected events could differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those set forth under the section titled “Risk Factors” included elsewhere in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 21, 2024.

Overview

We are a clinical-stage biotechnology company focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. We believe our lead novel and proprietary monoclonal antibody product candidate, DNTH103, has the potential to address a broad array of complement-dependent diseases as currently available therapies or those in development leave room for improvements in efficacy, safety, and/or dosing convenience. We have purposefully engineered DNTH103 to selectively bind to only the active form of the C1s complement protein (“C1s”) and to exhibit improved potency and an extended half-life. By selectively targeting only the active form of C1s, which drives disease pathology and constitutes only a small fraction of the total protein present in circulation, we aim to reduce the amount of drug required for a therapeutic effect. We intend to deliver our product candidate through a lower dose, less frequent, self-administered, convenient subcutaneous (“S.C.”) injection suitable for a pre-filled pen.

Our most advanced product candidate, DNTH103, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of the C1s complement protein. The active form of C1s is generated during complement activation by cleavage of the inactive proenzyme C1s. As a validated complement target in the autoimmune and inflammatory field, C1s inhibition prevents further progression of the classical pathway cascade. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. Data reported from DNTH103’s Phase 1 clinical trial in 60 healthy volunteers across eight dose cohorts validates the extended half-life and potent classical pathway inhibition and supports a potentially differentiated safety profile of DNTH103. The topline data confirmed its approximately 60-day half-life and highly potent classical pathway inhibition with every two weeks S.C. dosing of 300mg/2mL surpassing the calculated IC90 of 87ug/mL, establishing DNTH103’s best-in-class potential to be the first self-administered subcutaneous injection dosed as infrequently as every two weeks to treat a range of autoimmune disorders. Based on the clinical data available to date, DNTH103 was generally well tolerated with no serious adverse events or complement-related infections. DNTH103 is designed to selectively target the active form of C1s, inhibiting only the classical pathway, while leaving the lectin and alternative pathways intact. As a result, we aim to demonstrate that DNTH103 may have a reduced risk of infections from encapsulated bacteria when compared to C5 terminal inhibitors, thus potentially avoiding a U.S. Food and Drug Administration Boxed Warning and associated Risk Evaluation and Mitigation Strategy (“REMS”). We believe that DNTH103 has the potential to yield therapeutic benefit in multiple autoimmune and inflammatory disease indications where inappropriate activation of the classical pathway cascade drives or exacerbates the disease pathology by inhibiting the ability of activated C1s to effect downstream complement activity, ameliorating complement mediated cell death and disruption of normal cellular function.

2024 Private Placement

On January 22, 2024, in order to provide us with additional capital for our development programs, we entered into a securities purchase agreement for a private placement with certain institutional and accredited investors. At the closing of the private placement on January 24, 2024, we sold and issued 14,500,500 shares of common stock at a price per share of $12.00, and pre-funded warrants to purchase 4,666,332 shares of common stock at a purchase price of $11.999 per pre-funded warrant, which represents the per share purchase price of the common stock less the $0.001 per share exercise price for each pre-funded warrant, for an aggregate purchase price of approximately $230 million.

Completion of the Reverse Merger and Pre-Closing Financing

On September 11, 2023, we completed a business combination with Former Dianthus pursuant to which, among other matters, Former Dianthus became as a wholly owned subsidiary of ours (the “Reverse Merger”). In connection with the completion of the Reverse Merger, we changed our name from “Magenta Therapeutics, Inc.” to “Dianthus Therapeutics, Inc.,” and the business conducted by us became primarily the business conducted by Former Dianthus.

24


Concurrently with the execution and delivery of the Merger Agreement, and in order to provide Former Dianthus with additional capital for its development programs, Former Dianthus entered into a subscription agreement, as amended, with certain investors named therein. Immediately prior to the effective time of the Reverse Merger, Former Dianthus sold and issued 2,873,988 shares of Former Dianthus common stock and 210,320 pre-funded warrants, exercisable for 210,320 shares of Former Dianthus common stock, at a purchase price of approximately $23.34 per share or $23.34 per warrant, for an aggregate purchase price of approximately $72 million (the “pre-closing financing”).

See Item 1 of Part I “Financial Statements––Note 1 – Organization, Description of Business and Liquidity” for additional information.

Background

Since our inception in 2019, we have devoted substantially all of our resources to conducting research and development activities (including with respect to the DNTH103 program) and undertaking preclinical studies, conducting a clinical trial and the manufacturing of the product used in our clinical trials and preclinical studies, business planning, developing and maintaining our intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these activities.

We do not own or operate, and currently have no plans to establish, any significant laboratory or manufacturing facilities. We rely, and expect to continue to rely, on third parties for the testing and manufacture of our product candidates, as well as for commercial manufacturing should any of our product candidates obtain marketing approval. We believe this strategy allows us to maintain a more efficient infrastructure by eliminating the need to invest in our own significant laboratory and manufacturing facilities, equipment, and personnel while also enabling us to focus expertise and resources on the development of our product candidates.

To date, we have funded our operations primarily with proceeds from the sale of capital stock and have raised aggregate gross proceeds of $423.5 million from private placements. As of March 31, 2024, we had cash, cash equivalents and short-term investments of $377.1 million. Based on our current operating plan, we believe that our existing cash, cash equivalents and short-term investments should be sufficient to fund our operations into the second half of 2027. Until we achieve profitability, we plan to fund our operations and capital expenditures with cash on hand and expect to seek to raise any necessary additional capital through private or public equity or debt financings, loans or other capital sources, which could include income from collaborations, partnerships or other marketing, distribution, licensing or other strategic arrangements with third parties, or from grants. There can be no assurance that we will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to us. If we are unable to raise sufficient additional capital, we will be required to seek other alternatives which may include, among others, a delay or termination of our clinical trials or the development of our product candidates, temporary or permanent curtailment of our operations, a sale of our assets, or other alternatives with strategic or financial partners.

We have incurred significant recurring losses. We generated net losses of $13.7 million and $7.1 million for the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024, we had an accumulated deficit of $103.2 million. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on a variety of factors, including the timing, scope and results of our research and development activities. We expect our expenses and capital requirements will increase substantially in connection with our ongoing activities, if and as we:

advance the DNTH103 program through clinical development, including in any additional indications;
advance discovery programs from preclinical development into and through clinical development;
seek regulatory approvals for any product candidates that successfully complete clinical trials;
establish sales, marketing and distribution infrastructure to commercialize any approved product candidates;
contract to manufacture any of our investigational or approved product candidates;
expand clinical, scientific, management and administrative teams;
maintain, expand, protect and enforce our intellectual property portfolio, including patents, trade secrets and know-how;
acquire or in-license other product candidates or technologies;
implement operational, financial and management systems; and
operate as a public company.

25


We do not have any products approved for commercial sale and we have not generated any commercial revenue from product sales. Our ability to generate product revenue sufficient to achieve and maintain profitability will depend upon the successful development and eventual commercialization of DNTH103 or any future product candidates, which we expect, if it ever occurs, will take many years. We expect to spend a significant amount on development and marketing costs prior to such time. We will therefore require substantial additional capital to develop DNTH103 and any future product candidates and to support our continuing operations. We may never succeed in achieving regulatory and marketing approval for DNTH103 or any future product candidates. We may obtain unexpected results from our preclinical and clinical trials. We may elect to discontinue, delay, or modify preclinical and clinical trials of DNTH103 or any future product candidates. A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. Accordingly, until such time that we can generate a sufficient amount of revenue from product sales or other sources, if ever, we expect to finance our operations through private or public equity or debt financings, loans or other capital sources, which could include income from collaborations, partnerships or other marketing, distribution, licensing or other strategic arrangements with third parties, or from grants. However, we may be unable to raise additional capital from these sources on favorable terms, or at all. Our failure to obtain sufficient capital on acceptable terms when needed could have a material adverse effect on our business, results of operations or financial condition, including requiring us to to seek other alternatives which may include, among others, a delay or termination of our clinical trials or the development of our product candidates, temporary or permanent curtailment of our operations, a sale of our assets, or other alternatives with strategic or financial partners. We may also be required to license rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. We cannot provide assurance that we will ever generate positive cash flow from operating activities. See the section titled “—Liquidity and Capital Resources.

Global and Macroeconomic Developments

Uncertainty in the global economy presents significant risks to our business. We are subject to continuing risks and uncertainties in connection with the current macroeconomic environment, including increases in inflation, rising interest rates, general economic slowdown or a recession, changes in foreign currency exchange rates, recent bank failures, the prospect of a shutdown of the U.S. federal government, geopolitical factors, including rising tensions between China and Taiwan, the ongoing conflict in the Middle East, the attacks on marine vessels traversing the Red Sea and the conflict between Russia and Ukraine and the responses thereto, pandemics or other public health crises and supply chain disruptions. While we are closely monitoring the impact of the current macroeconomic conditions on all aspects of our business, including the impacts on participants in our clinical trials, employees, suppliers, vendors, business partners and regulators, the ultimate extent of the impact on our business remains highly uncertain and will depend on future developments and factors that continue to evolve. Most of these developments and factors are outside of our control and could exist for an extended period of time. We will continue to evaluate the nature and extent of the potential impacts to Dianthus’ business, results of operations, liquidity and capital resources. For additional information, see the section titled “Risk Factors” found elsewhere in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 21, 2024.

Components of Results of Operations

Revenue

Since inception, we have not generated any revenue from product sales, and we do not expect to generate any revenue from the sales of products in the foreseeable future.

We are a party to an option agreement and license agreement with Zenas BioPharma Limited (“Zenas BioPharma”), a related party. In September 2020, we entered into an option agreement with Zenas BioPharma (“Zenas Option”), through which we provided Zenas BioPharma an option to enter into an exclusive license agreement for the development and commercialization of products arising from our research of monoclonal antibody antagonists targeting certain specific complement proteins. In June 2022, we and Zenas BioPharma executed a license agreement (“Zenas License Agreement”). The Zenas Option and Zenas License Agreement are collectively referred to as the “Zenas Agreements.” The Zenas License Agreement provides Zenas BioPharma with a license in the People’s Republic of China, including Hong Kong, Macau, and Taiwan, for the development and commercialization of sequences and products under the first antibody sequence.

26


Under the Zenas Agreements, the consideration payable by Zenas Biopharma includes the following: (i) a $1.0 million upfront payment upon execution of the Zenas License Agreement; (ii) an approximate $1.1 million payment representing reimbursement for a portion of development costs previously incurred by us; (iii) reimbursement of a portion of costs related to chemistry, manufacturing and control (“CMC”) and expenses for the first antibody sequence through the manufacture of the first two batches of drug product; (iv) reimbursement of a portion of non-CMC-related costs and expenses for the development of the first antibody sequence through the first regulatory approval; (v) development milestones totaling up to $11.0 million; and (vi) royalties on net sales ranging from mid-single digits to low teen percentages.

In accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”), we determined that there is one combined performance obligation that consists of the license and data transfer, the CMC and non-CMC services, and the participation in a joint steering committee, and that the combined performance obligation is satisfied over time. Therefore, we will recognize the transaction price from the license agreement over our estimated period to complete our activities. We concluded that we would utilize a cost-based input method to measure our progress toward completion of our performance obligation and to calculate the corresponding amount of revenue to recognize each period. We believe this is the best measure of progress because other measures do not reflect how we transfer our performance obligation to Zenas Biopharma. In applying the cost-based input method of revenue recognition, we use actual costs incurred relative to budgeted costs expected to be incurred for the combined performance obligation. These costs consist primarily of third-party contract costs. Revenue will be recognized based on the level of costs incurred relative to the total budgeted costs for the performance obligations. A cost-based input method of revenue recognition requires us to make estimates of costs to complete the performance obligation. In making such estimates, judgment is required to evaluate assumptions related to cost estimates.

There is a sales or usage-based royalty exception within ASC 606 that applies when a license of intellectual property is the predominant item to which the royalty relates. In accordance with this royalty exception, we will recognize royalty revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). As of March 31, 2024 and December 31, 2023, no royalty revenue had been recognized.

We also determined that the milestone payments of $11.0 million are variable consideration under ASC 606, which need to be added to the transaction price when it is probable that a significant revenue reversal will not occur. Based on the nature of the milestones, such as the regulatory approvals which are generally not within our control, we will not consider achievement of this milestone to be probable until the uncertainty associated with such milestone has been resolved. When it is probable that a significant reversal of revenue will not occur, the milestone payment will be added to the transaction price for which we recognize revenue. As of March 31, 2024 and December 31, 2023, no milestones had been achieved.

For the three months ended March 31, 2024 and 2023, we recognized related party license revenue totaling $0.9 million and $0.5 million, respectively, associated with the Zenas Agreements.

If our development efforts for DNTH103 or any future product candidates are successful and result in regulatory approval, we may generate revenue from future product sales. If we enter into license or collaboration agreements for DNTH103 or any future product candidates or intellectual property, revenue may be generated in the future from such license or collaboration agreements. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of DNTH103 or any future product candidates or from license or collaboration agreements. We may never succeed in obtaining regulatory approval for DNTH103 or any future product candidates.

Operating Expenses

Research and Development

Research and development expenses account for a significant portion of our operating expenses and consist primarily of external and internal expenses incurred in connection with the discovery and development of DNTH103 and other potential product candidates.

External expenses include:

payments to third parties in connection with research and development, including agreements with third parties such as contract research organizations (“CROs”), clinical trial sites and consultants;
the cost of manufacturing products for use in our clinical trials and preclinical studies, including payments to contract development and manufacturing organizations (“CDMOs”) and consultants; and

27


payments to third parties in connection with the preclinical development of other potential product candidates, including for outsourced professional scientific development services, consulting research and collaborative research.

Internal expenses include:

personnel-related costs, including salaries, bonuses, related benefits and stock-based compensation expenses for employees engaged in research and development functions; and
facilities-related expenses, depreciation, supplies, travel expenses and other allocated expenses.

We recognize research and development expenses in the periods in which they are incurred. Our internal resources, employees and infrastructure are not directly tied to any one research or drug discovery program and are typically deployed across multiple programs. External expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers or our estimate of the level of service that has been performed at each reporting date. We utilize CROs for research and development activities and CDMOs for manufacturing activities and we do not have significant laboratory or manufacturing facilities. Therefore, we have no material facilities expenses attributed to research and development.

Product candidates in later stages of development generally have higher development costs than those in earlier stages. As a result, we expect that our research and development expenses will increase substantially over the next several years as we advance DNTH103 into larger and later-stage clinical trials, work to discover and develop additional product candidates, seek to expand, maintain, protect and enforce our intellectual property portfolio, and hire additional research and development personnel.

The successful development of DNTH103 or any future product candidates is highly uncertain, and we do not believe it is possible at this time to accurately project the nature, timing and estimated costs of the efforts necessary to complete the development of, and obtain regulatory approval for, DNTH103 or any future product candidates. To the extent DNTH103 or any future product candidates continue to advance into larger and later-stage clinical trials, our expenses will increase substantially and may become more variable. The duration, costs and timing of development of DNTH103 or any future product candidates are subject to numerous uncertainties and will depend on a variety of factors, including:

the timing and progress of our preclinical and clinical development activities;
the number and scope of preclinical and clinical programs we pursue;
our ability to establish a favorable safety profile with IND-enabling toxicology studies to enable clinical trials;
successful patient enrollment in, and the initiation and completion of, larger and later-stage clinical trials;
per subject trial costs;
the number and extent of our clinical trials required for regulatory approval;
the countries in which our clinical trials are conducted;
the length of time required to enroll eligible subjects in our clinical trials;
the number of subjects that participate in our clinical trials;
the drop-out and discontinuation rate of subjects in our clinical trials;
potential additional safety monitoring requested by regulatory agencies;
the duration of subject participation in our clinical trials and follow-up;
the extent to which we encounter any serious adverse events in our clinical trials;
the timing of receipt of regulatory approvals from applicable regulatory authorities;
the timing, receipt and terms of any marketing approvals and post-marketing approval commitments from applicable regulatory authorities;
the extent to which we establish collaborations, strategic partnerships, or other strategic arrangements with third parties, if any, and the performance of any such third party;
hiring and retaining research and development personnel;
our arrangements with our CDMOs and CROs;

28


development and timely delivery of commercial-grade drug formulations that can be used in our planned clinical trials and for commercial launch;
the impact of any business interruptions to our operations or to those of the third parties with whom we work; and
obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights.

Any of these factors could significantly impact the costs, timing and viability associated with the development of DNTH103 or any future product candidates.

General and Administrative Expenses

General and administrative expenses primarily consist of salaries, bonuses, related benefits, and stock-based compensation expense for personnel in executive, finance, and administrative functions; professional fees for legal, consulting, accounting, and audit services; and travel expenses, technology costs and other allocated expenses. General and administrative expenses also include corporate facility costs, including insurance, rent, utilities, depreciation, and maintenance, not otherwise included in research and development expenses. We recognize general and administrative expenses in the periods in which they are incurred.

We expect that our general and administrative expenses will increase in the future to support our continued research and development activities, pre-commercial preparation activities for the product candidates and, if any product candidate receives marketing approval, commercialization activities. In addition, we anticipate that we will incur additional expenses associated with being a public company, including expenses related to accounting, audit, legal, regulatory, public company reporting and compliance, director and officer insurance, investor and public relations, and other administrative and professional services.

Other Income/(Expense)

Other income/(expense) consists primarily of interest income generated from earnings on invested cash equivalents and short-term investments.

Income Tax

Since inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research tax credits due to uncertainty of realizing a benefit from those items. We maintain a full valuation allowance on our federal and state deferred tax assets as we have concluded that it is more likely than not that the deferred assets will not be utilized.

29


Results of Operations

Comparison of the Three Months Ended March 31, 2024 and March 31, 2023

The following table summarizes our results of operations and other comprehensive loss for the periods indicated:

Three Months Ended March 31,

 

2024

 

 

2023

 

(in thousands)

 

Revenues:

 

 

 

 

 

License revenue - related party

$

874

 

 

$

476

 

Operating expenses:

 

 

 

 

 

Research and development

 

13,078

 

 

 

5,847

 

General and administrative

 

5,640

 

 

 

2,312

 

Total operating expenses

 

18,718

 

 

 

8,159

 

Loss from operations

 

(17,844

)

 

 

(7,683

)

Other income/(expense):

 

 

 

 

 

Interest income

 

4,222

 

 

 

606

 

Loss on currency exchange, net

 

(12

)

 

 

(9

)

Other expense

 

(114

)

 

 

(3

)

Total other income

 

4,096

 

 

 

594

 

Net loss

$

(13,748

)

 

$

(7,089

)

Comprehensive loss:

 

 

 

 

 

Net loss

$

(13,748

)

 

$

(7,089

)

Other comprehensive (loss)/income:

 

 

 

 

 

Change in unrealized (losses)/gains related to available-for-sale debt securities

 

(74

)

 

 

104

 

Total other comprehensive (loss)/income

 

(74

)

 

 

104

 

Total comprehensive loss

$

(13,822

)

 

$

(6,985

)

 

License Revenue—Related Party

Under the terms of the Zenas Agreements, we recognized related party license revenue of $0.9 million and $0.5 million for the three months ended March 31, 2024 and 2023, respectively. The increase was primarily due increased clinical operations activity costs associated with the commencement of DNTH103's Phase 2 clinical trial in generalized Myasthenia Gravis (“gMG”) in the first quarter of 2024.

Research and Development Expenses

Research and development expenses were $13.1 million for the three months ended March 31, 2024, as compared to $5.8 million for the three months ended March 31, 2023, an increase of $7.3 million. This increase was due to (1) a $4.7 million increase in external research and development costs, consisting of preclinical study costs, CMC activities, third-party consulting services, clinical operation activities, license and milestone payments and discovery activities and (2) a $2.6 million increase in internal research and development costs, consisting of personnel and related costs, stock-based compensation expense, and other costs.

The $4.7 million increase in external research and development costs was due to a $4.6 million increase in expenses related to our lead product candidate, DNTH103, and a $0.1 million increase in discovery activities. For three months ended March 31, 2024, as compared to the three months ended March 31, 2023, there were increases related to DNTH103 of $2.6 million in clinical operations activities, $2.3 million in CMC activities and $0.3 million in third-party consulting services partially offset by a decrease related to DNTH103 of $0.6 million in preclinical study costs. The increased amount of DNTH103-related costs in clinical operations, CMC and consulting results from activities related to the commencement of a Phase 2 clinical trial in gMG in the first quarter of 2024 along with preparations to initiate additional Phase 2 clinical trials in Multifocal Motor Neuropathy in the second quarter of 2024 and Chronic Inflammatory Demyelinating Polyneuropathy in the second half of 2024. The decreased amounts of DNTH103-related preclinical study costs results from the substantial completion of a chronic toxicology study in the second half of 2023. The $0.1 million increase in discovery expenses related to development activities of potential molecules beyond DNTH103 in the three months ended March 31, 2024.

30


The $2.6 million increase in internal research and development costs was due to a $1.8 million increase in personnel and related costs, a $0.6 million increase in share-based compensation, and a $0.2 million increase in other costs. The increases were due to building out the research and development function to support multiple planned Phase 2 clinical trials.

General and Administrative Expenses

General and administrative expenses were $5.6 million for the three months ended March 31, 2024, as compared to $2.3 million for the three months ended March 31, 2023, an increase of $3.3 million. The increase was primarily due to increases of $0.8 million in personnel-related costs, $0.9 million in stock-based compensation expense, $0.7 million in professional services costs, $0.6 million in consulting costs and $0.3 million in other costs. The increases were due to building out the general and administrative function to operate as a public company and support our ongoing and multiple planned Phase 2 clinical trials.

Other Income/(Expense)

Other income/(expense) was $4.1 million for the three months ended March 31, 2024, as compared to $0.6 million for the three months ended March 31, 2023, an increase of $3.5 million. The increase was primarily due to an increase of $3.6 million in interest income from a larger investment balance and higher interest rates on investments.

Income Tax

The provision for income taxes consists primarily of income taxes related to federal and state jurisdictions in which we conduct business. We maintain a full valuation allowance on our federal and state deferred tax assets as we have concluded that it is more likely than not that the deferred assets will not be utilized.

Liquidity and Capital Resources

Sources of Liquidity

Since inception, we have not generated any revenue from product sales and have incurred significant operating losses and negative cash flows from operations. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we advance the clinical development of our lead product candidate, DNTH103, or any future product candidates. We expect that our research and development and general and administrative costs will continue to increase significantly, including in connection with conducting clinical trials and manufacturing for our lead product candidate or any future product candidates to support potential future commercialization and providing general and administrative support for our operations, including the costs associated with operating as a public company. As a result, we will need additional capital to fund our operations, which we may obtain from additional equity or debt financings, collaborations, licensing arrangements or other sources. See the section titled “Risk Factors” found elsewhere in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 21, 2024 for additional risks associated with our substantial capital requirements.

To date, we have funded our operations primarily through private placements of capital stock for gross proceeds of $423.5 million.

Future Capital Requirements

Since inception, we have not generated any revenue from product sales. We do not expect to generate any meaningful product revenue unless and until we obtain regulatory approval of and commercialize DNTH103 or any future product candidates, and we do not know when, or if, that will occur. Until we can generate significant revenue from product sales, if ever, we will continue to require substantial additional capital to develop DNTH103 or any future product candidates and fund operations for the foreseeable future. We expect our expenses to increase in connection with our ongoing activities as described in greater detail below. We are subject to all the risks involved in the development of new biopharmaceutical products, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may harm our business.

In order to complete the development of DNTH103 or any future product candidates and to build the sales, marketing and distribution infrastructure that we believe will be necessary to commercialize product candidates, if approved, we will require substantial additional capital. Accordingly, until such time that we can generate a sufficient amount of revenue from product sales or other sources, if ever, we expect to seek to raise any necessary additional capital through private or public equity or debt financings, loans or other capital sources, which could include income from collaborations, partnerships or other marketing, distribution, licensing or other strategic arrangements with third parties, or from grants. To the extent that we raise additional capital through equity financings or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these

31


securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, including restricting our operations and limiting our ability to incur liens, issue additional debt, pay dividends, repurchase our common stock, make certain investments or engage in merger, consolidation, licensing, or asset sale transactions. If we raise capital through collaborations, partnerships, and other similar arrangements with third parties, we may be required to grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. We may be unable to raise additional capital from these sources on favorable terms, or at all. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from recent bank failures, other general macroeconomic conditions and otherwise. Our failure to obtain sufficient capital on acceptable terms when needed could have a material adverse effect on our business, results of operations or financial condition, including requiring us to to seek other alternatives which may include, among others, a delay or termination of our clinical trials or the development of our product candidates, temporary or permanent curtailment of our operations, a sale of our assets, or other alternatives with strategic or financial partners. We cannot provide assurance that we will ever generate positive cash flow from operating activities.

To date, we have funded our operations primarily with proceeds from the sale of capital stock and have raised aggregate gross proceeds of $423.5 million. However, we have incurred significant recurring losses. We had an accumulated deficit of $103.2 million as of March 31, 2024. As of March 31, 2024, we had cash, cash equivalents and short-term investments of $377.1 million. Based on our current operating plan, we believe that our existing cash, cash equivalents and short-term investments should be sufficient to fund our operations into the second half of 2027. Until we achieve profitability, we plan to fund our operations and capital expenditures with cash on hand and expect to seek to raise any necessary additional capital through private or public equity or debt financings, loans or other capital sources, which could include income from collaborations, partnerships or other marketing, distribution, licensing or other strategic arrangements with third parties, or from grants. There can be no assurance that we will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to us. Our failure to obtain sufficient capital on acceptable terms when needed could have a material adverse effect on our business, results of operations or financial condition, including requiring us to to seek other alternatives which may include, among others, a delay or termination of our clinical trials or the development of our product candidates, temporary or permanent curtailment of our operations, a sale of our assets, or other alternatives with strategic or financial partners.

We based projections of operating capital requirements on our current operating plan, which includes several assumptions that may prove to be incorrect, and we may use all of our available capital resources sooner than we expect.

Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact amount and timing of our capital requirements. Our future funding requirements will depend on many factors, including:

the scope, timing, progress, results, and costs of researching and developing DNTH103, and conducting larger and later-stage clinical trials;
the scope, timing, progress, results, and costs of researching and developing other future product candidates that we may pursue;
the costs, timing, and outcome of regulatory review of our product candidates;
the costs of future activities, including product sales, medical affairs, marketing, manufacturing, and distribution, for any of our product candidates for which we receive marketing approval;
the costs of manufacturing commercial-grade products and sufficient inventory to support commercial launch;
the revenue, if any, received from commercial sale of our products, should any of product candidates receive marketing approval;
the cost and timing of attracting, hiring, and retaining skilled personnel to support our operations and continued growth;
the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;
our ability to establish, maintain, and derive value from collaborations, partnerships or other marketing, distribution, licensing, or other strategic arrangements with third parties on favorable terms, if at all;
the extent to which we acquire or in-license other product candidates and technologies, if any; and
the costs associated with operating as a public company.

32


A change in the outcome of any of these or other factors with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we may need additional capital to meet the capital requirements associated with such operating plans.

Cash Flows

The following table summarizes our cash flows for the periods indicated:

 

Three Months March 31,

 

2024

 

 

2023

 

(in thousands)

 

Net cash used in operating activities

$

(14,941

)

 

$

(10,284

)

Net cash (used in)/provided by investing activities

 

(5,507

)

 

 

18,131

 

Net cash provided by financing activities

 

217,847

 

 

 

 

Increase in cash, cash equivalents and restricted cash

$

197,399

 

 

$

7,847

 

 

Cash Flows from Operating Activities

For the three months ended March 31, 2024, net cash used in operating activities consisted of a net loss of $13.7 million and an increase in net operating assets and liabilities of $2.8 million, partially offset by net non-cash operating expenses of $1.6 million. The increase in net operating assets and liabilities was primarily attributable to a decrease in accounts payable, accrued expenses and lease liabilities of $3.0 million and increases in unbilled receivable from Zenas BioPharma of $0.3 million and receivable from Zenas BioPharma of $0.1 million, partially offset by decreases in prepaid expenses and other current assets of $0.3 million and other assets of $0.3 million. The non-cash operating expenses consisted mainly of stock-based compensation expense of $2.0 million and amortization of right-of-use lease assets of $0.1 million, partially offset by accretion of discount on short-term investments of $0.5 million.

For the three months ended March 31, 2023, net cash used in operating activities consisted of a net loss of $7.1 million and an increase in net operating assets and liabilities of $3.4 million, partially offset by net non-cash operating expenses of $0.2 million. The increase in net operating assets and liabilities was primarily due to a decrease in accounts payable, accrued expenses and lease liabilities of $4.7 million, partially offset by decreases in receivable from Zenas BioPharma of $0.8 million, unbilled receivable from Zenas BioPharma of $0.4 million and prepaid expenses and other current assets of $0.1 million. The non-cash operating expenses consisted mainly of stock-based compensation expense of $0.5 million and amortization of right-of-use lease assets of $0.1 million, partially offset by accretion of discount on short-term investments of $0.4 million.

Cash Flows from Investing Activities

For the three months ended March 31, 2024, net cash used in investing activities consisted of $20.5 million of purchases of short-term investments, partially offset by $15.0 million of proceeds from maturities of short-term investments.

For the three months ended March 31, 2023, net cash provided by investing activities consisted of $22.0 million of proceeds from maturities of short-term investments, partially offset by $3.9 million of purchases of short-term investments.

Cash Flows from Financing Activities

For the three months ended March 31, 2024, net cash provided by financing activities primarily consisted of $217.5 million of net proceeds from the private placement and $0.3 million of proceeds from the exercise of stock options.

For the three months ended March 31, 2023, net cash provided by financing activities consisted of $0.4 million of proceeds from promissory notes payable to related party, offset by a $0.4 million repayment of promissory notes payable to related party.

Contractual Obligations and Commitments

Lease Obligations

We lease space under operating leases agreements for administrative offices in New York, New York, and Waltham, Massachusetts and wet laboratory space in Watertown, Massachusetts, which expire in August 2025, January 2025 and August 2025, respectively.

33


 

Research and Development and Manufacturing Agreements

We enter into agreements with certain vendors for the provision of goods and services, which includes manufacturing services with CDMOs and development and clinical trial services with CROs. These agreements may include certain provisions for purchase obligations and termination obligations that could require payments for the cancellation of committed purchase obligations or for early termination of the agreements. The amount of the cancellation or termination payments vary and are based on the timing of the cancellation or termination and the specific terms of the agreement. These obligations and commitments are not presented separately.

License and Collaboration Agreements

In August 2019, Former Dianthus entered into a license agreement with Alloy Therapeutics, LLC (“Alloy”) for (i) a worldwide, non-exclusive license to use the Alloy technology solely to generate Alloy antibodies and platform assisted antibodies for internal, non-clinical research purposes, and (ii) with respect to Alloy antibodies and platform assisted antibodies that are selected by us for inclusion into a partnered antibody program, a worldwide, assignable license to make, have made, use, offer for sale, sell, import, develop, manufacture, and commercialize products comprising partnered antibody programs selected from Alloy antibodies and platform assisted antibodies in any field of use. In addition to annual license fees, we are obligated to pay development and commercial milestone payments of up to $12.8 million for the first partnered antibody, which has been selected for the DNTH103 program. The license agreement was amended in October 2022 to extend the agreement to a potential second partnered antibody. In addition to annual license fees, we are obligated to pay development and commercial milestone payments of up to $18.1 million for a second partnered antibody, if and when selected.

In September 2022, Former Dianthus entered into a commercial platform license agreement and services agreement with two subsidiaries of Ligand Pharmaceuticals Incorporated (“Ligand”). In November 2022, Ligand spun-off these subsidiaries into a separate legal entity, OmniAb, Inc. (“OmniAb”), for (i) a worldwide, non-exclusive, non-sublicensable license under the OmniAb technology to use chicken animals for generation of OmniAb antibodies for research purposes and (ii) a worldwide, non-exclusive license under the OmniAb technology to use rodent animals for generation of OmniAb antibodies for research purposes. In addition to annual license fees, we are obligated to pay development milestones payments of up to $12.2 million and to pay royalties in the low to mid-single digits.

In July 2020, Former Dianthus entered into a collaborative research agreement with IONTAS Limited (“IONTAS”) to perform certain milestone-based research and development activities under our first development program. The agreement was amended in January 2023 to extend services to additional development programs. We are obligated to pay development and commercial milestone payments of up to £5.4 million (approximately $6.8 million based on the March 31, 2024 exchange rate) with the first development program and of up to £2.5 million (approximately $3.2 million based on the March 31, 2024 exchange rate) with the second development program.

 

34


Critical Accounting Policies and Estimates

Our financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). The preparation of the financial statements and related disclosures requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate estimates and assumptions on a periodic basis. Our actual results may differ materially from these estimates.

We believe that the following accounting policies are critical to understanding our historical and future performance, as the policies relate to the more significant areas involving management’s judgments and estimates used in the preparation of our financial statements.

Research and Development Expenses

Research and development expenses are recorded as an expense, as incurred. Research and development expenses consists of (i) costs to engage contractors who specialize in our development activities; (ii) external research and development costs incurred under arrangements with third parties, such as CROs, CDMOs and consultants; and (iii) costs associated with preclinical and clinical activities and regulatory operations.

We enter consulting, research, and other agreements with commercial firms, researchers, and others for the provision of goods and services. Under such agreements, we may pay for services on a monthly, quarterly, project or other basis. Such arrangements are generally cancelable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided to us by our service providers or our estimate of the level of service that has been performed at each reporting date, whereas payments are dictated by the terms of each agreement. As such, depending on the timing of payment relative to the receipt of goods or services, we may record either prepaid expenses or accrued services. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on our behalf.

We make estimates of our accrued expenses as of each balance sheet date in our unaudited condensed consolidated financial statements based on facts and circumstances known to us at that time. There may also be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing expenses, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.

Stock-Based Compensation

We account for stock-based compensation awards in accordance with ASC Topic 718, Compensation—Stock Compensation, (“ASC 718”). ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations and comprehensive loss based on their fair values. All of our stock option awards are subject only to service-based vesting conditions. We estimate the fair value of our stock-based awards using the Black-Scholes option pricing model, which requires the input of assumptions, including (a) the fair value of the common stock, (b) the expected stock price volatility, (c) the calculation of expected term of the award, (d) the risk-free interest rate and (e) expected dividends. We estimate the fair value of the restricted stock awards using the fair value of our common stock. Forfeitures are recognized as they are incurred.

35


Prior to the Reverse Merger, management utilized valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation, to estimate the fair value of Former Dianthus’ common stock. Each valuation methodology included estimates and assumptions that required our judgment. These estimates and assumptions included objective and subjective factors, including external market conditions, the prices at which Former Dianthus sold shares of convertible preferred stock, the superior rights and preferences of the convertible preferred stock senior to Former Dianthus’ common stock at the time, and a probability analysis of various liquidity events, such as a public offering or sale of Former Dianthus, under differing scenarios. Changes to the key assumptions used in the valuations could have resulted in materially different fair values of Former Dianthus’ common stock at each valuation date. Following the Reverse Merger, the fair value of our common stock is based on the closing stock price on the date of grant as reported on the Nasdaq Capital Market.

Prior to the Reverse Merger, due to a lack of company-specific historical and implied volatility data, we based our estimate of expected volatility on the historical volatility of a representative group of companies with similar characteristics to us, including stage of product development and life science industry focus. We believed the group selected had sufficiently similar economic and industry characteristics and included companies that were most representative of us. Following the Reverse Merger, expected volatility at the date of grant is estimated using a “look-back” period, which coincides with the expected term, of our stock price as reported on the Nasdaq Capital Market.

We use the simplified method, as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term. The risk-free interest rate is based on observed interest rates appropriate for the term of the awards. The dividend yield assumption is based on history and expectation of paying no dividends.

Compensation expense related to stock-based awards is calculated on a straight-line basis by recognizing the grant date fair value, over the associated service period of the award, which is generally the vesting term.

Revenue Recognition—Zenas Agreements

We analyze the Zenas Agreements pursuant to ASC 606. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. As part of the accounting for contracts with customers, management develops assumptions that require judgment to determine whether promised goods and services represent distinct performance obligations and the standalone selling price for each performance obligation identified in the contract. This evaluation is subjective and requires us to make judgments about the promised goods and services and whether those goods and services are separable from other aspects of the contract. Further, determining the standalone selling price for performance obligations requires significant judgment, and when an observable price of a promised good or service is not readily available, we consider relevant assumptions to estimate the standalone selling price, including, as applicable, market conditions, development timelines, probabilities of technical and regulatory success and forecasted revenues.

We evaluate the performance obligations promised in the contract that are based on goods and services that will be transferred to the customer and determined whether those obligations are both (i) capable of being distinct and (ii) distinct in the context of the contract. Goods or services that meet these criteria are considered distinct performance obligations. We estimate the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that includes variable consideration, we evaluate the amount of potential transaction price and the likelihood that the transaction price will be received. We utilize either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.

We apply judgment in determining whether a combined performance obligation is satisfied at a point in time or over time, and, if over time, concluding upon the appropriate method of measuring progress to be applied for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, as estimates related to the measure of progress change, related revenue recognition is adjusted accordingly. Changes in the estimated measure of progress are accounted for prospectively as a change in accounting estimate.

36


When two or more contracts are entered into with the same customer at or near the same time, we evaluate the contracts to determine whether the contracts should be accounted for as a single arrangement. Contracts are combined and accounted for as a single arrangement if one or more of the following criteria are met: (i) the contracts are negotiated as a package with a single commercial objective; (ii) the amount of consideration to be paid in one contract depends on the price or performance of the other contract; or (iii) the goods or services promised in the contracts (or some goods or services promised in each of the contracts) are a single performance obligation.

Because the Zenas Agreements were negotiated with a single commercial objective, they are treated as a combined contract for accounting purposes. We assessed the Zenas Agreements in accordance with ASC 606 and concluded that it represents a contract with a customer and is within the scope of ASC 606. We determined that there is one combined performance obligation that consists of the license and data transfer, the research and development services, and the participation in the joint steering committee. We determined that Zenas BioPharma’s right to exercise an option with respect to a second antibody sequence does not represent a material right.

We determined that the combined performance obligation is satisfied over time; therefore, we will recognize the transaction price from the license agreement over our estimated period to complete our activities. We concluded that we would utilize a cost-based input method to measure our progress toward completion of our performance obligation and to calculate the corresponding amount of revenue to recognize each period. We believe this is the best measure of progress because other measures do not reflect how we transfer our performance obligation to Zenas Biopharma. In applying the cost-based input method of revenue recognition, we use actual costs incurred relative to budgeted costs expected to be incurred for the combined performance obligation. These costs consist primarily of third-party contract costs. Revenue will be recognized based on the level of costs incurred relative to the total budgeted costs for the performance obligations. A cost-based input method of revenue recognition requires us to make estimates of costs to complete our performance obligation. In making such estimates, judgment is required to evaluate assumptions related to cost estimates. We will re-evaluate the estimate of expected costs to satisfy the performance obligation each reporting period and will make adjustments for any significant changes.

Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements. Where applicable, amounts are recorded as unbilled revenue when our right to consideration is unconditional. We do not assess whether a contract with a customer has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less.

37


Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are a smaller reporting company, as defined by Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item.

Item 4. Controls and Procedures.

Management’s Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2024. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, due to the previously identified material weaknesses described below, our disclosure controls and procedures were not effective as of March 31, 2024. A material weakness (as defined in Rule 12b-2 under the Exchange Act) is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

As previously disclosed in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, filed with the SEC on November 9, 2023, we previously identified material weaknesses in our internal control over financial reporting related to: (a) our general segregation of duties, including the review and approval of journal entries as well as system access that has not been designed to allow for effective segregation of duties, which limits our ability to perform sufficient reviews and approval of journal entries posted to the general ledger and to consistently execute review procedures over general ledger account reconciliations, financial statement preparation and accounting for vendor and payroll transactions; and (b) our accounting software system has certain system limitations, including limited user access controls and change management controls, which limits our ability to ensure appropriate authorization and segregation of duties when processing transactions. We have concluded that these material weaknesses in our internal control over financial reporting are due to the fact that we have limited resources and do not have the necessary business processes and related internal controls formally designed and implemented coupled with the appropriate resources to oversee our business processes and controls. These material weaknesses did not result in any identified material misstatements to the financial statements, and there were no changes to previously released financial results. However, the deficiencies created a reasonable possibility that material misstatements to the unaudited condensed consolidated financial statements would not be prevented or detected on a timely basis.

Management has analyzed the material weaknesses and performed additional analysis and procedures in preparing our unaudited condensed consolidated financial statements. We have concluded that our unaudited condensed consolidated financial statements fairly present, in all material respects, our financial condition, results of operations and cash flows at and for the periods presented.

 

Remediation Efforts to Address Material Weaknesses

We are in the process of implementing measures designed to improve our internal control over financial reporting to remediate the material weaknesses identified above. Our planned remediation actions include the following:

Formalizing our internal control documentation and strengthening supervisory reviews by our management;
Adding additional accounting personnel and segregating duties among accounting personnel; and
Implementing new applications and systems that focus on creating strong internal controls, including user access controls and defined approval processes for posting of journal entries, recording of vendor invoices, payments expenses, payroll processing and general ledger maintenance.

38


We are currently working to improve our internal processes and implement enhanced controls, as described above, to address the material weaknesses in our internal control over financial reporting and to remedy the ineffectiveness of our disclosure controls and procedures. These material weaknesses will not be considered to be remediated until the applicable controls have operated for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively. We are committed to continuing to improve our internal control processes, and, as we continue to evaluate and work to improve our internal control over financial reporting, we may take additional measures to address control deficiencies, or we may modify certain of the remediation measures described above.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting during the quarter ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

39


PART II—OTHER INFORMATION

From time to time, we may be involved in litigation and other legal proceedings arising in the ordinary course of our business. We are not currently a party to or aware of any legal proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition, results of operations or cash flows. The outcome of any claims or litigation, regardless of the merits, is inherently uncertain. Regardless of the outcome, litigation and other legal proceedings can have a material adverse impact on us, our business, financial condition, results of operations or cash flows because of defense and settlement costs, diversion of management resources, in the case of intellectual property claims, requirements to change our product candidates, change our business practices, pay monetary damages or enter into short- or long-term royalty or licensing agreements, and other factors.

Item 1A. Risk Factors.

You should carefully consider the risks, uncertainties and other factors contained in the risks factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023, as well as the other information in this Quarterly Report on Form 10-Q, including our unaudited condensed consolidated financial statements and related notes and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and in our other public filings, in evaluating our business. The occurrence of any of the events or developments described in the above-mentioned risk factors could materially harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline. Additional risks, uncertainties and other factors not presently known to us or that we currently deem immaterial also may harm our business, financial condition, results of operations and growth prospects.

 

40


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Recent Sales of Unregistered Equity Securities

Except as disclosed in a Current Report on Form 8-K filed with the SEC on January 22, 2024, there were no other sales of unregistered equity securities during the quarter ended March 31, 2024.

Issuer Purchases of Equity Securities

We did not repurchase any of our equity securities during the quarter ended March 31, 2024.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

(c) Trading Plans. During the quarter ended March 31, 2024, no director or Section 16 officer adopted or terminated any Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements (in each case, as defined in Item 408(a) of Regulation S-K).

41


Item 6. Exhibits.

 

Exhibit

Number

Description

2.1†

 

Agreement and Plan of Merger, dated as of May 2, 2023, by and among Magenta Therapeutics, Inc., Dio Merger Sub, Inc. and Dianthus Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 to the Registrant's Current Report on Form 8-K filed with the SEC on May 3, 2023).

3.1

 

Fifth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on September 12, 2023).

3.2

 

Third Amended and Restated By-laws (incorporated by reference to Exhibit 3.2 to the Registrant’s Annual Report on Form 10-K filed with the SEC on March 21, 2024).

4.1

 

Form of Pre-Funded Warrant of Dianthus Therapeutics, Inc. (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on January 22, 2024).

4.2

 

Registration Rights Agreement, dated January 22, 2024, by and among Dianthus Therapeutics, Inc. and certain parties thereto (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on January 22, 2024).

10.1

 

Securities Purchase Agreement, dated as of January 22, 2024, by and between the Registrant and each purchaser identified in Annex A thereto (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on January 22, 2024).

10.2#

 

Dianthus Therapeutics, Inc. 2019 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.6 to the Registrant's Annual Report on Form 10-K filed with the SEC on March 21, 2024).

10.3#

 

Form of Stock Option Agreement for Executives under the Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.8 to the Registrant’s Annual Report on Form 10-K filed with the SEC on March 21, 2024).

10.4#

 

Dianthus Therapeutics, Inc. Equity Inducement Plan (incorporated by reference to Exhibit 99.2 to the Registrant’s Registration Statement on Form S-8 filed with the SEC on March 21, 2024).

31.1*

Principal Executive Officer Certification Pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*

Principal Financial Officer Certification Pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1**

Certifications Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.

101.SCH

 

Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

* Filed herewith.

** Furnished herewith. The certifications on Exhibit 32.1 hereto are deemed not “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.

† The annexes, schedules and certain exhibits to the Merger Agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. Dianthus Therapeutics, Inc. hereby agrees to furnish supplementally a copy of any omitted annex, schedule or exhibit to the SEC upon request.

# Management contract or compensatory plan or arrangement.

 

42


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

DIANTHUS THERAPEUTICS, INC.

Date: May 9, 2024

By:

/s/ Marino Garcia

Name: Marino Garcia

Title: President and Chief Executive Officer

(Principal Executive Officer)

 

 

DIANTHUS THERAPEUTICS, INC.

Date: May 9, 2024

By:

/s/ Ryan Savitz

Name: Ryan Savitz

Title: Chief Financial Officer and Chief Business Officer

(Principal Financial Officer)

 

 

43


EX-31.1 2 dnth-ex31_1.htm EX-31.1 EX-31.1

Exhibit 31.1

 

PRINCIPAL EXECUTIVE OFFICER CERTIFICATION PURSUANT TO RULES 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

 

I, Marino Garcia, certify that:

1.
I have reviewed this report on Form 10-Q of Dianthus Therapeutics, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Date:

May 9, 2024

By:

/s/ Marino Garcia

 

 

 

Marino Garcia

 

 

 

President and Chief Executive Officer

 

 

 

(Principal Executive Officer)

 


EX-31.2 3 dnth-ex31_2.htm EX-31.2 EX-31.2

Exhibit 31.2

 

PRINCIPAL FINANCIAL OFFICER CERTIFICATION PURSUANT TO RULES 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

 

I, Ryan Savitz, certify that:

 

1.
I have reviewed this report on Form 10-Q of Dianthus Therapeutics, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Date:

May 9, 2024

By:

/s/ Ryan Savitz

 

 

 

Ryan Savitz

 

 

 

Chief Financial Officer and Chief Business Officer

 

 

 

(Principal Financial Officer)

 


EX-32.1 4 dnth-ex32_1.htm EX-32.1 EX-32.1

Exhibit 32.1

 

CERTIFICATIONS PURSUANT TO 18 U.S.C.

SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Dianthus Therapeutics, Inc. (the “Company”) on Form 10-Q for the three months ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Marino Garcia, President and Chief Executive Officer of the Company, and Ryan Savitz, Chief Financial Officer and Chief Business Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to our knowledge:

 

(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date:

May 9, 2024

By:

/s/ Marino Garcia

 

 

 

Marino Garcia

 

 

 

President and Chief Executive Officer

 

 

 

(Principal Executive Officer)

 

 

 

 

Date:

May 9, 2024

By:

/s/ Ryan Savitz

 

 

 

Ryan Savitz

 

 

 

Chief Financial Officer and Chief Business Officer

 

 

 

(Principal Financial Officer)

 


EX-101.SCH 5 dnth-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets (unaudited) link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity/(Deficit) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity/(Deficit) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Organization, Description of Business and Liquidity link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Reverse Merger link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Short-Term Investments link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Restructuring and Other Charges link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Assets Sale link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Preferred Stock and Convertible Preferred Stock link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - License Revenue - Related Party link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - 401(k) Savings Plan link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Reverse Merger (Tables) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Short-Term Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Restructuring and Other Charges (Tables) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Preferred Stock and Convertible Preferred Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Organization, Description of Business and Liquidity - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Reverse Merger - Schedule of Company Obtained Assets and Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Short-Term Investments - Schedule of Short-term Investments (Detail) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Property and Equipment - Schedule of Property and Equipment, Net (Detail) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Property and Equipment - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Fair Value of Financial Instruments - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Detail) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Assets Sale (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Leases - Summary of the Components of Lease Costs and Rent (Details) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Common Stock - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995945 - Disclosure - Common Stock - Schedule of Common Stock Reserved For Future Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 995955 - Disclosure - Preferred Stock and Convertible Preferred Stock - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995965 - Disclosure - Restructuring and Other Charges (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 995975 - Disclosure - Restructuring and Other Charges - Summary of Restructuring Liability included in Accrued Payroll and Related Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 995985 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995995 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 996005 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Parenthetical) (Detail) link:presentationLink link:calculationLink link:definitionLink 996015 - Disclosure - Stock-Based Compensation - Schedule of Grant-date Fair Value of Stock Options Issued, Presented on a Weighted Average Basis (Detail) link:presentationLink link:calculationLink link:definitionLink 996025 - Disclosure - Stock-Based Compensation - Schedule of Stock Based Compensation Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 996035 - Disclosure - License Revenue - Related Party - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996045 - Disclosure - Net Loss Per Share - Schedule of Basic and diluted net loss per share of common stock (Detail) link:presentationLink link:calculationLink link:definitionLink 996055 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 996065 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996075 - Disclosure - 401(k) Savings Plan - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 996085 - Disclosure - Related Party Transactions - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink Assets Sale Assets Held For Sale [Text Block] The entire disclosure for assets held for sale. Unbilled receivable from related party Unbilled Receivables From Related Party Unbilled receivables from related party. 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Document Transition Report Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term Defined Benefit Plan Disclosure [Line Items] Money Market Funds [Member] Money Market Funds Payment of issuance costs in connection with the private placement Payments of Stock Issuance Costs Reduction in workforce, Percent Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Restructuring Cost and Reserve [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vesting period Debt Securities, Available-for-Sale Short-term investments Fair Value Fair Value Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Fair Value, Inputs, Level 1 [Member] Level 1 Schedule of Other Current Assets [Table Text Block] Summary of Prepaid Expenses and Other Current Assets WeightedAverageMember Weighted Average [Member] Fair Value Disclosures [Text Block] Fair Value of Financial Instruments Temporary Equity, Shares Authorized Convertible preferred stock, Shares authorized Income Taxes Income Tax, Policy [Policy Text Block] Revenue from Contract with Customer, Excluding Assessed Tax License revenue - related party Classification of Convertible Preferred Stock Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block] Accounts Payable And Accrued Expense [Abstract] Accounts Payable And Accrued Expense [Abstract] Prepaid Expense and Other Assets, Current [Abstract] Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Total unrecognized stock-based compensation expense related to unvested share-based awards Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Concentration Risk Type [Axis] Concentration Risk Type [Axis] Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Upfront payment. Upfront Payment [Member] Upfront Payment [Member] Schedule of Business Acquisitions, by Acquisition [Table] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 Fair Value on Recurring Basis Level 3 Loss on lease termination Loss on lease termination Gain Loss On Termination Of Lease Gain (Loss) on Termination of Lease Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of Company Obtained Assets and Liabilities OmniAb Inc [Member] OmniAb Inc [Member] OmniAb Inc, Inc member. Annual [Member] Annual [Member] Annual. No Trading Symbol Flag Subsequent Events [Text Block] Subsequent Events Shares of common stock issued in pre closing financing. Shares of Common Stock Issued in Pre Closing Financing Shares of common stock issued in pre-closing financing Revenue Recognition, Services, Licensing Fees [Policy Text Block] License Revenue - Related Party Temporary Equity, Shares Issued Convertible preferred stock, Share issued Increase (Decrease) in Due from Related Parties, Total Increase (Decrease) in Due from Related Parties Receivable from related party Long-term operating lease liabilities Operating Lease, Liability, Noncurrent Current portion of lease liabilities Schedule of Stock by Class [Table] Debt Securities, Available-for-Sale [Table] Shares pre-funded warrants to purchase Shares Pre-Funded Warrants To Purchase Shares pre-funded warrants to purchase Employee-Related Costs [Member] Employee Severance [Member] Class of Stock [Line Items] Related Party Transactions [Abstract] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total current assets Assets, Current Total liabilities and stockholders' equity Liabilities and Equity Entity Address, State or Province Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Number of Shares, Beginning Balance Number of Shares, Ending Balance Weighted average fair value of stock options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Total comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Trading Symbol Common stock, Shares issued Common Stock, Shares, Issued Debt Securities, Available-for-Sale [Line Items] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Consolidated Entities [Domain] Accounts Receivable, after Allowance for Credit Loss, Total Accounts Receivable, after Allowance for Credit Loss Related party receivable Cash Consideration Cash Consideration Asset Purchase Agreement The amount of cash to be received as part of an asset purchase agreement. Beginning balance, shares Ending balance, shares Shares, Outstanding Common stock, Shares outstanding Igenica Patent Portfolio [Member] Igenica patent portfolio member Aggregate purchase price of pre-funded warrant Payments for Repurchase of Warrants Common Stock, Capital Shares Reserved for Future Issuance Total common stock reserved for future issuance Accumulated Other Comprehensive Income (Loss) [Member] AOCI Attributable to Parent [Member] Other Comprehensive Income (Loss), Net of Tax, Total Other Comprehensive Income (Loss), Net of Tax Other comprehensive income loss Severance and Related Costs [Member] Severance and Related Costs [Member] Severance and related costs. Entity Address, City or Town Related Party Transaction [Line Items] Related Party Transaction [Line Items] Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate - operating lease Property, Plant and Equipment [Table Text Block] Schedule of Property and Equipment, Net Subsequent Event [Member] Subsequent Event [Member] Subsequent Event Type [Axis] Technology and Research Fees and Support [Member] Technology and Research Fees and Support [Member] Technology and research fees and support [member]. Issuance of common stock upon exercise of warrants Issuance of Common Stock Upon Exercise of Warrants Issuance of common stock upon exercise of warrants Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Current liabilities: Liabilities, Current [Abstract] Current assets: Assets, Current [Abstract] Preferred stock, par value Preferred Stock, Par or Stated Value Per Share Statement of Stockholders' Equity [Abstract] Current portion of operating lease liabilities Operating lease liability, current portion Operating Lease, Liability, Current Share based compensation arrangement by share based payment award aggregate intrinsic value granted. Share Based Compensation Arrangement By Share Based Payment Award Aggregate Intrinsic Value Granted Aggregate Intrinsic Value, Granted Property, Plant and Equipment, Net, Total Property and equipment, net Property, Plant and Equipment, Net Class of Stock [Domain] Class of Stock [Domain] Financial Advisor Domain Financial Advisor Domain Scenario, Unspecified [Domain] Scenario [Domain] Type of Arrangement and Non-arrangement Transactions [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Employee retention amount Restructuring Retention Costs Approved The amount of retention costs approved by the Company through specified dates as part of a corporate restructuring. Entity Central Index Key Pre-funded warrants to purchase Class of Warrant or Right, Number of Securities Called by Warrants or Rights Plan Name [Domain] Plan Name [Domain] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Vesting period Leases [Table] Leases. Related Party Related Party [Member] Related Party [Member] Pre-funded warrants increase or decrease percentage Pre-funded Warrants Increase or Decrease Percentage Pre-funded Warrants Increase or Decrease Percentage Loss on disposal of property and equipment Loss on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Assets, Fair Value Disclosure, Total Assets, Fair Value Disclosure Total assets measured at fair value Increase (Decrease) in Other Operating Assets, Total Increase (Decrease) in Other Operating Assets Other assets Preferred stock, Shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding Second development program member. Second Development Program [Member] Second Development Program [Member] Total current liabilities Liabilities, Current Entity Tax Identification Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Viridian, llc member. Viridian, LLC [Member] Viridian Llc [Member] Schedule of common stock shares reserved for future issuance Schedule Of Common Stock Shares Reserved For Future Issuance [Table TextBlock] Schedule of Common Stock Shares Reserved for Future Issuance Financial Instruments [Domain] Issuance of common stock and pre-funded warrants in connection with the private placement, net of issuance costs, shares Issuance of common stock and pre funded warrants in the pre closing financing net of issuance costs share Issuance Of Common Stock And Pre Funded Warrants In the Pre Closing Financing Net Of Issuance Costs Share Related and Nonrelated Party Status [Axis] Leases Lessee, Operating Leases [Text Block] Restricted Stock [Member] Restricted Stock Plan Name [Axis] Plan Name [Axis] Total assets Assets Right-of-use operating lease assets Operating Lease, Right-of-Use Asset Operating Lease, Right-of-Use Asset Inducement Plan [Member] Inducement Plan [Member] Inducement plan. Entity Registrant Name Related Party, Type [Domain] Share based compensation arrangement by share based payment award reserved and available for issuance increment percentage. Share Based Compensation Arrangement By Share Based Payment Award Reserved And Available For Issuance Increment Percentage Number of shares reserved and available for issuance increment percentage Retained Earnings (Accumulated Deficit), Total Accumulated deficit Retained Earnings (Accumulated Deficit) Supplemental Cash Flow Information [Abstract] Supplemental Disclosure Accumulated Deficit [Member] Retained Earnings [Member] Class of Stock [Axis] Class of Stock [Axis] Accrued external research and development expenses current Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development expenses. Accrued external research and development Common stock purchased Common stock purchased Issuance of common stock under Employee Stock Purchase Plan, shares Stock Issued During Period, Shares, Employee Stock Purchase Plans Minimum [Member] Minimum [Member] Revenues, Total Revenues Revenues Proceeds from Stock Options Exercised Proceeds from exercise of stock options Total operating lease liabilities Operating Lease, Liability Operating Lease, Liability Present value of operating lease liabilities Finance Lease, Liability, Total Finance Lease, Liability Financial lease liability US Government Agencies Debt Securities [Member] U.S. Government Agency Securities Equity Component [Domain] Equity Component [Domain] Stock-based Compensation Expense ImmunoGen ImmunoGen [Member] ImmunoGen. Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Entity Current Reporting Status Common stock, shares authorized Common Stock, Shares Authorized Research and development expense Research and Development Expense, Total Research and development Research and Development Expense First development program member. First Development Program [Member] First Development Program [Member] Certain Incentive Stock Options [Member] Certain Incentive Stock Options [Member] Assets Assets [Abstract] Shares available for issuance Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Convertible Preferred Stock [Member] Convertible Preferred Stock Convertible Preferred Stock [Member] Common stock; $0.001 par value per share; authorized shares -150,000,000 at March 31, 2024 and December 31, 2023; issued and outstanding shares - 29,348,626 and 14,817,696 at March 31, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued Expenses Percentage of outstanding shares owned. Percentage of Outstanding Shares Owned Percentage of outstanding shares Weighted Average Remaining Contractual Term, Options vested and expected to vest as of March 31, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Loss on Disposal and Impairment [Member] Loss on Disposal and Impairment [Member] Loss on disposal and impairment. Furniture and Fixtures [Member] First selected antibody member. First Selected Antibody [Member] First Selected Antibody [Member] Accrued Liabilities, Current, Total Accrued Liabilities, Current Accrued expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Cash and cash equivalents Current Fiscal Year End Date Share-Based Payment Arrangement, Noncash Expense, Total Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Loss from operations Operating Income (Loss) Entity Ex Transition Period Research and Development Expenses [Member] Research and Development Expense [Member] Alloy therapeutics, llc member. Alloy Therapeutics, LLC [Member] Alloy Therapeutics Llc [Member] Prepaid subscriptions, software and other administrative services. Prepaid Subscriptions, Software and Other Administrative Services Prepaid subscriptions, software and other administrative services Lessee, Leases [Policy Text Block] Leases Payments Payments Payments for Restructuring Royalty [Member] Royalty [Member] Prepaid materials, supplies and research and development services. Prepaid Materials, Supplies and Research and Development Services Prepaid materials, supplies and research and development services Stock based compensation expense Share-Based Payment Arrangement, Expense Leases [Line Items] Leases. Accounting Standards Update 2016-02 [Member] Accounts Payable, Accrued Expenses and Other Current Liabilities [Member] Accounts Payable and Accrued Liabilities [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Beginning Balance Aggregate Intrinsic Value, Ending Balance License [Member] License [Member] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Net Loss per Share Earnings Per Share, Policy [Policy Text Block] Other Nonoperating Income (Expense), Total Other Nonoperating Income (Expense) Other expense Stock issued, price per shares Sale of Stock, Price Per Share Operating expenses: Operating Expenses [Abstract] Property, Plant and Equipment [Abstract] Subsequent Events [Abstract] Other comprehensive (loss)/income: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Debt Securities, Available-for-Sale [Table Text Block] Schedule of short-term investments Second selected antibody member. Second Selected Antibody [Member] Second Selected Antibody [Member] Commitments and Contingencies Disclosure [Abstract] Share-based compensation arrangement by share-based payment award, options, grants in period, gross Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Number of Shares, Granted Other Accrued Liabilities, Current Other accrued expenses Ligand pharmaceuticals incorporated member. Ligand Pharmaceuticals Incorporated [Member] Ligand Pharmaceuticals Incorporated [Member] Stockholders' Equity Equity [Text Block] Common Stock Organization Consolidation And Presentation Of Financial Statements Disclosure [Table] Organization Consolidation And Presentation Of Financial Statements Disclosure [Table] Organization Consolidation And Presentation Of Financial Statements Disclosure [Table] Depreciation, Total Depreciation Depreciation expense Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for interest Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax, Total Gross Unrealized Gain Weighted-Average Exercise Price, Options vested and expected to vest as of March 31, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Equity, Attributable to Parent [Abstract] Stockholders' equity/(deficit): Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Tellus bioventures llc member. Tellus BioVentures LLC [Member] Tellus Bioventures Llc [Member] Lease, Cost [Table Text Block] Summary of the Components of Lease Costs and Rent Entity [Domain] Entity [Domain] Lease Contractual Term [Domain] Earnings Per Share [Abstract] Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of Maturities of Operating Lease Liabilities Accounting Policies [Abstract] Development, Regulatory and Commercial Milestone [Member] Development, Regulatory and Commercial Milestone [Member] Development, Regulatory and Commercial Milestone [Member] Scenario [Axis] Scenario [Axis] Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Net assets acquired Earnings Per Share, Basic, Total Net loss per share, basic Earnings Per Share, Basic Net loss per share attributable to common stockholders, basic Commitments and Contingencies Commitments and contingencies (Note 15) Mergers, Acquisitions and Dispositions Disclosures [Text Block] Reverse Merger Unbilled receivable from related party. Unbilled Receivable from Related Party Unbilled receivable from related party Income Statement [Abstract] Patent Costs Disclosure on accounting policy of patent costs. Patent Costs [Policy Text Block] Property, Plant and Equipment Disclosure [Text Block] Property and Equipment Related Party, Type [Axis] Revenue recognition milestone method pending. Revenue Recognition Milestone Method Pending Development milestones Split adjusted exchange ratio of reverse merger. Split Adjusted Exchange Ratio of Reverse Merger Exchange ratio of reverse merger Operating lease cost Operating Lease, Cost Retirement Benefits [Abstract] Restructuring Type [Axis] Number of Shares, Options vested and expected to vest as of March 31, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Range [Domain] Statistical Measurement [Domain] Unbilled Receivables, Current Unbilled receivable from related party Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Prefunded Warrants [Member] Prefunded Warrants [Member] Prefunded Warrants. Document Period End Date Range [Axis] Statistical Measurement [Axis] Accounts Receivable, Allowance for Credit Loss, Beginning Balance Accounts Receivable, Allowance for Credit Loss, Ending Balance Accounts Receivable, Allowance for Credit Loss Allowance for doubtful accounts Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Stockholders' Equity Note [Abstract] Restructuring charge related to severance cost Expense incurred Restructuring and Related Cost, Incurred Cost Earnings Per Share, Diluted, Total Net loss per share, diluted Earnings Per Share, Diluted Net loss per share attributable to common stockholders, diluted Proceeds from Notes Payable, Total Proceeds from Notes Payable Proceeds from issuance of promissory notes payable to related party Aggregate principal amount Product and Service [Domain] Product and Service [Domain] Lease, Cost [Abstract] Unrecognized Tax Benefits, Beginning Balance Unrecognized Tax Benefits, Ending Balance Unrecognized Tax Benefits Unrecognized tax benefits Milestone Payment Potential Milestone Receivable Asset Purchase Agreement The potential milestone payment that may be received as part of an asset purchase agreement. Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Short-Term Investments [Abstract] Revenue from Contract with Customer [Abstract] Revenues: Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Number of Shares, Options exercisable as of March 31, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Number of Shares, Options vested and expected to vest as of September 30, 2023 Related Party Transaction [Domain] Related Party Transaction [Domain] Fair Value, Recurring [Member] Fair Value on Recurring Basis Pre-funded warrants exercisable Pre-Funded Warrants Exercisable Pre-Funded warrants exercisable Additional paid-in capital Additional Paid in Capital, Common Stock US Treasury Securities [Member] U.S. Treasury Securities Defined contribution plan, Employer matching contribution, percent of employees' gross pay Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Loss on currency exchange, net Gain (Loss), Foreign Currency Transaction, before Tax, Total Gain (Loss), Foreign Currency Transaction, before Tax Schedule of Restructuring and Related Costs [Table] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Exercise of stock options, shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Number of Shares, Exercised Stock Options and Stock Appreciation Rights [Member] Stock Options and Stock Appreciation Rights [Member] Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] Proceeds from the private placement Proceeds From Private Placement Proceeds From Private Placement Entity Address, Postal Zip Code Entity Interactive Data Current 2024 Private Placement [Member] Private Placement [Member] Related and Nonrelated Party Status [Domain] Achievement of Development and Regulatory Milestones [Member] Achievement of Development and Regulatory Milestones [Member] Achievement of Development and Regulatory Milestones [Member] Disclosure of license revenue to related parties Disclosure of License Revenue to Related Parties [Text Block] License Revenue - Related Party Achievement of Development Milestone [Member] Achievement Of Development Milestone Member Equity [Abstract] Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: imputed interest Proceeds from pre closing financing. Proceeds from Pre Closing Financing Proceeds from pre-closing financing Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Number of units outstanding, Granted Warrants issued Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted-Average Exercise Price, Exercised Entity incorporation state code Entity Incorporation, State or Country Code Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Equity Components [Axis] Equity Components [Axis] Restructuring and Related Activities [Abstract] 401(k) Savings Plan Retirement Benefits [Text Block] Lease Termination [Member] Contract Termination [Member] Milestone. Milestone [Member] Milestone [Member] Local Phone Number Property, Plant and Equipment [Line Items] Sale of Stock [Axis] Sale of Stock [Axis] Weighted-Average Exercise Price, Options exercisable as of March 31, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Increase (Decrease) in Deferred Revenue Deferred revenue - related party Dianthus [Member] Dianthus member Dianthus [Member] Dianthus Repayments of Notes Payable Repayment of promissory notes payable to related party Principal and interest repaid Class of warrant or right maximum beneficial ownership percent Class Of Warrant Or Right Maximum Beneficial Ownership Percent Class of warrant or right maximum beneficial ownership percent License Agreement [Member] License Agreement [Member] License agreement. Statement of Cash Flows [Abstract] Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Prefunded warrants price per share Prefunded Warrants Price Per Share Prefunded warrants price per share Organization, Consolidation and Presentation of Financial Statements [Abstract] Accumulated other comprehensive (loss)/income Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated Other Comprehensive Income (Loss), Net of Tax Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment Warrants. Warrants [Member] Warrants Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Other Income Other Income Common stock, Par value Common Stock, Par or Stated Value Per Share Deferred Revenue, Noncurrent, Total Deferred Revenue, Noncurrent Deferred revenue noncurrent Deferred revenue - related party Business combination, recognized identifiable assets acquired and liabilities assumed, accrued liabilities. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities Accrued liabilities Accrued liabilities Debt Instrument, Interest Rate, Stated Percentage Interest rate Period for recognition of unrecognized expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Long-Lived Tangible Asset [Axis] Other assets and restricted cash. Other Assets and Restricted Cash Other assets and restricted cash Shares for issuance under the Plan (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Maximum [Member] Maximum [Member] Comprehensive loss: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Temporary Equity, Shares Outstanding Convertible preferred stock, Shares Outstanding Debt Securities, Available-for-Sale, Allowance for Credit Loss, Writeoff Credit losses recorded Related Party Transaction [Axis] Related Party Transaction [Axis] IONTAS limited member. IONTAS Limited [Member] IONTAS Limited [Member] APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Ownership [Domain] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Increase in cash, cash equivalents and restricted cash Property, Plant and Equipment Assets Held-for-Sale Disclosure [Abstract] Payables and Accruals [Abstract] Payables and Accruals [Abstract] NMDP Be The Match NMDP Be The Match [Member] NMDP Be The Match. General and Administrative Expenses [Member] General and Administrative Expense [Member] Development milestone. Development Milestone [Member] Development Milestone [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Number of Shares, Forfeited Commercial milestone. Commercial Milestone [Member] Commercial Milestone [Member] Recently Adopted Accounting Pronouncements [Axis] Recently adopted accounting pronouncements. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Accounts payable, accrued expenses and operating lease liabilities Accounts Payable, Accrued Expenses and Operating Lease Liabilities Accounts payable, accrued expenses and operating lease liabilities. City Area Code Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Interest Income, Other Interest income Accrued Liabilities And Other Liabilities [Line Items] Accrued Liabilities And Other Liabilities [Line Items] Accrued liabilities and other liabilities. Business Acquisition [Line Items] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation Less: accumulated depreciation General and administrative expense General and Administrative Expense, Total General and administrative General and Administrative Expense Issuance of common stock upon exercise of stock options Issuance of Common Stock Upon Exercise of Stock Options Issuance of common stock upon exercise of stock options Temporary Equity, Liquidation Preference Convertible preferred stock, Liquidation Preference Weighted-average number of shares of common stock outstanding, used in computing net loss per share of common stock, basic Weighted Average Number of Shares Outstanding, Basic, Total Weighted Average Number of Shares Outstanding, Basic Shares available for issuance under the Employee Stock Purchase Plan Shares Available for Issuance under the Employee Stock Purchase Plan Shares available for issuance under the Employee Stock Purchase Plan Summary of Restructuring Liability included in Accrued Payroll and Related Expenses Restructuring and Related Costs [Table Text Block] Other Commitments [Line Items] Other Commitments [Line Items] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Research and Development Expense, Policy [Policy Text Block] Research and Development Costs Operating lease description Lessee, Operating Lease, Description Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Schedule of Activity Relating to Restricted Stock Units Statement [Table] Statement [Table] Share-Based Payment Arrangement, Option, Activity [Table Text Block] Schedule of Stock Option Activity Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Grant-Date Fair Value of Stock Options Issued, Presented on a Weighted Average Basis Document Fiscal Period Focus Lessee, Operating Lease, Liability, to be Paid Total undiscounted operating lease payments Investment, Policy [Policy Text Block] Short-term Investments Related Party Transactions Disclosure [Text Block] Related Party Transactions Accrued Professional Fees, Current Accrued professional fees Statement [Line Items] Statement [Line Items] Anti-dilutive securities excluded from computation of earnings per share, amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Payment of annual license fees and annual antibody program fees. Payment of Annual License Fees and Annual Antibody Program Fees Payment of annual license fees and program fees Maintenance [Member] Maintenance [Member] Lease, Cost Total operating lease costs Operating lease costs Warrant [Member] Warrant [Member] Accounts Receivable, after Allowance for Credit Loss, Current, Total Accounts Receivable, after Allowance for Credit Loss, Current Receivable from related party Common Stock [Member] Common Stock [Member] Common Stock Other Commitments [Table] Other Commitments [Table] Temporary Equity, Par or Stated Value Per Share Convertible preferred stock, par value Investment [Text Block] Short-Term Investments Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased Common stock exercise price Schedule of Stock Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Accretion (Amortization) of Discounts and Premiums, Investments Accretion of discount on short-term investments Entity Common Stock, Shares Outstanding Antidilutive Securities, Name [Domain] Recently Adopted Accounting Pronouncements [Domain] Recently adopted accounting pronouncements. Zenas biopharma limited member. Zenas BioPharma Limited [Member] Zenas BioPharma Limited [Member] Cover [Abstract] Wedbush Member Wedbush Member Wedbush Member Document Fiscal Year Focus Crystal bioscience, inc member. Crystal Bioscience, Inc [Member] Crystal Bioscience Inc [Member] Income Taxes Paid, Net, Total Income Taxes Paid, Net Cash paid for taxes Sale of Stock [Domain] Sale of Stock [Domain] Preferred Stock [Member] Preferred Stock [Member] Share-Based Payment Arrangement [Policy Text Block] Stock-Based Compensation Equity awards available for grant under stock award plans Equity Awards Available for Grant Under Stock Award Plans Equity awards available for grant under stock award plans. 2019 Employee Stock Purchase Plan [Member] Two Thousand And Nineteen Employee Stock Purchase Plan [Member] Two thousand and nineteen employee stock purchase plan. Security Exchange Name Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Term of award Total other comprehensive (loss)/income Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent New Accounting Pronouncements, Policy [Policy Text Block] Recently Adopted Accounting Pronouncements Preferred stock, Shares issued Preferred Stock, Shares Issued Preferred stock, Shares authorized Preferred Stock, Shares Authorized Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Ending Balance Property, Plant and Equipment, Gross Property and equipment, gross Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted-Average Exercise Price, Forfeited Business Acquisition, Acquiree [Domain] Legal Entity [Axis] Legal Entity [Axis] Financial Instrument [Axis] Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock and pre-funded warrants in connection with the private placement, net of issuance costs Issuance of common stock and pre-funded warrants in the pre-closing financing net of issuance costs. Issuance of Common Stock and Pre-funded Warrants in the Pre-closing Financing Net of Issuance Costs Weighted-average shares of common stock outstanding Weighted-average common shares outstanding. WeightedAverageCommonSharesOutstanding Entity Emerging Growth Company Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Aggregate Intrinsic Value, Exercised Convertible Preferred Stock, Shares Issued upon Conversion Shares issued upon conversion of convertible preferred stock Amendment Flag Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued Expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Other current assets Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized Loss Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Organization consolidation and presentation of financial statements disclosure. Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Other Current Assets [Text Block] Prepaid Expenses and Other Current Assets Restructuring and Other Charges Restructuring and Related Activities Disclosure [Text Block] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 1 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 1 Fair Value on Recurring Basis Level 1 Leases [Abstract] Cowen and Company LLC [Member] Cowen and Company LLC [Member] Cowen And Company Llc Member Securities Act File Number Preferred Stock, Convertible, Terms Convertible preferred stock, Terms of conversion Receivable [Policy Text Block] Receivable from Related Party and Unbilled Receivable from Related Party 2024 (remaining 9 months) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Issuance costs in connection with the private placement included in accounts payable Issuance Costs in Connection With Private Placement Included in Accounts Payable Issuance costs in connection with private placement included in accounts payable Aggregate Intrinsic Value, Options exercisable as of March 31, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Change in unrealized (losses)/gains related to available-for-sale debt securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Two Thousand and Nineteen Stock Plan. Two Thousand and Nineteen Stock Plan [Member] 2019 Stock Plan [Member] Share-Based Payment Arrangement [Abstract] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Accrued Liabilities And Other Liabilities [Table] Accrued Liabilities And Other Liabilities [Table] Accrued Liabilities And Other Liabilities [Table] Accounts Payable, Current, Total Accounts payable Accounts Payable, Current Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted average grant date fair value per share, Beginning Balance Weighted average grant date fair value per share, Ending Balance Warrant per grant date fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 2 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 2 Fair Value on Recurring Basis Level 2 Total operating expenses Operating Expenses Accrued expenses and other current liabilities Accrued Liabilities and Other Liabilities Accrued expenses Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term Collaborative Arrangement [Member] Collaborative Arrangement [Member] Stockholders' Equity, Reverse Stock Split Reverse stock split description Schedule of Defined Benefit Plans Disclosures [Table] Preferred stock; $0.001 par value per share; authorized shares - 10,000,000 at March 31, 2024 and December 31, 2023; issued and outstanding - none at March 31, 2024 and December 31, 2023 Preferred Stock, Value, Issued Entity Small Business Entity Shell Company Sold and issued of shares Sale of Stock, Number of Shares Issued in Transaction Exercise price (in USD per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Class of Warrant or Right [Domain] Computer Equipment [Member] Earnings Per Share [Text Block] Entity Address, Address Line One Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Antidilutive Securities [Axis] Retention amount paid Restructuring Retention Costs The amount of retention costs recorded during the period as part of a corporate restructuring. 2018 Stock Option and Incentive Plan [Member] Two Thousand And Eighteen Stock Option And Incentive Plan [Member] Two thousand and eighteen stock option and incentive plan. Restricted Cash, Total Restricted Cash Restricted cash Payments for Capital Improvements Capital expenditures Capital expenditures Subsequent Event Type [Domain] Proceeds from Maturities, Prepayments and Calls of Short-Term Investments Proceeds from maturities of short-term investments Schedule of Stock by Class [Table Text Block] Schedule of Preferred Stock Activity Income Statement Location [Axis] Income Statement Location [Axis] Variable lease cost Variable Lease, Cost common stock price per share common Stock Price Per Share common stock price per share Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest License revenue member. License Revenue [Member] License Revenue [Member] Fairmount funds member. Fairmount Funds [Member] Fairmount Funds [Member] Prepaid Insurance Prepaid Insurance Fair Value, Inputs, Level 2 [Member] Level 2 Product and Service [Axis] Product and Service [Axis] MGTA-145 [Member] MGTA-145 [Member] MGTA-145. Employee Severance and Retention [Member] Employee severance and retention. Title of 12(b) Security Lease Contractual Term [Axis] Schedule of Financial Assets Measured at Fair Value on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] License Agreement With Harvard [Member] License Agreement With Harvard [Member] License Agreement With Harvard [Member] Prepaid Expenses and Other Current Assets [Member] Prepaid Expenses and Other Current Assets [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Financial Advisor Axis Financial Advisor Axis Segment Reporting, Policy [Policy Text Block] Segment Information Accrued issuance costs in connection with the private placement Accrued Issuance Costs In Private Placement Accrued issuance costs in private placement. Long-Lived Tangible Asset [Domain] Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Restricted Cash Common Stock, Dividends, Per Share, Declared Common Stock, Dividends, Per Share, Declared Contract with Customer, Liability, Total Contract with Customer, Liability Upfront payments Share-based compensation arrangement by share-based payment award, terms of award Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award Defined Contribution Plan, Employer Discretionary Contribution Amount Defined Contribution Plan, Employer Discretionary Contribution Amount License Agreement with ImmunoGen [Member] License Agreement with ImmunoGen [Member] License agreement with ImmunoGen [member]. Weighted Average Remaining Contractual Term, Options exercisable as of March 31, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Common stock, Shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Match Bio Therapies [Member] Match Bio Therapies [Member] Match Bio Therapies [Member] Share-Based Payment Arrangement [Text Block] Stock-Based Compensation Igenica Patent Portfolio and E478 Technology [Member] Igenica Patent Portfolio And E478 Technology [Member] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Potential milestone payments due Potential Milestone Payments Due The potential amount of milestone payments due upon achievement of specified targets. Income Statement Location [Domain] Income Statement Location [Domain] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted-Average Exercise Price, Granted Business Combination and Asset Acquisition [Abstract] Document Type Ownership [Axis] Reimbursement of development costs. Reimbursement of Development Costs Reimbursement of development costs Share based compensation arrangement by share based payment award aggregate intrinsic value forfeited. Share Based Compensation Arrangement By Share Based Payment Award Aggregate Intrinsic Value Forfeited Aggregate Intrinsic Value, Forfeited Net cash (used in)/provided by investing activities Net Cash Provided by (Used in) Investing Activities Document Quarterly Report Net cash provided by financing activities Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Additional number of shares reserved and available for issuance Entity Filer Category Restricted Cash and Cash Equivalents Total cash, cash equivalents and restricted cash Balance Sheet Location [Domain] Balance Sheet Location [Domain] Short-Term Investments, Total Short-Term Investments Short-term investments Reimbursement Payment Expense Reimbursement Asset Purchase Agreement The amount of expense reimbursement that may be received as part of an asset purchase agreement. Nonoperating Income (Expense) Total other income Total liabilities Liabilities Property, Plant and Equipment [Table] Payments to Acquire Short-Term Investments Purchases of short-term investments MGTA-45 [Member] MGTA-45 [Member] MGTA-45. Total stockholders' equity Beginning balance Ending balance Equity, Attributable to Parent Consolidated Entities [Axis] Net loss Nonoperating Income (Expense) [Abstract] Other income/(expense): Nature of the Business and Basis of Presentation Business Description and Basis of Presentation [Text Block] Stock issuance cost. Stock Issuance Cost Stock issuance cost Material Transfer And Evaluation Agreement [Member] Material Transfer and Evaluation Agreement [Member] Material transfer and evaluation agreement. Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Preferred Stock [Text Block] Preferred Stock and Convertible Preferred Stock Statement of Financial Position [Abstract] Basis of Presentation and Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Weighted-average number of shares of common stock outstanding, used in computing net loss per share of common stock, diluted Weighted Average Number of Shares Outstanding, Diluted, Total Weighted Average Number of Shares Outstanding, Diluted Impairment charge of lab equipment Impairment of Long-Lived Assets to be Disposed of Amortization of right-of-use operating lease assets Operating Lease, Right-of-Use Asset, Periodic Reduction Per Target [Member] Per Target [Member] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Operating Lease, Weighted Average Remaining Lease Term Weighted-Average remaining lease term Percentage of purchase price of common stock under the ESPP Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Use of Estimates Use of Estimates, Policy [Policy Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted-Average Exercise Price, Outstanding, Beginning balance Weighted-Average Exercise Price, Outstanding, Ending balance Weighted Average Number of Shares, Restricted Stock Less: weighted-average unvested restricted shares of common stock Less: weighted-average unvested restricted shares of common stock Schedule of Basic and diluted net loss per share of common stock Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Issuance costs in connection with the private placement included in accrued expenses Accrued issuance costs in connection with private placement Issuance Costs in Connection With Private Placement Included in Accrued Expenses Issuance Costs in Connection With Private Placement Included in Accrued Expenses Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Fair Value Disclosures [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Aggregate Intrinsic Value, Options vested and expected to vest as of March 31, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested Type of Restructuring [Domain] Employee-related Liabilities, Current, Total Accrued restructuring, Beginning Balance Accrued restructuring, Ending Balance Employee-related Liabilities, Current Accrued compensation MGTA-117 [Member] MGTA-117 [Member] MGTA-117. Business Acquisition [Axis] Deferred Revenue, Current, Total Deferred Revenue, Current Deferred revenue current Current portion of deferred revenue - related party Class of Warrant or Right [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover Page - shares
3 Months Ended
Mar. 31, 2024
May 06, 2024
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2024  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Entity Registrant Name Dianthus Therapeutics, Inc.  
Trading Symbol DNTH  
Entity Central Index Key 0001690585  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Entity Emerging Growth Company false  
Entity Small Business true  
Entity Shell Company false  
Entity Tax Identification Number 81-0724163  
Title of 12(b) Security Common Stock  
Entity Interactive Data Current Yes  
Security Exchange Name NASDAQ  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 7 Times Square, 43rd Floor  
Entity Address, City or Town New York  
Entity Address, Postal Zip Code 10036  
Entity Address, State or Province NY  
Securities Act File Number 001-38541  
City Area Code 929  
Local Phone Number 999-4055  
Entity Common Stock, Shares Outstanding   29,349,469
XML 8 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 329,724 $ 132,325
Short-term investments 47,312 41,393
Receivable from related party 435 294
Unbilled receivable from related party 441 184
Prepaid expenses and other current assets 3,014 3,255
Total current assets 380,926 177,451
Property and equipment, net 195 185
Right-of-use operating lease assets 530 615
Other assets and restricted cash 811 1,154
Total assets 382,462 179,405
Current liabilities:    
Accounts payable 2,612 2,610
Accrued expenses 5,847 6,504
Current portion of deferred revenue - related party 100 100
Current portion of operating lease liabilities 400 417
Total current liabilities 8,959 9,631
Deferred revenue - related party 719 736
Long-term operating lease liabilities 97 168
Total liabilities 9,775 10,535
Commitments and contingencies (Note 15)
Stockholders' equity/(deficit):    
Preferred stock; $0.001 par value per share; authorized shares - 10,000,000 at March 31, 2024 and December 31, 2023; issued and outstanding - none at March 31, 2024 and December 31, 2023 0 0
Common stock; $0.001 par value per share; authorized shares -150,000,000 at March 31, 2024 and December 31, 2023; issued and outstanding shares - 29,348,626 and 14,817,696 at March 31, 2024 and December 31, 2023, respectively 29 15
Additional paid-in capital 475,856 258,231
Accumulated deficit (103,171) (89,423)
Accumulated other comprehensive (loss)/income (27) 47
Total stockholders' equity 372,687 168,870
Total liabilities and stockholders' equity $ 382,462 $ 179,405
XML 9 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares
Mar. 31, 2024
Dec. 31, 2023
Sep. 11, 2023
Preferred stock, par value $ 0.001 $ 0.001  
Preferred stock, Shares authorized 10,000,000 10,000,000  
Preferred stock, Shares issued 0 0  
Preferred stock, Shares outstanding 0 0  
Common stock, Par value $ 0.001 $ 0.001  
Common stock, shares authorized 150,000,000 150,000,000  
Common stock, Shares issued 29,348,626 14,817,696 11,021,248
Common stock, Shares outstanding 29,348,626 14,817,696  
XML 10 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:    
Research and development $ 13,078 $ 5,847
General and administrative 5,640 2,312
Total operating expenses 18,718 8,159
Loss from operations (17,844) (7,683)
Other income/(expense):    
Interest income 4,222 606
Loss on currency exchange, net (12) (9)
Other expense (114) (3)
Total other income 4,096 594
Net loss $ (13,748) $ (7,089)
Net loss per share attributable to common stockholders, basic $ (0.54) $ (8.1)
Net loss per share attributable to common stockholders, diluted $ (0.54) $ (8.1)
Weighted-average number of shares of common stock outstanding, used in computing net loss per share of common stock, basic 25,665,475 874,709
Weighted-average number of shares of common stock outstanding, used in computing net loss per share of common stock, diluted 25,665,475 874,709
Comprehensive loss:    
Net Income (Loss) $ (13,748) $ (7,089)
Other comprehensive (loss)/income:    
Change in unrealized (losses)/gains related to available-for-sale debt securities (74) 104
Total other comprehensive (loss)/income (74) 104
Total comprehensive loss (13,822) (6,985)
Related Party [Member]    
Revenues:    
License revenue - related party $ 874 $ 476
XML 11 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity/(Deficit) - USD ($)
$ in Thousands
Total
Common Stock [Member]
Preferred Stock [Member]
Convertible Preferred Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Beginning balance at Dec. 31, 2022 $ (44,368) $ 0 $ 118,024 $ 1,661 $ (45,868) $ (161)
Beginning balance, shares at Dec. 31, 2022   875,279 33,336,282      
Stock-based compensation expense 533     533    
Net Income (Loss) (7,089)       (7,089)  
Other comprehensive income loss 104         104
Ending balance at Mar. 31, 2023 (50,820) $ 0 $ 118,024 2,194 (52,957) (57)
Ending balance, shares at Mar. 31, 2023   875,279 33,336,282      
Beginning balance at Dec. 31, 2023 168,870 $ 15 $ 0 258,231 (89,423) 47
Beginning balance, shares at Dec. 31, 2023   14,817,696 0      
Issuance of common stock and pre-funded warrants in connection with the private placement, net of issuance costs 215,333 $ 14   215,319    
Issuance of common stock and pre-funded warrants in connection with the private placement, net of issuance costs, shares   14,500,500        
Exercise of stock options $ 271 $ 0   271    
Exercise of stock options, shares 30,430 30,430        
Stock-based compensation expense $ 2,035     2,035    
Net Income (Loss) (13,748)       (13,748)  
Other comprehensive income loss (74)         (74)
Ending balance at Mar. 31, 2024 $ 372,687 $ 29 $ 0 $ 475,856 $ (103,171) $ (27)
Ending balance, shares at Mar. 31, 2024   29,348,626 0      
XML 12 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity/(Deficit) (Parenthetical)
$ in Thousands
3 Months Ended
Mar. 31, 2024
USD ($)
Stock issuance cost $ 14,665
XML 13 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash flows from operating activities:    
Net loss $ (13,748) $ (7,089)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation expense 22 14
Stock-based compensation expense 2,035 533
Accretion of discount on short-term investments (518) (358)
Amortization of right-of-use operating lease assets 85 67
Changes in operating assets and liabilities:    
Receivable from related party (141) 789
Unbilled receivable from related party (257) 377
Prepaid expenses and other current assets 241 116
Other assets 343 5
Accounts payable, accrued expenses and operating lease liabilities (2,986) (4,729)
Deferred revenue - related party (17) (9)
Net cash used in operating activities (14,941) (10,284)
Cash flows from investing activities:    
Capital expenditures (32) (14)
Purchases of short-term investments (20,475) (3,855)
Proceeds from maturities of short-term investments 15,000 22,000
Net cash (used in)/provided by investing activities (5,507) 18,131
Cash flows from financing activities:    
Proceeds from exercise of stock options 271 0
Proceeds from the private placement 229,998 0
Payment of issuance costs in connection with the private placement (12,422) 0
Proceeds from issuance of promissory notes payable to related party 0 377
Repayment of promissory notes payable to related party 0 (377)
Net cash provided by financing activities 217,847 0
Increase in cash, cash equivalents and restricted cash 197,399 7,847
Cash, cash equivalents and restricted cash, beginning of period 132,391 15,425
Cash, cash equivalents and restricted cash, end of period 329,790 23,272
Supplemental Disclosure    
Cash and cash equivalents 329,724 23,212
Restricted cash 66 60
Total cash, cash equivalents and restricted cash 329,790 23,272
Cash paid for interest 0 0
Cash paid for taxes 0 0
Issuance costs in connection with the private placement included in accounts payable 30 0
Issuance costs in connection with the private placement included in accrued expenses $ 2,213 $ 0
XML 14 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Pay vs Performance Disclosure    
Net Income (Loss) $ (13,748) $ (7,089)
XML 15 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Insider Trading Arrangements
3 Months Ended
Mar. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 16 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Organization, Description of Business and Liquidity
3 Months Ended
Mar. 31, 2024
Nature of the Business and Basis of Presentation

1. Organization, Description of Business and Liquidity

Business

Dianthus Therapeutics, Inc. (formerly Magenta Therapeutics, Inc.) (the “Company” or “Dianthus”) is a clinical-stage biotechnology company focused on developing next-generation complement therapeutics for patients with severe autoimmune and inflammatory diseases. The Company’s corporate headquarters are in New York, New York.

Currently, the Company is devoting substantially all efforts and resources toward product research and development of its product candidates. The Company has incurred losses from operations and negative operating cash flows since its inception. There can be no assurance that its research and development programs will be successful, that products developed, if any, will obtain necessary regulatory approval, or that any approved product, if any, will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its key employees, consultants, and advisors.

Reverse Merger and Pre-Closing Financing

On September 11, 2023, the Company completed its business combination with Dianthus Therapeutics OpCo, Inc. (formerly Dianthus Therapeutics, Inc.) (“Former Dianthus”) in accordance with the terms of the Agreement and Plan of Merger, dated as of May 2, 2023 (the “Merger Agreement”), by and among the Company, Dio Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”), and Former Dianthus, pursuant to which, among other matters, Merger Sub merged with and into Former Dianthus, with Former Dianthus surviving as a wholly owned subsidiary of the Company (the “Reverse Merger”). In connection with the completion of the Reverse Merger, the Company changed its name from “Magenta Therapeutics, Inc.” to “Dianthus Therapeutics, Inc.,” and the business conducted by the Company became primarily the business conducted by Former Dianthus. Unless context otherwise requires, references herein to “Dianthus,” the “Company,” or the “combined company” refer to Dianthus Therapeutics, Inc. (formerly Magenta Therapeutics, Inc.) after completion of the Reverse Merger, the term “Former Dianthus” refers to Dianthus Therapeutics OpCo, Inc. (formerly Dianthus Therapeutics, Inc.), and the term “Magenta” refers to the Company prior to completion of the Reverse Merger. The Company was incorporated in June 2015 and Former Dianthus was incorporated in May 2019.

Immediately prior to the effective time of the Reverse Merger, the Company effected a 1-for-16 reverse stock split of its common stock (the “Reverse Stock Split”). Unless noted otherwise, all references herein to share and per share amounts reflect the Reverse Stock Split.

At the effective time of the Reverse Merger, the Company issued an aggregate of 11,021,248 shares of Company common stock to the Former Dianthus stockholders, based on the exchange ratio of approximately 0.2181 shares of Company common stock for each share of Former Dianthus common stock, including those shares of Former Dianthus common stock issued upon the conversion of Former Dianthus preferred stock and those shares of the Former Dianthus common stock issued in the pre-closing financing (as defined below), resulting in 14,817,696 shares of Company common stock being issued and outstanding following the effective time of the Reverse Merger.

At the effective time of the Reverse Merger, the 2019 Stock Plan (as discussed in Note 12) was assumed by the Company, and each outstanding and unexercised option to purchase shares of Former Dianthus common stock immediately prior to the effective time of the Reverse Merger was assumed by the Company and converted into an option to purchase shares of Company common stock, with necessary adjustments to the number of shares and exercise price to reflect the exchange ratio, and each outstanding and unexercised warrant to purchase shares of Former Dianthus common stock immediately prior to the effective time of the Reverse Merger (including the Former Dianthus pre-funded warrants sold in the pre-closing financing) was converted into a warrant to purchase shares of Company common stock, with necessary adjustments to the number of shares and exercise price to reflect the exchange ratio.

The Reverse Merger was accounted for as a reverse recapitalization in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). Under this method of accounting, Former Dianthus was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the expectation that, immediately following the Reverse Merger: (i) Former Dianthus’ stockholders own a substantial majority of the voting rights in the combined company; (ii) Former Dianthus’ largest stockholders retain the largest interest in the combined company; (iii) Former Dianthus designated a majority (six of eight) of the initial members of the board of directors of the combined company; and (iv) Former Dianthus’ executive management team became the management team of the combined company. Accordingly, for accounting purposes: (i) the Reverse Merger was treated as the equivalent of Former Dianthus issuing stock to acquire the net assets of Magenta; (ii) the net assets of Magenta are recorded at their acquisition-date fair value in the unaudited condensed consolidated financial statements of Former Dianthus and (iii) the reported historical operating results of the combined company prior to the Reverse Merger are those of Former Dianthus. Additional information regarding the Reverse Merger is included in Note 3. Historical common stock figures of Former Dianthus have been retroactively restated based on the exchange ratio of approximately 0.2181.

On September 11, 2023, prior to the effective time of the Reverse Merger, the Company entered into a contingent value rights agreement (the “CVR Agreement”) with a rights agent, pursuant to which pre-Reverse Merger holders of Magenta common stock received one non-transferable contingent value right (each, a “CVR”) for each outstanding share of Magenta common stock held by such stockholder immediately prior to the effective time of the Reverse Merger on September 11, 2023. Subject to, and in accordance with, the terms and conditions of the CVR Agreement, each CVR represents the contractual right to receive a pro rata portion of the proceeds, if any, received by the Company as a result of (i) contingent payments made to the Company, such as milestone, royalty or earnout, when received under any pre-Reverse Merger disposition agreements related to Magenta’s pre-Reverse Merger assets and (ii) the Company’s sale of assets after the effective date of the Reverse Merger and prior to December 31, 2023, in each case, received within a three-year period following the closing of the Reverse Merger. As of March 31, 2024, no payments have been received under the CVR Agreement.

Concurrently with the execution and delivery of the Merger Agreement, and in order to provide Former Dianthus with additional capital for its development programs, Former Dianthus entered into a subscription agreement, as amended (the “Subscription Agreement”), with certain investors named therein (the “Investors”), pursuant to which, subject to the terms and conditions of the Subscription Agreement, immediately prior to the effective time of the Reverse Merger, Former Dianthus issued and sold, and the Investors purchased, (i) 2,873,988 shares of Former Dianthus common stock and (ii) 210,320 pre-funded warrants, exercisable for 210,320 shares of Former Dianthus common stock, at a purchase price of approximately $23.34 per share or $23.34 per warrant, for an aggregate purchase price of approximately $72.0 million (the “pre-closing financing”).

2024 Private Placement

On January 22, 2024, the Company entered into a securities purchase agreement for a private placement with certain institutional and accredited investors. At the closing of the private placement on January 24, 2024, the Company sold and issued 14,500,500 shares of common stock at a price per share of $12.00, and pre-funded warrants to purchase 4,666,332 shares of common stock at a purchase price of $11.999 per pre-funded warrant, which represents the per share purchase price of the common stock less the $0.001 per share exercise price for each pre-funded warrant, for an aggregate purchase price of approximately $230 million. The pre-funded warrants are exercisable at any time after the date of issuance. A holder of pre-funded warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. A holder of pre-funded warrants may increase or decrease this percentage to a percentage not in excess of 19.99% by providing at least 61 days’ prior notice to the Company.

Risks and Uncertainties

The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on its key personnel, market acceptance of products, product liability, protection of proprietary technology, ability to raise additional financing and compliance with government regulations. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve profitability.

The Company’s lead product candidate that is in development and any future product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure, and extensive compliance-reporting capabilities. Even if its product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales.

Liquidity

In accordance with Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the accompanying unaudited condensed consolidated financial statements were issued (the “issuance date”):

Since its inception, the Company has funded its operations primarily with outside capital and has incurred significant recurring losses, including net losses of $13.7 million and $7.1 million for the three months ended March 31, 2024 and 2023, respectively. In addition, the Company had an accumulated deficit of $103.2 million as of March 31, 2024;
The Company expects to continue to incur significant recurring losses and rely on outside capital to fund its operations for the foreseeable future; and
As of the issuance date, the Company expects that its existing cash, cash equivalents and short-term investments on hand will be sufficient to fund its obligations as they become due for at least twelve months beyond the issuance date. The Company expects that its research and development and general and administrative costs will continue to increase significantly, including in connection with conducting clinical trials and manufacturing for its existing product candidate and any future product candidates to support commercialization and providing general and administrative support for its operations, including the costs associated with operating as a public company.

In the event the Company is unable to secure additional outside capital, management will be required to seek other alternatives which may include, among others, a delay or termination of clinical trials or the development of its product candidates, temporary or permanent curtailment of the Company’s operations, a sale of assets, or other alternatives with strategic or financial partners.

The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties. Accordingly, the unaudited condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.

XML 17 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2024
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements as of March 31, 2024 and for the three months ended March 31, 2024 and 2023 have been prepared in conformity with U.S. GAAP, for interim financial information and pursuant to Article 10 of Regulation S-X of the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s audited financial statements and include only normal and recurring adjustments that the Company believes are necessary to fairly state the Company’s financial position and the results of its operations and cash flows. The results for the three months ended March 31, 2024 are not necessarily indicative of the results expected for the full fiscal year or any subsequent interim period. The unaudited condensed consolidated balance sheet as of December 31, 2023 has been derived from the audited financial statements at that date but does not include all disclosures required by U.S. GAAP for complete financial statements. Because all of the disclosures required by U.S. GAAP for complete financial statements are not included herein, these unaudited condensed consolidated financial statements and the notes accompanying them should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2023, which are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (“SEC”) on March 21, 2024. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results may differ materially from those estimates.

Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates including the following: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Significant estimates are used in the following areas, among others: the recognition of research and development expense, stock-based compensation expense and revenue recognition.

Cash and Cash Equivalents

All short-term, highly liquid investments with original maturities of 90 days or less are considered to be cash and cash equivalents. The carrying amounts reported in the unaudited condensed consolidated balance sheets for cash and cash equivalents are valued at cost, which approximates fair value.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and short-term investments. The Company regularly maintains deposits in accredited financial institutions in excess of federally insured limits. The Company invests its excess cash primarily in money market funds, U.S. treasury securities and U.S. government agency securities in accordance with the Company’s investment policy. The Company’s investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. The Company has not experienced any realized losses related to its cash, cash equivalents and short-term investments and management believes the Company is not exposed to significant risks of losses.

As of March 31, 2024 and December 31, 2023, the Company held cash deposits at Silicon Valley Bank (“SVB”) in excess of government insured limits. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation was appointed as receiver. No losses were incurred by the Company on deposits that were held at SVB. Management believes that the Company is not currently exposed to significant credit risk as the vast majority of the Company’s deposits were either owned directly by the Company and held in custody at a third-party financial institution or, subsequent to March 10, 2023, have been transferred to a third-party financial institution. The Company does not currently have any other significant relationships with SVB.

Short-term Investments

Short-term investments consist of investments in U.S. treasury and U.S. government agency securities. Management of the Company determines the appropriate classification of the securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. The Company classifies its short-term investments as available-for-sale pursuant to ASC 320, Investments – Debt and Equity Securities, and reports them at fair value in short-term investments with unrealized gains and losses reported as a component of accumulated other comprehensive income loss on the unaudited condensed consolidated balance sheet. Realized gains and losses and declines in value judged to be other than temporary are included as a component of interest income based on the specific identification method.

When the fair value is below the amortized cost of a marketable security, an estimate of expected credit losses is made in accordance with ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The credit-related impairment amount is recognized in the unaudited condensed consolidated statements of operations and comprehensive loss. Credit losses are recognized through the use of an allowance for credit losses account in the unaudited condensed consolidated balance sheet and subsequent improvements in expected credit losses are recognized as a reversal of an amount in the allowance account. If the Company has the intent to sell the security or it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis, then the allowance for the credit loss is written-off and the excess of the amortized cost basis of the asset over its fair value is recorded in the unaudited condensed consolidated statements of operations and comprehensive loss. There were no credit losses recorded during the three months ended March 31, 2024 or 2023.

Additional information regarding short-term investments is included in Note 4.

Receivable from Related Party and Unbilled Receivable from Related Party

The receivable from related party and unbilled receivable from related party results from option and license agreements with Zenas BioPharma Limited (“Zenas”), a related party. See Notes 13 and 16 for more information. The receivable represents amounts earned and billed to Zenas but not yet collected while unbilled receivable represents amounts earned but not yet billed to Zenas. The receivable and unbilled receivable are reported at net realizable value. The Company regularly evaluates the creditworthiness of Zenas and their financial condition and does not require collateral from Zenas. As of March 31, 2024 and December 31, 2023, no allowance for doubtful accounts was recorded as all accounts were considered collectible.

Property and Equipment

Property and equipment are recorded at cost. Depreciation is provided using the straight-line method over estimated useful lives of three years for computer equipment and five years for furniture and fixtures. Expenditures for major renewals and betterments that extend the useful lives are capitalized. Expenditures for normal maintenance and repairs are expensed as incurred. The cost of assets sold or abandoned, and the related accumulated depreciation are eliminated from the accounts and any gains or losses are recognized in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss of the respective period.

Leases

Operating leases are accounted for in accordance with ASU 2016-02, Leases, as amended (“ASC 842”). Right-of-use lease assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company’s leases do not provide an implicit rate, management used the Company’s incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The right-of-use asset is based on the measurement of the lease liability and includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. Rent expense for operating leases is recognized on a straight-line basis over the lease term. The Company does not have any leases classified as finance leases. Management have elected the practical expedient to exclude short-term leases from right-of-use assets and lease liabilities.

The Company’s leases do not have significant rent escalation, holidays, concessions, material residual value guarantees, material restrictive covenants or contingent rent provisions. The Company’s leases include both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component as management have elected the practical expedient to group lease and non-lease components for all leases.

Additional information and disclosures required under ASC 842 are included in Note 9.

Restricted Cash

In accordance with ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, restricted cash is included as a component of cash, cash equivalents and restricted cash in the accompanying unaudited condensed consolidated statements of cash flows. Restricted cash serves as collateral for a letter of credit securing office space. Restricted cash is recorded within other assets and restricted cash line item in the accompanying unaudited condensed consolidated balance sheet.

Fair Value Measurements

The Company calculates the fair value of assets and liabilities that qualify as financial instruments and includes additional information in the notes to the unaudited condensed consolidated financial statements when the fair value is different than the carrying value of these financial instruments.

The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. ASC Topic 820, Fair Value Measurements and Disclosures (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available.

Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect management’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality.

The three levels of the fair value hierarchy are described below:

Level 1 - Quoted prices in active markets for identical assets or liabilities.
Level 2 - Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs.

To the extent that a valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by management in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

Management has segregated all financial assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. The Company’s valuation techniques for its Level 2 financial assets included using quoted prices for similar assets in active markets and quoted prices for similar assets in markets that are not active.

The estimated fair value of receivable from related party, unbilled receivable from related party, accounts payable and accrued expenses approximate their carrying amounts due to the relatively short maturity of these instruments.

Additional information regarding fair value measurements is included in Note 7.

Classification of Convertible Preferred Stock

Convertible preferred stock was recorded at its original issuance price, less direct and incremental offering costs, as stipulated by its terms. The Company had applied the guidance in ASC 480-10-S99, Distinguishing Liabilities from Equity-Overall-SEC Materials, and had therefore classified the convertible preferred stock outside of stockholders’ equity/(deficit). In September 2023, all outstanding shares of convertible preferred stock were converted into shares of common stock immediately prior to the effective time of the Reverse Merger. Additional information and disclosures are included in Note 11.

Segment Information

Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s CODM is its Chief Executive Officer (“CEO”). The Company operates as a single operating segment and has one reportable segment.

License Revenue – Related Party

To date, the Company’s only revenue has been attributable to an upfront payment and cost reimbursements under the Company’s license agreement with Zenas. The Company has not generated any revenue from product sales and does not expect to generate any revenue from product sales for the foreseeable future.

The Company recognizes revenue pursuant to ASC 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the performance obligation is satisfied.

The Company evaluates the performance obligations promised in a contract that are based on goods and services that will be transferred to the customer and determine whether those obligations are both (i) capable of being distinct and (ii) distinct in the context of the contract. To the extent a contract includes multiple promised goods and services, the Company applies judgment to determine whether promised goods and services are both capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations.

The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential transaction price and the likelihood that the transaction price will be received. Variable consideration is included in the transaction price if, in management’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. The Company then allocates the transaction price to each performance obligation and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied.

Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company’s unaudited condensed consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve months this will be classified in current liabilities.

Additional information and disclosures required under ASC 606 are included in Note 13.

Research and Development Costs

Research and development expenses are recorded as expense, as incurred. Research and development expenses consists of (i) costs to engage contractors who specialize in the development activities of the Company; (ii) external research and development costs incurred under arrangements with third parties, such as contract research organizations and consultants; and (iii) costs associated with preclinical activities and regulatory operations.

The Company enters into consulting, research, and other agreements with commercial firms, researchers, and others for the provision of goods and services. Under such agreements, the Company may pay for services on a monthly, quarterly, project or other basis. Such arrangements are generally cancelable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided by the service providers and vendors, whereas payments are dictated by the terms of each agreement. As such, depending on the timing of payment relative to the receipt of goods or services, management may record either prepaid expenses or accrued services. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company.

Patent Costs

Patent costs are expensed as incurred and recorded within general and administrative expenses.

Income Taxes

Income taxes are recorded in accordance with ASC 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities and for loss and credit carryforwards using enacted tax rates anticipated to be in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if, based upon the weight of available evidence, it is more likely than not that some or all the deferred tax assets will not be realized.

The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position, as well as consideration of the available facts and circumstances. As of March 31, 2024 and December 31, 2023, the Company did not have any material uncertain tax positions. The Company recognizes interest and penalties related to uncertain tax positions, if any exist, in income tax expense.

Stock-Based Compensation

The Company accounts for stock-based compensation awards in accordance with ASC Topic 718, Compensation – Stock Compensation (“ASC 718”). ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the unaudited condensed consolidated statements of operations and comprehensive loss based on their fair values. All of the stock-based awards are subject only to service-based vesting conditions. Management estimates the fair value of the stock option awards using the Black-Scholes option pricing model, which requires the input of assumptions, including (a) the fair value of the Company’s common stock, (b) the expected stock price volatility, (c) the calculation of expected term of the award, (d) the risk-free interest rate and (e) expected dividends. Management estimates the fair value of the restricted stock awards, if any, using the fair value of the Company’s common stock. Forfeitures are recognized as they are incurred.

Prior to the Reverse Merger, management utilized valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation, to estimate the fair value of Former Dianthus common stock. Each valuation methodology included estimates and assumptions that required management’s judgment. These estimates and assumptions included objective and subjective factors, including external market conditions, the prices at which Former Dianthus sold shares of convertible preferred stock, the superior rights and preferences of the convertible preferred stock senior to Former Dianthus common stock at the time, and a probability analysis of various liquidity events, such as a public offering or sale of Former Dianthus, under differing scenarios. Changes to the key assumptions used in the valuations could have resulted in materially different fair values of Former Dianthus common stock at each valuation date. Following the Reverse Merger, the fair value of the Company’s common stock is based on the closing stock price on the date of grant as reported on the Nasdaq Capital Market.

Prior to the Reverse Merger, due to a lack of company-specific historical and implied volatility data, management based its estimate of expected volatility on the historical volatility of a representative group of companies with similar characteristics to the Company, including stage of product development and life science industry focus. Management believes the group selected had sufficiently similar economic and industry characteristics and includes companies that are most representative of the Company. Following the Reverse Merger, expected volatility at the date of grant is estimated using a “look-back” period, which coincides with the expected term, of the Company's stock price as reported on the Nasdaq Capital Market.

Management uses the simplified method, as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term. The risk-free interest rate is based on observed interest rates appropriate for the term of the awards. The dividend yield assumption is based on history and expectation of paying no dividends.

Compensation expense related to stock-based awards is calculated on a straight-line basis by recognizing the grant date fair value, over the associated service period of the award, which is generally the vesting term.

Additional information regarding stock-based compensation is included in Note 12.

Comprehensive Loss

The only component of comprehensive loss other than net loss is change in unrealized gains/losses related to available-for-sale debt securities.

Net Loss per Share

Basic and diluted net loss per share attributable to common stockholders are calculated in conformity with the two-class method required for participating securities. Convertible preferred stock is a participating security in distributions of the Company. During the three months ended March 31, 2023, the net loss attributable to common stockholders was not allocated to the convertible preferred shares as the holders of convertible preferred shares did not have a contractual obligation to share in losses. Under the two-class method, basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. During the three months ended March 31, 2023, the weighted-average number of shares of common stock outstanding used in the basic net loss per share calculation did not include unvested restricted common stock as these shares were considered contingently issuable shares until they vested.

Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, stock options and unvested restricted common stock, if any, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. For all periods presented, basic and diluted net loss per share were the same, as any additional share equivalents would be anti-dilutive.

Additional information is included in Note 14.

Recently Issued Accounting Pronouncements

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods beginning after December 14, 2024, with early adoption permitted. The Company is currently evaluating the guidance and has not determined the impact this standard may have on the consolidated financial statements.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures, to enhance the transparency and decision usefulness of income tax disclosures. The enhancement will provide information to better assess how an entity’s operations and related tax risks and tax planning and operational opportunities affect its tax rate and prospects for future cash flows. Investors currently rely on the rate reconciliation table and other disclosures, including total income taxes paid, to evaluate income tax risks and opportunities. ASU No. 2023-09 is effective for fiscal years beginning after December 15, 2024 and early adoption is permitted. The Company is currently evaluating the impact ASU No. 2023-09 will have on the consolidated financial statements and related disclosures.

XML 18 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Reverse Merger
3 Months Ended
Mar. 31, 2024
Business Combination and Asset Acquisition [Abstract]  
Reverse Merger

3. Reverse Merger

As described in Note 1, Merger Sub merged with and into Former Dianthus, with Former Dianthus surviving as a wholly owned subsidiary of the Company on September 11, 2023. The Reverse Merger was accounted for as a reverse asset acquisition accounted for as a reverse recapitalization in accordance with U.S. GAAP with Former Dianthus as the accounting acquirer of Magenta. At the effective time of the Reverse Merger, substantially all of the assets of Magenta consisted of cash and cash equivalents, marketable securities, as well as other nominal non-operating assets. Under such reverse recapitalization accounting, the assets and liabilities of Magenta were recorded at their fair value in Magenta’s financial statements at the effective time of the Merger, which approximated book value due to the short-term nature. No goodwill or intangible assets were recognized.

As part of the recapitalization, the Company obtained the assets and liabilities listed below:

 

Cash and cash equivalents

 

$

69,738

 

Other current assets

 

 

2,473

 

Accrued liabilities

 

 

(616

)

Net assets acquired

 

$

71,595

 

 

With respect to the CVRs issued in connection with the Reverse Merger, the Company believes that the achievement of the milestones outlined in the CVR Agreement are highly susceptible to factors outside the Company's influence that are not expected to be resolved for a long period of time, if at all. In particular, these amounts are primarily influenced by the actions and judgments of third parties and the buyers of such assets and are based on the buyers of such assets progressing the in-process research and development assets into clinical trials, and in the case of one of the agreements, to a regulatory milestone. If the Company were to

record a receivable for such contingent payments, it would also record a corresponding liability. As of March 31, 2024, no receivables are recorded on the unaudited condensed consolidated balance sheet relating to such contingent payments.

XML 19 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Short-Term Investments
3 Months Ended
Mar. 31, 2024
Short-Term Investments [Abstract]  
Short-Term Investments

4. Short-Term Investments

The following table provides a summary of short-term investments:

 

 

March 31, 2024

 

 

Amortized
Cost

 

 

Gross
Unrealized
Gain

 

 

Gross
Unrealized
Loss

 

 

Fair Value

 

Available-for-sale, short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

$

46,327

 

 

$

2

 

 

$

(27

)

 

$

46,302

 

U.S. government agency securities

 

 

1,011

 

 

 

 

 

 

(1

)

 

 

1,010

 

Total available-for-sale, short-term investments

 

$

47,338

 

 

$

2

 

 

$

(28

)

 

$

47,312

 

 

 

December 31, 2023

 

 

Amortized
Cost

 

 

Gross
Unrealized
Gain

 

 

Gross
Unrealized
Loss

 

 

Fair Value

 

Available-for-sale, short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

$

36,370

 

 

$

48

 

 

$

 

 

$

36,418

 

U.S. government agency securities

 

 

4,976

 

 

 

 

 

 

(1

)

 

 

4,975

 

Total available-for-sale, short-term investments

 

$

41,346

 

 

$

48

 

 

$

(1

)

 

$

41,393

 

XML 20 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Prepaid Expenses and Other Current Assets
3 Months Ended
Mar. 31, 2024
Prepaid Expense and Other Assets, Current [Abstract]  
Prepaid Expenses and Other Current Assets

5. Prepaid Expenses and Other Current Assets

The following table provides a summary of prepaid expenses and other current assets:

 

 

March 31,
2024

 

 

December 31,
2023

 

Prepaid materials, supplies and research and development services

 

$

1,512

 

 

$

2,155

 

Prepaid subscriptions, software and other administrative services

 

 

1,030

 

 

 

504

 

Prepaid insurance

 

 

472

 

 

 

596

 

Prepaid expenses and other current assets

 

$

3,014

 

 

$

3,255

 

XML 21 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment
3 Months Ended
Mar. 31, 2024
Property, Plant and Equipment [Abstract]  
Property and Equipment

6. Property and Equipment

The following table provides a summary of property and equipment:

 

 

March 31,
2024

 

 

December 31,
2023

 

Computer equipment

 

$

263

 

 

$

234

 

Furniture and fixtures

 

 

51

 

 

 

48

 

Subtotal

 

 

314

 

 

 

282

 

Less: accumulated depreciation

 

 

(119

)

 

 

(97

)

Property and equipment, net

 

$

195

 

 

$

185

 

 

Depreciation expense was $22 and $14 in the three months ended March 31, 2024 and 2023, respectively.
XML 22 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value of Financial Instruments
3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments

7. Fair Value of Financial Instruments

The following table provides a summary of financial assets measured at fair value on a recurring basis:

 

 

Fair Value at

 

 

 

 

 

 

 

 

 

 

Description

 

March 31,
2024

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Recurring Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

327,973

 

 

$

327,973

 

 

$

 

 

$

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

 

46,302

 

 

 

46,302

 

 

 

 

 

 

 

U.S. government agency securities

 

 

1,010

 

 

 

 

 

 

1,010

 

 

 

 

Total assets measured at fair value

 

$

375,285

 

 

$

374,275

 

 

$

1,010

 

 

$

 

 

 

Fair Value at

 

 

 

 

 

 

 

 

 

 

 

December 31,

 

 

 

 

 

 

 

 

 

 

Description

 

2023

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Recurring Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

131,193

 

 

$

131,193

 

 

$

 

 

$

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

 

36,418

 

 

 

36,418

 

 

 

 

 

 

 

U.S. government agency securities

 

 

4,975

 

 

 

 

 

 

4,975

 

 

 

 

Total assets measured at fair value

 

$

172,586

 

 

$

167,611

 

 

$

4,975

 

 

$

 

 

There were no transfers between levels for the three months ended March 31, 2024 or for the year ended December 31, 2023.

XML 23 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accrued Expenses
3 Months Ended
Mar. 31, 2024
Accrued Expenses

8. Accrued Expenses

The following table provides a summary of accrued expenses:

 

 

March 31,
2024

 

 

December 31,
2023

 

Accrued issuance costs in connection with the private placement

 

$

2,213

 

 

$

 

Accrued external research and development

 

 

1,635

 

 

 

456

 

Accrued compensation

 

 

1,443

 

 

 

5,361

 

Accrued professional fees

 

 

345

 

 

 

422

 

Other accrued expenses

 

 

211

 

 

 

265

 

Accrued expenses

 

$

5,847

 

 

$

6,504

 

XML 24 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Leases
3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Leases

9. Leases

The Company leases space under operating leases for administrative offices in New York, New York, and Waltham, Massachusetts and wet laboratory space in Watertown, Massachusetts. The Company also leased office space under operating leases, which had a non-cancelable lease term of less than one year and, therefore, management elected the practical expedient to exclude these short-term leases from right-of-use assets and lease liabilities.

The following table provides a summary of the components of lease costs and rent:

 

 

Three Months Ended March 31,

 

 

2024

 

 

2023

 

Operating lease cost

 

$

103

 

 

$

87

 

Variable lease cost

 

 

8

 

 

 

7

 

Total operating lease costs

 

$

111

 

 

$

94

 

 

The Company recorded operating lease costs of $95 and $94 within the general and administrative expenses line item in the unaudited condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2024 and 2023, respectively. The Company recorded the operating lease costs of $16 and nil within the research and development expenses line item in the unaudited condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2024 and 2023, respectively.

Maturities of operating lease liabilities, which do not include short-term leases, as of March 31, 2024, are as follows:

 

2024 (remaining 9 months)

 

$

314

 

2025

 

 

222

 

Total undiscounted operating lease payments

 

 

536

 

Less: imputed interest

 

 

(39

)

Present value of operating lease liabilities

 

$

497

 

 

 

 

 

Balance sheet classification:

 

 

 

Current portion of operating lease liabilities

 

$

400

 

Long-term operating lease liabilities

 

 

97

 

Total operating lease liabilities

 

$

497

 

 

The weighted-average remaining term of operating leases was 16 months and the weighted-average discount rate used to measure the present value of operating lease liabilities was 10.7% as of March 31, 2024.
XML 25 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Common Stock
3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Common Stock

10. Common Stock

At the closing of the private placement on January 24, 2024, the Company issued 14,500,500 shares of common stock and pre-funded warrants to purchase 4,666,332 shares of common stock with a $0.001 per share exercise price. The pre-funded warrants are exercisable at any time after the date of issuance.

At the effective time of the Reverse Merger on September 11, 2023, the Company issued an aggregate of 11,021,248 shares of Company common stock to the Former Dianthus stockholders, based on the exchange ratio of approximately 0.2181 shares of Company common stock for each share of Former Dianthus common stock, including those shares of Former Dianthus common stock issued upon the conversion of Former Dianthus preferred stock and those shares of the Former Dianthus common stock issued in the pre-closing financing. In conjunction with the pre-closing financing, the Company also issued pre-funded warrants to purchase 210,320 shares of common stock with a $0.001 per share exercise price. The pre-funded warrants are exercisable at any time after the date of issuance.

As of March 31, 2024 and December 31, 2023, the Company was authorized to issue up to 150,000,000 shares of $0.001 par value of Company common stock. As of March 31, 2024 and December 31, 2023, the Company had issued and outstanding shares of common stock of 29,348,626 and 14,817,696, respectively.

Each share of Company common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Company’s board of directors, if any. No dividends have been declared or paid by the Company through March 31, 2024.

The Company had the following shares of Company common stock reserved for future issuance as of March 31, 2024 and December 31, 2023:

 

 

As of March 31, 2024

 

 

As of December 31, 2023

 

Issuance of common stock upon exercise of stock options

 

 

3,097,438

 

 

 

1,749,475

 

Equity awards available for grant under stock award plans

 

 

441,590

 

 

 

879,461

 

Shares available for issuance under the Employee Stock Purchase Plan

 

 

99,578

 

 

 

37,078

 

Issuance of common stock upon exercise of warrants

 

 

4,881,329

 

 

 

214,997

 

Total common stock reserved for future issuance

 

 

8,519,935

 

 

 

2,881,011

 

XML 26 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Preferred Stock and Convertible Preferred Stock
3 Months Ended
Mar. 31, 2024
Stockholders' Equity Note [Abstract]  
Preferred Stock and Convertible Preferred Stock

11. Preferred Stock and Convertible Preferred Stock

Preferred Stock

As of March 31, 2024, the Company was authorized to issue up to 10,000,000 shares of preferred stock at a par value of $0.001. As of March 31, 2024, no shares of preferred stock were issued and outstanding.

Convertible Preferred Stock

On September 11, 2023, the Company completed the Reverse Merger with Former Dianthus in accordance with the Merger Agreement. Under the terms of the Merger Agreement, immediately prior to the effective time of the Reverse Merger, each share of Former Dianthus convertible preferred stock was converted into a share of Former Dianthus common stock. At closing of the Reverse Merger, the Company issued an aggregate of 7,269,183 shares of its common stock to Former Dianthus convertible preferred stockholders, based on the exchange ratio of approximately 0.2181 shares of Company common stock for each share of Former Dianthus common stock outstanding immediately prior to the Reverse Merger.

XML 27 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-Based Compensation
3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation

12. Stock-Based Compensation

2018 Stock Option and Incentive Plan

The Company grants stock-based awards under the Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan (the “2018 Incentive Plan”), which originally became effective on June 19, 2018 as the Magenta Therapeutics, Inc. 2018 Stock Option and Incentive Plan and was amended and restated in September 2023 and renamed the Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan. The 2018 Incentive Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, unrestricted stock awards, cash-based awards, and dividend equivalent rights. In connection with the Reverse Merger, the 2018 Incentive Plan also provided for the assumption of shares remaining available for delivery under the 2019 Stock Plan (as defined below), and such shares will be available for the granting of awards under the 2018 Incentive Plan in accordance with applicable stock exchange requirements. The Company also has outstanding stock options under the Magenta Therapeutics, Inc. 2016 Stock Option and Grant Plan, as amended (the “2016 Plan”), but is no longer granting awards under the 2016 Plan.

The 2018 Incentive Plan provides that the number of shares reserved and available for issuance under the 2018 Incentive Plan will automatically increase each January 1 by 4% of the outstanding number of shares of the Company’s common stock on the immediately preceding December 31 or such lesser number of shares as determined by the Company’s board of directors or compensation committee of the board of directors. The number of shares reserved for issuance under the 2018 Incentive Plan increased by 592,707 on January 1, 2024. Shares of common stock underlying any awards under the 2018 Incentive Plan, the 2019 Stock Plan and the 2016 Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) will be available for future awards under the 2018 Incentive Plan. As of March 31, 2024, 171,590 shares of the Company’s common stock were available for grant under the 2018 Incentive Plan.

The 2018 Incentive Plan is administered by either the board of directors or the compensation committee of the board of directors. The exercise prices, vesting and other restrictions are determined at the discretion of the administrator, except that the term of stock options and stock appreciation rights may not be greater than ten years (or five years for certain incentive stock options). Awards typically vest over 12 months to four years. The exercise price for stock options granted may not be less than the fair value of

common stock as of the date of grant (or 110% of the fair value of common stock for certain incentive stock options). The fair value of common stock is based on quoted market prices.

2019 Stock Plan

In July 2019, Former Dianthus’ Board of Directors adopted, and the Former Dianthus’ stockholders approved, the Dianthus Therapeutics, Inc. 2019 Stock Plan (the “2019 Stock Plan”). In connection with the Reverse Merger, the Company assumed options to purchase shares of Former Dianthus’s common stock that were outstanding under the 2019 Stock Plan immediately prior to the Reverse Merger and such options were converted into options to purchase 1,273,454 shares of Company’s common stock (the “Assumed Options”). No further awards will be made under the 2019 Stock Plan; however, the Assumed Options will remain outstanding under the 2019 Stock Plan in accordance with their terms, as adjusted to reflect the Reverse Merger.

2019 Employee Stock Purchase Plan

Employees may elect to participate in the Dianthus Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the “ESPP”). The purchase price of common stock under the ESPP is equal to 85% of the lower of the fair market value of the common stock on the offering date or the exercise date. The six-month offering periods previously began in December and June of each year. During the three months ended March 31, 2024 and 2023, there were no shares of common stock purchased under the ESPP. As of March 31, 2024, 99,578 shares remained available for issuance under the ESPP.

The ESPP provides that the number of shares reserved and available for issuance under the ESPP will automatically increase each January 1 through January 1, 2029, by the lesser of (i) 1% of the number of shares issued and outstanding on the immediately preceding December 31, (ii) 62,500 shares and (iii) such number of shares as determined by the Company’s board of directors or its appointed administrator. The number of shares reserved for issuance under the ESPP increased by 62,500 on January 1, 2024.

Stock Option Inducement Grant and Inducement Plan

In December 2023, the Company’s board of directors granted an option to purchase 96,000 shares of common stock to a new hire as an inducement grant. In February 2024, the Company’s board of directors approved the Dianthus Therapeutics, Inc. Equity Inducement Plan (the “Inducement Plan”), which provides for up to 300,000 shares of common stock for inducement awards. As of March 31, 2024, there were 270,000 shares available to be granted under the Inducement Plan.

Stock Options

The following table summarizes stock option activity for the three months ended March 31, 2024:

 

 

Number of
stock options
outstanding

 

 

Weighted
average
exercise price
per share

 

 

Weighted
average
remaining
contractual
term

 

 

Aggregate
intrinsic
value

 

 

 

 

 

 

 

 

(in years)

 

 

 

 

Balance at January 1, 2024

 

 

1,749,475

 

 

$

10.61

 

 

 

8.4

 

 

$

3,181

 

Options granted, fair value of $14.03 per share

 

 

1,400,200

 

 

 

18.10

 

 

 

 

 

 

16,669

 

Options exercised

 

 

(30,430

)

 

 

8.61

 

 

 

 

 

 

465

 

Options forfeited

 

 

(21,807

)

 

 

13.98

 

 

 

 

 

 

227

 

Balance at March 31, 2024

 

 

3,097,438

 

 

$

13.99

 

 

 

8.8

 

 

$

51,070

 

Exercisable options at March 31, 2024

 

 

776,110

 

 

$

11.81

 

 

 

7.8

 

 

$

15,598

 

Unvested options at March 31, 2024

 

 

2,321,328

 

 

$

14.72

 

 

 

9.1

 

 

$

35,472

 

 

The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the common stock for those options that had exercise prices lower than the fair value of the common stock.

The weighted average grant-date fair value per share of stock options granted during the three months ended March 31, 2024 was $14.03 per share.

The table below summarizes the assumptions used to determine the grant-date fair value of stock options issued, presented on a weighted average basis during the three months ended March 31, 2024 and 2023.

 

Three Months Ended March 31,

 

 

 

2024

 

 

2023

 

Risk-free interest rate

 

 

4.0

%

 

 

3.6

%

Expected term (in years)

 

 

6.0

 

 

6.1

 

Expected volatility

 

 

93.1

%

 

 

84.1

%

Expected dividend yield

 

 

0.0

%

 

 

0.0

%

Stock Warrants

In April 2021, Former Dianthus issued 4,677 warrants for the purchase of common stock at an exercise price of $1.65 per share. The warrants vested on July 30, 2023 and had a grant date fair value of $1.16 per warrant. Former Dianthus has not issued any warrants since April 2021. As of March 31, 2024, the warrants have a weighted average remaining contractual term of 7.1 years.

Stock-based Compensation Expense

The following table provides a summary of stock-based compensation expense related to stock options, restricted stock units, restricted stock, and warrants:

 

 

 

Three Months Ended March 31,

 

 

2024

 

 

2023

 

Research and development

 

$

839

 

 

$

191

 

General and administrative

 

 

1,196

 

 

 

342

 

Total stock-based compensation expense

 

$

2,035

 

 

$

533

 

 

As of March 31, 2024, there was $25.2 million of total unrecognized compensation cost related to granted stock options. The Company expects to recognize that cost over a remaining weighted-average period of 3.3 years.

XML 28 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
License Revenue - Related Party
3 Months Ended
Mar. 31, 2024
Related Party Transactions [Abstract]  
License Revenue - Related Party

13. License Revenue – Related Party

In September 2020, the Company entered into an Option Agreement with Zenas (“Zenas Option”), a related party (See Note 16). Through the Zenas Option, the Company provided Zenas an option to enter into an exclusive license agreement for the development and commercialization of products arising from its research of monoclonal antibody antagonists targeting certain specific complement proteins.

In September 2021, the Company notified Zenas that it had elected the first antibody sequence as a clinical candidate. In October 2021, Zenas notified the Company that it was exercising its option for such clinical candidate. The Zenas Option provided that upon the exercise of the option, the Company would negotiate in good faith a license agreement with Zenas pursuant to which it would grant Zenas the exclusive license with respect to the antibody sequences for the Zenas territory, which includes People’s Republic of China, including Hong Kong, Macau, and Taiwan. In accordance with Zenas Option, within 60 days following the execution of a license agreement, Zenas agreed to pay the Company a one-time payment of $1.0 million for the exercise of the corresponding option. In addition, in connection with the exercise of the Zenas Option, Zenas was required to reimburse the Company for a portion of chemistry, manufacturing, and controls-related (“CMC”) costs and expenses from the date of delivery of its option exercise notice through the execution of a license agreement.

In June 2022, the Company and Zenas executed the license agreement (“Zenas License”). The Zenas Option and Zenas License are collectively referred to as the “Zenas Agreements.” The Zenas License provides Zenas with a license in the People’s Republic of China, including Hong Kong, Macau, and Taiwan, for the development and commercialization of sequences and products under the first antibody sequence. The Company is also obligated to perform certain research and development and CMC services, and will also participate in a joint steering committee (“JSC”). Under the Zenas License, Zenas also has the right to exercise an option with respect to a second antibody sequence. If Zenas exercises the option and pays the Company the option exercise fee related to the second antibody sequence, the Company will grant Zenas an exclusive license to the sequences and products under this second antibody sequence.

Since the Zenas Agreements were negotiated with a single commercial objective, they are treated as a combined contract for accounting purposes. The Company assessed the Zenas Agreements in accordance with ASC 606 and concluded that it represents a contract with a customer and is within the scope of ASC 606. The Company determined that there is one combined performance obligation that consists of the license and data transfer, the research and development and CMC services, and the participation in the JSC. The Company determined that Zenas’ right to exercise an option with respect to a second antibody sequence does not represent a material right.

The consideration under the Zenas Agreements includes the following payments by Zenas to the Company: (i) a $1.0 million upfront payment upon execution of the Zenas License; (ii) an approximate $1.1 million payment representing reimbursement for a portion of development costs previously incurred by the Company; (iii) reimbursement of a portion of all CMC-related costs and expenses for the first antibody sequence through the manufacture of the first two batches of drug product; (iv) reimbursement of a portion of all non-CMC-related costs and expenses for the development of the first antibody sequence through the first regulatory approval; (v) development milestones totaling up to $11.0 million; and (vi) royalties on net sales ranging from the mid-single digits to the low teens.

The Company determined that the combined performance obligation is satisfied over time; therefore, the Company will recognize the transaction price from the license agreement over the Company’s estimated period to complete its activities. The Company concluded that it will utilize a cost-based input method to measure its progress toward completion of its performance obligation and to calculate the corresponding amount of revenue to recognize each period. The Company believes this is the best measure of progress because other measures do not reflect how the Company transfers its performance obligation to Zenas. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs expected to be incurred for the combined performance obligation. These costs consist primarily of third-party contract costs. Revenue will be recognized based on the level of costs incurred relative to the total budgeted costs for the combined performance obligation. A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligation. In making such estimates, judgment is required to evaluate assumptions related to cost estimates.

The Company also determined that the milestone payments of $11.0 million are variable consideration under ASC 606 which need to be added to the transaction price when it is probable that a significant revenue reversal will not occur. Based on the nature of the milestones, such as the regulatory approvals which are generally not within the Company’s control, the Company will not consider achievement of this milestone to be probable until the uncertainty associated with such milestone has been resolved. When it is probable that a significant reversal of revenue will not occur, the milestone payment will be added to the transaction price for which the Company recognizes revenue. As of March 31, 2024, no milestones had been achieved.

There is a sales or usage-based royalty exception within ASC 606 that applies when a license of intellectual property is the predominant item to which the royalty relates. In accordance with this royalty exception, the Company will recognize royalty revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). As of March 31, 2024, no royalty revenue had been recognized.

For the three months ended March 31, 2024 and 2023, the Company recognized related party license revenue totaling $0.9 million and $0.5 million, respectively, associated with the Zenas Agreements. As of March 31, 2024, the Company recorded a related party receivable of $0.4 million, unbilled related party receivable of $0.4 million, current deferred related party revenue of $0.1 million and noncurrent deferred related party revenue of $0.7 million on its unaudited condensed consolidated balance sheet. As of December 31, 2023, the Company recorded a related party receivable of $0.3 million, unbilled related party receivable of $0.2 million, current deferred related party revenue of $0.1 million and noncurrent deferred related party revenue of $0.7 million on its unaudited condensed consolidated balance sheet.

XML 29 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Loss Per Share
3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Earnings Per Share [Text Block]

14. Net Loss Per Share

Basic and diluted net loss per share of common stock are calculated as follows:

 

 

 

Three Months Ended March 31,

 

 

2024

 

 

2023

 

Numerator:

 

 

 

 

 

 

Net loss

 

$

(13,748

)

 

$

(7,089

)

Denominator:

 

 

 

 

 

 

Weighted-average shares of common stock outstanding

 

 

25,665,475

 

 

 

875,279

 

Less: weighted-average unvested restricted shares of common stock

 

 

 

 

 

(570

)

Weighted-average shares used to compute net loss per share of common stock, basic and diluted

 

 

25,665,475

 

 

 

874,709

 

Net loss per share attributable to common stockholders, basic and diluted

 

$

(0.54

)

 

$

(8.10

)

 

The Company’s potential dilutive securities, which include convertible preferred stock, stock options, unvested restricted shares of common stock, and warrants for the purchase of common stock, have been excluded from the computation of diluted net loss per share as the effect would be antidilutive. Therefore, the weighted-average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share is the same. The following potential dilutive securities, presented on an as converted basis, were excluded from the calculation of net loss per share due to their anti-dilutive effect:

 

 

Three Months Ended March 31,

 

 

2024

 

 

2023

 

Convertible preferred stock (as converted)

 

 

 

 

 

7,269,183

 

Stock options outstanding

 

 

3,097,438

 

 

 

1,447,743

 

Unvested restricted shares of common stock

 

 

 

 

 

444

 

Warrants for the purchase of common stock

 

 

4,881,329

 

 

 

4,677

 

Total

 

 

7,978,767

 

 

 

8,722,047

 

XML 30 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

15. Commitments and Contingencies

Alloy Therapeutics, LLC

In August 2019, the Company entered into a license agreement with Alloy Therapeutics, LLC (“Alloy”). The license agreement was amended in October 2022. The license agreement with Alloy grants to the Company the following:

A worldwide, non-exclusive license to use the Alloy technology solely to generate Alloy antibodies and platform assisted antibodies for internal, non-clinical research purposes, and
With respect to Alloy antibodies and platform assisted antibodies that are selected by the Company for inclusion into a partnered antibody program, a worldwide, assignable license to make, have made, use, offer for sale, sell, import, develop, manufacture, and commercialize products comprising partnered antibody programs selected from Alloy antibodies and platform assisted antibodies in any field of use.

The Company pays annual license fees and annual partnered antibody program fees totaling $0.1 million to Alloy. The Company is also obligated to pay a $0.1 million fee to Alloy if the Company sublicenses a product developed with Alloy antibodies or platform assisted antibodies. Upon the achievement, with the first selected antibody for products developed with Alloy, of (i) certain development milestones and (ii) certain commercial milestones, the Company is obligated to make additional payments to Alloy of up to $1.8 million and $11.0 million, respectively. Upon the achievement, with the second selected antibody for products developed with Alloy, of (i) certain development milestones and (ii) certain commercial milestones, the Company is obligated to make additional payments to Alloy of up to $3.1 million and $15.0 million, respectively. The Company did not record any amounts owed under the Alloy license agreement during the three months ended March 31, 2024 or 2023.

OmniAb, Inc.

In September 2022, the Company entered into a commercial platform license agreement and services agreement with two subsidiaries of Ligand Pharmaceuticals Incorporated. In November 2022, Ligand spun-off these subsidiaries into a separate legal entity, OmniAb, Inc. (“OmniAb”). The platform license agreement and services agreement with OmniAb grants to the Company the following.

A worldwide, non-exclusive, non-sublicensable license under the OmniAb technology to use chicken animals (solely at OmniAb’s facilities and through OmniAb personnel) for generation of OmniAb antibodies for research purposes.
A worldwide, non-exclusive license under the OmniAb technology to use rodent animals (solely at approved contract research organization (“CRO”) facilities and through approved CRO personnel) for generation of OmniAb antibodies for research purposes. Such license is non-sublicensable except to an approved CRO.

Upon the achievement of certain development milestones, the Company is obligated to make additional payments to OmniAb of up to $12.2 million. Upon the achievement of certain commercial milestones, the Company is obligated to make royalty payments in the low to mid-single digits. The Company recorded nil and $0.1 million for amounts owed under the OmniAb license agreement within research and development expenses line item in the unaudited condensed consolidated statements of operations and comprehensive loss during the three months ended March 31, 2024 and 2023, respectively.

IONTAS Limited

In July 2020, the Company entered into a collaborative research agreement with IONTAS Limited (“IONTAS”) to perform certain milestone-based research and development activities for the Company under its first development program. This agreement was amended in January 2023 to extend their services to additional development programs. IONTAS provides dedicated resources to perform the research and development activities and receives compensation for those resources as well as success-based milestone payments.

Upon the achievement, with the first development program with IONTAS, of (i) certain development milestones and (ii) certain commercial milestones, the Company is obligated to make additional payments to IONTAS of up to £3.1 million (approximately $3.9 million based on the March 31, 2024 exchange rate) and £2.3 million (approximately $2.9 million based on the March 31, 2024 exchange rate), respectively. Upon the achievement, with the second development program with IONTAS, of certain development milestones, the Company is obligated to make additional payments to IONTAS of up to £2.5 million (approximately $3.2 million based on the March 31, 2024 exchange rate). The Company recorded $0.3 million and $0.4 million during the three months ended March 31, 2024 and 2023, respectively, for amounts owed under the IONTAS collaborative research license agreement within the research and development expenses line item in the unaudited condensed consolidated statement of operations and comprehensive loss.

Indemnification Agreements

In the ordinary course of business, the Company may provide indemnification of varying scope and terms to employees, consultants, vendors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. To date, the Company has not incurred any material costs as a result of such indemnification agreements. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and has not accrued any liabilities related to such obligations in its unaudited condensed consolidated financial statements as of March 31, 2024 and December 31, 2023.

Litigation

From time to time, the Company may be exposed to litigation relating to potential products and operations. The Company is not currently engaged in any legal proceedings that are expected, individually or in the aggregate, to have a material adverse effect on its financial condition, results of operations or cash flows.

Other

As of March 31, 2024 and December 31, 2023, the Company had standing agreements with consultants, contractors or service providers whose terms do not yield material long-term commitments.

XML 31 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Related Party Transactions
3 Months Ended
Mar. 31, 2024
Related Party Transactions [Abstract]  
Related Party Transactions

16. Related Party Transactions

Zenas BioPharma Limited

The Company is a party to option and license agreements with Zenas, a related party. The Company considers Zenas to be a related party because (i) Tellus BioVentures LLC (“Tellus”), whose sole member is a significant shareholder in the Company and serves as Chairman of the Board of Directors of the Company, is also a significant shareholder in Zenas and serves as Chief Executive Officer and Chairman of the Board of Directors of Zenas and (ii) Fairmount Healthcare Fund LP and Fairmount Healthcare Fund II LP (together, the “Fairmount Funds”), who are significant shareholders in the Company and have a seat on the Board of Directors of the Company, are also significant shareholders in Zenas and have a seat on the Board of Directors of Zenas. As of March 31, 2024, Tellus and affiliated entities owned approximately 5%, and the Fairmount Funds and affiliated entities owned approximately 9% of the Company’s outstanding shares. See Note 13 for more information. In connection with these agreements, the Company recognized $0.9 million and $0.5 million within the license revenue – related party line item in the unaudited condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024, the Company recorded a related party receivable of $0.4 million, unbilled related party receivable of $0.4 million, current deferred related party revenue of $0.1 million and noncurrent deferred related party revenue of $0.7 million on its unaudited condensed consolidated balance sheet. As of December 31, 2023, the Company recorded a related party receivable of $0.3 million, unbilled related party receivable of $0.2 million, current deferred related party revenue of $0.1 million and noncurrent deferred related party revenue of $0.7 million on its unaudited condensed consolidated balance sheet.

In 2020, Zenas issued 156,848 common shares to the Company in exchange for the Zenas Option. The Company determined that the fair value on the date of issuance and as of March 31, 2024 and December 31, 2023, respectively, was not material to its unaudited condensed consolidated financial statements. The Company used the measurement alternative as the measurement attribute for accounting for the Zenas common shares which does not require it to assess the fair value of the common stock at each reporting period as the fair value of the Zenas common shares is not readily determinable nor is there a reliable source for observable transactions from which the Company could determine a fair value. In addition, the Company does not have ready access to significant events occurring at Zenas. If the Company does identify observable price changes in orderly transactions for the identical or similar common shares of Zenas, the Company will measure the common shares at fair value as of the date that the observable transaction occurred.

On March 13, 2023, the Fairmount Funds issued promissory notes in the aggregate principal amount of $0.4 million to Former Dianthus at an interest rate of 4.5% per annum. On March 15, 2023, Former Dianthus repaid principal and interest in the amount of $0.4 million to the Fairmount Funds in satisfaction of its obligations under the promissory notes.
XML 32 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Subsequent Events
3 Months Ended
Mar. 31, 2024
Subsequent Events [Abstract]  
Subsequent Events

17. Subsequent Events

The Company evaluated subsequent events from March 31, 2024, the date of these unaudited condensed consolidated financial statements, through May 9, 2024, which represents the date the unaudited condensed consolidated financial statements were issued, for events requiring recording or disclosure in the unaudited condensed consolidated financial statements for the three months ended March 31, 2024. The Company concluded that no events have occurred that would require recognition or disclosure in the unaudited condensed consolidated financial statements.

XML 33 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2024
Basis of Presentation

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements as of March 31, 2024 and for the three months ended March 31, 2024 and 2023 have been prepared in conformity with U.S. GAAP, for interim financial information and pursuant to Article 10 of Regulation S-X of the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s audited financial statements and include only normal and recurring adjustments that the Company believes are necessary to fairly state the Company’s financial position and the results of its operations and cash flows. The results for the three months ended March 31, 2024 are not necessarily indicative of the results expected for the full fiscal year or any subsequent interim period. The unaudited condensed consolidated balance sheet as of December 31, 2023 has been derived from the audited financial statements at that date but does not include all disclosures required by U.S. GAAP for complete financial statements. Because all of the disclosures required by U.S. GAAP for complete financial statements are not included herein, these unaudited condensed consolidated financial statements and the notes accompanying them should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2023, which are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (“SEC”) on March 21, 2024. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results may differ materially from those estimates.

Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates including the following: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Significant estimates are used in the following areas, among others: the recognition of research and development expense, stock-based compensation expense and revenue recognition.

Cash and Cash Equivalents

Cash and Cash Equivalents

All short-term, highly liquid investments with original maturities of 90 days or less are considered to be cash and cash equivalents. The carrying amounts reported in the unaudited condensed consolidated balance sheets for cash and cash equivalents are valued at cost, which approximates fair value.

Concentration of Credit Risk

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and short-term investments. The Company regularly maintains deposits in accredited financial institutions in excess of federally insured limits. The Company invests its excess cash primarily in money market funds, U.S. treasury securities and U.S. government agency securities in accordance with the Company’s investment policy. The Company’s investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. The Company has not experienced any realized losses related to its cash, cash equivalents and short-term investments and management believes the Company is not exposed to significant risks of losses.

As of March 31, 2024 and December 31, 2023, the Company held cash deposits at Silicon Valley Bank (“SVB”) in excess of government insured limits. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation was appointed as receiver. No losses were incurred by the Company on deposits that were held at SVB. Management believes that the Company is not currently exposed to significant credit risk as the vast majority of the Company’s deposits were either owned directly by the Company and held in custody at a third-party financial institution or, subsequent to March 10, 2023, have been transferred to a third-party financial institution. The Company does not currently have any other significant relationships with SVB.

Short-term Investments

Short-term Investments

Short-term investments consist of investments in U.S. treasury and U.S. government agency securities. Management of the Company determines the appropriate classification of the securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. The Company classifies its short-term investments as available-for-sale pursuant to ASC 320, Investments – Debt and Equity Securities, and reports them at fair value in short-term investments with unrealized gains and losses reported as a component of accumulated other comprehensive income loss on the unaudited condensed consolidated balance sheet. Realized gains and losses and declines in value judged to be other than temporary are included as a component of interest income based on the specific identification method.

When the fair value is below the amortized cost of a marketable security, an estimate of expected credit losses is made in accordance with ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The credit-related impairment amount is recognized in the unaudited condensed consolidated statements of operations and comprehensive loss. Credit losses are recognized through the use of an allowance for credit losses account in the unaudited condensed consolidated balance sheet and subsequent improvements in expected credit losses are recognized as a reversal of an amount in the allowance account. If the Company has the intent to sell the security or it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis, then the allowance for the credit loss is written-off and the excess of the amortized cost basis of the asset over its fair value is recorded in the unaudited condensed consolidated statements of operations and comprehensive loss. There were no credit losses recorded during the three months ended March 31, 2024 or 2023.

Additional information regarding short-term investments is included in Note 4.

Receivable from Related Party and Unbilled Receivable from Related Party

Receivable from Related Party and Unbilled Receivable from Related Party

The receivable from related party and unbilled receivable from related party results from option and license agreements with Zenas BioPharma Limited (“Zenas”), a related party. See Notes 13 and 16 for more information. The receivable represents amounts earned and billed to Zenas but not yet collected while unbilled receivable represents amounts earned but not yet billed to Zenas. The receivable and unbilled receivable are reported at net realizable value. The Company regularly evaluates the creditworthiness of Zenas and their financial condition and does not require collateral from Zenas. As of March 31, 2024 and December 31, 2023, no allowance for doubtful accounts was recorded as all accounts were considered collectible.

Property and Equipment

Property and Equipment

Property and equipment are recorded at cost. Depreciation is provided using the straight-line method over estimated useful lives of three years for computer equipment and five years for furniture and fixtures. Expenditures for major renewals and betterments that extend the useful lives are capitalized. Expenditures for normal maintenance and repairs are expensed as incurred. The cost of assets sold or abandoned, and the related accumulated depreciation are eliminated from the accounts and any gains or losses are recognized in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss of the respective period.

Leases

Leases

Operating leases are accounted for in accordance with ASU 2016-02, Leases, as amended (“ASC 842”). Right-of-use lease assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company’s leases do not provide an implicit rate, management used the Company’s incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The right-of-use asset is based on the measurement of the lease liability and includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. Rent expense for operating leases is recognized on a straight-line basis over the lease term. The Company does not have any leases classified as finance leases. Management have elected the practical expedient to exclude short-term leases from right-of-use assets and lease liabilities.

The Company’s leases do not have significant rent escalation, holidays, concessions, material residual value guarantees, material restrictive covenants or contingent rent provisions. The Company’s leases include both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component as management have elected the practical expedient to group lease and non-lease components for all leases.

Additional information and disclosures required under ASC 842 are included in Note 9.

Restricted Cash

Restricted Cash

In accordance with ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, restricted cash is included as a component of cash, cash equivalents and restricted cash in the accompanying unaudited condensed consolidated statements of cash flows. Restricted cash serves as collateral for a letter of credit securing office space. Restricted cash is recorded within other assets and restricted cash line item in the accompanying unaudited condensed consolidated balance sheet.

Fair Value Measurements

Fair Value Measurements

The Company calculates the fair value of assets and liabilities that qualify as financial instruments and includes additional information in the notes to the unaudited condensed consolidated financial statements when the fair value is different than the carrying value of these financial instruments.

The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. ASC Topic 820, Fair Value Measurements and Disclosures (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available.

Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect management’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality.

The three levels of the fair value hierarchy are described below:

Level 1 - Quoted prices in active markets for identical assets or liabilities.
Level 2 - Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs.

To the extent that a valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by management in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

Management has segregated all financial assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. The Company’s valuation techniques for its Level 2 financial assets included using quoted prices for similar assets in active markets and quoted prices for similar assets in markets that are not active.

The estimated fair value of receivable from related party, unbilled receivable from related party, accounts payable and accrued expenses approximate their carrying amounts due to the relatively short maturity of these instruments.

Additional information regarding fair value measurements is included in Note 7.

Classification of Convertible Preferred Stock

Classification of Convertible Preferred Stock

Convertible preferred stock was recorded at its original issuance price, less direct and incremental offering costs, as stipulated by its terms. The Company had applied the guidance in ASC 480-10-S99, Distinguishing Liabilities from Equity-Overall-SEC Materials, and had therefore classified the convertible preferred stock outside of stockholders’ equity/(deficit). In September 2023, all outstanding shares of convertible preferred stock were converted into shares of common stock immediately prior to the effective time of the Reverse Merger. Additional information and disclosures are included in Note 11.

Segment Information

Segment Information

Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s CODM is its Chief Executive Officer (“CEO”). The Company operates as a single operating segment and has one reportable segment.

License Revenue - Related Party

License Revenue – Related Party

To date, the Company’s only revenue has been attributable to an upfront payment and cost reimbursements under the Company’s license agreement with Zenas. The Company has not generated any revenue from product sales and does not expect to generate any revenue from product sales for the foreseeable future.

The Company recognizes revenue pursuant to ASC 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the performance obligation is satisfied.

The Company evaluates the performance obligations promised in a contract that are based on goods and services that will be transferred to the customer and determine whether those obligations are both (i) capable of being distinct and (ii) distinct in the context of the contract. To the extent a contract includes multiple promised goods and services, the Company applies judgment to determine whether promised goods and services are both capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations.

The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential transaction price and the likelihood that the transaction price will be received. Variable consideration is included in the transaction price if, in management’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. The Company then allocates the transaction price to each performance obligation and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied.

Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company’s unaudited condensed consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve months this will be classified in current liabilities.

Additional information and disclosures required under ASC 606 are included in Note 13.

Research and Development Costs

Research and Development Costs

Research and development expenses are recorded as expense, as incurred. Research and development expenses consists of (i) costs to engage contractors who specialize in the development activities of the Company; (ii) external research and development costs incurred under arrangements with third parties, such as contract research organizations and consultants; and (iii) costs associated with preclinical activities and regulatory operations.

The Company enters into consulting, research, and other agreements with commercial firms, researchers, and others for the provision of goods and services. Under such agreements, the Company may pay for services on a monthly, quarterly, project or other basis. Such arrangements are generally cancelable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided by the service providers and vendors, whereas payments are dictated by the terms of each agreement. As such, depending on the timing of payment relative to the receipt of goods or services, management may record either prepaid expenses or accrued services. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company.

Patent Costs

Patent Costs

Patent costs are expensed as incurred and recorded within general and administrative expenses.

Income Taxes

Income Taxes

Income taxes are recorded in accordance with ASC 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities and for loss and credit carryforwards using enacted tax rates anticipated to be in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if, based upon the weight of available evidence, it is more likely than not that some or all the deferred tax assets will not be realized.

The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position, as well as consideration of the available facts and circumstances. As of March 31, 2024 and December 31, 2023, the Company did not have any material uncertain tax positions. The Company recognizes interest and penalties related to uncertain tax positions, if any exist, in income tax expense.

Stock-Based Compensation

Stock-Based Compensation

The Company accounts for stock-based compensation awards in accordance with ASC Topic 718, Compensation – Stock Compensation (“ASC 718”). ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the unaudited condensed consolidated statements of operations and comprehensive loss based on their fair values. All of the stock-based awards are subject only to service-based vesting conditions. Management estimates the fair value of the stock option awards using the Black-Scholes option pricing model, which requires the input of assumptions, including (a) the fair value of the Company’s common stock, (b) the expected stock price volatility, (c) the calculation of expected term of the award, (d) the risk-free interest rate and (e) expected dividends. Management estimates the fair value of the restricted stock awards, if any, using the fair value of the Company’s common stock. Forfeitures are recognized as they are incurred.

Prior to the Reverse Merger, management utilized valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation, to estimate the fair value of Former Dianthus common stock. Each valuation methodology included estimates and assumptions that required management’s judgment. These estimates and assumptions included objective and subjective factors, including external market conditions, the prices at which Former Dianthus sold shares of convertible preferred stock, the superior rights and preferences of the convertible preferred stock senior to Former Dianthus common stock at the time, and a probability analysis of various liquidity events, such as a public offering or sale of Former Dianthus, under differing scenarios. Changes to the key assumptions used in the valuations could have resulted in materially different fair values of Former Dianthus common stock at each valuation date. Following the Reverse Merger, the fair value of the Company’s common stock is based on the closing stock price on the date of grant as reported on the Nasdaq Capital Market.

Prior to the Reverse Merger, due to a lack of company-specific historical and implied volatility data, management based its estimate of expected volatility on the historical volatility of a representative group of companies with similar characteristics to the Company, including stage of product development and life science industry focus. Management believes the group selected had sufficiently similar economic and industry characteristics and includes companies that are most representative of the Company. Following the Reverse Merger, expected volatility at the date of grant is estimated using a “look-back” period, which coincides with the expected term, of the Company's stock price as reported on the Nasdaq Capital Market.

Management uses the simplified method, as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term. The risk-free interest rate is based on observed interest rates appropriate for the term of the awards. The dividend yield assumption is based on history and expectation of paying no dividends.

Compensation expense related to stock-based awards is calculated on a straight-line basis by recognizing the grant date fair value, over the associated service period of the award, which is generally the vesting term.

Additional information regarding stock-based compensation is included in Note 12.

Comprehensive Loss

Comprehensive Loss

The only component of comprehensive loss other than net loss is change in unrealized gains/losses related to available-for-sale debt securities.

Net Loss per Share

Net Loss per Share

Basic and diluted net loss per share attributable to common stockholders are calculated in conformity with the two-class method required for participating securities. Convertible preferred stock is a participating security in distributions of the Company. During the three months ended March 31, 2023, the net loss attributable to common stockholders was not allocated to the convertible preferred shares as the holders of convertible preferred shares did not have a contractual obligation to share in losses. Under the two-class method, basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. During the three months ended March 31, 2023, the weighted-average number of shares of common stock outstanding used in the basic net loss per share calculation did not include unvested restricted common stock as these shares were considered contingently issuable shares until they vested.

Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, stock options and unvested restricted common stock, if any, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. For all periods presented, basic and diluted net loss per share were the same, as any additional share equivalents would be anti-dilutive.

Additional information is included in Note 14.

Recently Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods beginning after December 14, 2024, with early adoption permitted. The Company is currently evaluating the guidance and has not determined the impact this standard may have on the consolidated financial statements.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures, to enhance the transparency and decision usefulness of income tax disclosures. The enhancement will provide information to better assess how an entity’s operations and related tax risks and tax planning and operational opportunities affect its tax rate and prospects for future cash flows. Investors currently rely on the rate reconciliation table and other disclosures, including total income taxes paid, to evaluate income tax risks and opportunities. ASU No. 2023-09 is effective for fiscal years beginning after December 15, 2024 and early adoption is permitted. The Company is currently evaluating the impact ASU No. 2023-09 will have on the consolidated financial statements and related disclosures.

XML 34 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2024
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share The following potential dilutive securities, presented on an as converted basis, were excluded from the calculation of net loss per share due to their anti-dilutive effect:

 

 

Three Months Ended March 31,

 

 

2024

 

 

2023

 

Convertible preferred stock (as converted)

 

 

 

 

 

7,269,183

 

Stock options outstanding

 

 

3,097,438

 

 

 

1,447,743

 

Unvested restricted shares of common stock

 

 

 

 

 

444

 

Warrants for the purchase of common stock

 

 

4,881,329

 

 

 

4,677

 

Total

 

 

7,978,767

 

 

 

8,722,047

 

XML 35 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Reverse Merger (Tables)
3 Months Ended
Mar. 31, 2024
Business Combination and Asset Acquisition [Abstract]  
Schedule of Company Obtained Assets and Liabilities

As part of the recapitalization, the Company obtained the assets and liabilities listed below:

 

Cash and cash equivalents

 

$

69,738

 

Other current assets

 

 

2,473

 

Accrued liabilities

 

 

(616

)

Net assets acquired

 

$

71,595

 

XML 36 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Short-Term Investments (Tables)
3 Months Ended
Mar. 31, 2024
Short-Term Investments [Abstract]  
Schedule of short-term investments

The following table provides a summary of short-term investments:

 

 

March 31, 2024

 

 

Amortized
Cost

 

 

Gross
Unrealized
Gain

 

 

Gross
Unrealized
Loss

 

 

Fair Value

 

Available-for-sale, short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

$

46,327

 

 

$

2

 

 

$

(27

)

 

$

46,302

 

U.S. government agency securities

 

 

1,011

 

 

 

 

 

 

(1

)

 

 

1,010

 

Total available-for-sale, short-term investments

 

$

47,338

 

 

$

2

 

 

$

(28

)

 

$

47,312

 

 

 

December 31, 2023

 

 

Amortized
Cost

 

 

Gross
Unrealized
Gain

 

 

Gross
Unrealized
Loss

 

 

Fair Value

 

Available-for-sale, short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

$

36,370

 

 

$

48

 

 

$

 

 

$

36,418

 

U.S. government agency securities

 

 

4,976

 

 

 

 

 

 

(1

)

 

 

4,975

 

Total available-for-sale, short-term investments

 

$

41,346

 

 

$

48

 

 

$

(1

)

 

$

41,393

 

XML 37 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Prepaid Expenses and Other Current Assets (Tables)
3 Months Ended
Mar. 31, 2024
Prepaid Expense and Other Assets, Current [Abstract]  
Summary of Prepaid Expenses and Other Current Assets

The following table provides a summary of prepaid expenses and other current assets:

 

 

March 31,
2024

 

 

December 31,
2023

 

Prepaid materials, supplies and research and development services

 

$

1,512

 

 

$

2,155

 

Prepaid subscriptions, software and other administrative services

 

 

1,030

 

 

 

504

 

Prepaid insurance

 

 

472

 

 

 

596

 

Prepaid expenses and other current assets

 

$

3,014

 

 

$

3,255

 

XML 38 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment (Tables)
3 Months Ended
Mar. 31, 2024
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment, Net

The following table provides a summary of property and equipment:

 

 

March 31,
2024

 

 

December 31,
2023

 

Computer equipment

 

$

263

 

 

$

234

 

Furniture and fixtures

 

 

51

 

 

 

48

 

Subtotal

 

 

314

 

 

 

282

 

Less: accumulated depreciation

 

 

(119

)

 

 

(97

)

Property and equipment, net

 

$

195

 

 

$

185

 

XML 39 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value of Financial Instruments (Tables)
3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets Measured at Fair Value on Recurring Basis

The following table provides a summary of financial assets measured at fair value on a recurring basis:

 

 

Fair Value at

 

 

 

 

 

 

 

 

 

 

Description

 

March 31,
2024

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Recurring Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

327,973

 

 

$

327,973

 

 

$

 

 

$

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

 

46,302

 

 

 

46,302

 

 

 

 

 

 

 

U.S. government agency securities

 

 

1,010

 

 

 

 

 

 

1,010

 

 

 

 

Total assets measured at fair value

 

$

375,285

 

 

$

374,275

 

 

$

1,010

 

 

$

 

 

 

Fair Value at

 

 

 

 

 

 

 

 

 

 

 

December 31,

 

 

 

 

 

 

 

 

 

 

Description

 

2023

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Recurring Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

131,193

 

 

$

131,193

 

 

$

 

 

$

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

 

36,418

 

 

 

36,418

 

 

 

 

 

 

 

U.S. government agency securities

 

 

4,975

 

 

 

 

 

 

4,975

 

 

 

 

Total assets measured at fair value

 

$

172,586

 

 

$

167,611

 

 

$

4,975

 

 

$

 

XML 40 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accrued Expenses (Tables)
3 Months Ended
Mar. 31, 2024
Schedule of Accrued Expenses

The following table provides a summary of accrued expenses:

 

 

March 31,
2024

 

 

December 31,
2023

 

Accrued issuance costs in connection with the private placement

 

$

2,213

 

 

$

 

Accrued external research and development

 

 

1,635

 

 

 

456

 

Accrued compensation

 

 

1,443

 

 

 

5,361

 

Accrued professional fees

 

 

345

 

 

 

422

 

Other accrued expenses

 

 

211

 

 

 

265

 

Accrued expenses

 

$

5,847

 

 

$

6,504

 

XML 41 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Leases (Tables)
3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Summary of the Components of Lease Costs and Rent

The following table provides a summary of the components of lease costs and rent:

 

 

Three Months Ended March 31,

 

 

2024

 

 

2023

 

Operating lease cost

 

$

103

 

 

$

87

 

Variable lease cost

 

 

8

 

 

 

7

 

Total operating lease costs

 

$

111

 

 

$

94

 

Schedule of Maturities of Operating Lease Liabilities

Maturities of operating lease liabilities, which do not include short-term leases, as of March 31, 2024, are as follows:

 

2024 (remaining 9 months)

 

$

314

 

2025

 

 

222

 

Total undiscounted operating lease payments

 

 

536

 

Less: imputed interest

 

 

(39

)

Present value of operating lease liabilities

 

$

497

 

 

 

 

 

Balance sheet classification:

 

 

 

Current portion of operating lease liabilities

 

$

400

 

Long-term operating lease liabilities

 

 

97

 

Total operating lease liabilities

 

$

497

 

XML 42 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Common Stock (Tables)
3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Schedule of Common Stock Shares Reserved for Future Issuance

The Company had the following shares of Company common stock reserved for future issuance as of March 31, 2024 and December 31, 2023:

 

 

As of March 31, 2024

 

 

As of December 31, 2023

 

Issuance of common stock upon exercise of stock options

 

 

3,097,438

 

 

 

1,749,475

 

Equity awards available for grant under stock award plans

 

 

441,590

 

 

 

879,461

 

Shares available for issuance under the Employee Stock Purchase Plan

 

 

99,578

 

 

 

37,078

 

Issuance of common stock upon exercise of warrants

 

 

4,881,329

 

 

 

214,997

 

Total common stock reserved for future issuance

 

 

8,519,935

 

 

 

2,881,011

 

XML 43 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity

The following table summarizes stock option activity for the three months ended March 31, 2024:

 

 

Number of
stock options
outstanding

 

 

Weighted
average
exercise price
per share

 

 

Weighted
average
remaining
contractual
term

 

 

Aggregate
intrinsic
value

 

 

 

 

 

 

 

 

(in years)

 

 

 

 

Balance at January 1, 2024

 

 

1,749,475

 

 

$

10.61

 

 

 

8.4

 

 

$

3,181

 

Options granted, fair value of $14.03 per share

 

 

1,400,200

 

 

 

18.10

 

 

 

 

 

 

16,669

 

Options exercised

 

 

(30,430

)

 

 

8.61

 

 

 

 

 

 

465

 

Options forfeited

 

 

(21,807

)

 

 

13.98

 

 

 

 

 

 

227

 

Balance at March 31, 2024

 

 

3,097,438

 

 

$

13.99

 

 

 

8.8

 

 

$

51,070

 

Exercisable options at March 31, 2024

 

 

776,110

 

 

$

11.81

 

 

 

7.8

 

 

$

15,598

 

Unvested options at March 31, 2024

 

 

2,321,328

 

 

$

14.72

 

 

 

9.1

 

 

$

35,472

 

Schedule of Grant-Date Fair Value of Stock Options Issued, Presented on a Weighted Average Basis

The table below summarizes the assumptions used to determine the grant-date fair value of stock options issued, presented on a weighted average basis during the three months ended March 31, 2024 and 2023.

 

Three Months Ended March 31,

 

 

 

2024

 

 

2023

 

Risk-free interest rate

 

 

4.0

%

 

 

3.6

%

Expected term (in years)

 

 

6.0

 

 

6.1

 

Expected volatility

 

 

93.1

%

 

 

84.1

%

Expected dividend yield

 

 

0.0

%

 

 

0.0

%

Schedule of Stock Based Compensation Expense

The following table provides a summary of stock-based compensation expense related to stock options, restricted stock units, restricted stock, and warrants:

 

 

 

Three Months Ended March 31,

 

 

2024

 

 

2023

 

Research and development

 

$

839

 

 

$

191

 

General and administrative

 

 

1,196

 

 

 

342

 

Total stock-based compensation expense

 

$

2,035

 

 

$

533

 

XML 44 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Loss Per Share (Tables)
3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Basic and diluted net loss per share of common stock

Basic and diluted net loss per share of common stock are calculated as follows:

 

 

 

Three Months Ended March 31,

 

 

2024

 

 

2023

 

Numerator:

 

 

 

 

 

 

Net loss

 

$

(13,748

)

 

$

(7,089

)

Denominator:

 

 

 

 

 

 

Weighted-average shares of common stock outstanding

 

 

25,665,475

 

 

 

875,279

 

Less: weighted-average unvested restricted shares of common stock

 

 

 

 

 

(570

)

Weighted-average shares used to compute net loss per share of common stock, basic and diluted

 

 

25,665,475

 

 

 

874,709

 

Net loss per share attributable to common stockholders, basic and diluted

 

$

(0.54

)

 

$

(8.10

)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share The following potential dilutive securities, presented on an as converted basis, were excluded from the calculation of net loss per share due to their anti-dilutive effect:

 

 

Three Months Ended March 31,

 

 

2024

 

 

2023

 

Convertible preferred stock (as converted)

 

 

 

 

 

7,269,183

 

Stock options outstanding

 

 

3,097,438

 

 

 

1,447,743

 

Unvested restricted shares of common stock

 

 

 

 

 

444

 

Warrants for the purchase of common stock

 

 

4,881,329

 

 

 

4,677

 

Total

 

 

7,978,767

 

 

 

8,722,047

 

XML 45 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Organization, Description of Business and Liquidity - Additional Information (Detail)
$ / shares in Units, $ in Thousands
3 Months Ended
Jan. 24, 2024
$ / shares
shares
Jan. 22, 2024
USD ($)
$ / shares
shares
Mar. 31, 2024
USD ($)
$ / shares
shares
Mar. 31, 2023
USD ($)
shares
Dec. 31, 2023
USD ($)
shares
Sep. 11, 2023
$ / shares
shares
Dec. 31, 2022
shares
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]              
Reverse stock split description     Immediately prior to the effective time of the Reverse Merger, the Company effected a 1-for-16 reverse stock split of its common stock (the “Reverse Stock Split”). Unless noted otherwise, all references herein to share and per share amounts reflect the Reverse Stock Split.        
Net Income (Loss) | $     $ (13,748) $ (7,089)      
Accumulated deficit | $     $ (103,171)   $ (89,423)    
Common stock, Shares issued     29,348,626   14,817,696 11,021,248  
Exchange ratio of reverse merger     0.2181     0.2181  
Shares of common stock issued in pre-closing financing     2,873,988        
Shares pre-funded warrants to purchase     210,320        
Pre-Funded Warrants Exercisable     210,320        
Prefunded warrants price per share | $ / shares     $ 23.34        
common stock price per share | $ / shares     $ 23.34        
Proceeds from pre-closing financing | $     $ 72,000        
Prefunded Warrants [Member]              
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights           210,320  
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares           $ 0.001  
2024 Private Placement [Member]              
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]              
Stock issued, price per shares | $ / shares   $ 12          
Sold and issued of shares 14,500,500 14,500,500          
2024 Private Placement [Member] | Prefunded Warrants [Member]              
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]              
Stock issued, price per shares | $ / shares   $ 11.999          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 4,666,332 4,666,332          
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 0.001 $ 0.001          
Aggregate purchase price of pre-funded warrant | $   $ 230,000          
Class of warrant or right maximum beneficial ownership percent   9.99%          
Pre-funded warrants increase or decrease percentage   19.99%          
Common Stock [Member]              
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]              
Common stock, Shares issued     29,348,626   14,817,696 14,817,696  
Common stock, Shares outstanding     29,348,626 875,279 14,817,696 14,817,696 875,279
XML 46 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Summary Of Significant Accounting Policies [Line Items]      
Credit losses recorded $ 0 $ 0  
Allowance for doubtful accounts 0   $ 0
Financial lease liability 0    
Unrecognized tax benefits $ 0   $ 0
XML 47 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Reverse Merger - Schedule of Company Obtained Assets and Liabilities (Detail)
$ in Thousands
Sep. 11, 2023
USD ($)
Business Acquisition [Line Items]  
Cash and cash equivalents $ 69,738
Other current assets 2,473
Accrued liabilities (616)
Net assets acquired $ 71,595
XML 48 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Short-Term Investments - Schedule of Short-term Investments (Detail) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost $ 47,338 $ 41,346
Gross Unrealized Gain 2 48
Gross Unrealized Loss (28) (1)
Fair Value 47,312 41,393
U.S. Treasury Securities    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 46,327 36,370
Gross Unrealized Gain 2 48
Gross Unrealized Loss (27) 0
Fair Value 46,302 36,418
U.S. Government Agency Securities    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 1,011 4,976
Gross Unrealized Gain 0 0
Gross Unrealized Loss (1) (1)
Fair Value $ 1,010 $ 4,975
XML 49 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Detail) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Prepaid Expense and Other Assets, Current [Abstract]    
Prepaid materials, supplies and research and development services $ 1,512 $ 2,155
Prepaid subscriptions, software and other administrative services 1,030 504
Prepaid Insurance 472 596
Prepaid expenses and other current assets $ 3,014 $ 3,255
XML 50 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment - Schedule of Property and Equipment, Net (Detail) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 314 $ 282
Less: accumulated depreciation (119) (97)
Property, Plant and Equipment, Net, Total 195 185
Computer Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 263 234
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 51 $ 48
XML 51 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Property, Plant and Equipment [Abstract]    
Depreciation expense $ 22 $ 14
XML 52 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value of Financial Instruments - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Detail) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments $ 47,312 $ 41,393
Fair Value on Recurring Basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total assets measured at fair value 375,285 172,586
Level 1 | Fair Value on Recurring Basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total assets measured at fair value 374,275 167,611
Level 2 | Fair Value on Recurring Basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total assets measured at fair value 1,010 4,975
Money Market Funds | Fair Value on Recurring Basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 327,973 131,193
Money Market Funds | Level 1 | Fair Value on Recurring Basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 327,973 131,193
U.S. Treasury Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments 46,302 36,418
U.S. Treasury Securities | Fair Value on Recurring Basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments 46,302 36,418
U.S. Treasury Securities | Level 1 | Fair Value on Recurring Basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments 46,302 36,418
U.S. Government Agency Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments 1,010 4,975
U.S. Government Agency Securities | Fair Value on Recurring Basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments 1,010 4,975
U.S. Government Agency Securities | Level 2 | Fair Value on Recurring Basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments $ 1,010 $ 4,975
XML 53 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value of Financial Instruments - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Fair Value Disclosures [Abstract]    
Fair Value on Recurring Basis Level 1 $ 0 $ 0
Fair Value on Recurring Basis Level 2 0 0
Fair Value on Recurring Basis Level 3 $ 0 $ 0
XML 54 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Payables and Accruals [Abstract]    
Accrued issuance costs in connection with the private placement $ 2,213 $ 0
Accrued external research and development 1,635 456
Accrued compensation 1,443 5,361
Accrued professional fees 345 422
Other accrued expenses 211 265
Accrued expenses $ 5,847 $ 6,504
XML 55 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Leases - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Leases [Line Items]    
Operating lease description The Company leases space under operating leases for administrative offices in New York, New York, and Waltham, Massachusetts and wet laboratory space in Watertown, Massachusetts. The Company also leased office space under operating leases, which had a non-cancelable lease term of less than one year and, therefore, management elected the practical expedient to exclude these short-term leases from right-of-use assets and lease liabilities.  
Operating lease costs $ 111 $ 94
Weighted-Average remaining lease term 16 months  
Weighted-average discount rate - operating lease 10.70%  
General and Administrative Expenses [Member]    
Leases [Line Items]    
Operating lease costs $ 95 94
Research and Development Expense [Member]    
Leases [Line Items]    
Operating lease costs $ 16 $ 0
XML 56 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Leases - Summary of the Components of Lease Costs and Rent (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Lease, Cost [Abstract]    
Operating lease cost $ 103 $ 87
Variable lease cost 8 7
Total operating lease costs $ 111 $ 94
XML 57 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Leases - Schedule of Maturities of Operating Lease Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Leases [Abstract]    
2024 (remaining 9 months) $ 314  
2025 222  
Total undiscounted operating lease payments 536  
Less: imputed interest (39)  
Present value of operating lease liabilities 497  
Current portion of operating lease liabilities 400 $ 417
Long-term operating lease liabilities 97 $ 168
Operating Lease, Liability $ 497  
XML 58 R52.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Common Stock - Additional Information (Details)
3 Months Ended
Jan. 24, 2024
$ / shares
shares
Jan. 22, 2024
$ / shares
shares
Mar. 31, 2024
$ / shares
shares
Dec. 31, 2023
$ / shares
shares
Sep. 11, 2023
$ / shares
shares
Common stock, shares authorized     150,000,000 150,000,000  
Common stock, Shares issued     29,348,626 14,817,696 11,021,248
Common stock, Shares outstanding     29,348,626 14,817,696  
Exchange ratio of reverse merger     0.2181   0.2181
Common stock, Par value | $ / shares     $ 0.001 $ 0.001  
Common Stock, Dividends, Per Share, Declared | $ / shares     $ 0    
Prefunded Warrants [Member]          
Pre-funded warrants to purchase         210,320
Exercise price (in USD per share) | $ / shares         $ 0.001
2024 Private Placement [Member]          
Sold and issued of shares 14,500,500 14,500,500      
2024 Private Placement [Member] | Prefunded Warrants [Member]          
Pre-funded warrants to purchase 4,666,332 4,666,332      
Exercise price (in USD per share) | $ / shares $ 0.001 $ 0.001      
Common Stock          
Common stock, shares authorized     150,000,000 150,000,000  
Common stock, Shares issued     29,348,626 14,817,696 14,817,696
Common stock, Shares outstanding     29,348,626 14,817,696  
Common stock, Par value | $ / shares     $ 0.001 $ 0.001  
XML 59 R53.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Common Stock - Schedule of Common Stock Reserved For Future Issuance (Details) - shares
Mar. 31, 2024
Dec. 31, 2023
Equity [Abstract]    
Issuance of common stock upon exercise of stock options 3,097,438 1,749,475
Equity awards available for grant under stock award plans 441,590 879,461
Shares available for issuance under the Employee Stock Purchase Plan 99,578 37,078
Issuance of common stock upon exercise of warrants 4,881,329 214,997
Total common stock reserved for future issuance 8,519,935 2,881,011
XML 60 R54.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Preferred Stock and Convertible Preferred Stock - Additional Information (Details)
Sep. 11, 2023
shares
Mar. 31, 2024
$ / shares
shares
Dec. 31, 2023
$ / shares
shares
Class of Stock [Line Items]      
Preferred stock, Shares authorized   10,000,000 10,000,000
Preferred stock, par value | $ / shares   $ 0.001 $ 0.001
Preferred stock, Shares issued   0 0
Preferred stock, Shares outstanding   0 0
Convertible preferred stock, Terms of conversion Under the terms of the Merger Agreement, immediately prior to the effective time of the Reverse Merger, each share of Former Dianthus convertible preferred stock was converted into a share of Former Dianthus common stock.    
Shares issued upon conversion of convertible preferred stock 7,269,183    
Exchange ratio of reverse merger 0.2181 0.2181  
XML 61 R55.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Restructuring and Other Charges - Summary of Restructuring Liability included in Accrued Payroll and Related Expenses (Details)
$ in Thousands
Mar. 31, 2024
USD ($)
Restructuring Cost and Reserve [Line Items]  
Accrued restructuring, Beginning Balance $ 5,361
Accrued restructuring, Ending Balance $ 1,443
XML 62 R56.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-Based Compensation - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jan. 01, 2024
Apr. 30, 2021
Mar. 31, 2024
Mar. 31, 2023
Sep. 30, 2023
Dec. 31, 2023
Feb. 29, 2024
Apr. 30, 2020
Jul. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Weighted average fair value of stock options granted     $ 14.03            
Number of Shares, Options vested and expected to vest as of September 30, 2023     776,110            
Number of Shares, Granted     1,400,200            
Warrant [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Common stock exercise price   $ 1.65              
Vesting period         7 years 1 month 6 days        
Warrants issued   4,677              
Warrant per grant date fair value               $ 1.16  
2018 Stock Option and Incentive Plan [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Share-based compensation arrangement by share-based payment award, terms of award     The 2018 Incentive Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, unrestricted stock awards, cash-based awards, and dividend equivalent rights. In connection with the Reverse Merger, the 2018 Incentive Plan also provided for the assumption of shares remaining available for delivery under the 2019 Stock Plan (as defined below), and such shares will be available for the granting of awards under the 2018 Incentive Plan in accordance with applicable stock exchange requirements. The Company also has outstanding stock options under the Magenta Therapeutics, Inc. 2016 Stock Option and Grant Plan, as amended (the “2016 Plan”), but is no longer granting awards under the 2016 Plan.            
Shares available for issuance     171,590            
Total unrecognized stock-based compensation expense related to unvested share-based awards     $ 25.2            
Period for recognition of unrecognized expense     3 years 3 months 18 days            
Percentage of purchase price of common stock under the ESPP     110.00%            
Number of shares reserved and available for issuance increment percentage     4.00%            
Additional number of shares reserved and available for issuance 592,707                
2018 Stock Option and Incentive Plan [Member] | Restricted Stock [Member] | Minimum [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Vesting period     12 months            
2018 Stock Option and Incentive Plan [Member] | Restricted Stock [Member] | Maximum [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Vesting period     4 years            
2018 Stock Option and Incentive Plan [Member] | Stock Options and Stock Appreciation Rights [Member] | Maximum [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Term of award     10 years            
2018 Stock Option and Incentive Plan [Member] | Certain Incentive Stock Options [Member] | Maximum [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Term of award     5 years            
2019 Employee Stock Purchase Plan [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Share-based compensation arrangement by share-based payment award, terms of award     The ESPP provides that the number of shares reserved and available for issuance under the ESPP will automatically increase each January 1 through January 1, 2029, by the lesser of (i) 1% of the number of shares issued and outstanding on the immediately preceding December 31, (ii) 62,500 shares and (iii) such number of shares as determined by the Company’s board of directors or its appointed administrator. The number of shares reserved for issuance under the ESPP increased by 62,500 on January 1, 2024.            
Shares available for issuance     99,578            
Percentage of purchase price of common stock under the ESPP     85.00%            
Common stock purchased     0 0          
Additional number of shares reserved and available for issuance 62,500                
2019 Employee Stock Purchase Plan [Member] | Minimum [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Number of shares reserved and available for issuance increment percentage     1.00%            
Additional number of shares reserved and available for issuance     62,500            
2019 Stock Plan [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Number of Shares, Options vested and expected to vest as of September 30, 2023                 1,273,454
Inducement Plan [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Number of Shares, Granted     270,000     96,000      
Inducement Plan [Member] | Maximum [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Shares for issuance under the Plan (shares)             300,000    
XML 63 R57.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-Based Compensation - Schedule of Stock Option Activity (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]    
Number of Shares, Beginning Balance 1,749,475  
Number of Shares, Granted 1,400,200  
Number of Shares, Exercised (30,430)  
Number of Shares, Forfeited (21,807)  
Number of Shares, Ending Balance 3,097,438 1,749,475
Number of Shares, Options exercisable as of March 31, 2024 776,110  
Number of Shares, Options vested and expected to vest as of March 31, 2024 2,321,328  
Weighted-Average Exercise Price, Outstanding, Beginning balance $ 10.61  
Weighted-Average Exercise Price, Granted 18.1  
Weighted-Average Exercise Price, Exercised 8.61  
Weighted-Average Exercise Price, Forfeited 13.98  
Weighted-Average Exercise Price, Outstanding, Ending balance 13.99 $ 10.61
Weighted-Average Exercise Price, Options exercisable as of March 31, 2024 11.81  
Weighted-Average Exercise Price, Options vested and expected to vest as of March 31, 2024 $ 14.72  
Weighted Average Remaining Contractual Term 8 years 9 months 18 days 8 years 4 months 24 days
Weighted Average Remaining Contractual Term, Options exercisable as of March 31, 2024 7 years 9 months 18 days  
Weighted Average Remaining Contractual Term, Options vested and expected to vest as of March 31, 2024 9 years 1 month 6 days  
Aggregate Intrinsic Value, Beginning Balance $ 3,181  
Aggregate Intrinsic Value, Granted 16,669  
Aggregate Intrinsic Value, Exercised 465  
Aggregate Intrinsic Value, Forfeited 227  
Aggregate Intrinsic Value, Ending Balance 51,070 $ 3,181
Aggregate Intrinsic Value, Options exercisable as of March 31, 2024 15,598  
Aggregate Intrinsic Value, Options vested and expected to vest as of March 31, 2024 $ 35,472  
XML 64 R58.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-Based Compensation - Schedule of Stock Option Activity (Parenthetical) (Detail)
3 Months Ended
Mar. 31, 2024
$ / shares
Share-Based Payment Arrangement [Abstract]  
Weighted average fair value of stock options granted $ 14.03
XML 65 R59.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-Based Compensation - Schedule of Grant-date Fair Value of Stock Options Issued, Presented on a Weighted Average Basis (Detail)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]    
Risk-free interest rate 4.00% 3.60%
Expected term 6 years 6 years 1 month 6 days
Expected volatility 93.10% 84.10%
Expected dividend yield 0.00% 0.00%
XML 66 R60.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-Based Compensation - Schedule of Stock Based Compensation Expense (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Stock based compensation expense $ 2,035 $ 533
Stock-based Compensation Expense | Research and Development Expenses [Member]    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Stock based compensation expense 839 191
Stock-based Compensation Expense | General and Administrative Expenses [Member]    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Stock based compensation expense $ 1,196 $ 342
XML 67 R61.htm IDEA: XBRL DOCUMENT v3.24.1.u1
License Revenue - Related Party - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Jun. 30, 2022
Dec. 31, 2023
Sep. 30, 2021
Related Party Transaction [Line Items]          
Deferred revenue current $ 100     $ 100  
Deferred revenue noncurrent 719     736  
Zenas BioPharma Limited [Member]          
Related Party Transaction [Line Items]          
Reimbursement of development costs     $ 1,100    
License revenue - related party 900 $ 500      
Related party receivable 400     300  
Unbilled receivable from related party 400     200  
Deferred revenue current 100     100  
Deferred revenue noncurrent 700     $ 700  
Zenas BioPharma Limited [Member] | Milestone [Member]          
Related Party Transaction [Line Items]          
Development milestones     11,000    
Zenas BioPharma Limited [Member] | Royalty [Member]          
Related Party Transaction [Line Items]          
License revenue - related party $ 0        
Zenas BioPharma Limited [Member] | Upfront Payment [Member]          
Related Party Transaction [Line Items]          
Upfront payments     $ 1,000   $ 1,000
XML 68 R62.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Loss Per Share - Schedule of Basic and diluted net loss per share of common stock (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Earnings Per Share [Abstract]    
Net Income (Loss) $ (13,748) $ (7,089)
Weighted-average shares of common stock outstanding 25,665,475 875,279
Less: weighted-average unvested restricted shares of common stock 0 (570)
Weighted Average Number of Shares Outstanding, Basic 25,665,475 874,709
Weighted Average Number of Shares Outstanding, Diluted 25,665,475 874,709
Net loss per share attributable to common stockholders, basic $ (0.54) $ (8.1)
Net loss per share attributable to common stockholders, diluted $ (0.54) $ (8.1)
XML 69 R63.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 7,978,767 8,722,047
Convertible Preferred Stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 0 7,269,183
Employee Stock Option    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3,097,438 1,447,743
Restricted Stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 0 444
Warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 4,881,329 4,677
XML 70 R64.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies - Additional Information (Details)
$ in Thousands, £ in Millions
3 Months Ended
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Mar. 31, 2024
GBP (£)
Other Commitments [Line Items]      
Research and development expense $ 13,078 $ 5,847  
Alloy Therapeutics Llc [Member]      
Other Commitments [Line Items]      
Payment of annual license fees and program fees 100    
Research and development expense 0 0  
Alloy Therapeutics Llc [Member] | Development Milestone [Member] | First Selected Antibody [Member] | Maximum [Member]      
Other Commitments [Line Items]      
Potential milestone payments due 1,800    
Alloy Therapeutics Llc [Member] | Development Milestone [Member] | Second Selected Antibody [Member] | Maximum [Member]      
Other Commitments [Line Items]      
Potential milestone payments due 3,100    
Alloy Therapeutics Llc [Member] | Commercial Milestone [Member] | First Selected Antibody [Member] | Maximum [Member]      
Other Commitments [Line Items]      
Potential milestone payments due 11,000    
Alloy Therapeutics Llc [Member] | Commercial Milestone [Member] | Second Selected Antibody [Member] | Maximum [Member]      
Other Commitments [Line Items]      
Potential milestone payments due 15,000    
IONTAS Limited [Member]      
Other Commitments [Line Items]      
Research and development expense 300 400  
IONTAS Limited [Member] | Development Milestone [Member] | First Development Program [Member]      
Other Commitments [Line Items]      
Potential milestone payments due 3,900   £ 3.1
IONTAS Limited [Member] | Development Milestone [Member] | Second Development Program [Member]      
Other Commitments [Line Items]      
Potential milestone payments due 3,200   2.5
IONTAS Limited [Member] | Commercial Milestone [Member] | First Development Program [Member]      
Other Commitments [Line Items]      
Potential milestone payments due 2,900   £ 2.3
OmniAb Inc [Member]      
Other Commitments [Line Items]      
Research and development expense 0 $ 100  
OmniAb Inc [Member] | Development Milestone [Member]      
Other Commitments [Line Items]      
Potential milestone payments due $ 12,200    
XML 71 R65.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Related Party Transactions - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 15, 2023
Mar. 13, 2023
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Sep. 11, 2023
Dec. 31, 2020
Related Party Transaction [Line Items]              
Common stock, Shares issued     29,348,626   14,817,696 11,021,248  
Common stock, Par value     $ 0.001   $ 0.001    
Unbilled receivable from related party     $ 441   $ 184    
Deferred revenue current     100   100    
Deferred revenue noncurrent     719   736    
Aggregate principal amount     0 $ 377      
Principal and interest repaid     0 377      
Zenas BioPharma Limited [Member]              
Related Party Transaction [Line Items]              
Common stock, Shares issued             156,848
Related party receivable     400   300    
Unbilled receivable from related party     400   200    
Deferred revenue current     100   100    
Deferred revenue noncurrent     $ 700   $ 700    
Zenas BioPharma Limited [Member] | Dianthus [Member]              
Related Party Transaction [Line Items]              
Aggregate principal amount   $ 400          
Interest rate   4.50%          
Zenas BioPharma Limited [Member] | Tellus Bioventures Llc [Member]              
Related Party Transaction [Line Items]              
Percentage of outstanding shares     5.00%        
Zenas BioPharma Limited [Member] | Fairmount Funds [Member]              
Related Party Transaction [Line Items]              
Percentage of outstanding shares     9.00%        
Principal and interest repaid $ 400            
License Revenue [Member] | Zenas BioPharma Limited [Member]              
Related Party Transaction [Line Items]              
Revenues     $ 900 $ 500      
EXCEL 72 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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kQU#)*Y5R8H7.XRKE00TL5<;I" M#8ZGBU^]>M$&I7<1'H")+0NP=E@N"R+M_N#S#F\,_T>13B[4*&SNA:'*8]'. MM9^/AEZ8,C]JT?LE BZ'SBONAS?%OFF4O )80+O#*.,(4H3T&^5@7 M"O$VX+XZSO[UK* RU>3]ZN?8!Z7V"#N<^2=K7Z38=&V@(\79M:3N%F\II ^! M?YM0>FV\/1 ,X\H=*GY_X?L!%5P?O,#' IVW"S(OU-*-?DY74*"?\C=<,J7Y M4-!A&>I:0<\L+'06G!E+EYAX;_<@&/[J)0F6;K$P^OP*S^55&$-0,*LG'6V( M&,]7N8K3K)8B/=9G+%8>*#=9;B@H)!WL_C'*.C.,^RU[M[2YSZK^QAK/M_O8 MTB)V8CP_*95(?EL2!3N]^8J259 JLZ[:K^,:R/1U& !FW4(6'YQ_[E/:X/8Y M5KPD9.,O'C% ;,$/06P#CPB+5FF0H2>4O 4K1(%\1*MX$Y%5R!DKWZR1/WL\ MR9]N5SQ00& T]1@UA=]^/$)Y];?WW[EFW36QSLT^&4IM0RO;PAN,5C-)K=-: MNQ159L=$D7/D9&2@*GE Y1B=%[*:8^GDZ)P7EFJ&0L/&]H.B9T?EZ,Q+,I>0 M9,R8M.S[M .C6URWNL%Q7AC27S5UV?09W+1&HW1)#)!(5S.);C7F2 WVYGD% MM)ZCZMOQI/$< K- KO$E5?D/9A% ;8<$RZV 3AO#YH^%N=OCW"2OAP?DC+U> MOI1SN\$)_2SGAH5-U8'.H?"FGJ9S_+O>,35*P#O5]&\B_PB1)/.#C=.64(VE MDTX-H 567E$6K !G[ C.>0+G/ 'S0.]SGL YEOAK/M*49X4]"2'O\'1,8W+R0! M<=F5ER0'3&:ZF'^SN6YD0H"=.UH%(2K9=)]CV/Q#$K\%F$]<'CYC'B3&V-C&XAFR>S0LA/06AHD]37/._<8-H%H]U8 MM^(N>D/I$/Q*MY"]6^$=B#AR&R=,4[C;[O#&J4:ENA+Z20.;73]'+T$8(@A! M0%AXQ&]:1>ZO)OF9SK)8%P ?>[#"&P$Z42"Y,LANF")$E M/R3X=#/T$'HK0GXR6M".MW[UGN.+%5:+$O3T&B?9,TJVE%.8W$#]7(=T_8<$ M[;S OV;6)UX+-Z(!A="'3 EKQ\4JBM@8S3EW+]<+I)_]#+6393<;HI! M<@O"$# )_"TSXXT]5W6(:Q)^5NBY[;BD=+)%X&A#-XA Q0*R$HKR*'LE,CC> M[@&9CU#0=[G&PS)CN P]KRS)0^JYF\S&-M]" #&ZM_LFI#;2H M.NQRV=& /RF''R=_&H/=N"3-<7V5M0/$*DEQ_T+*Z: M2RBC!BY680HROC'0RJX] !+W1F__R/G*YB-_^ZL[%"Z^<\-2>&EE-X+0VH#F:9!6I- MPF)F7ZJQ>Q1+N0!8$18R9[09A)A4T-84LS$+;*J#YJ6!(?/"R7U#:G[KZSL+ M]'6/=BE=T(;PD9G(>MTD9^/HEGF40>PN+U?C:6:!KZD$8U7\SRR0/(ST-\Y1 MS?D #.5(@VBQ66#1G:1+=U'318S42DNS0-^P8F1#*.2@&#TU:;)O[.6@I5?= M1>Y@8J8LL'.4\K4QWJE+&)Q*\.P:=CH30AY&-&W#:V91G'D@PZ4V:G@F%-I+ MM-(B_*0I49/KQRV^Y>CNF?0V&$C4[!MS?M*T-Y8(*@]D'[3*NL-\L+O(68N: MGT5A^JDDS/9!_K- _S"299N$@E'0ZIK>-+Q+O!PB/ O:-),IITZ3F#/]MI2_ MVB15S *M/7S'?;(\YM%JI(_D5<\?F07.AGFFU)DL@R+18:%__(=J'()TM /D MX,'IU62<>30/:L\0!\T1F@62A^&@;9*/1D&K:X+2!!SUM[^.@TLW>^U,S@O* MV53G!F+MCV(ZG%FI] V^W3!.]PE:)ALO8M:W:Y2NDF!'W;^7^Q1C,@7MYC[ M-]99KSW+M6:Z=7*[MQ07FA MQ=N7(.+,@(:"0E)B&LB\(@J3EN$BUN0?>D"IL"]FFQ7L=:"H'5/3 ME=7-<./J=CBZ4KZ.#B4SNM'Q#B58\8A\"%W:B5W/CN4&4P@>0M"Q!3 :[VW3 M/)N=1>1;*\ZMZ?JV6L*5^VQXD)4,IA:HFLVUOO6"A!1V7JY9C*<7WD48C?LC M%)AS8 35I^%R:Z=8N]>R735=9/T<-VZNR0&)E[8!#[.YI8J> ,=Q*UD8/B@! M! XO;+J4NAGV/8YGO^W<_+;RC$7J0Y-_'O@CYQ]NRKIL9D= MG9V[9^>N&B;,0E /Z/0OXT3@$N M:NIVF#)H9L!5S^INMY-H]VXP4.<5E%"1X.;$[^W MI";0D3W3=,\-=Z\RR-J#>X\P<:%R#:9&XW'#)#>NH/P8Q)>R"?83OUN"(AEO MMW%$JD ?UU4#MHK5'?U5JPRR:,S$^'V-0TQ4*=T3%)TR%VC-Y[MQ >6'4];3 MC3$RQEU\0\E+[-YM?.! $/1 J>P\MMQ75;Y:3>%*.HG68RE$ ^B M.6Q"/MJ-BVIV,.7P" 7TLWDR"> O]8YSQW0AA4HV:Q$*9C$@M9-(9ST")V\7 MT7!A>RYJ[4(;[_M2W'?3Q>^[JAL,8AA"*74R[XOMV3":^V %41RL!*38<_7] M<7$;<>O/B8$ )X6?'=6=OO"0*HDV^^R9-6S7W5'3>ZT>[\;E;#H0 M\8W5P#[&[0N=N'A@R@JRO$E23!+C471\U6LT@!@[>-JM8>V2&FVSZ>:V7,2- MZ]SID$N5A%NB[L2?W?]Z\MX(RPN](]/%126(..VS($'EA)/FRVZ\@OV WG-8 M]-S"HA\P<5+2)!%8#UC%3W(:O4016@=9"W[?>;ESJ+/Z,6K+@LZAS^?09S5. M:MRIY$+HS [FA<1SD/,YR-DDR%ENM#LN(=@U$_%H +6)8C9?P0W.U<9^W E/ M)Z[#"C[F_4N*_K7'2]^\H:-+KZ_NOBG00S7P]GG39&O ?4[1H$-WI'_/NJQD,\YMEZ!7N+%OB)Y*&QYG M/-V9:%LSN)IF60/G$_HB6 N2.,)_I!WCTS;GUGH9-\S%YZYFY^B/L;N:-5KR MYH6RWF.' &[6G M!+]-1;+N+ ,\1L7O]&_IT/ M.N,Z0'2_*=DPIDD,@-AX,DWW6^23$S9_@X;YBAO,I!NAR!G-0-B?#9=Y>HV3 M#.]L6SC5CU);(' \E^%HJH.@FV*O.CYZR8H7\N+-"T(X#MZ/S(1+M%K"#19@ M'AP#5U8#1?P0$A M0G%LYO)!XP)NW/L.!RM_]YL1-B,F0".:Q&"FX[STJLZ>79NM6K_@RJUUS@1W M[T(;'II1#-XZK1=-EW+C;)L< M[KSA*E<&62RAB?=# I2B+ MMUW )0DMA6Q\E+PA_S9.;O>8T!#D07O1JH@B>5&5K!Q@53'J]!+6ZA&\EEN M7&FS@Y+K/PILS.8*$_A?JLG QWA="Y@([\YA$35:PL@)M _>P21PMN>B+EQW M:;8W.7::\ITRDX&9YC+ PDXAA1W9Q11P/"#\V M;8V60W_/C3=]&&ZN>/,[L\19F#"F07T?QGO2/CI[-Z U2S_I K]3G,/@;\5T MI7,MZRV?4'8?IT76]!$J+-7,[R:KH6JX"S)/96\0[+J"VFZ0!]\ZX;?=:@Z M?R['T=$6VW #%$RS';'-0F;KALG!2U6&1/57$J@K$$$=XF]*@6_U8F_VQN!OG M(]J^H$2Q[?JX@?UR(N5<8:4F#@.?%X!X$(Y?R(7*XQ/3@@!EL?O#KW_:8?]N M='!6T,E5_ 5%Q)>VW7G1X3Y<2>E6/W;8ZY8FF7#5\-\*9.&__/;H11LDW63U MUTFW]='[&FSW6^7&RK]/CS$)Q9=_LY_B4N'EJ63+9G/L@;)_2?%;["4'J);! M_'TZ,)3C[8%0;.23M\5_?$Z\*,7"'0@3NI?88*(UH'J]5@V:\C!K6\R<#][P M;AY"CU9\U8HMBL%NRB[WBHRY<;[A4-MM5N".!A/MPL \>J0^TYXD#3$2R_6O M7H+92+9,'H/-JUX5T,T8N@$S_G$/.A+[6*H6FE1#IQ5.@D@OG)1^M]BM-J,% MSL'8JCCE\IA)L?@K HI"_@6^))Y&!I6/L]C:/,-7 /G^).N$;K M8*7D#P83W6(/&DE+/=X%20N_JRO$#5W-\E5YN O&#AJS2AH=^:H34(RVV\(] M7>ZS-/,B'Q.X"O&U<4/'4,-+>^'_W@-65! RL];T!4-U,O&)<86]W3\VF3& MX$:\_ (U[DPYUJVG/#_CW%%TY84A\B\/'*-L8*L'O\6J;J&#W6)$CBS_,=_M M^S9(:%S+GBV"A;/(>2GX#XV M%#N:ICCB8]HZCV$(Z!%U4/, N843@; M 3$2A]])$XG4B\@14<+1;/KSZ)R5I4:$E&OL!2^7VY;[4D\:9:.Z;,OU\PP-ZA:^T:*;M\I5>=*8&E5) M,)0%3CIOK$DX+CN<3QH5DS' BGO\C-3>%U@MGYYTLF'#Y57$.9PT2IRN57OD M]T_+U$RB4TZ:\HPC6DI&7YT$. YINJ G3_(J: YBC(3G4\.K7H=3QCR-@5J' MC,FC4F[%/,M0^?V92CM2J3*P;0S,SH5(1SH]=B1_/4G98#J^7(^%/".V#V+; M!G8R;/_MC.WNV&X9D,I0_L,9Y3U1KHVA95C^^QG+G;&LCP%F"/[Q+.WUUTD, M@I.YU?5L]NE%T-IX:H[CLVF[.X[5,>$P;ML[/X6Q-&O0(FD/E M.>+/!I*NB&\,U.D,G!D3R! M*FFE[-_3?KOUD@,6'H)-%.#;C2==K%;Q/H+.70\8X2MHM.A(E3]55JT1$,JR M??CN_=^^^Z"M"V4V=^@$?B->47MP MVK.;>_M%GJ[12U;HE!=OF-L##\3R-UBOH&;[%^@-A_]^A5^^@%0K_Q4/1O%Z MK3BS7DO:HU)A7]?Q_B5;[T-V8BE'62J>>:RFLM!A0>K#6Y/&GE=Q;0LN-(H6-D-I[*21V%' $]'83VXZ_?O>]6EIS2O&2%8Y)4(UE6M//^FG M#TFV/HB3SBPXY[2,I?^R E/HST\B#\3>84Z+R,-:N#9'^:LL2JT2YM M7V5!-9IB'1!\KUXPOX9=%>TL[WQ\93 # U)A-PTVC_E*^<:1KK#(O_+25_P# MI/F_8;5!78IPY(]:1Z9(IG3O2%N2OWG>P#Z!:\:,U?7X*R.LHU0@%7S:A"Y$ M;.G]=RT7<0G8[O=BGX"00DE4VKDCPY,N4/N%LMDR1Z)/\ANPLA?/ EB M^X1:7+U>7W'#:%KAFCGU[C),-W;GL7O:$T(P[;@E'+?CU& M([0^"D!G=S:9:3DV+X!, "RV[>%X-*9FU6A[3:%R.JOBM+">4/(60 J/D!I4T&#ZC+>1 MRG_2VI8'_82](-6G9\@FVR>'XB"UH?::"18[*6+*>RZ_$PV6:^T45^]I49KR MIR1.4_!E>R'0@;'.OORVLZ@IMAZ&1!#Z)73W= ^6DB+]:@@B30V'\-."SFN%/O8 M6CH:Q60KU<\LXG4,&:H4BJ41/69A$S<16\R#R6=B]&Y0.D5\#4O IX[8CL]. M2^Y[ZC;RL1\C4Q5@%K;Q\5\H4YUC%NBV1ML5%61?S+ .3P<18Q]<+XI"NT1L*XQTP;OHPR$,0NR\V#E30$&J5!.3&I4_Q M.ON"N42.7G\;1 %@-0O>D %875:S9N-A>\;O\CZ!["8]Y17#;&]8=P>ZWQY' MGJ .G$(L8=?UHLY"^Q\ MYW8Q2Q$U8[(53.CDTZN'!9K>HXXF]"6AR3>H20[ ML*AHRN)RD5[VZR>4':7JCC/HF" M;$^DZ]O@*_Q)'V^BF>#>W5-G&6JGN"*T&HH?_LJ>.KK49B1' BG9XZ KOQN>$$HT'-;NXZ M+3O>:YU\-9^0D0&O]OU\0FX&EF#$!+QAS;W'8J5TI<7+V3(I2R4L7B'%[DM# M'+^B^G!7$=3I- K+-_+6"Y)?O'"/Y-%JQ6N1_TH]+!])+#7R+[)B!4A#WB=) M$&U(X/HQWN%S)I\AHC[&$3I\])+?40:MX_3F*<5@>_8U3K*7!T;'@-/;!/UK MCZ*5K/%5FYGVP9)M34N3)C/M@R6K$LOYD,!\\(!/,13>%7A1DZ-IV&_8PSZH=]%NGZ7W$+ST M7N\'T,RP#T:/NZ7S?P^W_KFV1<\3+AA$4T:\=HI]0"X/=79 ;I.9;*";;!\X MD>OEM\*,K^BFGJM*'&G6N;W73-]G4S?C7!EB-$(DKZBYS*@>[X8U:.RT/94F M/ NG= M-NN2 ,=%4YX7 (97;D@_;7"6<%\+;Z(]2VI5I9?-"X5 *W;FPS+G4 MQ 3DJM%.I1>\/WG/BQT8*Y)+.I8-40'G@RL;NN>+ 5!9MD\M^O0?;Z.8I?4OS$ ME3 MR0XZP>!3"@/>%T8@8$+[^>M\%V4Q-5Y6 )SBB\>$GP^3X^># U[:,>#Z2XOP M@@$_ZMC[UF"&G.3"S\(0Y [&/\Q$]>ML:A^)VTPG.%N6TU@M42]$&I$L/2Z9 M#.K-$34HNWEC*9V:Z#O5:'M5G>H;T@8EJ\=; ^$1D5SD!R_)] '5DH$#2W@? M-YGW_5^EH57UW]VK>7*\*8 G7YQ,I%WRB&!T!Z1'K_B+AO.T6&!8(-,D$P#$ M?RN PW_Y[=&+-DAZ8ZJ_3KJMC][78+O?*C=6_GUZC$E.NOR;>]RE9KX]HC)Z M=]L=%@)A,\OU?1QM[H,W1#NUI\_Q)0B2NSA%_G*M@,U\OBN2@#8^6#YVA,?T M?=-K^K[WR!]WVW05&P\A[P$QAE#W&2K>,PB-5( MU(X?N@)^#!\)O/!C$*(TBR.,H!4*WO*VV4:X[;#*)#@&%O_]#W]_1JO7* [C MS:$MTE4+6&.AI+;S781U896@*8YPPQC2H+^6"@2J=<53C\Y4ZYBY::ZL^YTZ M0LX5)@>C)S-U3L2CC!I/%6,*'1'0(='33AX+59*HH>=4,=!>O11O3 O];19. MIT:SK^;=GPNE]:E!V(:_GSH>#66G]S7AZ5R=L<"0L3EB%A[YA%]/H M=/'01W8?VYS#J=-BY\NJ-&D>&L5>Q6F6WD4/"7Z=,X2YQ$KIJC2<:8-< M:LRL-F :)MD^&3TSU!]0PUR[Z[ZT%R7^W[2R&Q)DRT$\Y-VV6AT0L[;RJ(_Q\:?SZPM-E8BYN%F:(FS)@5G M.@/P\>#,4(]BJ/OKR;?EO$<>%A>]ELQ.WRA#%#]*5[ M^ A< W7VJ&[&P$9#BB&MN;4ZQ!HB[_$#@-!R1V*RH@W9US5*5TE +IX"F4VS M+()#;IC>D5 9Y!H1:RL Z.=8 ^4G%&%:".%=\+=!% !JL^ -,15)FXII-M+J?4:]52+>Y.9]FS*)?[R*PHVKUCIN7C#_[K!*A!0//_Q&27; M:GVUSLNX"3"($6"P?01#(4I6&K-ZVV4<,"Q(A(Y2]H/NO3_5\'.=,"$BI_$- MGX5Y3_[TY^:G$H&=*L6T$(\-;M>I)^:UDL-$?!E*.R=][71<6\ZX3C4[P9Q- MYX+D+&S;K:^5D1@[=RIJ+Q2?MD=@"+1)1>O9U!ZGV'O:;[=>,RA\+$-%0:YX@RJ#% 2 9:V_0O7A* --"TY_JX MX[3OV-)S9*2L9G,TQ=%6V)%0Z2PD,B/DU)$RK.3@KF.NR&7YZ&6LQ=%R M7;Y*@N/R>!_"8W&0R Q;_ .#]Z!-5\$F1<3*K1.25=>^ ^L1+3P6QDNZ#82 MKO?H$Z:MYR\H?$,?8TS\*C]HY^6<1T!/@!T%\'/D,^T$PA%7>.C%%O[6!5KE M6HX(N?E&C23=8K1KVV_(>M!/<@V83W&TZ@*/,,\UD-H!\ML/+HEOVH"K/@_F M?-2#_BB4/K?S42$&0>"4ZL7Q(DS]_ ]JG_R18B]"&Q)7?E3X4S+Y,4)R'6Q: MW1E#U=CE00-P3PE1H@C$SRW&2&O6X@W/$,U7PPL\M]6KKF9MHY]NHQE'>C#1"6C[6V M=>&&: -1Z^,L8[O!1%H99+7G38#95G* IH3L C:T[Y./MP="L9%/WA;_42@W MK._DUSS1/O>Y;^@9)1GHQ$GLX1+BO[QB42&%<@7(OXL$!!N<2>,2%CM\E>LM M:%F38K ]E@J/ZW+]JY=@5&;+Y!%B6;0713=CZ(8_^,<]B"_L8ZFZ)8YJJ%N( MS:D86N'2E$\O#)%_>>#;9@-5%[SOJFZA0_.TJ,>[!<+-5Y2L@A3A>[U"^8\Y MPE5I)-W6YL?[G/TLR+?*PW MF\(@3AF86S_ML,I^X?\3:[S$O/@*):T?03%=KA_1&ZC<'U&RD?-O\\DNH/_! M2Y8)$;9\T@G] 24$OJI;IB@#.P0 MI:X(>GW_U)-8M#8"$4\2C7P,W#AHTY0K]O+V;A*2.W4*,C*8E:H1R4GNY/'4 M9'(I492!<>/D$::TA:@PU6Q\F$6T@KEEK-P#06[SB!]J274:&]2I]USJ077-%JZ3S@DU-F V(G+<,I). M45M'9?M^/GV5#"^DSNXZB\*:'?'$#;LSB=KKB*62_7B4PIG'14YMS=ACA.\= M&G"^4[)GQIK.X,87\?]15T)^RQD!N$?X1"+LD;\F_CY':?X0F\W<51 MQD-.&0^F\--Q_)6P_'D71US29V+;DA"8M.)LVR4&AH#AYXN7^.G%&R8"D"PQ M??P$TO9GR$:B!@48 &T8I3"T7V1H?RF5Z(1/<[22KS^_(EZAG[)5UL$5]B+U MH/98;GH*XVID1^K*I[O@-KWR=D'FA?0 E.RJV8=JN(X;SYS:_]6-R];^L!;^>A=FAV;O?@?^/TM7#Q0HX#QP$RJXB_RJ. ML.*C$+-=D1S4%5A[$6AEK,0Y?I"S#.-6&2193/O!V7N,0 M ,XHHU$YP"HCFZN&F61>5,\=Y %=L4 MQ!SX/55G'K58P#T@19("*:X[M)J53B9XW'W_J.)-/O5(/ZTH4HY1TS_\LS M MF D,Y_CD?L35Z-LZ;4-,KRM9\++JK],:<3 M%V<1%-*(0G?C0BP;^AX1%B_V*ZAO'6UX.]XK3$\;ASK3]E:T2E"2BN?0O(*8 M>9M,9$93;;9Z+!T?ZP0/^^2QY@]Q2DXQO0F#;1#!SUCF"6)?WS5PB)7=0$OY MT#05"YIF60/G&:\-+$K8GK; AWK\L""D229L'_^MV#K^RV^/P%^E!3^JOTZZ MK8_>UV"[WRHW5OY]>HQ)*+3\FSV3=JYO:KB#H<>D>04WN$>QM8M5%KS1MO5Z M([[Y_*%-<"#$@*>R@D]UT9V&&:X= >SMCA;?]#4]>DQGVZLIQZ,9./JU%:=4 MHP>FGA+6'A$6V>!QI[V^=KLD?JOY0XRG#1T]6$4(.6/V936QFTR;#J?X$M&](G^Y5H!E/M\-!;^- E?I(=I?/YJ%]\%0 M91*1JU%+3M7YH%!K "L2U>*D"4>JKW!$E'!TJL300RU2\BC9S3MU_+76M^0^ M4 /DGSHF&PU%A2V\054\:=8UHE11UD['<"F[F+SS'-[1>S"%T83R"YKP6OG6S!'?.WU,@<=>KH&OK*SB1LIJL(HC?*S:1H M2G_D20V!@X;,N-M*KROV6M@>SV$T&Y0^[;=;+SE4WI*\0QK6&,*]#Q5-+U:K M9(_\!^^ 5P^+U_KFZPY%Z9%VF#_9T!O^ZK-#XN<)-1VU_9&;Y[GA=3V'S8P5 M-G..N#B^B(LC=_F? S(:,_$(?0C"=$-_0M5X>PF@K)?V;9R4T*V 0#E\X @( M4<[V0*@IQ$=UI$;S).OW>/!G_[>_''>8S!%I, 9G.(;_8T?""IXR+\F.1 \\ M>_XGM*V>G;UG9Z\U?]+9T>N&NAGL_"9CZ9+8+UN%%=S"XX> M>E[JW.OC\O] C5;H5J>UO%<P'>?X2/[_&^]2+?$QD-]#)!Z%(*%X,7"^" M6/_@C=245=M&NBYESRK(,*OQWY2&V+.KZ1K65FUITK'6MLXJZVH-QN4Q]OQ) M4"GDLL9L8&\;TO+B\E ,85(4*59=>P.K;J;^"Q\?4LJ-21LKE0[_G7,Z?_;; MQR#2I_.7?C^G\XL5:@TZ/-<*U.KF.. G;[QDJ>J6&59Z[KF^-105$B\3?EE .E.V#C 5\TP7.KX'C)5<(W\>^M$JK3V; M B\M3HUB"7] PV[+8R:Y+I2Z.UR/ZD1WKX.211?HCGPCQ7643[F+.$,!M=KX M9F1YN/:YH9MA1?Y^13:DOQ;2<<=WF*RA$T%E>A?18@B_(F+K\"_ 6K=!Y,=K M_,3?>D%"ZN@.?<8==V$]+N@))6_!"LGA_@2%.:'Z).T0]0RM7\3?25V*./L' MRA[1*MY$&F5RO._9C3$,5AFK:JJUI\C'GM[I4[HG?BSR3S#N_=0D(=_$T,7+ MA&9R^$VDS85VNP2M JI2D&;UFE)F;>;;YURL,R;#RJK MK-,DYB )%=XI>\-G+GUF)OS\\=U<\C^_8/DB9T\J86703QP?HJCY_"Z"0 EB M)R 9H\^O7L3>+J(43/2*P$I H%1H=MO="8FP;&M.C[/'XCHH!RSJIPK6E M]H>1--[Z=XX/9=Q 4T2Q3.4BU7SQ^- HM8'\E,3IX%==\Z7C0ULCWRJ#.3G; MK'S^!!&<&QDF-QL.N34W0BKE?H@\CK)S<-LL$C]DX6^E0/$*!%&VHG8B= M2F#;+) S7(1<*7%M^!"SDSZ-ICK+Y9BO>:#"2IUE9]#0*FBME* AYW:GGATZ M>$2<[-D<+V79.;H;)GQ.T;VW[PG-X@1:"<+&P7^SR*-T3*@IAQV>] ET:AAQ MFJB8Y&6J!%7. J&=&&,MS',66;[2F-M6/*U3["C'[9]/^X5V[)EIC$J=!)3Q)!OOYRFO]6 9.B%G4FA]5\&JPRYSO09=[,&)0^1@M M MRC^!$S@6JEK>J1ZQS'PXI]3I']J"QE@#MU)G/WF(\BIV'0MAM'>U0].5*' M5 J.]Q/F4N,)J2.EP4?CR?@O$I3)\FQ-U,9_/^A.Q,FFO$3^*T/7Z. MG<0XR4S\*$_;J^#84:J3G?AQG+B-W*WC,$FDX@=SMG'9=C2QU"Q^((-:LL[J MS>!I7_R<9FYE<>R4VN2.\1,95XP?TB)'S15DJ'8ZP6?TI%2JWG M#0M2]Z@9Z_7O'"W*YIIJK3/DBA9SIA>H\_?;+W2TM'(;)VL49)BMC)9*KOG2 MT:+-&E?Z[?OC1=JY^$AK4'ZA80D1V-01A.8\Q_!/4Y&?\>>/%L%JHQYG[L2S M-/[UUG[=7?0JO=LF0:R#H'C '1POFCD<5C'=;A/'BVR))&,#W6VWX2["3X%' M__;^&"OXU24F"Q@V_?K1HEL]-'5_-V,YNW ^Z$YAX)T>+=C5=J8#5 M%EV=>"='B_;6MWSJTQAP@T?[/@B,X [#%$1IL!JS'XGZ>ZZ4N;[8;!+2D+R\ M/Z++U>RVHW[J:(FJIHV1M)9)Z,OHTXZ3&M.NIB&VXF-'2V[.\+#?/ASQ2]#\ M&BHHR)J2H-K/\4E,C4$="E#S6(^A):3^&W(C>&>$JG/#N^_&J#ZWHW[CS$LR MEX*IW#L/;03BB0<@CG :'0(A!BU^\R-%=D1XDW_BR!XC &/00B/GT^@7;S%* M^07Z--Q$Y_-H&S(R1H6%>3P+D\6BS"+QW[T#,O:3CI&Y?I9UQPB)F47ZNH-G MU#*>9A;Y[0X>4^M(G'GDN!_MTP1!-.-DOY_E[6$#@>:1U^[> ?4-)9I' OQ( MYS9UU-$\DN+=.ZQ.T3&C),R?#VO2"*=Y)-.[]ZII@@=&R8X_>6/%N-%7_$S. M9@DKTGE#2!<_G;,UPN)=$<+'N&OU;'-PY%&!"+'\5,Y6!A>56&64&S^VL]UA M(BE[@*@X?F83V!R.K\#1 R&&5Y0%*R\\5SL:9M&CC?]MW?-IE*C?MKLX::8Y MY6E.UP+9<49)D..+R"DQSY1&-S[0W2%_&5U4L(N/)$C/['2N[#0GFPM,*%M* M,X]!^OMM@D!.09@&LD<,^M ,U/B[QY<>(0,ME]_'2!!M_N!IT"6'Z9<87\8@ MQ$Q_*LI4?/FTT'J-Q6P?\_2ID5KZ[EE"ZLR@IY.)3N]D1N+SLVA([_AE4;T: ML^AB?21G4WYZIFO/[+AR1WZOX1J0%J7H&'6V C2C=J,7(=D&_M-R76TH2DBW MU$RV*JN,\BUK(E_1!)%TV):"7!YC;:MGS5Q QC#$=U_MSE#!SM!?L4?F=(_( MEX/ >)^*_LTF6P/N+L+/ N;Z>(M G??L-#0W6C?#-3#*+5G- &%SK($"[?^P M-/5Z$?G7Z V%\0YVQPB%-XR5 F0RTQI8/Z$()5X(30W];1 %P 2A':X)8&9S MW35]]&@C/%CA6@25<9R3 MFH6]:R3QL43?AB+7+/!M(**)N&L0A>:,LO+3*B+-2.B:!>HF>\.T9#T+*W5K M*C64H6>!/*GQ:9@$=9U4SDWT?SY986LR!C"X'#$+]\F8RJ;T=.JZ&:^I->P= M4-5QLNP0N<>DB7GK(Y8*HCUB&L>#EV2'HB7V7;2.DRUEWL0%4C"DH_"!B% ] M8T)*L=8$OK &^W?C-'L6F9R'J?;X_[?WK<^-X\:^_\JI?,]C]R393>KF5OFY M<1W/R-?V[-;)ERV:A"0F%*F I&:4O_X"("7Q@2<%$@U*55L[M@F0Z!\:C4:C M'[?[UA.M2QN3=SDT'W('J;+6*[LY(^@0Z?M+7*SOR+HE*A-^CH,/=F\NH$;> M!\3<2,U\G(:64Z[_ Z5!?AMG6[)5;(+G>$/CW;C&-V5S$'"*UZ/D*L/@!7:) MS''1()#\=B*._/+K"\ZB,BQRLE'7RE'.91=Y6\L<\RE.$%E)*=]4SVWB K0% MKF'@S+NPF66H7E&\^2B)XDAUK\6R85%@*BL/.E47=XLLVP=)L9=?/+7:6 >S MUKR8\L_TT!.;%>N,' 98G"@?5@V]"P6K^)G?W^V&8E>3<1+@$Q3N6KA:)5%Y^6V=# M_Y(2E29!T6DX^5V)Z1%2,'Y)!W>^.?4IL68:.0&"QE &_SE+0Y/Q-]K#,"_H M'@7YEVE&IZVYWUKJGL2:4"H..Q=Q R$^)1TS?DA/+Q<'DM[9IWW=U8=XKLM1 MZT!UY*S>*>YF(L51L>0$,QSV,4KP43#E7:(9LC7HGZEG?>6J+,,&A M?=;@6)-AXG4[!GZ>+T==F\RL[V3-5 N^46C6 $VE7SR/ZP3@ZUH]R[ W7"%'Y+PN;.;A'( MA%3.P,^L>BYWU.TVEB\L#QG8@BH#6\CX(:?@Y-DI%2_O"E.SIS-H.[GEJC*' MBR6;>+*%DYF/:;H'QOL"Y(U> 9/01CYE)@N&4-I[!S12:^G6&ZT9L<*WN N3 M[,@KV0SRVX(9>@VNYN /K6%H):I=IJF-= 3Z15PBZ.!CM-E+U0GRL?,2=)^MY MH[_=\U\@2^\VXA?!'%J\,R?Q054F%U)V5)5Y;3CM+5M_0XP MJ_8B#M3IM("A5X^C&[6NNL=4*.;NY&AR[+$]E7/'5E?#Z<16R)6(B[#23G!& M4$L03D:="V/5X1?E\T)/F/@7@-\KGGO_B;'V-ATAN=2ZB>=\1#<%,H&1? MA+NQ"5[< \#%E/N@CE]Q4:7+32/J'$S$$DI#NJ//)KU5,SD:H?(SH>GTEZ83 MNO0D:OH6RV=4F@AO_[Y&.-@BPMAA_IR$XO.JI+5+(UZ(4I:R,DMIO;#;O:)X MB*P''#+HD*1V55D/ATGK,US0FF#WZ*-0S ._+9RA*U+F\UL[&_YMD 0IS7>) MD$Z]#6%S4 1(IT#2P1T3E1\Y^G=)LSSOJ !7K !!:TC#EZ\"87O+^]1CG)*Y MCH/D)MK%>8:YHY*UM.[9''V4^5IBVFTUF#1EV1O9%@*B8'Y)\RT*XV6,(F&> M-W%;RX"1,^E[@%=(DK:JV\39*J!L3 [U)SU,LH3Y;1VJ$4+-^Z2>*VZ>S=[A MC-1%0131QEAEKAC\MM.NRD-"]L.2$V02Y+>;=*BOE)>YZ[3[=-)A?0J^Q9MR M(QQ8^_GTB DF]/3LFNWS,<9Y\8825@N5VE,^LHB?!%+9',Y)[9;(QO4FP/\R M.ZYUNUF&NI',1"/'JJ0U(*#W1\S,CO?M;F!VK&>%QXVXO6WEK$H>02\RTC)( MZN3TCPA1B5#][;#ZB*A8X6!#GW%UN&%OLC(E.0I_M\IVOX]07,T&^>$T">27 M7Y_1*D@>R/>Y^9MY+:"5GKQ6T)Q]]N>S,7]&08X.&3G(@J-6*@G?")N#(D#* M,9(.(]LA>&)$V.Y:_-4N603DN$#/\0Y%3VE!U&SJA$.SS=!J-9^"?V;X+@ER MF:.YR1L@DGD:HM(-V_0MEA?.<[P*TNB%958-V>51D.14TN-MA@-IE0C=KK:O MQIBV(KD,:SZW_.TW%&;T+*9[4)*VMSPVJI B3&6;QKE"W-BV"IL51# UOW,H MV'I?=JU"&ATLC^X=A>LT2[+5G@C2@TRMM>*W]L>=1/9$<-YT60W,99'L8H M#9%TZB6MG:WR3V05$-6$NC9(CV;]=A,QAH90U>UJ_9#!S(TW*XR0O$22H*4[ MDT!=@Z3%3U6F"43YM M-F6:K1 _^E*[&Q"'Z6$>LD?_:9ESZD5$56GXMG9"T<0^I!#L M>1$PJ7Q%FTC)W#(O BR%2V>+J\3NDW,-AM/PSFQDZ&LY3[0<,8_(]+PC MY\HN6BZ6K1!(4QUB[L@-\O!L(BKPFYS_:I0Y8!XJ]4B6[.P!XKA]'F#IN%Y> M!A0\_FAA-'L8]*L021T[9XV3J5OH$3*91>U"$>/[=TJ/N#V4+P(ZI2?I2;,< MZ-IYD3#V$G%PG48O AH-_]/FNE3X>!& &1PAY:[5%XF6,&6CX ;Z(D#2UM%,?>(O M KUS-0JNM_Y%)&94^ORW+(@<[_H#2K^;I\XZP)0O=E>^"(XZQYBO&XIP$4!J M:1F:\0UC :PKIFVJB'PH9@U7TFR.!SL]0^M8).9BW9;RD,O3&:Z7,7@-T15 M ,^LH1J\(PX,*[H(,/5/DV+-]B* .E>LR:+!QJ@D"P9 ;0DGB3J;-4#6Y9I( MOY]MI6)M(69T_W013'?^Y1$_SG&,RL\06,Y8FG7"*!U MQB+4#84=H[HX.!R5?"=VDKH(?&P+>TXP@ATK M,$QV+4DASR-J7M3QO$=+,H/1+4K)#P4E[11'_ZRHT*#7UUFJKGIX;-^,/THZ M 72,=>%C_"DHR()(5ZWG"-/#DYS>(2]T61*+.I!4LH1>/A8Q9AND24$L[3>X M2WQ[K$;>9\I&9@AIF2RS=UQK4EUK4HTFFRBW8<0V&+QO-KK99.50^:1Z*0Q- MQ&A#:FHFYXC[BPC:&K 5M)1C,Q$[UY#,:ZZ8/A1.*?R'U%"8U#?@EPL6_>& O^6%PR)=84N=9TMAZP:LD*?/;.*.W"'3';:1N[XLF26MHXDEE M$59V)FH( 5U&@N]<0Q* ;LVLNZYW)!6X2U[Y(:#=S=V@MT@6+2(!D$V92J[ MHI^#I$0O"#.SE=JZ)>QI&>)_H#2@)LXM2_G;2=/71UK6W+Z>C' <)$P!6R), MUOG#CD!1[6/JBR6C_LZ8Y06C;1!'=38Q>JBK'+E+3"^5ZWS6,FEH\ ++$U0[ M:04KM%@NRB(O@C2*TU5EEZ7;3=>(J]O+\C@UBM=J%*J=Z+).E3.R>R$G;.]. M_'$R6?*E7;^AE4'G*/S=*MO]/D)Q-5[RPVF8DE1M!X[@M)AH8 ^M)'&]4;4> M.SQ/,T./^/!E\C9A41KV5N.^?:[BL*4;RC^NIG)/(AX+>U M#..7E.C("8I.'\D?<;9IFCQXJ.IT<^FTS1R::M:K]SZQ,S:O,93!?\[2T&3\ MC?8.E9@L1"AB'/$Y*]#A:"94603-'<[!1_&4Y@4NZ5[ZE!+-$>7%*V'M2@4_ M*2W"2=%^@4.YO:T3Y"^6&K,D; [#IW+D9%7S= PW=7+CAQD8^9%=!)[7RO6: M40EJO[!&(0:QK]:L<3)U]6HG&1)X4XV!&, LY5)WK&L!=S6WZ7B#M9/C:WE; M70AZ',^LHSSC>$Q=LAB3>%YQ^*L%[%R9Z1K!V(?B6NU>OR( WV%KU@ 9>7T= M@1*Z8%T25GH.TB)9?(F(R3S(1#AQF/$B(#LKZDPK/>_LMG]C_[E3F:^.(]M% M<)B&3YQ&&L*+6)0J5]+.>N.I&G-==$*_O@,F/<^ZN2*A8Y_DV%$,O/EFO\94 M'H 'GI)906?/7G)'PY:E7+T1SA4M0ULYWU'R(G*KG&DE%WMH7AQZ MZ2>HA> M'$A:Q@4#O]6+ /#LP^ 06_(DR9"\T=-,_(PO@B=-]@UM=^=9%SDVV#-$55GF M#8S2>;NE@W#! MCC7U5&C;& -&""+IG"4HB(RXB$J[9W,<=R^X".B,]7:M@)>+*"T[]C'\@JKT M#A%XHBBEBR@W:XWW!!Z^8X#H^PXKB2R[B'JSUGA.IX3AO*$*(EEV*#T];J*'-+HGPD@RSG:[B0?Y&.=AD/PO M"O C^0LOJTDG]H[P%J;U2"/T[7]0+ZVBL-U$@ZPO($\+ M52Q[A$VGQ;,:126>Z;PRDX885G[S28?\&"<(WQ&D5AD6,T"[U:0#?/AVVO@V]/$5G!\3*N[KP^E[RDO\KV$PWZ#84E-5I]]_W'.ZTTS1EG MK\FD>+);,&IVVR$BO -^FEQE\XG1?/@6KNEM@$ WXC:;&-4PPV2+81S'+ EW MU*^1EKN/Q-JD!-Q$$:9.J]4_U+KWG7#8O+8N!GM'?ES@]^RK.$UZOZ6+ M@;YD>1$D_XBW4F[@-G8Q7,:)"_R"LUV3EC;"Z\3:O:P39_BGNQSNS=DIYI$./2K^ M&B99CJ*__:; )3K],2-[XK?B(6'6XK_])D>K36,+[5Z\'>^CXK3X?11OCO=N M1.,37+<);V.XMY+U]8?DNFPP$G_H(;$,DAP9DQHQ2_1O-RT[:YMHJ9U;$+=_ ML-N")CTFO\,;@_0_0B2]EMA'Y3NQKW]'H5L4'J;^$Y]%-I!Z6[22_I1R >EP'&O_$&:/0#5"74[AYC (#0)6. MZRPR"O$ %3N.\\DHI /4Z_CN+*-0#U"M$WG'C$(_0/VNZ6HS"LV@M+NV#\\H M]()2YOH.0J/<+0%4YN2>1WHHU+'D[5CQZ2/)3YD*,O*VE.#;S)#\0IM,3*EG2 MU %Z?>=+FMTL"<-%A9:,<"\VAD"!?M8+&SL^XK3(H>B==;A=GA"S( M:@RHE],S"G+T&J_6Q6+Y)4=,;Q50(N_C;DZB**X,?2]!'#VE=\$V+H*DL6A% M,Z/N"&1^#KO67KG@U?V@D21?/8I.0XFAM69^>[#-5@J0=O69MF*DV\WR2%D] MT/J0F9(/DZ- ')*/44L.;XC2]@X/$ 51)E'T$."4S'%.9&6Y*1EJ1/+'82QB M"XV.$(Y]ZI,=B&'*ER DE;E=&/=0%[=ED!5;!I0]'9N4I*8DISK/86U558BS MS1:C-8V"W:&JV,ISEN=$JUDLWX-O8C7(Z"U.SP1Q=<*BEO$LI;L/2D/QWO"*:W1M2ST&0WIVV,H+H MW52"AD,K2XC!O:5!.9 9Y0X9$R _,HIHKRNI0.&O/,_I5M^4B3-K^"!"C+85 MK9O#)AZR+J$Y *[[1D[ M \W D-9Q-_D)([F,3Q"B6V_/<= ^1/!OS6=!O5S-D=VY>TZ^F8;3O[7WG/QS MU#V)1P!D5"PF5-0Z2T+&PIKFH\]'GB?B,]LT11XGGH.@O6/*G59F@8*,?(6K MB^?TF^T6.KXRG@-RSF:JX77C>2)/,\FI8Y^B< M(QREKF6>IPO7/XV.+Q4FSE;7:^(;CX*QAZ#XCC8T?23>5TN.\.,",] B=N7T@C!+ M026 5[+J#6%+JG6,^O M!X: ,8V4!%//0N>T/.NJL]HG[5G7HC4ZH,^[/JW6H7[>E6J5!H%Y%ZO5,RC, MZ';X^#1?+&MG9/*4.<\TW(RH@]'UDMB+2^)STXSK%!!H-@0Q:">YT<]*T5E[ MTCQ#]VB'DHP%R=;C$TZ!K(^[V=#PIWRAMT8U=Y;>#@Z>+RE&04*UH;]G"=T1?R*"@%*U2.NBJ-2Q"L71/ M?DU75=EO10+#T3X'0D2Q&NBT4"[97F_WS2?J(CLZ+P!!I.'FX;[(01VQ2L.- MJ+9M]OA3/SR/I/#VD'-J^;N$.8CYU5U/V4$CP3HJ7>1!MR+*LZO+OBV7O!D V(V;O@$9J/06Z3I2F;[GZ5<+QJM/.!LRQ[/B< M^E>#<*65ODV_U![N.Q1V3>2MW$>CF9=!8VY2W\# ,-%NE.=QW,*;7;;5-[YY#.W"+M38CD.&SGYE=2R.&#(FUO5LBWSRG?] 6 M9G3EY7E(H-'6QKDD\YS\@1)7>O7F.22&(F/LP]V$E \2%JI[P(L(F-5 SG,< M!O'&Q&P!+FI6<"=[$4&RPDO=BXB.-;P3OHB 6>/+XTL)H%5K8#,-';Q;!^D* MY4\I:4"8HHC)@;4=5LU-M!O5!1V<1^GU)O8:6FC)M2\)&X?AZ3T,],+QM]K""1OJ91K@(E)3:='0$E5!=4&I:#+^PPEA58Q M^^U!C:SBKVA=,YHUA%8?(!KB24(059#,_&-)-=1? HR)*DHTQ_H* M3O(5J]W?[4Y5I0AJNF2R[%'LV8*=0K"K-59<2H M*\T+]JR1/WMI,=UCA9,**-#J>@T.\HKK2LM/#BH M>0*!S#/_3 QFXX@OM?0(\@O.<"7(+"^MFT4^7)"1L.B\IX +,@K6[LRFJMM@R8;D,$Z+DJV3$@(V"/\:>Y))_0YTR;[Q5&2\]AD$__>$91S[W2M+E' M9!WUG'XW;#-B5O<):X#H2QY]0ZSGD!AH7V96VXOP]AQBVKT(5]#QS;\7X5,Z M020Y.)]1/>OQU3V2XQY9!3>N41&'! ?G?C6]:;[Z2CIWJGFD]'T>JEV"9=J_II1P=P?B$3B7/7'(%\_)MG7:Q&N^6I_ MY#B$$3DVWZ/JWZ?T&)E>GZP5]0 ,7@"(R/LJTU8C7TDL3%FNV]L=PY7;;:41 M!4'=!PJZKB[L XSUA,YD+GUY? M&(Z-U"R5AG&"6H::]XP._@5GNYC(_MO]%R*P&VOL)BSB796;5#[-HWS*&7#W M:(M1&#,.%1#<:N+2T]+._ UXD<-@G&P9%Q+?TD8#:#-SO+'(GV9W]@R1S0%[@LFLUN@ER0(4=/0%:7OG2^\]NPF)^HW1VSK# MQ3O"FTI2Z*Q >5] 9\H7C+9!'-W7MM%#?JNT\OJ@J7P9(8L>/NAB9Z_0];TS2W4!YF)3TQ,H>G35QN M0$0;%5+1;N6^2M\S!?.59C);+(G2S&!LR@E% 3S3UT [:G#L%6<;/& (G,]9 M0:1"L)<8_87-G=I6.YMP;Y-N_Z'1LO*FZPN*NGC+P[>0.2"]$EWT8;E$XO+7 MTPX"VI+@')K//G7;/HX0E8:I+C7#4@VG/&JE= -L"Z;G."!'4QXIY[[-Y6:: M;6C*7G7XCI>UA MAP'F?)HBEOV?UC/JVB8J04VE6$.EG>BGM.$YP"-Z3_11+/M;N Y:,-=$MIY M!$YW_/,$1,,3H .(ZFH=,D[7XIUG[,Y#EA1H8*YU/-7R0<-KHB4?%&X(GB<@ M&:;1:7L_>([.&9IPV='>1MG$N8)K:8:J.&UXSD^9ZE" MTLW24Y-E/I$T,]Q#R'UXZ^8;+J MYPF8J3%)ZI+G.41G*1)2(#T'QI(B<:X7I.=)#6VK&'RG2<]!.D.EZ'E>>@[% M5!J$N0NHY\#:T1U,'$GG"=@9%U%MIR_/X=$LB#RQ2ZOGH-K1.4Q<6SU/HW:6OM'WO/4<#3N"7NS=ZSD\$PAZ[W-*6_>@ZSH3>X[/ (%CU7O9 M<_CL2"@3AV??4YE/SF]MQVK?X=/S@M8%V:N,C/0.@>!;8K3 JR"MK0#W* ]Q MO*VN&6[+G."24QWQ.2:[6$1K5CE/<-B;JVM61H]R&@U!\<"'#>8D+'D;Y#'1 M05\PRNG2I']])VOCEHSA7P*D![S(CT1.UZ"3J_\R(-]5O8D>LJQ! ^/"?QF( M-O%6;C8!WB^6;_$JC9=Q2#K5IQ-:4RA+XI#JV\[WX:OR<''*0U^>T (T,C95 MJA'GO/*J4%P5BJM",8Y"<=92!PW1!:L6)T-%U_SD?&.^:A.7IDWP+U,;=Z8' M)_#>X,?%=B6MY.I5]8_LA5X[AJ'%>-8YPBL9;% 6C0+E@'^9^W8$G>'%-=(.E$#W^?.P@JB\4KVM(H;S/E3J^O MPVV#Q0O1N/E5=8A[0W@7ARA_)O\C!\YT]8B$&I9N;Y>5[A Y05/)<4_&FF1L M.ZCOO:5LJM/3=M%(HJ:F!8LDD?.6JK7[*BNZ:I2@.;!2HHN#2^T3TUWC'0WI M2>7[V9 W.53C-UN,UG3%[E U*R8R3KN[,P(? IRR:R>$V<3HT:7JY; 2R=>& MM0!G*?FQ"C'+3>;-^#77*P(P]N#K%<$9$ZUKK@,-!OPD[^"RVW;-AIXGG--/ MM*!A?O0\$8XF%C)[Y46DW9"8.CW/>:!'O\Q.>A%!^/HVUC'@^ $:'%*+[!@( M_ @-@?.,N6- ]!=H$!F8>4?1H\ IT&<8A4(#34I46 M_%%@ *>)FEO^9^CIRRS95S]?/_Q\!PTV7*.H3-!B>4,F/HJ3DNX";RBLJV$\ M?*L2*=(&?8_=+TC@W-%8DU/&8$?O9++PM015U'LD2B> M51LL:QSVP?)D7L;H<(B)6.<;UCV M+K8T/I[.8O_][AQ%V646U>&SE R,NQ?+V[ITXMUD*;MP^]02RWUOW4Z[>2N7 M,$)>!:OR+ON*Z JA7!2D^^)[M$R#H42 M6Z,C! V!;)$A.MSGJ?6"=G,(Q@$VDISYY$8BB2)H[38N.U^415X$*2WE+0*^ MU\[RYL@4AYOHGV5>T$O08SWQ.%LL:P7C$\(K_G:IW]GVJ"M8EHUYK6;T*25; M^%V2,1?<0UE/[M#-WC#*^,F''EO:QGOV4F*"8LXU2*H[V5>Z_2P;O [+B#ER(1M82FG MQSD^^L/]BA&;LN/#XVB_,P%!^2YW9H6Z=OUC MAE_1MI:HIQ&*[ N*7K87&P_3VA)<90*FUU"+KRG9>M?QEJROL.'KT%J*P]XT M]@YS* 2_P(=2\/67R4% :\N1OL#ZZ+,0H2BG7G*::H>JBW=>,*->1Q\C:^S> M]8)VNU#[H4BO=#LA%]T+5,BD*]V.1KOVGYO'DN@.^+B>Q+>TGE(LN .D!',N M4T$3*?6[XEZ_'JAL > )C;4Y=Q"11V.P+\1R)M3H5K@5/\;?!6: A.I2N>5M MJ7'3Z0DDO)4P$B:>+!P-EUSMB^YVQAC^#3)H,.!G1YM"L1G[M&%T3^\IB 87 MLZ?4!J([=- 8:.TWRBOVUI%*AIDG6,@V&EM@C+O#V,J.X_;$J:GZ00;PC!-9 MVZ7"4R(GVX\ZKAV0\WP"651BC1DR>,,7E,"[QE-B)UM8.MX]D#/)PEAM$K4! M,G@0&%#LB04Y?:];MNL8""$#!8'%A+YRGB9(GFYM]KWT/$VI/,TUK8$SH:>Y MF"?"T="]T=.TSE."*?6U]#3G\S3XR;U ?4T/[4*_TW _]369]&2L*/6%]37[ M]#3HB3UU?4U3/9T&?:Z;L*_9K]TBK/8\]C6M]F2X*MV:?4W,/9','.AP[6M. M;T$X%.!J?!"]RKUFE["[.DRK>F-IS<[K;@]PU?8CC743T$^?/0S M3>HJ@)367$N+9'\3D96$(E$">][@3+N[&3D_=9CY"[P>O?M4-Z?QO5$#=("C M_,N6[![H^S]\]^<_?"_-?*/7=T8)ZSW,V.;"94JA'-F=IP;I(D M^TJV5/I[5623NF+\0AJC;+D43,)9KW3'=HUQW6?E1[$LDYJ=\E.Y21'?Z75V M1ERE&%4%$@^I>44U[_EMG0W]2XJKBF/_0=%[\*TZ?PA#4T6M_0PQ'*B'G6X! M3+0@R(Z<>C?O Y0^/X/@Y&[Q Y6U(]<8*AR>(,5S )X6*N\#4(:KHTWCG*9^ M!QJC:UR*A2W*C@H*V8EZW&W+6'A!AFH"/M/5\'WV'K8 D^"LX+-+JP54A,<0 MKPS-)]-ZRS/M5+ZESHVP^*@/-4C"?Y=Q?D!+ M6C9,V@5 Z2O.^/+;?>,W:8DQT]C2'B* MR#9+) M%N%XT=-Q$7VDO'O*LW*#H+LAIX7 :^[8C.HXXU=;('W4.9G-VJ[$C M:99D=3_+UO?[6JZ*TV=W6LP/4O=7 E9708DQZ5"U7!1KX5W"R!^US*;)M?\4[ [>)/LU&FDMA%1:W=.Y$WA'I]P;ZQ5+.13JJF?<);G]%XU2.C* M_HF,_A8M,YKZYMLP(:'Y;H<+XJ=LAW#*A/8*I2&[3FV2H%@>FMV]FWOJTC/6 MW+??#0::T]#;A&A2+^SNK2%XD"*K[T6];IJN>>PSB^ M -35]#VWV3OCQ\Z1P7-SO748Q<<+3PWS+S@CVG&QKR_;MW1EG5#C/?V,"L>V M^<.H7A+J<-X8FLH@K]$1@-^R<)1Z_LJ*[NZ*XHK&Q220Z8Q5G> 1<[NG&YOD MHD&G)SRRZ-"DQE:=GO,DR[UIF$:7E 7"Q\%)S9VBUBXSDYS*)&PQ(MI@E8)I MFZ ZN55M*V!_%TZ)R,1GZ_7N;C)+3-0!LEF3X3S&W^A/H!:&N&6F4?!H]*N0 -BI9US$#CT *FN?5Y@H[, #8>/-[G MEQB@!74J?O"U"\AP# @ T#MV:3%/D^<\M^@-$\?V5+JYPB=?GV,<@QC\'28GX9O"3:#H^K;R$/[$[0!3=%*)D.#L-OC)DT^)S15! -$E3&/+O?<'>XLT"&S#!H[_U77T'HGJ&?LA3M/P7X M7ZB@.='E1@)!8_<+X79?LR7%]!&C?Y+-S0I3^KTG"=9 $RJ M5?PI_:<1@WH<^FD/%QE9M?N#FL'3"/\>(TRTNK7Y7(K?X9[4IY0<9?-GM$/) M=W(+JJ3'-:+E; '?9Q&&L)Z,EW5V3]Q4J\F]C.0.]ZA'ZBTO6==K@(VGCO'N MA+J\C(&LQS5X931&9.=.?=5)W-[;*[]1S"$M>Z$](P)DJSX #U31$1LT;'KN M]_KG;R[KR0Z"GJ C]; ?#9[97#".+N8,3N5S@=+D.,'E.]Z1%S(XVC>WU@WG M_L?T7<.L)MLB-2P8JFU LIX]@4ISOQP3J_EMGFJ#NA*LGA'&+V_I/@ M_NK^%3'?_)< "RJI2QI:KK#R:54$?_R3N Y0ZSD(P)B&%H1UA8CF$\F"-'B! M72)S7#0()+^=B".__/H:I"O$1;_[=-)A?0J^Q9MR(QQ8^_GTB'%FNOW,&:<^ M;;9$M:(;UF+YG*6KYWAW*#CXGMU2+75+MBG)N3C(TW_V@P.O8 MP/+7'[YMR;$'O:)X\U'BG%&H#YE!;\OC?B*G]3@,7LAND18O&2Z661)G8A"E M[2V/[26C'XF#Y%.] MP)D(995-GE)RG!6=B)HMO'6\NNA<"UI7FHIC90L6\?G'$QQD]Y4V@)C-9:3X M?'@L%-0^MX&F5VLAF)_PFBS! PPT)F(>$)P**;6*AI)P3H/SLOX)3"']RLX$^P9 MJHT_]::@:0\W?(-E<[[6UWE^0::]W:55#O9T '1D;+AD =Y\Y 4FQR^1%Y>D MQSCP/^5Y&:0AHH6^\J?T!1/972"RE$/A39!F3RNPYRC\W2K;_3Y"<84X^>$$ M-/GEUV>T"I('L@=Q73QX+28:6/5%K@=/[_$X<_M Y!TF,O05Y8AZ8A.NNJ>^ MV!F3S@?A=%=B+)]IL_LR^WY<0H.KF>&?G^(Y\@15_O+G;/T$J.FK.)4@#9KJNC-JNU M@RXLRLW:4TC.Y!PM1$%#([T,DV@YC$%ZN@9D4I7FJ(%G@P,2/: @&[''D1*& M:A]DXZ4]@ R41-^M>&: J%1,WXU39FBH=-0QT/@36#0TE5Q/K7?/*"!R<(PP M0,&QO/J@U"37;6+9,%"]7FA4:SYV%R3!;,)O!1'/S(A,/T)7D#A^1];#&1G/ M1)HBM-BR._9TQ:"]1WF(8[8V!*2H>D&;%6F FKS/?$AQ'S/X$TH)QR14K$<; M(D"I2"_B':J5/6D4CEY?A^N(+ %ZX!6NF,-SAP&($D5;BKU.3W?VNI84^@7% MJS71F&]VY*\KHC]3SC\\?$=X\YW(@F?Z&I@$4[TA*]/BE5I62*]-:(%.O,LM)IEE;U0%-OU8$@H92JL$-/ACH M-$-R; (RF] <+DWUS,]M=!: M 82KAWIJ@;O+-ILL?2NR\%\@LW&=%K(B^Q:G(8!L6PS8V_U=$N32,I2R'N[( M.$!*W4F+/:UTG:4T?:(LLY:TCSO'I/9HI(8F?EMWM?9.*U1JR.BWB MD\'Q]&*C.3#W@5!+:@$\$U9K,D)Y#^GPX%80>CU@$-&M8_HDE"W MAC/\15GD19!&Y.BH2T.SBV5I_;9-XN(F^B2;T]%4"['0A0R'-?%YMD$&\LWR M6$PC67*0X1B7:=1F*T_OW VQD=FU/(^$&HC P23F>>330.I;%K4Q(/@S% A, M379C@/$#%#",3'QC(/$C8"0D5D%/_9#H 0-A0D&E0*;179829B]BHD)TGD%T M4ZIW=#; WB3R+YHZ;:_.2N=>^3>91/-*3-$)"#&&5QN:G8$0IW'K)^D B@CU MW9^JE\,;)X&TI>Z^1%A5SYL'P-Z]D_8+X!'99*DOVRP=3JWD3;.YVO7CJE"Z M(\_BME#?Q*L&0;5[>F[+&XC#M >."S>$4YT6G"HL1$#!S2,MV1>5^-D]/(1I:, MTX!IM"<9- U_Q#ND,EIH=05@P^C.29UDCJ7KU+-IJ-_@,LN):&B'*\>7+&=\ MES\D\29.69D$1)97)$^88>/-,&!I\Z:TY+R\ES-R:(VC#AM*HS_$[?TG8:2\ M3CHU[+F!+=VGDPZK4UNR-[#V\^D1XRRV]C/;)A"J1=!DS!TI+0Y)4O2 (<': M8WM*0YKY,I+DW]+M[;PLP!%^:3R>J+5E[FFA]HI8$26JIA-VN-EN<;;KV:.U MNUD>:0\0-L?UE\7,KM-M.DP-L728R(]L.\\9.>"D]%A+%1TRIL62)8(0<*RT M"P!"JFJT<36JJDBMDA)>'W?Y(O6K[7+)TN_OK;W;Y&S'-W]K')T\-X,S]FJ:H,CS MA*RBM6:4M@//K^!-UXN^S<)S8/0EJI9=Q',O!=MLXKVWPM!]1F[6\=Q=X7Q0 MN"8BS_T4AJ)B8&V:H>?"6[G9!'C?$<&':E-[HI0E9403 QS*E@5[\O;DI,*T M2ZY?O1VNW@[78M)73P6@G@INKR:O%\?*B U6&;&ALBER((O:NPL4"O94D\@? M,]R"6T"!L+GM,H0-K8]5OS@I/>(;974GKV^^KQ=]EW[1YZ@T\?4:[WK) 7DY MP3787B\XP.!CQ"02QW^U.3>@7?? UPI#(P6G@Q /.C MDHI<1(9F>IDSW^_NT)\$*4TP*[6&=1I9/CJ_?\W>UUF9!VE$1,<#*V"'JNQ1 M"R8DJ'Q-J6MBO*.I;27'Z:&O<@9_Q0+D Q*C:KN-N\4TF,5/!*21%K^-\JDK M<,,^-5)@VP 9)5DCK2;.!VH@3-VCZW'!P3KSK-30WFX#5PB(%F8[U;TR3YS] M[USC68M?/Y$3AS2>M?7<[1U;'!9U8@_INN"WG5$H[HR*RFHISI_)>8MJN\?S M.,L+5>)P39:ZB=JL^R+_9&F=_8?];%M^MMX]PV![463[Z6R5$]ZI\MYNMQB% M,4.N2@DOB7,WZ3_)^JG8?(/;PG6^MC$&.6X- V+PXL")+F M>US-<$7R@T?K!P.SC_BW0AV_;&+/&%?_87H^]]]L^P0R=V-I7@AX!FKHK M75'T&IQHC+C2SBJQ0>:<>P":\//^K5SVOY_)WG<43Z*-U.HG_ .JLC<]I=1? M@UWTL$"I]W60UIIM(P]T1Q*](FK%9SY E:M3&23,FF$;Z5'&Z-]4U<365?3H MLJT.PB,=:?K?\0^R@Z7@Y'DSU76(Y(O^P<@]Y/Z$L]SZ4I=\R3_8E'*K3>;D M8K/S^1D"?#P 3VX7LCDT;P-Y[#D7"LK9G.N=YWG4 M]OY.AA.]A!#C0L6A% M7/^X%A.-XESE"7"RC'].D/,D-: 6Z_&\SEIA$//C&3.2/9ELM?B5>L UZ>_X MFWE.]DB[NGU'-T]Q5J49;?N4>4KD%$[.O1C%OHL;:/0N($FKWI:JY5'7BM#E M2V;(2 R(Y+84G,3;J6>1A=/H>*3M!NDY*,!V[[9KI:?8ND\,#HF!SMRQ![B' M0D84AESOG.H]#[@?)-A[_KF>@P!,D"M]@.<.MPVQI^-J#!E'M\)N@ASR$V;2 M4+ *W]O;P7T<-A[1==_SY/">X2WP\_<\%_V( MLGLD__\Q /_!>\"'Q@J,@>:/WJ,Y4>C!&.#_91;@VPE-&,7"!.F:S0C@Z>,? M1L$?DM%T6NG"#8\8!6-(%III,1XGLF*42;KX$SXGIF(4H+T_@XX:B3$*Y-X? M0T>)VA@%ZGD<-B>)]!@%?__/GA"B+>:5<[IAQ:7/>^#6I>P<9Z'6,K7=).SC M,:W?V#6FL>H5/=X:DC/#X"L \E/;(4DO5[7-;UT3)\\^_R^ !#VGVW.]FG>] M]N[8M%I&*.+/3"VU1?RKU]D9<4\IV=#0\0KPN188DA4IZP&-#.E"D_=QF0 6 M$>UO31;Q/=JA)-NRN]F*453I8)4]G9'U$TJ)ED?KK-Q$&Z*($?4PH&XU.H3I M]?4V-'RI"0H1R#OS359D_M MI,^$?0@5KV3EI.6A#O)+@(N]I#Y?[LPTVAS@.]FN\R"L<9+:.I7= !@O!6,D MJDCKB99QTN1=SD@_7.?_$A?K.\*Q9%GB0P7NO8!$>1^'%H,3JE*+!Z>AY42L M_T!ID-_&V9;L"9O@.=[$Y'OB]/>RYB#@%+.OQ$)F\())BXR\X"PJPX(%<59; M=\YE%WE;RQSS*4X064DIWP+$;>("M 6N81#4.N(V\V]VSRYE)YCE5Q1O/DJ< M,ZUGL6RHRDP7Y,VZJHL[^9#M@Z38RTVQK3;6P:S5I6/$0F.%%.N,:-G,DXV/ MJF9?RV/^LB6*<%K4U@SQ6N>V<[@5,+0>B0[/V_L?OH5)2=&ZR7-$_HO>@V_" M/<'\3>YNO,(P*],B)UR"XAWSQ$.B&@W\MLZ&_B4EVEB"HM-P\KL28R2L,2'I MX(R(>[1$9 A1S31R @2-H0S^ :,M0P>D> M,MG3"5'QPH*< 6F<=:)K>_$4&3.E@V_6@9QS9Z1#R2!+D>>I=8;@)# M>9[T M9@@2,DN5Y^EGAL ALGEYGAC& A1-"YJG?AYDC3]G>7Y(I'+21V[2(H[BI&0) M%A$ADPP(Y96T1%$E33?;LJ@=B1X"3$/QCR]R'"IWYNA[3- UK=MZ/0#_DC-I MT7,\L?(1=[[.ABO$X*[5^]S4*]*RP/%[1&L%E/Z^M98^*NI!5+O:E MZ+3P]CK5MIK%OW:UHZ% MIX/L!?:5-M:9H Q=1W(I&:XZO':@[U)893M\ H+$QG4XURS!W+DIH)^6)K)"$Y<4#LA-=80]"8L KC MA'::OL7R 9A&&._?":[!%I'U'N;/ M22@^#$M:N[3LT:S:N"ZCE__K=J](AR;K 8<,.B2I,4_68QYDN#='OJTS7-!, MU??HHU"P%;\MG*$K$N;Q6_L]?/<,=!LDM ; VQHAG;QPPN:@")!.A:3#'(AP MSU)OY4>._EW2#"D[JB,HI)*@-:3ARY>VL+UE5>@Q3LF+%L*/^2)UGG'@!B]Y!OZ"X)\KQ./RX3O,+V[I3SQDCD M.GF_X;3BY8#=078($D;PV_DG"4?B;L7066EA[B+M/IUT6)^";_&FW @'UGX^ M/6("7CP]\R]CB7U5"N?%&TH0M8Q3:_)'%O%S?2B;P[%DW*(T7&\"K!"=JFZ6 MH6X$F6ED 9*T!@3T_HB9F16OW0T0058X9ZRT0G7<$?532]R;/*,A1I_*CA&^$S4$1(.4828X/%3&N@/%)W$/0<[U#TE!;DT$7]-6E$,$WY_RGX M9X:9]4(B8$S> )',TQ"5 1^F;[DL28\_Q*DBC%Y99*F2.$D&24RT";S,< M2)/YZG:U[0;"E'.)XT?SN>5OOZ$PHP8)76N!M+WEL5%O(UI)F="N/ER+&]L^ ML64%D[)_'+:2^A#X5FX)'TLN:/0[ M6Q[U$U%T@ER9;)O7; SC66/?K8_*"O.9L,-X]J97M"H3VG'/O"4-5HKY2V!J M44/T)]L3LMBDQF$K8S::X46"Z C? _N&.1 = MHXUD,0N@H=$*T=6(9^@$+8L=[CU!0Q9=:P\.3P)CM9A$&I?0KKPK<*/W! ,9 M:YP+PIP80A5GT(1#Y@WO"1(RMK #Q9R80Q$QT%HJ8N]\T#B(M0Z-V[Q3''/; MY=Y3BK7<4H\T][SF05.MQ>]2Y_I6&@A33=03;&3B<2QP9B4P5;[^+963XU7O M+P1*]_M#*GN)A/&$>E'UB_/(]V0=R+SYH(I6X&!J;S@;&^_W R')] M5D0!9("T\WY*,QHQB'BQ")!)EPL526C%@=IV@(._I!K$0C0EA"+FP%\\+J=0 MGH095-$-34Z0^>![@H1L^[0#A2<;IEPHJL(9&FHWWS+I">T\=CB7>$\80*TQ M:06;==*)JD,V0(.B)3('A' T43*.%? $,9EHG1:RV91P/=?51#N2PU. M8N-,4=J+^O,4CR':^+1R=$*F,):C R,;(<,T@HXJ=N8: X@_^B-$9*&DGD*C M+4\DP:B>DFY=BDRB@]D"QK[<,#*YC@'-G_R1)**X9$]A,98BG>AFR&3;7RAJ MKZDQ\/BS%ZM#-Z8<,D+V.$;L,#(&_3]XP2&Z\?R0$9I$IHQK7O[1;V;II56 MC)%=@2((UQ@#@+^ !* 1Q##*Q0L\%UIUJ.\H0,"]AQ-[WHT"!%QKL=0U=Q0L MX!F^)/YWHR ]P@O#'SWJD#U_[P%.U9]G@@[21UJ9V6H[RD"*")G/O)#04=Y M*JG]K"A)K=?77=&O<(VB,D'4+M8=:'X:J;1LM=D[G)%:#XYM(O%'2?F*CO!A MLTVR/<*?@B)<$RYL/2?+M9$JFW^>J,A'MK[S43G:!]M-5G^L$PG2-V/<7LFF# IP0#VEKY(%UI*AN& M_Y) N6UY=:8Y8?**$AI(\1+@8M\T?D(\Z0C&JCKD*+L!.-^(IN%VWWJB=9WLC>D6=)'-&%R#(SQ)*2P9+& MULO&)$F9W\89M=11/:&1U;G/SI+6#O/&;S99RMP+W]8!&=-3GI>GG;*7,)[? MVMGPI8D!.X/GMW58I(5M*Y4 QHT]AEX$E+):<#H]H9(EE39Z?5V3QD:D0T>S MH67!\W.,8ZJT2N5-OY$[G4V5G+*KEPG;NY.4G)29?"'9;PB"9<5:K5K6Z+S@ M:@"_&L '5886NZOVRT-SVHYS/'E%1$LK)=64N.V@+73M;:K?QS*LS"A,=-^J M!DHL*UDF:@H"7.G)FM,0Q* ;LVLNZT'HD_88>Z0BUWJBCIMRKB_EVLWS7>"SMM]*JG>V6UB!-$?A[U;9[O<1BBLT MR0\G$"4Y)@\#X[28:&#M[):]4;4>.V,_C925'<:3]8!&AG0%R?M,*KD67U.$ M\W6\%8BL]G,W0Q-JC=T6L( MZAS-[%3BLW_]V#)$GS?1]A:]KQ$SZHAQXK9SK@:]HA#%.ZK(?$8B)UM^6\LP M?DF)\I2@Z/21_!%GFZ:A@X>J3C>7+L^(B)*H9KU:K@A0%C2&,OC/61J:C+_1 MWN$&D84(18PC/F<%.NCLPNU T-SA''P43VE>X)+NMT\IV9517KP2UJ[4F].& M()P4[1D&WG9'"$0^G+- P4]WW61 M5/,"BW,DO8YHY_"0)WC("IK9!,2/@H$# JD'!&5.GV9S0J&B[41WJC32\68# M#<"USO*USO*USC*'>*[?W('JGFN8)[3R=D=38OW8^70DNS*:NF5",W"M PV, MDO-5OG8'OI"9I#U!0+0>SH? DU6B=_TB=P%LW;ZHM25/<^T87L+P/10]I=W2 M]8O8Z7%&N CX0>I..2/RM:Q/!NZ;D*&9[G0]Q'@/&3GKVIF)MRSD6I:6A;"V M.^Z,,!&(G4FJ5=@B>5J[G5C;A5RU<21]Y>1H/2/B!6N"[]T-F>[IMUSAX0=R M9<*1UH; KQXR$M,Q#-=8#KDJWQBZAE:@ V10P.CTLZAB.$3(B.)*($,Q/=<( M7#\A5^R;AE^:H3R0T9B>92:O4S5A?<,AC",.H((,A@,->-**=[;J'8XF;?2# MUB##,ZV%H7._#+IDY&AV!5$@(&@TIN63L4MR>&_YEX>SS*/PIC7,)-$>%@N7 MA$$2EDEP>-P"TE+EDA,A&7E;FK.*+4>3;7-_SK^D01G1NT5.P9+&2+DSSI]0 M.LSCI'[_AS_\]W%&\W)3E4CY+?G@AC^9U=5+)SE ZWXXR->$J^D_#_\NXUV0 ML""UXB[ >!^G*W93W'1\^(KBU;I@=U%*%G=!<<,?B#K%49Y;9PD9?4[I.R5Z M:'-JOY67%$LFNN- =6SI#YT5+W-I:W.Y/R0UIHY'%V]F_2%.;^V]X-J P)I[ M)VZ4 O9MG>&"%N=^2G?DJ,)4T.:%/G0"A\C31J%FNK=D:4%V$I2&C,V])%TN M6#M^J-VUZ@&I8MGZ@C.B.!9[6IBNH,Y"9-:W=&K9W9,_%"I$K<2,Z0^-^JNS M=@ELBUL/*%2*6^X=:7=!?@^?4#W9([JL\8=.L>!9$+$3T(WC&04Y>J5D+)9? MTZDF@4Z'/ER".GM*[8!L70=(03#[1+)1)^E?R M)S<=Z,0.40=;"\!+4B4B6+!\NZ+8 WK[HI@Q,//DK9Z1&7\E9Q@/65EAM.4?00X)1,:D[TB7)3LK5*JS6'L5=3JBF.3S16;MO99HO1FAJ) M=ZBZMG[.\IPH4HOE>_"MZ20&'0"EOMCV7#\XKO,-2G\RHW>B9+L\"KM)=EMM MW"5@U[,URM5,>1ZF'=9L[W3;ZE5[I[,HM08T^ENRD0D2F] ML[Q'.Y1DS$A9]_")VL]$/+87RY$( 7M(>GA$-BKDHF$65!IN$!U0_'$;UA3W MM5&5&I#H)0\.PN*7N%C?$;6!],)$^TI**MSHT9+\%S4%ET\HR 373R@EK1*: M8#O:Q&F<%[3/KL?='M!K)+H>,TS(22M[0=B,=SUL9;=H2=IX-N=*.<9=&A[1 M9S+'AWP154.V60WUYIOL4DXEG_OW<\(>[@Z,=A31[L'RS+>Z/S_W5Z;H[-QH MZ7[8W>U#-.AC.W",=_YQQ8@CS_ZCD;CYXFDEW#EIM'*Z" ><"P=HP?Y,SLI5' 2Z)JE[.R#'2\+FDF;S!&9E< M)9=+#J^EWU9YZH7PF&1?H1C@J7L9&=(+SG8QP>%V_X4,_BD]:D@WA'EVPLA0 MTFT9%ZT3F0\V)4)P)TRC[2;2\QMIM*ST'L*0F%X6W:/J7_)[)1:)?%S3'&4T MX=_#(S3 M( UU%M4Q[2AS9%LP\O*';PB'<4Z%E?<\H2E?[A$YJ(0Q^XA/-A^P$H:[%OW! M]3QN8@5M;@.V.V^HJM?F*P\"^<'R%5>T^8.KG9WK/:M+&4HS:GT_VPVL*B;5 MV+U>,.&] KTD0T5TS#38Y^9(R/]G],8PM2!*:E96NID*PFCQ(<7"F-GA,"LUTP:<\ M+VDRU[LLGP>_:"XH:41.<^OZUI^X+ M7.9N.%Y.<(EH-'":<6IZBPXG==6$@X#&]I(CJQ[;\U[@CNT5]RC\I2#O!&W& M),J-WHSQ7N!24*DN?$3R2]'/8<:0YL4-=_2M)@YS1/'O!+A#%C1VOM05AF?I MBI?WM9S+06X<;HU3W=YI7JLAQEWN/ Q\&0AA-L#F@V>,;_S1GB]O9L@PXQT+7EPUGO W0I/7,;[I"N],/ MHG/Q*0D3'27.T2>$5PB??GD@.D;V%4VM*IE._[5 __$$<%FPMKF^_O9E@>[J$TC]4<"M[-'V/[*+.#B MB<#1T>-\=!Y@7$;Y#'?R5;^CE-:V9]PEN>G$'<:"ME/E>)# M8)%+U+Q-,#,&:*?^[;<-]7"?Z.)B(!+=*PO3UT E6%="#$%!\]W>0:,3A6[G MW6"@$2]V+>J%W6$K&.VR.TB?7Y1#@7 MQT%"J-]NDZHP'C^CS!O"NSCT*XC[#&#>RH\\Q''EA/*6+8NO 3Z]H95JHX>, M!WJ$(3*=;D\I653TGG=H9,K,:AS8<2<9O"!YOB9#7S8.58-6DY"L(6]SS82- M)2/CN%,SZ!MJ51BN61/N=&+G/?V,"F";IKH:7B?^B-^>Z7U^[8IFE+>J])S\ M',G/2>7LE49-9QCAZWG[(R"3_&S*(ZHXU8R4JA.$LDQG,A__?&/K];#%=<<3 MXB2I.P] 2>B^&?NPQW-LZ;V\^)*"K?XD;A@,0=V11@6A/&&!B%5,B)&F MS.VA8AH!.IW?OC80RMK4O+YN\^Z:UMM6='(]3T)!+)L@42?[/IA:LK)_'M?L MZ0Q\#=''Q5_=;YPI,!10P@DQ>P]LU;4NUGDPSK^O$741S=+*\9H]97S'3%MI M;6. DI'V.#RNFMIR1JY:^6-%D)+V^KV@3Q 1UO%@^$N""Y'_)5N27@!L9 M(=+W,V'-]Z\HV:%/&>' P5>( (KPSK[*L(*QAY/,?R%L$+B\>]:L]UX'>PL@ M2N@F2UG0,_Q8DMT!'0Y)L+:!QHCK7"DL+T0N''[/MD)- MX,7^YFN H[SI+?03)H!^H6S-WLX:4+.Y5VX2Y\-S>-!BCB];&C->)3:I(^?K M="<^&:?/!Z=JW^2:0U/&..2L=SB)LZ^\E.0L2\0'92.??F MM.8'SP/Y&_X02 M9A#^KS@Z#)*H>D'^'&^(\(P^HO:K$=9*L-$[8 ME/_M-P6F1YC@(V<%X^K??R\FX@6CQY(JEP<\:X2KW!$5-?(V%5G5Z'+&@6>0 M%*=Y$5#SL)BB99#D4I*X*JU"PKZS"H^.N:/,=A^<&F9:RA-^YL7M&*BN,,4Y]* MNI*H] B23W&"\B)+47M>!G0$.7=U9LL@N8EV<9[A>S:H Y6BIR!)N<-[L@B3 MVSC+PQ@1(?>4ANU)D[4 25([H2&Z2S):4?F8C?2T]2F:-5<@V2%0$>#]%-*N M[OL1)'33(42AC[B0$?P/E 8YF9\MV;XV 5=KD38!.8L_QSBFQJ_GI,./G <@ M"> G,KVA:M:*-;W=GYK4!D=VHKI9K3!:!059:%3NYW'X38N7#!?++(DSZMC\QQ]^?$?A.LV2;+7OG,S,.H$D?)C# MS8$!AO2%LLN%&$7RI?X ME)M;E*)E3/7'Q=>4G+S6\?:%*,>-B1[:NPO%MGK@^K2JDV^U(ERGI3];UQL] M6-.V3$(S&IC'6)NO5:U \O<[2I*2ZIL[\N<2H[RGQ_?<.L.2-+,J^9N_KK,R#E"Z8!ZH]()0V;L/(7\F2H;G==NP*J2/8 MAG8'*>9Z)\073#1)(BB8I!&>(SNM.,*$/7%L'>^*@C1J2X.;^E4BT2%N#XZI M>W4>CIM*_X$_4NX7YBF!HH J@2L4LKNJZBHN*PO*(%'#I*G;VNJ]GI5=KSZ] MU2G"N2>[SC.0PN2-8-XZ;K_@;(6#35>EE[<"2=I+1LTJS2N:TRF,): Y^!P< M3^!'V3F@)Y@5JC9+?-Y$VUOTOD:?@B+L7$3RG\&<7X3? [Q"G5-,[\\@!U]= MW/><&=ZS VNU3ACRAO"$HU9<;.LFV:0'X(MF*B?2(MG?1-FV8/F#J79"1D@$ M9DI^#&NMNW7]:M@))#]W(E?).21%(7WI+W&Q[L:Q5F5 :<7%COIV-(Q;>IM' M0OG3J@B^^^.?VK*L\T>0,_\8Q'A#8:<"JF,*Y#\#2<9S3$[1T0N[;0X1^79( M)I*P5H:W&0YZU]/:S4$2VSX0?R8G_^.!6'5Z%C8&2>C1Q[1EDV;:7=8A4ZLI M2"(U]X^;;W%NN.5478;MMU%,7D%3+HRYWXY=7J!":^RO^'.CV71 I[<"S*E^ M>TKWQ2[VNO=!1GU KC"Z#_/V9N!;LR7+<$M1M_M.P*J\O"HQSR.OVP:,]JDT MVHD\<01>L=K-0:X*;CQ'Q;WM,_93^KY&'$?+SXB0W3JBM"SOX[T?WD'_#F%: M7O!X>=*4]1VG7(V6(-F%EA]8I$1R;;,\2.A-T69+CS5]?QYU0Y $CL"O(RX% M0&)5K2Y]V2Z)/EW4%_]M=N$_@\DA7#]%'5]&T&3US?RMU!NBNX!6(W]4][OL M*TJKT!5:%[;GWR1^#G/R^B*D*M^[P(="OGUW'<-.G#MR" XWU1ICTO"%++)P M_WX(XSO2*6G1)0I,#.#39E.F&1$C'<'2_3-(=FR4M:B20V\D)-%$CBSIQ7O(V(,GJAH0W+X_XSP#? M$M6.>/6=#;O/.UDJBW46O:"65Z)^>RA*F_KXI[;J>F?(K;)/]/SA>W\>P)FC MGUV'5J@[GF.'O@ *QVK<26AXA/4FW[07.-XXYF=_BXGL6<8AK8]TNIZGIWD> MW<;=P!%^3H'#UJH8] 9_E@6S'_P=)5%=2+AG_)&U &O\:9R"N>$LXN<<;1A" M(,N M(:U'Y)Y1W 6D3KXYA7%FX\2Y^RIW.7>I(='%T#,R%>&-*E]NCIZDU5E M-K9;G.U.)S^MIE#$E,;55R_R/=FG-"HK MQY6^!RC_&4@RZLNYQ;*"O#88U4'LU=\.Y^\ZAHD^.]V;#.L-1B+I&>\MIF!B MN])X&9Z.K_<'8=TB8*WSBK(U%/&G%OR/,;QY+>_6+:3&[QG MC6,:E1-=:]2@KF#-5,,#4QLY27KNL>>^#K0WS?C;E$&"L[ ]TJJ_)WG;OU MSE]!#MVH3HZV8#YU 2>46[<-K4BVSJE>T#,Q7S$N:'1M M[5MM4^,X$OZ^OT(W4[<%54E("*\.-U49R.RF:A8X"%=S'Q6[C77(DE>2$W*_ M_KIEA[R00 9FN 4R50-QW&IU=YZG7Q1SE+A4?OJ%'27 (_S-CIQP$CYUOE6; MC5KC:*NX1(&M4N*HKZ,1LVXDX1\?4FZNA0H8SYW^FT@S;1Q7KI7Q*!+J.F ' MV6WK@U<;B<'=(J&J"8CKQ 7UVJY0*'&TA?>]7#:6BK5R52O^"T&CGKE6L5/5 MZ2RHM_R]F*="CH*>2,&R4QBR"YUR-1;L:^=TBK(.;EV52W&M D-[TFZT?KQ/ MJ*4VP<>Z_]<:)L)!U68\A" S4!T:GA7;#0N+^UI&K3G;'C0';1F*R"5!+%PU M1$E09$/G-A%]X5@19=* 0@@DQ/Z>M[^RSK?.\56O^Z\.._ORI7O]^R4G5]=7%ZU3WNL=\8NKKYV+EFCR:N-G0V^R_W#KM$C1?=7A=E.]^.?V^?_M9A[>,>;L :A\V="FM?LO;)V7FO,9=P%[R+&+ Y+Z<\GQC1KS6;S[].A*'6_5#1* \:^"D4&5[W+ M#WCYX5.C-@[<5,0*E8UZ?5[A_PG?+.$#8 8& H80(:J%Q2OJQYA6[(LV*6O4 MJ_]D.F8G ENT)+>LEP!N#[D3H:VPK@IKDV1 [=BD*5M#936H;+\"J'S&^$<$ MBG3$;I0>2HBNH3*#F$BC)J4=HU5<*,;5B.7*F1S05HX?(ZHB*'&6XI417+*8 MA_B683K%IM;I0NZ>@((0K.5F1"(IOP'<=TJGQ?$GF(5%).V%$"T\YMC99&@A172"*7*("4T(A;OYWU M]H3<)BR6>FC'?#%P+:PSF.<9IS<+N]'*RA3L[=B8>]:ND?\\Y.^\ N3W9F#R MZ\?;[7KCL&5+<)?=,>5-'<<"+SV"NHP;\%A%[(F^!,(4 _2[+X5-2)S$4JP9 M5#?H>-I;8YKJ/-C98%:#.C0XCP;:-X9J,8-R(_YYF%$M1U M!8^SI<0X]?[!7FUO;W^"@3=.H-W]1OU@IW&PO;/3W*T?/H%,?/.O3Z83L!A= M1)5O1QZ'?(4ZI9#G=O4EU++T >%;[E0T03HWJ #S^4!87R50"I370X/MI+Y, MUR@#DGL^E%W0!-.5LG[138&U!FVQ6HJ(.V]HWXI(X!A-#HBB5_-54Y$F'"BP M?_+IP_IFR]<4;0$-SK?^J^/;R@7@'NU6+QTKLP\9.Q 1D8I;K3C52&Z1D#2Z$-.X MB<:H1QX*WA=2N!$U;HNVI1S@">*Q7]!W1G1J]/&E^+9T*,M-AMRSOM$,0VTB M;X ?@JY!8?\HD8)X!S+B-HG@@%?0#'. R+ :KHGV4XD6O@*B=09/[PQ,*%6(IL,>7T=>Z6F[!*P>5WTD C7/SX M_,_ZX^'0YPHH0H'VM$CYFAL_DQO1*^#&28&Z^^BET[)RLO!W%G/D.VH/=7(Z M#'-#()UJFQ:I3;5U>(.^:4-E-D1-?^885-2]L6Q-C'S#NC G7MH>(N3\61\= M ZK\SK+-PJZ$V[LNDRJ*YR=$OM3ZD)1E<,2DN %9'OS-R5>>'Z452?E.&/BT MB<:,K4QR.Y6::M7/^#=29 MIL(Y@(=*:5]CQT@"D4 +O98-I!96+DN5$7_38#?."/!G+M !3_Y!4$:^P[/8GMG\Q1AAC'RWI2% M>.$1_;I[6Q\A$".P28L-)N(*XA-\\4"$^^\,2RI4B@9'J(&6 Z N1_'K\JM/ M4]8;2#.I1X!WAXDNB@R?(1H2X\=T@;4ED%T_C/1$YY;PZD7]<_Y\J-RYCQD- MC-^:GIU%8^EN%8F"PR]JNX6H56@^V*\ABTIYI(ODF87 %D=$4#QPB\K-6#,= M3Q6Y,QA+ET(H%U_8/M M&2%\8>;M+Q\6]K$?HM?5/A:2F\#_K-(;#SPT./OD[[P9Y8/*19JOU^I[0K4& MU$/B(%0N19"1?:M L=9X#!S?#<<5DN'2^12Q,/UDV\+/X<<&X*_C_!]\Q XK M;+N^O?->0_!Y].8__>6/!2\+RI;=FGT2=%&(7G,.>HERN'*->WV@6_O[MOU] M5DE9IXTUK-;^OD=_GY$VS@U8$4'YP-AQ(B!FG5L(<_H6DYT5I]3K=+*&V]K? M=^/O,]+)QGGQ? Z7][/(YD-I!'_3>=+;/S2<.G/VI]+%%V.+ MN3]&7WBR#2J:^2OUQ$QP=@U%%J[RV($)N!SRD?49]FB+_E;^TR]'6_ZO[/\' M4$L#!!0 ( )6"J5@JZ321E0@ +4_ / 9&YT:"UE>#,Q7S(N:'1M M[5MM4^+(%OZ^OZ+O3-TMK0($07<,WJEB%'>IFJLN8M7LQR;I0%^3=+:[ [*_ M_CZG$^1%4&:<<5=EJD82M',@$$L=[N.[DTJE4J!);-O(OX=6JJ6WF M*Y6M2KUJTUT+>2RCB=>3L3#L7(Q95\4\F0KVE;4JAJP5M[;,(SE(/$UKTFHT M?KJ.KR*EO?=5]Z\Y'DHKRB;EOO!2+\\!ZFY]FXL_O:X?5YC,:YV-= MH;_A!KLY N$KS:U4B9G M&-S[K_MEGKI(<%6.VHWBBQUA5KG5Y<]MJG"]-C MG%NR7GU.]/TS;Q!\Y5S9ZGYJG;>ORA=?/K?_F'IQO_JL'GK5_%QEW*;A]VFF M=DJL.^$)N^(C:?\J,5]H*\,)LT-NO;=T>^?2<"!-&O&)%T;B=M&X_V6&O#.= MRTF4C>7:-IT992@<&Z_/C7 <7#9XIE&]4J_7_SWO@6+NYX)!H<#45IF0PF5G M\@-6OOM8JTP=-^>Q?,I:M;H\X=\$:C;D(\&T&$DQ%@' + W.J AC*F%G2L>L M5BW_SE3(3B7JLF%F6&\HL+S(K/1-B742OS*#"-5@LTIL"Y7-H++_ J#R"?X/ M"!3QA-TD:AR)8"!*"X@)%&9*E&4TBLN$\63"LL3J3$!7CMN(J0A*G,4XTY)' M+.0^OM),Q:ADK#5LR/(T,]9=,!L%"F0!NA-P9O$I@ L1Q6<]=ETF(^.JJ41S[ M419@3D!X#DLEP%_J:,*@O"'R$*FB:,:. IAF:6EH&DB:N$02600!4$(!MVXY MX_3QN1FR,%)C,^6+%@-IK$:<9YR^S/6&EJ4YV)NI,O>TW2+_:H'/8ZD?*9!A'BVL5Y:!-M?)%@*\-VP%& P'0YT!LW_I#G@P$:R%0=[,( M$J[W/=@1NVZH:W[I+#^5U$@F.5EH?D;1?(Y#.:9)EXT7"A<6"K$0V;G,+$A0 MU>4]SI8"XU3R>X>5P\-?9AAXY00Z^*56_="H?=AO-.H'U:-O(!/?_>>3Z508 M>!>HHG%SZ,*[9<3E%&0"&+'$:#4MQ2Z6<1IU0(LYP2LSH,(_*J;KX8Q5%?D"!N M&,:+8(/LM.7;M_.M_^+XMG$"N$>[S5/'QNP#8T"AY'T923NAPFW5LA0#'$$<]G/Z+HC.M3XN%=\6!J693L$]XPI-WU18Z '[.BUY@5D1NDL_QT=?_AB(6!2$4F[W+Z*K/K5=@DX?([:4$M7/AX M_\_ZT^;0Q0J1NP+Z-&GR+3=^)#>"%\"-TQQU]]%+NV5%9^&NK.;(5^0>JN24 M[V>:0#I7-JV:-E;&X@(]7L-DQL=,?V9P*N;>63"W M[5L\U4S/=.#HJJ[2Y*^?<%Y@S MCJ6U0CR42OL*%2,)!!(:NEEV0"UD+D.9$9_4V$TC@O@SDS# D3]+?+='N+O= MH'CS&Q2M"*T"_"O!"=J[HETP7PJ N"C%[C8*QH+?4&V5MPZNNG)-CWNV,]UW M_BIJ%#U]OG.X(AOP .-N$L&ZVE4]$H8H^G]#]#857@&Y9W)8L ,/G+6%(EX MY1;]MGK;;B$0(U"DA1J!N 1\"I<\@'#WS+"@0BDO<&0R4M%(4)63\$'QZ%,7 M^4;$::0F E?'0Y4G&;Y -!#C^U2!E360?=6OJ/Q(X];PZEGMLVY_J%BYCX@F MM%N:7IB%LG2U#**@^<5LMR)HYC,?-2I@42$/ND0\-<(S^1:1R-^RQ>1Z.C-M M3^6QTYM*%T*0"A8)>EBI?T HO=P;;!&IG%8J>[7'A.J[!\$'8N7[E[1G#$^4^DLN-Y_Z6Z8M5;_LN:U&\G)Q'^6JE>BB3YHA*2/1! MQ5!@C/3[&Y"X01Q5>@-E]*(S@D_:H7O]&Y-P^MMOISA_&4=\)MV=QLO1L0"[]JGWE;KE( M@H6?NP_U#&<#D0?<,@^MT!Z/QGQB7(0]WJ,?W7_\Z7C/_5S__U!+ P04 M" "5@JE8P[U$$8H% !<.0 #P &1N=&@M97@S,E\Q+FAT;>U;;7/:.!#^ M?K]BKYUVDAEL;$Q(L+G,4$+N,G,-:: SO8_"EK&N?CM)#M!??RL;$R O?2%M M2C&3@=A:[>ZSVF9&K]=C-LA.+ MM8"R22!M0S]B,4ITZMB>RZ6EE)_$4A/L$[5-(Y5.84F326H;3M[FDXB%9!DQ2 M3:3$I7;*J3;E)"W,30N/QTGH.1N^/>H.^C)EG@QLGTG-14D:*Q_ZLX"-F80B MRDH#!B'][B$(J7\G @]CW@[BZY=FRW!^(#@7[5+^#0.Q1 M'K*8/D48>OWKT<7Y1:\[NAA<#N'J_?7P??=R!*,!F"?P7A_J/7WO@S3L]U1X MP+2.#.@.H7LVN!KUS]:B5QVMP#J._^C#L7K_I7O:'VN##W_U_H-L; M ;8T#*-1U92G ?=O)B3SY]\Z:VR']B(&O(BIJQ((IDP&( ,*[S+",2?#.5Q3 M->5"XL,9PXDWR 2, HK6:2:9*VIP$;LZ'*A.KU_.&H;I.KTD2DD\+RX]YQ!0 M\WG"(S -[1WX"<]-R(!3"A%Z$@B@F+D>O"7<#< R:YA?C280 3X+\?[2K2%U M,\XD0V@D]J _92[D*B5*\0%O+9:_G)(8AN6'R M4VW1\9S%)$:UX;+CK=(WF4"V"O&@3KRG!$O225&;%6\%,*B5NH?$CXF:%@;S$(ZAZZ;#[ B=0W;B:RI?DG&X6.<3'$$ M)M1^?D+\4,*O+B8+3U4-LBW=LJQ7CL=$&I*Y[8=TM@YYX7NI/I?0A$0V.3DX M#3%$PAX30?-"O1F&6R<7IIZO4%AZLWG<-MMF\\@T6E;[^!8WBY7S6@[_$<0O M3@_,PS*P*Q$M])N&L:GQ>6H@UK.RS/E9B#7/1?J%JL@L"P^G_V6,TP@["$65 M6^(=$*QO',RC ^]P2:_;,K4L40N.F6VKZ:@*L,PW]5ARS\/):M:U]%8+HU]1 MK:+:(U1K[ C56(Q+@"A?L:JUAR3HC8=W<^J4/"1,+3[0M%"4JZEF$H: W2A7 MM9EF4RL*"L4E*BU6RV)AD]<\QL5K/[A@X2<8A M+2V/$XX/1;EIM5^$GJI6#8F09,@@-J.>4VAN6SJR9"&/= A)*J@M:$HP<6BQ MR83*>:GYA@DV9B&3<[N47@BAE+=.P"/=.FZ]RK>AI/> 3/-8/VJ;GQ&R]$;C MLXHL_<18%\)_^*;_BPVR//;WCL\40Z&-.24?[?Q;4S?NV^W:=.-&K5I=$B[$ M,)N4+S_G,]1#F76&8[ZZZ+TWWK\"T+=D#NWBB6L?X+Z9_U*C^O 6T$,!J(OZ M^O/N?>'8TWKQ59ET9^[YN9.IPK:;V+8J[17-]RU=*FR[B6T+FG_1=G5%_[U( MHPK;;F+;@OX'5SC+NRPEX5W6'WXI[2NJ[US*5-CV&MN>3M[5EEZUI5=MZ=W= MTELY>5(&XXG""U7UJ>:E"MM/BVT+:M]3-"J2_]+)4F';36Q;D/SKCZ%6M6 O M'2O$'_5N:GO'-D4$L! A0#% @ E8*I6'MG*VB=" ;#\ \ M ( !MR<# &1N=&@M97@S,5\Q+FAT;5!+ 0(4 Q0 ( )6"J5@JZ321E0@ M +4_ / " 8$P P!D;G1H+65X,S%?,BYH=&U02P$"% ,4 M " "5@JE8P[U$$8H% !<.0 #P @ %#.0, 9&YT:"UE ?>#,R7S$N:'1M4$L%!@ % 4 -0$ /H^ P $! end XML 81 dnth-20240331_htm.xml IDEA: XBRL DOCUMENT 0001690585 us-gaap:CommonStockMember 2024-03-31 0001690585 dnth:IontasLimitedMember 2023-01-01 2023-03-31 0001690585 dnth:SecondSelectedAntibodyMember srt:MaximumMember dnth:DevelopmentMilestoneMember dnth:AlloyTherapeuticsLlcMember 2024-03-31 0001690585 dnth:FirstSelectedAntibodyMember srt:MaximumMember dnth:DevelopmentMilestoneMember dnth:AlloyTherapeuticsLlcMember 2024-03-31 0001690585 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0001690585 us-gaap:CommonStockMember 2023-03-31 0001690585 dnth:InducementPlanMember 2024-01-01 2024-03-31 0001690585 dnth:AlloyTherapeuticsLlcMember 2024-01-01 2024-03-31 0001690585 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001690585 dnth:PrefundedWarrantsMember us-gaap:PrivatePlacementMember 2024-01-22 2024-01-22 0001690585 us-gaap:WarrantMember 2020-04-30 0001690585 2023-01-01 2023-03-31 0001690585 dnth:UpfrontPaymentMember dnth:ZenasBiopharmaLimitedMember 2022-06-30 0001690585 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001690585 dnth:DianthusMember dnth:ZenasBiopharmaLimitedMember 2023-03-13 0001690585 us-gaap:WarrantMember 2021-04-01 2021-04-30 0001690585 us-gaap:ComputerEquipmentMember 2024-03-31 0001690585 us-gaap:PrivatePlacementMember 2024-01-24 2024-01-24 0001690585 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001690585 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-03-31 0001690585 us-gaap:CommonStockMember 2023-09-11 0001690585 srt:MaximumMember us-gaap:RestrictedStockMember dnth:TwoThousandAndEighteenStockOptionAndIncentivePlanMember 2024-01-01 2024-03-31 0001690585 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-03-31 0001690585 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0001690585 us-gaap:PrivatePlacementMember 2024-01-22 2024-01-22 0001690585 us-gaap:RetainedEarningsMember 2024-03-31 0001690585 dnth:InducementPlanMember 2023-01-01 2023-12-31 0001690585 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0001690585 2023-09-11 0001690585 dnth:FirstDevelopmentProgramMember dnth:CommercialMilestoneMember dnth:IontasLimitedMember 2024-03-31 0001690585 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001690585 dnth:PrefundedWarrantsMember 2023-09-11 0001690585 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001690585 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001690585 us-gaap:RoyaltyMember dnth:ZenasBiopharmaLimitedMember 2024-01-01 2024-03-31 0001690585 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001690585 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001690585 dnth:FairmountFundsMember dnth:ZenasBiopharmaLimitedMember 2024-03-31 0001690585 us-gaap:ComputerEquipmentMember 2023-12-31 0001690585 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001690585 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001690585 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001690585 dnth:TwoThousandAndNineteenEmployeeStockPurchasePlanMember 2024-01-01 2024-01-01 0001690585 2024-01-01 2024-03-31 0001690585 us-gaap:ConvertiblePreferredStockMember 2024-01-01 2024-03-31 0001690585 dnth:ZenasBiopharmaLimitedMember 2023-12-31 0001690585 dnth:TwoThousandAndNineteenEmployeeStockPurchasePlanMember 2023-01-01 2023-03-31 0001690585 dnth:ZenasBiopharmaLimitedMember 2023-01-01 2023-03-31 0001690585 us-gaap:USTreasurySecuritiesMember 2023-12-31 0001690585 srt:MaximumMember dnth:InducementPlanMember 2024-02-29 0001690585 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001690585 us-gaap:RetainedEarningsMember 2023-12-31 0001690585 dnth:TellusBioventuresLlcMember dnth:ZenasBiopharmaLimitedMember 2024-03-31 0001690585 dnth:DevelopmentMilestoneMember dnth:OmniabIncMember 2024-03-31 0001690585 dnth:PrefundedWarrantsMember us-gaap:PrivatePlacementMember 2024-01-22 0001690585 us-gaap:CommonStockMember 2023-12-31 0001690585 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001690585 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001690585 dnth:FirstSelectedAntibodyMember srt:MaximumMember dnth:CommercialMilestoneMember dnth:AlloyTherapeuticsLlcMember 2024-03-31 0001690585 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001690585 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001690585 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001690585 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001690585 dnth:ZenasBiopharmaLimitedMember 2024-03-31 0001690585 us-gaap:RestrictedStockMember 2024-01-01 2024-03-31 0001690585 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001690585 dnth:WarrantsMember 2023-01-01 2023-03-31 0001690585 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001690585 srt:MinimumMember dnth:TwoThousandAndNineteenEmployeeStockPurchasePlanMember 2024-01-01 2024-03-31 0001690585 2024-05-06 0001690585 srt:MaximumMember dnth:StockOptionsAndStockAppreciationRightsMember dnth:TwoThousandAndEighteenStockOptionAndIncentivePlanMember 2024-01-01 2024-03-31 0001690585 us-gaap:WarrantMember 2021-04-30 0001690585 dnth:TwoThousandAndNineteenStockPlanMember 2019-07-31 0001690585 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001690585 2023-01-01 2023-12-31 0001690585 dnth:TwoThousandAndEighteenStockOptionAndIncentivePlanMember 2024-03-31 0001690585 us-gaap:RetainedEarningsMember 2023-03-31 0001690585 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001690585 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0001690585 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001690585 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001690585 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0001690585 us-gaap:RelatedPartyMember 2023-01-01 2023-03-31 0001690585 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001690585 dnth:OmniabIncMember 2024-01-01 2024-03-31 0001690585 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001690585 2023-12-31 0001690585 dnth:MilestoneMember dnth:ZenasBiopharmaLimitedMember 2022-06-30 0001690585 dnth:IontasLimitedMember 2024-01-01 2024-03-31 0001690585 dnth:PrefundedWarrantsMember us-gaap:PrivatePlacementMember 2024-01-24 0001690585 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001690585 dnth:TwoThousandAndNineteenEmployeeStockPurchasePlanMember 2024-03-31 0001690585 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001690585 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001690585 dnth:AlloyTherapeuticsLlcMember 2023-01-01 2023-03-31 0001690585 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-03-31 0001690585 us-gaap:FurnitureAndFixturesMember 2024-03-31 0001690585 2024-03-31 0001690585 dnth:FairmountFundsMember dnth:ZenasBiopharmaLimitedMember 2023-03-15 2023-03-15 0001690585 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001690585 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0001690585 us-gaap:CommonStockMember 2022-12-31 0001690585 dnth:ZenasBiopharmaLimitedMember 2022-01-01 2022-06-30 0001690585 us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001690585 dnth:LicenseRevenueMember dnth:ZenasBiopharmaLimitedMember 2024-01-01 2024-03-31 0001690585 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001690585 us-gaap:RelatedPartyMember 2024-01-01 2024-03-31 0001690585 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001690585 us-gaap:RetainedEarningsMember 2022-12-31 0001690585 srt:MaximumMember dnth:CertainIncentiveStockOptionsMember dnth:TwoThousandAndEighteenStockOptionAndIncentivePlanMember 2024-01-01 2024-03-31 0001690585 2023-09-11 2023-09-11 0001690585 dnth:SecondDevelopmentProgramMember dnth:DevelopmentMilestoneMember dnth:IontasLimitedMember 2024-03-31 0001690585 dnth:WarrantsMember 2024-01-01 2024-03-31 0001690585 2022-12-31 0001690585 2023-03-31 0001690585 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001690585 dnth:LicenseRevenueMember dnth:ZenasBiopharmaLimitedMember 2023-01-01 2023-03-31 0001690585 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0001690585 us-gaap:ConvertiblePreferredStockMember 2023-01-01 2023-03-31 0001690585 dnth:SecondSelectedAntibodyMember srt:MaximumMember dnth:CommercialMilestoneMember dnth:AlloyTherapeuticsLlcMember 2024-03-31 0001690585 dnth:OmniabIncMember 2023-01-01 2023-03-31 0001690585 dnth:FirstDevelopmentProgramMember dnth:DevelopmentMilestoneMember dnth:IontasLimitedMember 2024-03-31 0001690585 us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0001690585 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001690585 us-gaap:PrivatePlacementMember 2024-01-22 0001690585 dnth:ZenasBiopharmaLimitedMember 2024-01-01 2024-03-31 0001690585 srt:MinimumMember us-gaap:RestrictedStockMember dnth:TwoThousandAndEighteenStockOptionAndIncentivePlanMember 2024-01-01 2024-03-31 0001690585 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-03-31 0001690585 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001690585 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001690585 dnth:DianthusMember dnth:ZenasBiopharmaLimitedMember 2023-03-13 2023-03-13 0001690585 dnth:TwoThousandAndEighteenStockOptionAndIncentivePlanMember 2024-01-01 2024-01-01 0001690585 dnth:TwoThousandAndNineteenEmployeeStockPurchasePlanMember 2024-01-01 2024-03-31 0001690585 dnth:TwoThousandAndEighteenStockOptionAndIncentivePlanMember 2024-01-01 2024-03-31 0001690585 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001690585 dnth:ZenasBiopharmaLimitedMember 2020-12-31 0001690585 dnth:UpfrontPaymentMember dnth:ZenasBiopharmaLimitedMember 2021-09-30 0001690585 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001690585 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0001690585 us-gaap:USTreasurySecuritiesMember 2024-03-31 pure shares iso4217:GBP iso4217:USD iso4217:USD shares false Q1 0001690585 --12-31 10-Q true 2024-03-31 2024 false 001-38541 Dianthus Therapeutics, Inc. DE 81-0724163 7 Times Square, 43rd Floor New York NY 10036 929 999-4055 Common Stock DNTH NASDAQ Yes Yes Non-accelerated Filer true false false 29349469 329724000 132325000 47312000 41393000 435000 294000 441000 184000 3014000 3255000 380926000 177451000 195000 185000 530000 615000 811000 1154000 382462000 179405000 2612000 2610000 5847000 6504000 100000 100000 400000 417000 8959000 9631000 719000 736000 97000 168000 9775000 10535000 0.001 0.001 10000000 10000000 0 0 0 0 0 0 0.001 0.001 150000000 150000000 29348626 29348626 14817696 14817696 29000 15000 475856000 258231000 -103171000 -89423000 -27000 47000 372687000 168870000 382462000 179405000 874000 476000 13078000 5847000 5640000 2312000 18718000 8159000 -17844000 -7683000 4222000 606000 -12000 -9000 -114000 -3000 4096000 594000 -13748000 -7089000 -0.54 -0.54 -8.1 -8.1 25665475 25665475 874709 874709 -13748000 -7089000 -74000 104000 -74000 104000 -13822000 -6985000 0 0 14817696 15000 258231000 -89423000 47000 168870000 14665000 14500500 14000 215319000 215333000 30430 0 271000 271000 2035000 2035000 -13748000 -13748000 -74000 -74000 0 0 29348626 29000 475856000 -103171000 -27000 372687000 33336282 118024000 875279 0 1661000 -45868000 -161000 -44368000 533000 533000 -7089000 -7089000 104000 104000 33336282 118024000 875279 0 2194000 -52957000 -57000 -50820000 -13748000 -7089000 22000 14000 2035000 533000 518000 358000 85000 67000 141000 -789000 -257000 377000 -241000 -116000 -343000 -5000 -2986000 -4729000 -17000 -9000 -14941000 -10284000 32000 14000 20475000 3855000 15000000 22000000 -5507000 18131000 271000 0 229998000 0 12422000 0 0 377000 0 377000 217847000 0 197399000 7847000 132391000 15425000 329790000 23272000 329724000 23212000 66000 60000 329790000 23272000 0 0 0 0 30000 0 2213000 0 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Organization, Description of Business and Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dianthus Therapeutics, Inc. (formerly Magenta Therapeutics, Inc.) (the “Company” or “Dianthus”) is a clinical-stage biotechnology company focused on developing next-generation complement therapeutics for patients with severe autoimmune and inflammatory diseases. The Company’s corporate headquarters are in New York, New York.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Currently, the Company is devoting substantially all efforts and resources toward product research and development of its product candidates. The Company has incurred losses from operations and negative operating cash flows since its inception. There can be no assurance that its research and development programs will be successful, that products developed, if any, will obtain necessary regulatory approval, or that any approved product, if any, will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its key employees, consultants, and advisors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse Merger and Pre-Closing Financing</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 11, 2023, the Company completed its business combination with Dianthus Therapeutics OpCo, Inc. (formerly Dianthus Therapeutics, Inc.) (“Former Dianthus”) in accordance with the terms of the Agreement and Plan of Merger, dated as of May 2, 2023 (the “Merger Agreement”), by and among the Company, Dio Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”), and Former Dianthus, pursuant to which, among other matters, Merger Sub merged with and into Former Dianthus, with Former Dianthus surviving as a wholly owned subsidiary of the Company (the “Reverse Merger”). In connection with the completion of the Reverse Merger, the Company changed its name from “Magenta Therapeutics, Inc.” to “Dianthus Therapeutics, Inc.,” and the business conducted by the Company became primarily the business conducted by Former Dianthus. Unless context otherwise requires, references herein to “Dianthus,” the “Company,” or the “combined company” refer to Dianthus Therapeutics, Inc. (formerly Magenta Therapeutics, Inc.) after completion of the Reverse Merger, the term “Former Dianthus” refers to Dianthus Therapeutics OpCo, Inc. (formerly Dianthus Therapeutics, Inc.), and the term “Magenta” refers to the Company prior to completion of the Reverse Merger. The Company was incorporated in June 2015 and Former Dianthus was incorporated in May 2019.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immediately prior to the effective time of the Reverse Merger, the Company effected a 1-for-16 reverse stock split of its common stock (the “Reverse Stock Split”). Unless noted otherwise, all references herein to share and per share amounts reflect the Reverse Stock Split.</span></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the effective time of the Reverse Merger, the Company issued an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,021,248</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Company common stock to the Former Dianthus stockholders, based on the exchange ratio of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2181</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Company common stock for each share of Former Dianthus common stock, including those shares of Former Dianthus common stock issued upon the conversion of Former Dianthus preferred stock and those shares of the Former Dianthus common stock issued in the pre-closing financing (as defined below), resulting in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,817,696</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Company common stock being issued and outstanding following the effective time of the Reverse Merger.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the effective time of the Reverse Merger, the 2019 Stock Plan (as discussed in Note 12) was assumed by the Company, and each outstanding and unexercised option to purchase shares of Former Dianthus common stock immediately prior to the effective time of the Reverse Merger was assumed by the Company and converted into an option to purchase shares of Company common stock, with necessary adjustments to the number of shares and exercise price to reflect the exchange ratio, and each outstanding and unexercised warrant to purchase shares of Former Dianthus common stock immediately prior to the effective time of the Reverse Merger (including the Former Dianthus pre-funded warrants sold in the pre-closing financing) was converted into a warrant to purchase shares of Company common stock, with necessary adjustments to the number of shares and exercise price to reflect the exchange ratio.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Reverse Merger was accounted for as a reverse recapitalization in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). Under this method of accounting, Former Dianthus was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the expectation that, immediately following the Reverse Merger: (i) Former Dianthus’ stockholders own a substantial majority of the voting rights in the combined company; (ii) Former Dianthus’ largest stockholders retain the largest interest in the combined company; (iii) Former Dianthus designated a majority (six of eight) of the initial members of the board of directors of the combined company; and (iv) Former Dianthus’ executive management team became the management team of the combined company. Accordingly, for accounting purposes: (i) the Reverse Merger was treated as the equivalent of Former Dianthus issuing stock to acquire the net assets of Magenta; (ii) the net assets of Magenta are recorded at their acquisition-date fair value in the unaudited condensed consolidated financial statements of Former Dianthus and (iii) the reported historical operating results of the combined company prior to the Reverse Merger are those of Former Dianthus. Additional information regarding the Reverse Merger is included in Note 3. Historical common stock figures of Former Dianthus have been retroactively restated based on the exchange ratio of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2181</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 11, 2023, prior to the effective time of the Reverse Merger, the Company entered into a contingent value rights agreement (the “CVR Agreement”) with a rights agent, pursuant to which pre-Reverse Merger holders of Magenta common stock received one non-transferable contingent value right (each, a “CVR”) for each outstanding share of Magenta common stock held by such stockholder immediately prior to the effective time of the Reverse Merger on September 11, 2023. Subject to, and in accordance with, the terms and conditions of the CVR Agreement, each CVR represents the contractual right to receive a pro rata portion of the proceeds, if any, received by the Company as a result of (i) contingent payments made to the Company, such as milestone, royalty or earnout, when received under any pre-Reverse Merger disposition agreements related to Magenta’s pre-Reverse Merger assets and (ii) the Company’s sale of assets after the effective date of the Reverse Merger and prior to December 31, 2023, in each case, received within a three-year period following the closing of the Reverse Merger. As of March 31, 2024, no payments have been received under the CVR Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concurrently with the execution and delivery of the Merger Agreement, and in order to provide Former Dianthus with additional capital for its development programs, Former Dianthus entered into a subscription agreement, as amended (the “Subscription Agreement”), with certain investors named therein (the “Investors”), pursuant to which, subject to the terms and conditions of the Subscription Agreement, immediately prior to the effective time of the Reverse Merger, Former Dianthus issued and sold, and the Investors purchased, (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,873,988</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Former Dianthus common stock and (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">210,320</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-funded warrants, exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">210,320</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Former Dianthus common stock, at a purchase price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">23.34</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">23.34</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per warrant, for an aggregate purchase price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">72.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the “pre-closing financing”).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2024 Private Placement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 22, 2024, the Company entered into a securities purchase agreement for a private placement with certain institutional and accredited investors. At the closing of the private placement on January 24, 2024, the Company sold and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,500,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock at a price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,666,332</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.999</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per pre-funded warrant, which represents the per share purchase price of the common stock less the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share exercise price for each pre-funded warrant, for an aggregate purchase price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">230</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The pre-funded warrants are exercisable at any time after the date of issuance. A holder of pre-funded warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the number of shares of common stock outstanding immediately after giving effect to such exercise. A holder of pre-funded warrants may increase or decrease this percentage to a percentage not in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% by providing at least 61 days’ prior notice to the Company.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on its key personnel, market acceptance of products, product liability, protection of proprietary technology, ability to raise additional financing and compliance with government regulations. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s lead product candidate that is in development and any future product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure, and extensive compliance-reporting capabilities. Even if its product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with Accounting Standards Update No. 2014-15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Subtopic 205-40), the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the accompanying unaudited condensed consolidated financial statements were issued (the “issuance date”):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its inception, the Company has funded its operations primarily with outside capital and has incurred significant recurring losses, including net losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. In addition, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">103.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024; </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expects to continue to incur significant recurring losses and rely on outside capital to fund its operations for the foreseeable future; and </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the issuance date, the Company expects that its existing cash, cash equivalents and short-term investments on hand will be sufficient to fund its obligations as they become due for at least twelve months beyond the issuance date. The Company expects that its research and development and general and administrative costs will continue to increase significantly, including in connection with conducting clinical trials and manufacturing for its existing product candidate and any future product candidates to support commercialization and providing general and administrative support for its operations, including the costs associated with operating as a public company. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event the Company is unable to secure additional outside capital, management will be required to seek other alternatives which may include, among others, a delay or termination of clinical trials or the development of its product candidates, temporary or permanent curtailment of the Company’s operations, a sale of assets, or other alternatives with strategic or financial partners.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties. Accordingly, the unaudited condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> Immediately prior to the effective time of the Reverse Merger, the Company effected a 1-for-16 reverse stock split of its common stock (the “Reverse Stock Split”). Unless noted otherwise, all references herein to share and per share amounts reflect the Reverse Stock Split. 11021248 0.2181 14817696 14817696 0.2181 2873988 210320 210320 23.34 23.34 72000000 14500500 12 4666332 11.999 0.001 230000000 0.0999 0.1999 -13700000 -7100000 -103200000 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited condensed consolidated financial statements as of March 31, 2024 and for the three months ended March 31, 2024 and 2023 have been prepared in conformity with U.S. GAAP, for interim financial information and pursuant to Article 10 of Regulation S-X of the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s audited financial statements and include only normal and recurring adjustments that the Company believes are necessary to fairly state the Company’s financial position and the results of its operations and cash flows. The results for the three months ended March 31, 2024 are not necessarily indicative of the results expected for the full fiscal year or any subsequent interim period. The unaudited condensed consolidated balance sheet as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> has been derived from the audited financial statements at that date but does not include all disclosures required by U.S. GAAP for complete financial statements. Because all of the disclosures required by U.S. GAAP for complete financial statements are not included herein, these unaudited condensed consolidated financial statements and the notes accompanying them should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2023, which are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (“SEC”) on March 21, 2024. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results may differ materially from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates including the following: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Significant estimates are used in the following areas, among others: the recognition of research and development expense, stock-based compensation expense and revenue recognition.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All short-term, highly liquid investments with original maturities of 90 days or less are considered to be cash and cash equivalents. The carrying amounts reported in the unaudited condensed consolidated balance sheets for cash and cash equivalents are valued at cost, which approximates fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and short-term investments. The Company regularly maintains deposits in accredited financial institutions in excess of federally insured limits. The Company invests its excess cash primarily in money market funds, U.S. treasury securities and U.S. government agency securities in accordance with the Company’s investment policy. The Company’s investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. The Company has not experienced any realized losses related to its cash, cash equivalents and short-term investments and management believes the Company is not exposed to significant risks of losses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company held cash deposits at Silicon Valley Bank (“SVB”) in excess of government insured limits. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation was appointed as receiver. No losses were incurred by the Company on deposits that were held at SVB. Management believes that the Company is not currently exposed to significant credit risk as the vast majority of the Company’s deposits were either owned directly by the Company and held in custody at a third-party financial institution or, subsequent to March 10, 2023, have been transferred to a third-party financial institution. The Company does not currently have any other significant relationships with SVB.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Short-term Investments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments consist of investments in U.S. treasury and U.S. government agency securities. Management of the Company determines the appropriate classification of the securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. The Company classifies its short-term investments as available-for-sale pursuant to ASC 320, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investments – Debt and Equity Securities,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and reports them at fair value in short-term investments with unrealized gains and losses reported as a component of accumulated other comprehensive income loss on the unaudited condensed consolidated balance sheet. Realized gains and losses and declines in value judged to be other than temporary are included as a component of interest income based on the specific identification method.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">When the fair value is below the amortized cost of a marketable security, an estimate of expected credit losses is made in accordance with ASU No. 2016-13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The credit-related impairment amount is recognized in the unaudited condensed consolidated statements of operations and comprehensive loss. Credit losses are recognized through the use of an allowance for credit losses account in the unaudited condensed consolidated balance sheet and subsequent improvements in expected credit losses are recognized as a reversal of an amount in the allowance account. If the Company has the intent to sell the security or it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis, then the allowance for the credit loss is written-off and the excess of the amortized cost basis of the asset over its fair value is recorded in the unaudited condensed consolidated statements of operations and comprehensive loss. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> credit losses recorded during the three months ended March 31, 2024 or 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional information regarding short-term investments is included in Note 4.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Receivable from Related Party and Unbilled Receivable from Related Party</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The receivable from related party and unbilled receivable from related party results from option and license agreements with Zenas BioPharma Limited (“Zenas”), a related party. See Notes 13 and 16 for more information. The receivable represents amounts earned and billed to Zenas but not yet collected while unbilled receivable represents amounts earned but not yet billed to Zenas. The receivable and unbilled receivable are reported at net realizable value. The Company regularly evaluates the creditworthiness of Zenas and their financial condition and does not require collateral from Zenas. As of March 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> allowance for doubtful accounts was recorded as all accounts were considered collectible.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are recorded at cost. Depreciation is provided using the straight-line method over estimated useful lives of three years for computer equipment and five years for furniture and fixtures. Expenditures for major renewals and betterments that extend the useful lives are capitalized. Expenditures for normal maintenance and repairs are expensed as incurred. The cost of assets sold or abandoned, and the related accumulated depreciation are eliminated from the accounts and any gains or losses are recognized in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss of the respective period.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating leases are accounted for in accordance with ASU 2016-02, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, as amended (“ASC 842”). Right-of-use lease assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company’s leases do not provide an implicit rate, management used the Company’s incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The right-of-use asset is based on the measurement of the lease liability and includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. Rent expense for operating leases is recognized on a straight-line basis over the lease term. The Company does </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t have any leases classified as finance leases. Management have elected the practical expedient to exclude short-term leases from right-of-use assets and lease liabilities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s leases do not have significant rent escalation, holidays, concessions, material residual value guarantees, material restrictive covenants or contingent rent provisions. The Company’s leases include both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component as management have elected the practical expedient to group lease and non-lease components for all leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional information and disclosures required under ASC 842 are included in Note 9.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with ASU 2016-18, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Statement of Cash Flows (Topic 230): Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, restricted cash is included as a component of cash, cash equivalents and restricted cash in the accompanying unaudited condensed consolidated statements of cash flows. Restricted cash serves as collateral for a letter of credit securing office space. Restricted cash is recorded within other assets and restricted cash line item in the accompanying unaudited condensed consolidated balance sheet.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company calculates the fair value of assets and liabilities that qualify as financial instruments and includes additional information in the notes to the unaudited condensed consolidated financial statements when the fair value is different than the carrying value of these financial instruments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. ASC Topic 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements and Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect management’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The three levels of the fair value hierarchy are described below:</span></p><div style="margin-left:7.87%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.617714099641811%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1 - Quoted prices in active markets for identical assets or liabilities.</span></div></div><div style="margin-left:7.87%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.617714099641811%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2 - Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.</span></div></div><div style="margin-left:7.87%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.617714099641811%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent that a valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by management in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management has segregated all financial assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. The Company’s valuation techniques for its Level 2 financial assets included using quoted prices for similar assets in active markets and quoted prices for similar assets in markets that are not active.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated fair value of receivable from related party, unbilled receivable from related party, accounts payable and accrued expenses approximate their carrying amounts due to the relatively short maturity of these instruments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional information regarding fair value measurements is included in Note 7.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Classification of Convertible Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Convertible preferred stock was recorded at its original issuance price, less direct and incremental offering costs, as stipulated by its terms. The Company had applied the guidance in ASC 480-10-S99, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Distinguishing Liabilities from Equity-Overall-SEC Materials</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and had therefore classified the convertible preferred stock outside of stockholders’ equity/(deficit). In September 2023, all outstanding shares of convertible preferred stock were converted into shares of common stock immediately prior to the effective time of the Reverse Merger. Additional information and disclosures are included in Note 11.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s CODM is its Chief Executive Officer (“CEO”). The Company operates as a single operating segment and has one reportable segment.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Revenue – Related Party</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, the Company’s only revenue has been attributable to an upfront payment and cost reimbursements under the Company’s license agreement with Zenas. The Company has not generated any revenue from product sales and does not expect to generate any revenue from product sales for the foreseeable future.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes revenue pursuant to ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (“ASC 606”). ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the performance obligation is satisfied.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluates the performance obligations promised in a contract that are based on goods and services that will be transferred to the customer and determine whether those obligations are both (i) capable of being distinct and (ii) distinct in the context of the contract. To the extent a contract includes multiple promised goods and services, the Company applies judgment to determine whether promised goods and services are both capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential transaction price and the likelihood that the transaction price will be received. Variable consideration is included in the transaction price if, in management’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. The Company then allocates the transaction price to each performance obligation and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company’s unaudited condensed consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve months this will be classified in current liabilities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional information and disclosures required under ASC 606 are included in Note 13.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses are recorded as expense, as incurred. Research and development expenses consists of (i) costs to engage contractors who specialize in the development activities of the Company; (ii) external research and development costs incurred under arrangements with third parties, such as contract research organizations and consultants; and (iii) costs associated with preclinical activities and regulatory operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company enters into consulting, research, and other agreements with commercial firms, researchers, and others for the provision of goods and services. Under such agreements, the Company may pay for services on a monthly, quarterly, project or other basis. Such arrangements are generally cancelable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided by the service providers and vendors, whereas payments are dictated by the terms of each agreement. As such, depending on the timing of payment relative to the receipt of goods or services, management may record either prepaid expenses or accrued services. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:-1.764%;padding-left:1.733%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patent costs are expensed as incurred and recorded within general and administrative expenses.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are recorded in accordance with ASC 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities and for loss and credit carryforwards using enacted tax rates anticipated to be in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if, based upon the weight of available evidence, it is more likely than not that some or all the deferred tax assets will not be realized.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position, as well as consideration of the available facts and circumstances. As of March 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t have any material uncertain tax positions. The Company recognizes interest and penalties related to uncertain tax positions, if any exist, in income tax expense.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for stock-based compensation awards in accordance with ASC Topic 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation – Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (“ASC 718”). ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the unaudited condensed consolidated statements of operations and comprehensive loss based on their fair values. All of the stock-based awards are subject only to service-based vesting conditions. Management estimates the fair value of the stock option awards using the Black-Scholes option pricing model, which requires the input of assumptions, including (a) the fair value of the Company’s common stock, (b) the expected stock price volatility, (c) the calculation of expected term of the award, (d) the risk-free interest rate and (e) expected dividends. Management estimates the fair value of the restricted stock awards, if any, using the fair value of the Company’s common stock. Forfeitures are recognized as they are incurred.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the Reverse Merger, management utilized valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Valuation of Privately Held Company Equity Securities Issued as Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to estimate the fair value of Former Dianthus common stock. Each valuation methodology included estimates and assumptions that required management’s judgment. These estimates and assumptions included objective and subjective factors, including external market conditions, the prices at which Former Dianthus sold shares of convertible preferred stock, the superior rights and preferences of the convertible preferred stock senior to Former Dianthus common stock at the time, and a probability analysis of various liquidity events, such as a public offering or sale of Former Dianthus, under differing scenarios. Changes to the key assumptions used in the valuations could have resulted in materially different fair values of Former Dianthus common stock at each valuation date. Following the Reverse Merger, the fair value of the Company’s common stock is based on the closing stock price on the date of grant as reported on the Nasdaq Capital Market.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the Reverse Merger, due to a lack of company-specific historical and implied volatility data, management based its estimate of expected volatility on the historical volatility of a representative group of companies with similar characteristics to the Company, including stage of product development and life science industry focus. Management believes the group selected had sufficiently similar economic and industry characteristics and includes companies that are most representative of the Company. Following the Reverse Merger, expected volatility at the date of grant is estimated using a “look-back” period, which coincides with the expected term, of the Company's stock price as reported on the Nasdaq Capital Market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management uses the simplified method, as prescribed by the SEC Staff Accounting Bulletin No. 107, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Share-Based Payment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to calculate the expected term. The risk-free interest rate is based on observed interest rates appropriate for the term of the awards. The dividend yield assumption is based on history and expectation of paying no dividends.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compensation expense related to stock-based awards is calculated on a straight-line basis by recognizing the grant date fair value, over the associated service period of the award, which is generally the vesting term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional information regarding stock-based compensation is included in Note 12.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The only component of comprehensive loss other than net loss is change in unrealized gains/losses related to available-for-sale debt securities.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted net loss per share attributable to common stockholders are calculated in conformity with the two-class method required for participating securities. Convertible preferred stock is a participating security in distributions of the Company. During the three months ended March 31, 2023, the net loss attributable to common stockholders was not allocated to the convertible preferred shares as the holders of convertible preferred shares did not have a contractual obligation to share in losses. Under the two-class method, basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. During the three months ended March 31, 2023, the weighted-average number of shares of common stock outstanding used in the basic net loss per share calculation did not include unvested restricted common stock as these shares were considered contingently issuable shares until they vested.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, stock options and unvested restricted common stock, if any, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. For all periods presented, basic and diluted net loss per share were the same, as any additional share equivalents would be anti-dilutive.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional information is included in Note 14.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. ASU 2023-07 expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods beginning after December 14, 2024, with early adoption permitted. The Company is currently evaluating the guidance and has not determined the impact this standard may have on the consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes (Topic 740), Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to enhance the transparency and decision usefulness of income tax disclosures. The enhancement will provide information to better assess how an entity’s operations and related tax risks and tax planning and operational opportunities affect its tax rate and prospects for future cash flows. Investors currently rely on the rate reconciliation table and other disclosures, including total income taxes paid, to evaluate income tax risks and opportunities. ASU No. 2023-09 is effective for fiscal years beginning after December 15, 2024 and early adoption is permitted. The Company is currently evaluating the impact ASU No. 2023-09 will have on the consolidated financial statements and related disclosures.</span></p></div> <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited condensed consolidated financial statements as of March 31, 2024 and for the three months ended March 31, 2024 and 2023 have been prepared in conformity with U.S. GAAP, for interim financial information and pursuant to Article 10 of Regulation S-X of the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s audited financial statements and include only normal and recurring adjustments that the Company believes are necessary to fairly state the Company’s financial position and the results of its operations and cash flows. The results for the three months ended March 31, 2024 are not necessarily indicative of the results expected for the full fiscal year or any subsequent interim period. The unaudited condensed consolidated balance sheet as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> has been derived from the audited financial statements at that date but does not include all disclosures required by U.S. GAAP for complete financial statements. Because all of the disclosures required by U.S. GAAP for complete financial statements are not included herein, these unaudited condensed consolidated financial statements and the notes accompanying them should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2023, which are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (“SEC”) on March 21, 2024. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results may differ materially from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates including the following: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Significant estimates are used in the following areas, among others: the recognition of research and development expense, stock-based compensation expense and revenue recognition.</span></p> <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All short-term, highly liquid investments with original maturities of 90 days or less are considered to be cash and cash equivalents. The carrying amounts reported in the unaudited condensed consolidated balance sheets for cash and cash equivalents are valued at cost, which approximates fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and short-term investments. The Company regularly maintains deposits in accredited financial institutions in excess of federally insured limits. The Company invests its excess cash primarily in money market funds, U.S. treasury securities and U.S. government agency securities in accordance with the Company’s investment policy. The Company’s investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. The Company has not experienced any realized losses related to its cash, cash equivalents and short-term investments and management believes the Company is not exposed to significant risks of losses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company held cash deposits at Silicon Valley Bank (“SVB”) in excess of government insured limits. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation was appointed as receiver. No losses were incurred by the Company on deposits that were held at SVB. Management believes that the Company is not currently exposed to significant credit risk as the vast majority of the Company’s deposits were either owned directly by the Company and held in custody at a third-party financial institution or, subsequent to March 10, 2023, have been transferred to a third-party financial institution. The Company does not currently have any other significant relationships with SVB.</span></p> <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Short-term Investments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments consist of investments in U.S. treasury and U.S. government agency securities. Management of the Company determines the appropriate classification of the securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. The Company classifies its short-term investments as available-for-sale pursuant to ASC 320, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investments – Debt and Equity Securities,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and reports them at fair value in short-term investments with unrealized gains and losses reported as a component of accumulated other comprehensive income loss on the unaudited condensed consolidated balance sheet. Realized gains and losses and declines in value judged to be other than temporary are included as a component of interest income based on the specific identification method.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">When the fair value is below the amortized cost of a marketable security, an estimate of expected credit losses is made in accordance with ASU No. 2016-13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The credit-related impairment amount is recognized in the unaudited condensed consolidated statements of operations and comprehensive loss. Credit losses are recognized through the use of an allowance for credit losses account in the unaudited condensed consolidated balance sheet and subsequent improvements in expected credit losses are recognized as a reversal of an amount in the allowance account. If the Company has the intent to sell the security or it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis, then the allowance for the credit loss is written-off and the excess of the amortized cost basis of the asset over its fair value is recorded in the unaudited condensed consolidated statements of operations and comprehensive loss. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> credit losses recorded during the three months ended March 31, 2024 or 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional information regarding short-term investments is included in Note 4.</span></p> 0 0 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Receivable from Related Party and Unbilled Receivable from Related Party</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The receivable from related party and unbilled receivable from related party results from option and license agreements with Zenas BioPharma Limited (“Zenas”), a related party. See Notes 13 and 16 for more information. The receivable represents amounts earned and billed to Zenas but not yet collected while unbilled receivable represents amounts earned but not yet billed to Zenas. The receivable and unbilled receivable are reported at net realizable value. The Company regularly evaluates the creditworthiness of Zenas and their financial condition and does not require collateral from Zenas. As of March 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> allowance for doubtful accounts was recorded as all accounts were considered collectible.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> 0 0 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are recorded at cost. Depreciation is provided using the straight-line method over estimated useful lives of three years for computer equipment and five years for furniture and fixtures. Expenditures for major renewals and betterments that extend the useful lives are capitalized. Expenditures for normal maintenance and repairs are expensed as incurred. The cost of assets sold or abandoned, and the related accumulated depreciation are eliminated from the accounts and any gains or losses are recognized in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss of the respective period.</span></p> <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating leases are accounted for in accordance with ASU 2016-02, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, as amended (“ASC 842”). Right-of-use lease assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company’s leases do not provide an implicit rate, management used the Company’s incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The right-of-use asset is based on the measurement of the lease liability and includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. Rent expense for operating leases is recognized on a straight-line basis over the lease term. The Company does </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t have any leases classified as finance leases. Management have elected the practical expedient to exclude short-term leases from right-of-use assets and lease liabilities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s leases do not have significant rent escalation, holidays, concessions, material residual value guarantees, material restrictive covenants or contingent rent provisions. The Company’s leases include both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component as management have elected the practical expedient to group lease and non-lease components for all leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional information and disclosures required under ASC 842 are included in Note 9.</span></p> 0 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with ASU 2016-18, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Statement of Cash Flows (Topic 230): Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, restricted cash is included as a component of cash, cash equivalents and restricted cash in the accompanying unaudited condensed consolidated statements of cash flows. Restricted cash serves as collateral for a letter of credit securing office space. Restricted cash is recorded within other assets and restricted cash line item in the accompanying unaudited condensed consolidated balance sheet.</span></p> <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company calculates the fair value of assets and liabilities that qualify as financial instruments and includes additional information in the notes to the unaudited condensed consolidated financial statements when the fair value is different than the carrying value of these financial instruments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. ASC Topic 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements and Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect management’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The three levels of the fair value hierarchy are described below:</span></p><div style="margin-left:7.87%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.617714099641811%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1 - Quoted prices in active markets for identical assets or liabilities.</span></div></div><div style="margin-left:7.87%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.617714099641811%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2 - Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.</span></div></div><div style="margin-left:7.87%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.617714099641811%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent that a valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by management in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management has segregated all financial assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. The Company’s valuation techniques for its Level 2 financial assets included using quoted prices for similar assets in active markets and quoted prices for similar assets in markets that are not active.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated fair value of receivable from related party, unbilled receivable from related party, accounts payable and accrued expenses approximate their carrying amounts due to the relatively short maturity of these instruments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional information regarding fair value measurements is included in Note 7.</span></p> <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Classification of Convertible Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Convertible preferred stock was recorded at its original issuance price, less direct and incremental offering costs, as stipulated by its terms. The Company had applied the guidance in ASC 480-10-S99, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Distinguishing Liabilities from Equity-Overall-SEC Materials</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and had therefore classified the convertible preferred stock outside of stockholders’ equity/(deficit). In September 2023, all outstanding shares of convertible preferred stock were converted into shares of common stock immediately prior to the effective time of the Reverse Merger. Additional information and disclosures are included in Note 11.</span></p> <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s CODM is its Chief Executive Officer (“CEO”). The Company operates as a single operating segment and has one reportable segment.</span></p> <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Revenue – Related Party</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, the Company’s only revenue has been attributable to an upfront payment and cost reimbursements under the Company’s license agreement with Zenas. The Company has not generated any revenue from product sales and does not expect to generate any revenue from product sales for the foreseeable future.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes revenue pursuant to ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (“ASC 606”). ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the performance obligation is satisfied.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluates the performance obligations promised in a contract that are based on goods and services that will be transferred to the customer and determine whether those obligations are both (i) capable of being distinct and (ii) distinct in the context of the contract. To the extent a contract includes multiple promised goods and services, the Company applies judgment to determine whether promised goods and services are both capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential transaction price and the likelihood that the transaction price will be received. Variable consideration is included in the transaction price if, in management’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. The Company then allocates the transaction price to each performance obligation and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company’s unaudited condensed consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve months this will be classified in current liabilities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional information and disclosures required under ASC 606 are included in Note 13.</span></p> <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses are recorded as expense, as incurred. Research and development expenses consists of (i) costs to engage contractors who specialize in the development activities of the Company; (ii) external research and development costs incurred under arrangements with third parties, such as contract research organizations and consultants; and (iii) costs associated with preclinical activities and regulatory operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company enters into consulting, research, and other agreements with commercial firms, researchers, and others for the provision of goods and services. Under such agreements, the Company may pay for services on a monthly, quarterly, project or other basis. Such arrangements are generally cancelable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided by the service providers and vendors, whereas payments are dictated by the terms of each agreement. As such, depending on the timing of payment relative to the receipt of goods or services, management may record either prepaid expenses or accrued services. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company.</span></p> <p style="text-indent:-1.764%;padding-left:1.733%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patent costs are expensed as incurred and recorded within general and administrative expenses.</span></p> <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are recorded in accordance with ASC 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities and for loss and credit carryforwards using enacted tax rates anticipated to be in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if, based upon the weight of available evidence, it is more likely than not that some or all the deferred tax assets will not be realized.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position, as well as consideration of the available facts and circumstances. As of March 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t have any material uncertain tax positions. The Company recognizes interest and penalties related to uncertain tax positions, if any exist, in income tax expense.</span></p> 0 0 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for stock-based compensation awards in accordance with ASC Topic 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation – Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (“ASC 718”). ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the unaudited condensed consolidated statements of operations and comprehensive loss based on their fair values. All of the stock-based awards are subject only to service-based vesting conditions. Management estimates the fair value of the stock option awards using the Black-Scholes option pricing model, which requires the input of assumptions, including (a) the fair value of the Company’s common stock, (b) the expected stock price volatility, (c) the calculation of expected term of the award, (d) the risk-free interest rate and (e) expected dividends. Management estimates the fair value of the restricted stock awards, if any, using the fair value of the Company’s common stock. Forfeitures are recognized as they are incurred.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the Reverse Merger, management utilized valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Valuation of Privately Held Company Equity Securities Issued as Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to estimate the fair value of Former Dianthus common stock. Each valuation methodology included estimates and assumptions that required management’s judgment. These estimates and assumptions included objective and subjective factors, including external market conditions, the prices at which Former Dianthus sold shares of convertible preferred stock, the superior rights and preferences of the convertible preferred stock senior to Former Dianthus common stock at the time, and a probability analysis of various liquidity events, such as a public offering or sale of Former Dianthus, under differing scenarios. Changes to the key assumptions used in the valuations could have resulted in materially different fair values of Former Dianthus common stock at each valuation date. Following the Reverse Merger, the fair value of the Company’s common stock is based on the closing stock price on the date of grant as reported on the Nasdaq Capital Market.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the Reverse Merger, due to a lack of company-specific historical and implied volatility data, management based its estimate of expected volatility on the historical volatility of a representative group of companies with similar characteristics to the Company, including stage of product development and life science industry focus. Management believes the group selected had sufficiently similar economic and industry characteristics and includes companies that are most representative of the Company. Following the Reverse Merger, expected volatility at the date of grant is estimated using a “look-back” period, which coincides with the expected term, of the Company's stock price as reported on the Nasdaq Capital Market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management uses the simplified method, as prescribed by the SEC Staff Accounting Bulletin No. 107, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Share-Based Payment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to calculate the expected term. The risk-free interest rate is based on observed interest rates appropriate for the term of the awards. The dividend yield assumption is based on history and expectation of paying no dividends.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compensation expense related to stock-based awards is calculated on a straight-line basis by recognizing the grant date fair value, over the associated service period of the award, which is generally the vesting term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional information regarding stock-based compensation is included in Note 12.</span></p> <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The only component of comprehensive loss other than net loss is change in unrealized gains/losses related to available-for-sale debt securities.</span></p> <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted net loss per share attributable to common stockholders are calculated in conformity with the two-class method required for participating securities. Convertible preferred stock is a participating security in distributions of the Company. During the three months ended March 31, 2023, the net loss attributable to common stockholders was not allocated to the convertible preferred shares as the holders of convertible preferred shares did not have a contractual obligation to share in losses. Under the two-class method, basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. During the three months ended March 31, 2023, the weighted-average number of shares of common stock outstanding used in the basic net loss per share calculation did not include unvested restricted common stock as these shares were considered contingently issuable shares until they vested.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, stock options and unvested restricted common stock, if any, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. For all periods presented, basic and diluted net loss per share were the same, as any additional share equivalents would be anti-dilutive.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional information is included in Note 14.</span></p> <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. ASU 2023-07 expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods beginning after December 14, 2024, with early adoption permitted. The Company is currently evaluating the guidance and has not determined the impact this standard may have on the consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes (Topic 740), Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to enhance the transparency and decision usefulness of income tax disclosures. The enhancement will provide information to better assess how an entity’s operations and related tax risks and tax planning and operational opportunities affect its tax rate and prospects for future cash flows. Investors currently rely on the rate reconciliation table and other disclosures, including total income taxes paid, to evaluate income tax risks and opportunities. ASU No. 2023-09 is effective for fiscal years beginning after December 15, 2024 and early adoption is permitted. The Company is currently evaluating the impact ASU No. 2023-09 will have on the consolidated financial statements and related disclosures.</span></p> <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Reverse Merger</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As described in Note 1, Merger Sub merged with and into Former Dianthus, with Former Dianthus surviving as a wholly owned subsidiary of the Company on September 11, 2023. The Reverse Merger was accounted for as a reverse asset acquisition accounted for as a reverse recapitalization in accordance with U.S. GAAP with Former Dianthus as the accounting acquirer of Magenta. At the effective time of the Reverse Merger, substantially all of the assets of Magenta consisted of cash and cash equivalents, marketable securities, as well as other nominal non-operating assets. Under such reverse recapitalization accounting, the assets and liabilities of Magenta were recorded at their fair value in Magenta’s financial statements at the effective time of the Merger, which approximated book value due to the short-term nature. No goodwill or intangible assets were recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the recapitalization, the Company obtained the assets and liabilities listed below:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,738</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current assets</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,473</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">616</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net assets acquired</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,595</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to the CVRs issued in connection with the Reverse Merger, the Company believes that the achievement of the milestones outlined in the CVR Agreement are highly susceptible to factors outside the Company's influence that are not expected to be resolved for a long period of time, if at all. In particular, these amounts are primarily influenced by the actions and judgments of third parties and the buyers of such assets and are based on the buyers of such assets progressing the in-process research and development assets into clinical trials, and in the case of one of the agreements, to a regulatory milestone. If the Company were to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">record a receivable for such contingent payments, it would also record a corresponding liability. As of March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, no receivables are recorded on the unaudited condensed consolidated balance sheet relating to such contingent payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the recapitalization, the Company obtained the assets and liabilities listed below:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,738</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current assets</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,473</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">616</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net assets acquired</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,595</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 69738000 2473000 616000 71595000 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Short-Term Investments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary of short-term investments:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gain</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Loss</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Available-for-sale, short-term investments:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,327</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,302</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,011</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,010</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total available-for-sale, short-term investments</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,338</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,312</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gain</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Loss</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Available-for-sale, short-term investments:</span></p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,370</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,418</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,976</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,975</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total available-for-sale, short-term investments</span></p></td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,346</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,393</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div> <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary of short-term investments:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gain</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Loss</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Available-for-sale, short-term investments:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,327</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,302</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,011</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,010</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total available-for-sale, short-term investments</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,338</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,312</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gain</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Loss</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Available-for-sale, short-term investments:</span></p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,370</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,418</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,976</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,975</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total available-for-sale, short-term investments</span></p></td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,346</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,393</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 46327000 2000 27000 46302000 1011000 0 1000 1010000 47338000 2000 28000 47312000 36370000 48000 0 36418000 4976000 0 1000 4975000 41346000 48000 1000 41393000 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Prepaid Expenses and Other Current Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary of prepaid expenses and other current assets:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.486%;"></td> <td style="width:1.429%;"></td> <td style="width:1%;"></td> <td style="width:13.458%;"></td> <td style="width:1%;"></td> <td style="width:1.429%;"></td> <td style="width:1%;"></td> <td style="width:13.201%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31,<br/>2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid materials, supplies and research and development services</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,512</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,155</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid subscriptions, software and other administrative services</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,030</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">504</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid insurance</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">472</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">596</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,014</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,255</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div> <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary of prepaid expenses and other current assets:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.486%;"></td> <td style="width:1.429%;"></td> <td style="width:1%;"></td> <td style="width:13.458%;"></td> <td style="width:1%;"></td> <td style="width:1.429%;"></td> <td style="width:1%;"></td> <td style="width:13.201%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31,<br/>2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid materials, supplies and research and development services</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,512</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,155</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid subscriptions, software and other administrative services</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,030</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">504</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid insurance</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">472</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">596</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,014</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,255</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 1512000 2155000 1030000 504000 472000 596000 3014000 3255000 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary of property and equipment:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31,<br/>2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">263</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">234</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Subtotal</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">314</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">282</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: accumulated depreciation</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">119</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">195</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">185</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span> <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary of property and equipment:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31,<br/>2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">263</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">234</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Subtotal</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">314</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">282</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: accumulated depreciation</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">119</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">195</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">185</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 263000 234000 51000 48000 314000 282000 119000 97000 195000 185000 22000 14000 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary of financial assets measured at fair value on a recurring basis:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value at</span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31,<br/>2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Recurring Assets:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">327,973</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">327,973</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,302</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,302</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,010</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,010</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">375,285</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">374,275</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,010</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:43.606%;"></td> <td style="width:1.321%;"></td> <td style="width:1%;"></td> <td style="width:12.61%;"></td> <td style="width:1%;"></td> <td style="width:1.321%;"></td> <td style="width:1%;"></td> <td style="width:10.168%;"></td> <td style="width:1%;"></td> <td style="width:1.321%;"></td> <td style="width:1%;"></td> <td style="width:10.168%;"></td> <td style="width:1%;"></td> <td style="width:1.321%;"></td> <td style="width:1%;"></td> <td style="width:10.168%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value at</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Recurring Assets:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,193</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,193</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,418</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,418</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,975</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,975</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">172,586</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">167,611</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,975</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transfers between levels for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or for the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary of financial assets measured at fair value on a recurring basis:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value at</span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31,<br/>2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Recurring Assets:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">327,973</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">327,973</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,302</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,302</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,010</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,010</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">375,285</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">374,275</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,010</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:43.606%;"></td> <td style="width:1.321%;"></td> <td style="width:1%;"></td> <td style="width:12.61%;"></td> <td style="width:1%;"></td> <td style="width:1.321%;"></td> <td style="width:1%;"></td> <td style="width:10.168%;"></td> <td style="width:1%;"></td> <td style="width:1.321%;"></td> <td style="width:1%;"></td> <td style="width:10.168%;"></td> <td style="width:1%;"></td> <td style="width:1.321%;"></td> <td style="width:1%;"></td> <td style="width:10.168%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value at</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Recurring Assets:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,193</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,193</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,418</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,418</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,975</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,975</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">172,586</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">167,611</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,975</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 327973000 327973000 46302000 46302000 1010000 1010000 375285000 374275000 1010000 131193000 131193000 36418000 36418000 4975000 4975000 172586000 167611000 4975000 0 0 0 0 0 0 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Accrued Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary of accrued expenses:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.64%;"></td> <td style="width:1.6%;"></td> <td style="width:1%;"></td> <td style="width:12.58%;"></td> <td style="width:1%;"></td> <td style="width:1.6%;"></td> <td style="width:1%;"></td> <td style="width:12.58%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31,<br/>2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued issuance costs in connection with the private placement</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,213</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued external research and development</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,635</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">456</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,443</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,361</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional fees</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">345</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">422</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued expenses</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">211</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">265</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,847</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,504</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div> <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary of accrued expenses:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.64%;"></td> <td style="width:1.6%;"></td> <td style="width:1%;"></td> <td style="width:12.58%;"></td> <td style="width:1%;"></td> <td style="width:1.6%;"></td> <td style="width:1%;"></td> <td style="width:12.58%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31,<br/>2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued issuance costs in connection with the private placement</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,213</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued external research and development</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,635</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">456</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,443</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,361</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional fees</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">345</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">422</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued expenses</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">211</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">265</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,847</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,504</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 2213000 0 1635000 456000 1443000 5361000 345000 422000 211000 265000 5847000 6504000 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company leases space under operating leases for administrative offices in New York, New York, and Waltham, Massachusetts and wet laboratory space in Watertown, Massachusetts. The Company also leased office space under operating leases, which had a non-cancelable lease term of less than one year and, therefore, management elected the practical expedient to exclude these short-term leases from right-of-use assets and lease liabilities.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary of the components of lease costs and rent:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable lease cost</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating lease costs</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">111</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recorded operating lease costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">95</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">94</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> within the general and administrative expenses line item in the unaudited condensed consolidated statements of operations and comprehensive loss for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. The Company recorded the operating lease costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">nil</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> within the research and development expenses line item in the unaudited condensed consolidated statements of operations and comprehensive loss for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2024 and 2023, respectively.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Maturities of operating lease liabilities, which do not include short-term leases, as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024, are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024 (remaining 9 months)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">314</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">222</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total undiscounted operating lease payments</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">536</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present value of operating lease liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">497</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Balance sheet classification:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of operating lease liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">400</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term operating lease liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating lease liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">497</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average remaining term of operating leases was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months and the weighted-average discount rate used to measure the present value of operating lease liabilities was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span> The Company leases space under operating leases for administrative offices in New York, New York, and Waltham, Massachusetts and wet laboratory space in Watertown, Massachusetts. The Company also leased office space under operating leases, which had a non-cancelable lease term of less than one year and, therefore, management elected the practical expedient to exclude these short-term leases from right-of-use assets and lease liabilities. <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary of the components of lease costs and rent:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable lease cost</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating lease costs</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">111</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 103000 87000 8000 7000 111000 94000 95000 94000 16000 0 <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Maturities of operating lease liabilities, which do not include short-term leases, as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024, are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024 (remaining 9 months)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">314</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">222</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total undiscounted operating lease payments</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">536</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present value of operating lease liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">497</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Balance sheet classification:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of operating lease liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">400</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term operating lease liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating lease liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">497</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 314000 222000 536000 39000 497000 400000 97000 497000 P16M 0.107 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the closing of the private placement on January 24, 2024, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,500,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock and pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,666,332</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock with a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share exercise price. The pre-funded warrants are exercisable at any time after the date of issuance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the effective time of the Reverse Merger on September 11, 2023, the Company issued an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,021,248</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Company common stock to the Former Dianthus stockholders, based on the exchange ratio of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2181</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Company common stock for each share of Former Dianthus common stock, including those shares of Former Dianthus common stock issued upon the conversion of Former Dianthus preferred stock and those shares of the Former Dianthus common stock issued in the pre-closing financing. In conjunction with the pre-closing financing, the Company also issued pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">210,320</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock with a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share exercise price. The pre-funded warrants are exercisable at any time after the date of issuance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company was authorized to issue up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">150,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> par value of Company common stock. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had issued and outstanding shares of common stock of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">29,348,626</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,817,696</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each share of Company common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Company’s board of directors, if any. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dividends have been declared or paid by the Company through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company had the following shares of Company common stock reserved for future issuance as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024 and December 31, 2023:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.54%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:12.66%;"></td> <td style="width:1%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.48%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of March 31, 2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon exercise of stock options</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,097,438</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,749,475</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity awards available for grant under stock award plans</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">441,590</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">879,461</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for issuance under the Employee Stock Purchase Plan</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99,578</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,078</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon exercise of warrants</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,881,329</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">214,997</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total common stock reserved for future issuance</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,519,935</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,881,011</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div> 14500500 4666332 0.001 11021248 0.2181 210320 0.001 150000000 150000000 0.001 0.001 29348626 29348626 14817696 14817696 0 <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company had the following shares of Company common stock reserved for future issuance as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024 and December 31, 2023:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.54%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:12.66%;"></td> <td style="width:1%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.48%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of March 31, 2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon exercise of stock options</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,097,438</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,749,475</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity awards available for grant under stock award plans</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">441,590</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">879,461</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for issuance under the Employee Stock Purchase Plan</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99,578</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,078</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon exercise of warrants</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,881,329</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">214,997</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total common stock reserved for future issuance</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,519,935</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,881,011</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 3097438 1749475 441590 879461 99578 37078 4881329 214997 8519935 2881011 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. Preferred Stock and Convertible Preferred Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company was authorized to issue up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock at a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock were issued and outstanding.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 11, 2023, the Company completed the Reverse Merger with Former Dianthus in accordance with the Merger Agreement.</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Under the terms of the Merger Agreement, immediately prior to the effective time of the Reverse Merger, each share of Former Dianthus convertible preferred stock was converted into a share of Former Dianthus common stock.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> At closing of the Reverse Merger, the Company issued an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,269,183</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock to Former Dianthus convertible preferred stockholders, based on the exchange ratio of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2181</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Company common stock for each share of Former Dianthus common stock outstanding immediately prior to the Reverse Merger.</span></p> 10000000 0.001 0 0 Under the terms of the Merger Agreement, immediately prior to the effective time of the Reverse Merger, each share of Former Dianthus convertible preferred stock was converted into a share of Former Dianthus common stock. 7269183 0.2181 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2018 Stock Option and Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company grants stock-based awards under the Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan (the “2018 Incentive Plan”), which originally became effective on June 19, 2018 as the Magenta Therapeutics, Inc. 2018 Stock Option and Incentive Plan and was amended and restated in September 2023 and renamed the Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2018 Incentive Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, unrestricted stock awards, cash-based awards, and dividend equivalent rights. In connection with the Reverse Merger, the 2018 Incentive Plan also provided for the assumption of shares remaining available for delivery under the 2019 Stock Plan (as defined below), and such shares will be available for the granting of awards under the 2018 Incentive Plan in accordance with applicable stock exchange requirements. The Company also has outstanding stock options under the Magenta Therapeutics, Inc. 2016 Stock Option and Grant Plan, as amended (the “2016 Plan”), but is no longer granting awards under the 2016 Plan.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2018 Incentive Plan provides that the number of shares reserved and available for issuance under the 2018 Incentive Plan will automatically increase each January 1 by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the outstanding number of shares of the Company’s common stock on the immediately preceding December 31 or such lesser number of shares as determined by the Company’s board of directors or compensation committee of the board of directors. The number of shares reserved for issuance under the 2018 Incentive Plan increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">592,707</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on January 1, 2024. Shares of common stock underlying any awards under the 2018 Incentive Plan, the 2019 Stock Plan and the 2016 Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) will be available for future awards under the 2018 Incentive Plan. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">171,590</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company’s common stock were available for grant under the 2018 Incentive Plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2018 Incentive Plan is administered by either the board of directors or the compensation committee of the board of directors. The exercise prices, vesting and other restrictions are determined at the discretion of the administrator, except that the term of stock options and stock appreciation rights may not be greater than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for certain incentive stock options). Awards typically vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12 months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The exercise price for stock options granted may not be less than the fair value of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">common </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">stock as of the date of grant (or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">110</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the fair value of common stock for certain incentive stock options). The fair value of common stock is based on quoted market prices.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2019 Stock Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2019, Former Dianthus’ Board of Directors adopted, and the Former Dianthus’ stockholders approved, the Dianthus Therapeutics, Inc. 2019 Stock Plan (the “2019 Stock Plan”). In connection with the Reverse Merger, the Company assumed options to purchase shares of Former Dianthus’s common stock that were outstanding under the 2019 Stock Plan immediately prior to the Reverse Merger and such options were converted into options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,273,454</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Company’s common stock (the “Assumed Options”). No further awards will be made under the 2019 Stock Plan; however, the Assumed Options will remain outstanding under the 2019 Stock Plan in accordance with their terms, as adjusted to reflect the Reverse Merger.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2019 Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employees may elect to participate in the Dianthus Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the “ESPP”). The purchase price of common stock under the ESPP is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the lower of the fair market value of the common stock on the offering date or the exercise date. The six-month offering periods previously began in December and June of each year. During the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock purchased under the ESPP. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">99,578</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares remained available for issuance under the ESPP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ESPP provides that the number of shares reserved and available for issuance under the ESPP will automatically increase each January 1 through January 1, 2029, by the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the number of shares issued and outstanding on the immediately preceding December 31, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">62,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares and (iii) such number of shares as determined by the Company’s board of directors or its appointed administrator. The number of shares reserved for issuance under the ESPP increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">62,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on January 1, 2024.</span></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Option Inducement Grant and Inducement Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the Company’s board of directors granted an option to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">96,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock to a new hire as an inducement grant. In February 2024, the Company’s board of directors approved the Dianthus Therapeutics, Inc. Equity Inducement Plan (the “Inducement Plan”), which provides for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">300,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock for inducement awards. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">270,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares available to be granted under the Inducement Plan.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes stock option activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.11%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.662%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:8.942%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.662%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>stock options<br/>outstanding</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>average<br/>exercise price<br/>per share</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>average<br/>remaining<br/>contractual<br/>term</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>intrinsic<br/>value</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in years)</span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at January 1, 2024</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,749,475</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.61</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,181</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options granted, fair value of $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.03</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> per share</span></p></td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,400,200</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.10</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,669</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercised</span></p></td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,430</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.61</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">465</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options forfeited</span></p></td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,807</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.98</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">227</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at March 31, 2024</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,097,438</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.99</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.8</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51,070</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable options at March 31, 2024</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">776,110</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.81</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.8</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,598</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested options at March 31, 2024</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,321,328</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.72</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.1</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,472</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the common stock for those options that had exercise prices lower than the fair value of the common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted average grant-date fair value per share of stock options granted during the three months ended March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.03</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below summarizes the assumptions used to determine the grant-date fair value of stock options issued, presented on a weighted average basis during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2024 and 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:59.792%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:16.883000000000003%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:16.883000000000003%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.0</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.6</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93.1</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84.1</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Warrants</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2021, Former Dianthus issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,677</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants for the purchase of common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.65</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The warrants vested on July 30, 2023 and had a grant date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.16</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per warrant. Former Dianthus has not issued any warrants since April 2021. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the warrants have a weighted average remaining contractual term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7.1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based Compensation Expense</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary of stock-based compensation expense related to stock options, restricted stock units, restricted stock, and warrants:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">839</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">191</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,196</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">342</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,035</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">533</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of total unrecognized compensation cost related to granted stock options. The Company expects to recognize that cost over a remaining weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.3 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> The 2018 Incentive Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, unrestricted stock awards, cash-based awards, and dividend equivalent rights. In connection with the Reverse Merger, the 2018 Incentive Plan also provided for the assumption of shares remaining available for delivery under the 2019 Stock Plan (as defined below), and such shares will be available for the granting of awards under the 2018 Incentive Plan in accordance with applicable stock exchange requirements. The Company also has outstanding stock options under the Magenta Therapeutics, Inc. 2016 Stock Option and Grant Plan, as amended (the “2016 Plan”), but is no longer granting awards under the 2016 Plan. 0.04 592707 171590 P10Y P5Y P12M P4Y 1.10 1273454 0.85 0 0 99578 The ESPP provides that the number of shares reserved and available for issuance under the ESPP will automatically increase each January 1 through January 1, 2029, by the lesser of (i) 1% of the number of shares issued and outstanding on the immediately preceding December 31, (ii) 62,500 shares and (iii) such number of shares as determined by the Company’s board of directors or its appointed administrator. The number of shares reserved for issuance under the ESPP increased by 62,500 on January 1, 2024. 0.01 62500 62500 96000 300000 270000 <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes stock option activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.11%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.662%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:8.942%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.662%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>stock options<br/>outstanding</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>average<br/>exercise price<br/>per share</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>average<br/>remaining<br/>contractual<br/>term</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>intrinsic<br/>value</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in years)</span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at January 1, 2024</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,749,475</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.61</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,181</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options granted, fair value of $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.03</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> per share</span></p></td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,400,200</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.10</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,669</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercised</span></p></td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,430</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.61</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">465</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options forfeited</span></p></td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,807</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.98</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">227</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at March 31, 2024</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,097,438</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.99</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.8</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51,070</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable options at March 31, 2024</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">776,110</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.81</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.8</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,598</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested options at March 31, 2024</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,321,328</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.72</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.1</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,472</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 1749475 10.61 P8Y4M24D 3181000 14.03 1400200 18.1 16669000 30430 8.61 465000 21807 13.98 227000 3097438 13.99 P8Y9M18D 51070000 776110 11.81 P7Y9M18D 15598000 2321328 14.72 P9Y1M6D 35472000 14.03 <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below summarizes the assumptions used to determine the grant-date fair value of stock options issued, presented on a weighted average basis during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2024 and 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:59.792%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:16.883000000000003%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:16.883000000000003%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.0</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.6</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93.1</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84.1</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> </table> 0.04 0.036 P6Y P6Y1M6D 0.931 0.841 0 0 4677 1.65 1.16 P7Y1M6D <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary of stock-based compensation expense related to stock options, restricted stock units, restricted stock, and warrants:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">839</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">191</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,196</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">342</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,035</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">533</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 839000 191000 1196000 342000 2035000 533000 25200000 P3Y3M18D <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. License Revenue – Related Party</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2020, the Company entered into an Option Agreement with Zenas (“Zenas Option”), a related party (See Note 16). Through the Zenas Option, the Company provided Zenas an option to enter into an exclusive license agreement for the development and commercialization of products arising from its research of monoclonal antibody antagonists targeting certain specific complement proteins.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, the Company notified Zenas that it had elected the first antibody sequence as a clinical candidate. In October 2021, Zenas notified the Company that it was exercising its option for such clinical candidate. The Zenas Option provided that upon the exercise of the option, the Company would negotiate in good faith a license agreement with Zenas pursuant to which it would grant Zenas the exclusive license with respect to the antibody sequences for the Zenas territory, which includes People’s Republic of China, including Hong Kong, Macau, and Taiwan. In accordance with Zenas Option, within 60 days following the execution of a license agreement, Zenas agreed to pay the Company a one-time payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the exercise of the corresponding option. In addition, in connection with the exercise of the Zenas Option, Zenas was required to reimburse the Company for a portion of chemistry, manufacturing, and controls-related (“CMC”) costs and expenses from the date of delivery of its option exercise notice through the execution of a license agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, the Company and Zenas executed the license agreement (“Zenas License”). The Zenas Option and Zenas License are collectively referred to as the “Zenas Agreements.” The Zenas License provides Zenas with a license in the People’s Republic of China, including Hong Kong, Macau, and Taiwan, for the development and commercialization of sequences and products under the first antibody sequence. The Company is also obligated to perform certain research and development and CMC services, and will also participate in a joint steering committee (“JSC”). Under the Zenas License, Zenas also has the right to exercise an option with respect to a second antibody sequence. If Zenas exercises the option and pays the Company the option exercise fee related to the second antibody sequence, the Company will grant Zenas an exclusive license to the sequences and products under this second antibody sequence.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since the Zenas Agreements were negotiated with a single commercial objective, they are treated as a combined contract for accounting purposes. The Company assessed the Zenas Agreements in accordance with ASC 606 and concluded that it represents a contract with a customer and is within the scope of ASC 606. The Company determined that there is one combined performance obligation that consists of the license and data transfer, the research and development and CMC services, and the participation in the JSC. The Company determined that Zenas’ right to exercise an option with respect to a second antibody sequence does not represent a material right.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consideration under the Zenas Agreements includes the following payments by Zenas to the Company: (i) a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upfront payment upon execution of the Zenas License; (ii) an approximate $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million payment representing reimbursement for a portion of development costs previously incurred by the Company; (iii) reimbursement of a portion of all CMC-related costs and expenses for the first antibody sequence through the manufacture of the first two batches of drug product; (iv) reimbursement of a portion of all non-CMC-related costs and expenses for the development of the first antibody sequence through the first regulatory approval; (v) development milestones totaling up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million; and (vi) royalties on net sales ranging from the mid-single digits to the low teens.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined that the combined performance obligation is satisfied over time; therefore, the Company will recognize the transaction price from the license agreement over the Company’s estimated period to complete its activities. The Company concluded that it will utilize a cost-based input method to measure its progress toward completion of its performance obligation and to calculate the corresponding amount of revenue to recognize each period. The Company believes this is the best measure of progress because other measures do not reflect how the Company transfers its performance obligation to Zenas. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs expected to be incurred for the combined performance obligation. These costs consist primarily of third-party contract costs. Revenue will be recognized based on the level of costs incurred relative to the total budgeted costs for the combined performance obligation. A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligation. In making such estimates, judgment is required to evaluate assumptions related to cost estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also determined that the milestone payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million are variable consideration under ASC 606 which need to be added to the transaction price when it is probable that a significant revenue reversal will not occur. Based on the nature of the milestones, such as the regulatory approvals which are generally not within the Company’s control, the Company will not consider achievement of this milestone to be probable until the uncertainty associated with such milestone has been resolved. When it is probable that a significant reversal of revenue will not occur, the milestone payment will be added to the transaction price for which the Company recognizes revenue. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024, no milestones had been achieved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is a sales or usage-based royalty exception within ASC 606 that applies when a license of intellectual property is the predominant item to which the royalty relates. In accordance with this royalty exception, the Company will recognize royalty revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). As of March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> royalty revenue had been recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the three months ended March 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recognized related party license revenue totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, associated with the Zenas Agreements. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded a related party receivable of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, unbilled related party receivable of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, current deferred related party revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and noncurrent deferred related party revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on its unaudited condensed consolidated balance sheet. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded a related party receivable of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, unbilled related party receivable of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, current deferred related party revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and noncurrent deferred related party revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on its unaudited condensed consolidated balance sheet.</span></p> 1000000 1000000 1100000 11000000 11000000 0 900000 500000 400000 400000 100000 700000 300000 200000 100000 700000 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14. Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted net loss per share of common stock are calculated as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.393%;"></td> <td style="width:1.6%;"></td> <td style="width:1%;"></td> <td style="width:12.703000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.6%;"></td> <td style="width:1%;"></td> <td style="width:12.703000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Numerator:</span></p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,748</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,089</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Denominator:</span></p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares of common stock outstanding</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,665,475</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">875,279</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: weighted-average unvested restricted shares of common stock</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">570</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares used to compute net loss per share of common stock, basic and diluted</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,665,475</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">874,709</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share attributable to common stockholders, basic and diluted</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.54</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.10</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s potential dilutive securities, which include convertible preferred stock, stock options, unvested restricted shares of common stock, and warrants for the purchase of common stock, have been excluded from the computation of diluted net loss per share as the effect would be antidilutive. Therefore, the weighted-average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share is the same. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following potential dilutive securities, presented on an as converted basis, were excluded from the calculation of net loss per share due to their anti-dilutive effect: </span></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.967%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.357%;"></td> <td style="width:1%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.357%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible preferred stock (as converted)</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,269,183</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options outstanding</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,097,438</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,447,743</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted shares of common stock</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">444</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants for the purchase of common stock</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,881,329</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,677</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,978,767</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,722,047</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div> <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted net loss per share of common stock are calculated as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.393%;"></td> <td style="width:1.6%;"></td> <td style="width:1%;"></td> <td style="width:12.703000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.6%;"></td> <td style="width:1%;"></td> <td style="width:12.703000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Numerator:</span></p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,748</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,089</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Denominator:</span></p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares of common stock outstanding</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,665,475</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">875,279</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: weighted-average unvested restricted shares of common stock</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">570</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares used to compute net loss per share of common stock, basic and diluted</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,665,475</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">874,709</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share attributable to common stockholders, basic and diluted</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.54</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.10</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> </table> -13748000 -7089000 25665475 875279 0 570 25665475 25665475 874709 874709 -0.54 -0.54 -8.1 -8.1 <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following potential dilutive securities, presented on an as converted basis, were excluded from the calculation of net loss per share due to their anti-dilutive effect: </span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.967%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.357%;"></td> <td style="width:1%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.357%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible preferred stock (as converted)</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,269,183</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options outstanding</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,097,438</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,447,743</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted shares of common stock</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">444</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants for the purchase of common stock</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,881,329</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,677</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,978,767</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,722,047</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 0 7269183 3097438 1447743 0 444 4881329 4677 7978767 8722047 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15. Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Alloy Therapeutics, LLC</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2019, the Company entered into a license agreement with Alloy Therapeutics, LLC (“Alloy”). The license agreement was amended in October 2022. The license agreement with Alloy grants to the Company the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A worldwide, non-exclusive license to use the Alloy technology solely to generate Alloy antibodies and platform assisted antibodies for internal, non-clinical research purposes, and </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to Alloy antibodies and platform assisted antibodies that are selected by the Company for inclusion into a partnered antibody program, a worldwide, assignable license to make, have made, use, offer for sale, sell, import, develop, manufacture, and commercialize products comprising partnered antibody programs selected from Alloy antibodies and platform assisted antibodies in any field of use. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company pays annual license fees and annual partnered antibody program fees totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to Alloy. The Company is also obligated to pay a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million fee to Alloy if the Company sublicenses a product developed with Alloy antibodies or platform assisted antibodies. Upon the achievement, with the first selected antibody for products developed with Alloy, of (i) certain development milestones and (ii) certain commercial milestones, the Company is obligated to make additional payments to Alloy of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. Upon the achievement, with the second selected antibody for products developed with Alloy, of (i) certain development milestones and (ii) certain commercial milestones, the Company is obligated to make additional payments to Alloy of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t record any amounts owed under the Alloy license agreement during the three months ended March 31, 2024 or 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">OmniAb, Inc.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2022, the Company entered into a commercial platform license agreement and services agreement with two subsidiaries of Ligand Pharmaceuticals Incorporated. In November 2022, Ligand spun-off these subsidiaries into a separate legal entity, OmniAb, Inc. (“OmniAb”). The platform license agreement and services agreement with OmniAb grants to the Company the following.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A worldwide, non-exclusive, non-sublicensable license under the OmniAb technology to use chicken animals (solely at OmniAb’s facilities and through OmniAb personnel) for generation of OmniAb antibodies for research purposes. </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A worldwide, non-exclusive license under the OmniAb technology to use rodent animals (solely at approved contract research organization (“CRO”) facilities and through approved CRO personnel) for generation of OmniAb antibodies for research purposes. Such license is non-sublicensable except to an approved CRO. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon the achievement of certain development milestones, the Company is obligated to make additional payments to OmniAb of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Upon the achievement of certain commercial milestones, the Company is obligated to make royalty payments in the low to mid-single digits. The Company recorded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">nil</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for amounts owed under the OmniAb license agreement within research and development expenses line item in the unaudited condensed consolidated statements of operations and comprehensive loss during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2024 and 2023, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">IONTAS Limited</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2020, the Company entered into a collaborative research agreement with IONTAS Limited (“IONTAS”) to perform certain milestone-based research and development activities for the Company under its first development program. This agreement was amended in January 2023 to extend their services to additional development programs. IONTAS provides dedicated resources to perform the research and development activities and receives compensation for those resources as well as success-based milestone payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon the achievement, with the first development program with IONTAS, of (i) certain development milestones and (ii) certain commercial milestones, the Company is obligated to make additional payments to IONTAS of up to £</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million based on the March 31, 2024 exchange rate) and £</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million based on the March 31, 2024 exchange rate), respectively. Upon the achievement, with the second development program with IONTAS, of certain development milestones, the Company is obligated to make additional payments to IONTAS of up to £</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million based on the March 31, 2024 exchange rate). The Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2024 and 2023, respectively, for amounts owed under the IONTAS collaborative research license agreement within the research and development expenses line item in the unaudited condensed consolidated statement of operations and comprehensive loss.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnification Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to employees, consultants, vendors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. To date, the Company has not incurred any material costs as a result of such indemnification agreements. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and has not accrued any liabilities related to such obligations in its unaudited condensed consolidated financial statements as of March 31, 2024 and December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Litigation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, the Company may be exposed to litigation relating to potential products and operations. The Company is not currently engaged in any legal proceedings that are expected, individually or in the aggregate, to have a material adverse effect on its financial condition, results of operations or cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had standing agreements with consultants, contractors or service providers whose terms do not yield material long-term commitments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> 100000 100000 1800000 11000000 3100000 15000000 0 0 12200000 0 100000 3100000 3900000 2300000 2900000 2500000 3200000 300000 400000 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16. Related Party Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Zenas BioPharma Limited</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is a party to option and license agreements with Zenas, a related party. The Company considers Zenas to be a related party because (i) Tellus BioVentures LLC (“Tellus”), whose sole member is a significant shareholder in the Company and serves as Chairman of the Board of Directors of the Company, is also a significant shareholder in Zenas and serves as Chief Executive Officer and Chairman of the Board of Directors of Zenas and (ii) Fairmount Healthcare Fund LP and Fairmount Healthcare Fund II LP (together, the “Fairmount Funds”), who are significant shareholders in the Company and have a seat on the Board of Directors of the Company, are also significant shareholders in Zenas and have a seat on the Board of Directors of Zenas. As of March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Tellus and affiliated entities owned approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, and the Fairmount Funds and affiliated entities owned approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Company’s outstanding shares. See Note 13 for more information. In connection with these agreements, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million within the license revenue – related party line item in the unaudited condensed consolidated statements of operations and comprehensive loss for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded a related party receivable of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, unbilled related party receivable of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, current deferred related party revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and noncurrent deferred related party revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on its unaudited condensed consolidated balance sheet. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded a related party receivable of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, unbilled related party receivable of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, current deferred related party revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and noncurrent deferred related party revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on its unaudited condensed consolidated balance sheet.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2020, Zenas issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">156,848</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common shares to the Company in exchange for the Zenas Option. The Company determined that the fair value on the date of issuance and as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024 and December 31, 2023, respectively, was not material to its unaudited condensed consolidated financial statements. The Company used the measurement alternative as the measurement attribute for accounting for the Zenas common shares which does not require it to assess the fair value of the common stock at each reporting period as the fair value of the Zenas common shares is not readily determinable nor is there a reliable source for observable transactions from which the Company could determine a fair value. In addition, the Company does not have ready access to significant events occurring at Zenas. If the Company does identify observable price changes in orderly transactions for the identical or similar common shares of Zenas, the Company will measure the common shares at fair value as of the date that the observable transaction occurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 13, 2023, the Fairmount Funds issued promissory notes in the aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to Former Dianthus at an interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per annum. On March 15, 2023, Former Dianthus repaid principal and interest in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to the Fairmount Funds in satisfaction of its obligations under the promissory notes.</span> 0.05 0.09 900000 500000 400000 400000 100000 700000 300000 200000 100000 700000 156848 400000 0.045 400000 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17. Subsequent Events</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluated subsequent events from March 31, 2024, the date of these unaudited condensed consolidated financial statements, through May 9, 2024, which represents the date the unaudited condensed consolidated financial statements were issued, for events requiring recording or disclosure in the unaudited condensed consolidated financial statements for the three months ended March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company concluded that no events have occurred that would require recognition or disclosure in the unaudited condensed consolidated financial statements.</span></p> false false false false